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~Summary~
Oestrogen deprivation strategies, notably aromatase inhibitors, are o f  
increasing value in hormone sensitive breast cancer. Unfortunately, however, 
oestrogen deprivation, like all other antihormones, is subject to acquisition o f  
resistance. Further understanding o f resistance is required to design 
approaches to effectively treat this state. This project aimed to delineate and 
target the underlying autocrine signalling mechanisms promoting this resistant 
phenotype, using a unique severely oestrogen and growth factor deprived 
in vitro breast cancer m odel, MCF-7X.
The M CF-7X model revealed breast cancer cells are readily able to survive 
oestrogen deprivation, but are not oestrogen hypersensitive and lack input 
from classical growth factor receptors under conditions o f parallel exogenous 
growth factor deprivation, contrasting previous models derived in the presence 
o f  stripped serum. However, there was a retained importance o f oestrogen 
receptor (ERa) signalling, supporting use o f  the pure anti-oestrogen faslodex, 
which reduces E R a  level, AF-1 phosphorylation at serine 118 (via an 
unknown kinase) and ERa-regulated transcriptional activity in  M CF-7X cells. 
Furthermore, intracellular kinase signalling, primarily PI3K/AKT, contributed 
in M CF-7X cells, again driving transcriptional and growth-promoting activity 
o f  ERa, in this instance via E R a  serine 167 phosphorylation. Critically, 
individual/dual targeting with faslodex and/or PI3K inhibition, while initially 
partially inhibitory o f  E R a  phosphorylation and growth, ultimately supported 
emergence o f  resistance. This was invariably associated w ith gain o f  the 
growth factor receptors EGFR/HER2 and IGF1R and kinase-prom oted 
re-activation o f E R a  phosphorylation/function. However, triple treatment 
using faslodex, PI3K and M APK blockade to completely eliminate E R a  
phosphorylation substantially improved anti-tumour response and prevented 
resistance. Clearly, intelligent design o f  combination treatments o f  faslodex 
with targeted therapies to totally deplete E R a activity is needed to m axim ally 
inhibit oestrogen deprivation resistance. In contrast, the project showed 
sequential use o f  such agents m ay translate into poorer prognosis, since 
faslodex resistant cells were more aggressive (potentially driven by HER2).
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CHAPTER 1 INTRODUCTION
1.1 BREAST CANCER
1.1.1 Statistics and Risk Factors
Breast cancer is the most common form of cancer among women in almost all of 
Europe and North America, contributing to an estimate of 1 in 7 women developing 
the disease. The incidence of in situ breast cancer has increased almost 5-fold since 
the 1970’s, this is somewhat attributed to the development and use o f widespread 
mammography screening (Emster and Barclay, 1997). The American Cancer Society 
(American Cancer Society, 2005-2006) estimates for 2005, there will be 212,930 new 
breast cancer cases in the US, o f which 1,690 will be men and 211,240 will be 
women. Sadly, the estimate of deaths is set at 40,870 (460 men and 40,410 women), 
with various circumstances and factors having adverse bearing on outcome (e.g. lack 
of optimal health care, late detection). The prognosis of breast cancer is largely 
dependent upon the disease stage at diagnosis. A patient presenting with early breast 
cancer, where the tumour is confined to the breast (+/- axillary lymph nodes), can 
exhibit up to a 98% 5-year survival rate. Conversely, a patient presenting with 
advanced breast cancer, distant metastases and multiple lymph node involvement has 
an estimated 26% 5-year survival rate (American Cancer Society, 2005-2006). 
Therefore it is important that there is early detection, and further understanding of 
more aggressive phenotypes to ultimately extend patients’ quality of life and survival.
Anyone can develop cancer, and breast cancer is no exception to the rule. Although 
bias is toward the postmenopausal woman, the disease does have the potential to 
affect a small number of premenopausal women and an even fewer number o f men 
(the focus throughout this thesis is on female breast cancer). An individuals’ risk of 
developing breast cancer is multi-factorial, which is why it is necessary for both basic 
researchers and clinicians to provide insight into this disease. Endocrine status and 
hormonal involvement, in particular oestrogens, play a predominant role in the 
development of breast cancer as discovered by Beatson (1896) over a century ago. 
There is a prevailing theory postulating that oestrogens enhance the rate o f cell 
division yielding a mechanism of carcinogenesis which contributes to the promotion 
and progression of breast cancer (Preston-Martin et al., 1993). Increased rate o f cell 
proliferation means less time for DNA repair, therefore creating an environment that 
is more susceptible to gene damage (Jefcoate et al., 2000). Clearly oestrogen-induced 
proliferation has an important role in carcinogenesis however a controversial 
hypothesis suggests a indirect and/or direct genotoxicity originating from oestrogen
2
CHAPTER 1 INTRODUCTION
metabolites, in particular the 4-hydroxy catechol metabolite, are also likely to make 
important contributions (Yager, 2000). Mechanistically cytochrome p450 1B1 
catalyses the hydroxylation of oestradiol, to 4-hydroxy oestradiol, which is converted 
to the 3,4 oestradiol quinine leading to the destabilisation of the glycosidyl bond 
which links guanine and adenine to the DNA backbone (Santen et al., 2004b). This 
process forms DNA point mutations that serve as potential initiators o f neoplastic 
transformation.
It must be stated that the increased risk associated with hormone environment is not 
constant throughout an individuals’ life. There are events that contribute to the 
increased risk of breast cancer which are a part of life’s natural progression, such as 
early menarche (before the age o f twelve, Kampert et al., 1988), late age at first 
pregnancy (after the age o f thirty, White, 1987) and delayed menopause (over the age 
of 45, Gomes et al., 1995). The unifying consequence of these temporal events is 
prolonged exposure of the breast to endogenous oestrogens. Parallel information on 
exogenous oestrogen exposure has come from studies which have shown that 
hormone replacement therapy (HRT) related to duration, promotes a small but 
significant increase in the risk o f breast cancer (1.35-fold increase, Collaborative 
Group on Hormonal Factors in Breast Cancer, 1997). Recent data (5.2 year follow-up 
and termination of the study) of the Womens’ Health Initiative Study reports that the 
short-term HRT combination of oestrogen plus progestin also increases the risk of 
breast cancer. Moreover the cancers that were diagnosed were at a more advanced 
stage (25.4% vs. 16.0% respectively) compared to the placebo group (Chlebowski et 
al., 2003).
Also associated with a greater risk of breast cancer are generally postmenopausal 
individuals who suffer from obesity (Huang et al., 1997; Magnusson et al., 1998) 
where oestrogen production is more significant (discussed in 1.2.1 Oestrogen 
Production). This latter relationship may again be explained by increased oestrogen 
availability, since the degree of obesity correlates linearly with total-body aromatase 
activity in adipose tissue (Jefcoate et al., 2000). Obesity may not be an easy obstacle 
to overcome, however dietary intake, low physical activity, and alcohol consumption 
can be controlled. A number of beneficial dietary components present in soy, fruits 
and vegetables can alter circulating oestrogen levels and modify other cell signalling 
pathways (Clarke et al., 2003). Moderate alcohol consumption has been associated
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with harmful effects on circulating oestrogen levels and therefore related to an 
increased relative risk of developing breast cancer (Lash and Aschengrau, 2000). 
Although these risk factors have only been linked through circumstance and 
environment, these are nonetheless very important lifestyle issues that have been 
reported to increase the relative risk of developing the disease (Howe et al., 1990; 
Bowlin et al., 1997). Migration studies can further support the importance o f diet as 
well as environmental influence on the development of breast cancer. Women from 
Asian and other developing countries that have migrated and adapted to a Western 
world lifestyle assume the rate of breast cancer incidence within one or two 
generations (Thomas and Karagas, 1987; McPherson et al., 2000).
Despite breast cancer predominantly arising in women without family history, any 
family history (maternal or paternal) could pose a risk to a patient. The increased risk 
is small except in women with a first-degree relative (mother or sister) who had breast 
cancer, and further increased if the relative had either premenopausal or bilateral 
breast cancer (Ottman et al., 1983). Genetically predisposed breast cancers occur at a 
younger age, are more likely to be bilateral, and appear in multiple family members 
over three or more generations (Casey, 1997). In 1990, the Breast Cancer -1 (BRCA- 
1) gene was discovered as the first breast cancer susceptibility gene and localised to 
chromosome 17q21 by linkage analysis of multiple families affected by early onset 
breast and ovarian cancer (Hall et al., 1990). Approximately four years later, the 
Breast Cancer -2  (BRCA-2) gene was localised to chromosome 13q 12-13 (Wooster 
et al., 1994) and similar to BRCA-1 the inactivating mutations are scattered 
throughout the coding region (Wooster et al., 1995). There is indication that 
approximately 10% of women diagnosed with breast cancer under the age of 35, 
harbour a BRCA-1 alteration (Langston et al., 1996). Together the BRCA-1 and 
BRCA-2 mutations account for nearly all o f the hereditary breast cancer cases, 
moreover, it is estimated that inherited mutations or alterations in these breast cancer 
susceptibility genes account for approximately 5-10% of breast cancer cases 
(American Cancer Society, 2005-2006).
1.1.2 Staging and Prognostic Factors
Like other cancers, breast cancer is the end result of a multistage process that 
involves a series of cellular and molecular changes that alter cell function (such as 
decreased apoptosis) and growth, ultimately causing increased cell proliferation.
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Staging is performed in order to estimate prognosis, to direct an appropriate therapy 
to the patient and provide a standard for reporting results. The tumour size, lymph 
node involvement, and any associated distant metastases (TNM) are all considered 
when evaluating a tumour on presentation. Among patient’s with breast cancer, 
lymph node status provides a considerable amount of precise prognostic information 
and is beneficial in deciding whether inclusion of cytotoxic therapy is appropriate 
(Fisher et al., 1981). O f considerable importance is the assessment of oestrogen 
receptor (ER) and progesterone receptor protein levels present in the tumour. The 
expression level of these two hormone receptors can help predict a patients’ response 
to hormonal manipulation. Extensive clinical and experimental literature provides 
evidence that, when ER is present, oestrogen is a key stimulus for growth o f breast 
cancer cells (Buzdar and Howell, 2001; Schiff et al., 2003). Patients presenting with 
an ER positive (ER+) tumour phenotype are therefore appropriate for anti-hormonal 
(AH) treatment strategies. Current anti-hormonal strategies involve either anti- 
oestrogens, notably tamoxifen, or in the case o f postmenopausal women oestrogen 
deprivation by aromatase inhibition, and LHRH agonist in premenopausal women. 
Unfortunately, 30% of patients present with an ER negative phenotype (Gee et al.,
2004) and are unaffected by systemic hormonal treatment. As such they are 
considered de novo resistant and are treated with chemotherapeutic strategies 
(MacGregor and Jordan, 1998). In general, ER negative tumours are associated with 
poor patient survival and early recurrence (Bezwoda et al., 1991).
1.2 OESTROGEN AND OESTROGEN RECEPTOR SIGNALLING
1.2.1 Oestrogen Production
Endogenous levels of steroid hormones are periodic throughout the menstrual cycle, 
for example oestrogen levels are higher during the luteal phase compared with the 
follicular phase of the menstrual cycle. In addition to variations in the underlying 
hormonal patterns between and within a woman, there are considerable variations in 
menstrual cycle length (Barnett et al., 2004). The primary location of oestrogen 
synthesis is in the ovaries (mainly production of oestradiol, E2) in premenopausal 
women. Ovarian function and oestrogen synthesis is regulated by the hypothalamic 
pulse release of luteinizing hormone releasing hormone (LHRH), followed by the 
release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the 
pituitary (Ali and Coombes, 2002). Once this signal reaches the ovaries, cyclic AMP 
(cAMP) levels are increased. This activates the transcription factor cAMP-response
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element binding protein (CREB) thereby increasing the expression of aromatase (Ali 
and Coombes, 2002) (see Figure 1.1, left). Aromatase is an enzyme of the 
cytochrome P450 (CYP) superfamily and a product of the CYP19 gene located on 
chromosome 15q21.2 (Dixon, 2004). This enzyme has the sole responsibility for the 
conversion of the androgens, androstenedione and testosterone to oestrogens, 
oestrone (Ei) and oestradiol respectively (Buzdar and Howell, 2001). Although only 
one gene encodes for the aromatase enzyme in both reproductive and non- 
reproductive tissues, this gene contains at least ten different promoters (Bulun et al., 
2003). These promoters vary in different types of normal tissues and in breast, and 
the promoters are stimulated by different ligand-induced pathways (Joensuu et al., 
2005).
Considerably lower levels of oestradiol and oestrone are synthesized by aromatase in 
other normal tissues, including mesenchymal cells of adipose tissue, osteoblasts and 
chondrocytes in the bone, the vascular endothelium, aortic smooth muscle and many 
regions in the brain (Simpson and Davis, 2001). The oestrogens synthesised 
particularly within the bone, breast and brain seem to be only biologically active at a 
local tissue level in a paracrine or ‘intracrine’ fashion. Intracrine activity is defined 
by the formation of active hormones that exert their action in the same cells in which 
synthesis took place without release into the pericellular compartment (Labrie et al.,
1997). In the case of adipose tissue oestrogen production (see Figure 1.1, right), the 
factors with the most impact on aromatase expression are interleukin-6 (IL-6), 
interleukin-11 (IL-11), oncostatin M (OSM) and tumour necrosis factor-a (TNF-a). 
These agents act via promoter 1.4 of the aromatase gene, and require glucocorticoids 
as co-stimulators (Simpson and Davis, 2001). In postmenopausal women, ovarian 
synthesis of oestrogen ceases, therefore residual oestrogen synthesis relies on the 
availability of circulating adrenal precursors dehydroepiandrosterone (DHEA) and 
DHEA sulphate (DHEA-S) as well as the level of aromatase enzyme in peripheral 
tissues, including adipose (Simpson et al., 2000). The major aromatization pathway 
in postmenopausal woman is androstenedione into oestrone, which accounts for as 
much as 90% of the total oestrogens synthesised (Lonning et al., 1990; Joensuu et al.,
2005).
In the breast cancer patient the breast tumour can produce factors that also stimulate 
aromatase expression locally (see Figure 1.1, middle). This stimulation is associated
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primarily with switching of the aromatase gene promoter from 1.4 to promoter II. 
Locally produced prostaglandin E2 (PGE2) activates prostaglandin E receptors on 
breast cancer cells, which increases cAMP levels followed by CREB transcription 
leading to aromatase expression (Zhao et al., 1996). An increase in prostaglandin 
levels could be associated with the activation of the COX-2 pathway. This pathway 
has a number of inducible targets involved with cell growth, invasion, anti-apoptosis, 
angiogenesis and the HER2 pathway (Brodie et al., 2001). Activating PGE2 and thus 
aromatase over-expression, consequently leads to an increase in oestrogen production 
which then feeds back to drive further COX-2 stimulation, creating a positive loop 
mechanism (Goss and Strasser-Weippl, 2004). Bulun et al. (2003) also suggest that 
oestrogen-dependent breast cancer utilizes 4 promoters (II, 1.3, 1.7 and 1.4) for 
aromatase expression which increases total P450 aromatase mRNA compared with 
normal breast (which exclusively uses promoter 1.4). It has been determined that the 
concentration of oestradiol present in breast tumours of postmenopausal women is at 
least 20-fold greater than that found in the plasma (Pasqualini et al., 1996). Using an 
aromatase inhibitor decreases the intra-tumoural levels of oestradiol and oestrone, 
paralleled with a loss of aromatase activity (discussed in more detail see section 
1.3.3). This may suggest it is the aromatase activity of the tumour and the 
surrounding adipose tissue that is responsible for the high concentrations of 
oestrogens within tumour cells (de Jong et al., 1997).
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Figure 1.1 Oestrogen Production (Ali and Coombes, 2002)
Ovarian production of oestrogen (left) is regulated by the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the 
pituitary. These molecules cause an increase in cyclic AMP (cAMP) levels which facilitates the transcription of cAMP-response element binding 
protein (CREB), ultimately increasing expression of aromatase. Aromatase is then responsible for the conversion of androstenedione and testosterone 
to oestrone and oestradiol respectively. A breast tumour (middle) can locally produce aromatase via production of prostaglandin E2 (PGE2) activating 
its receptors which increases cAMP followed by CREB transcription and aromatase expression. In adipose tissue (right) interleukin-6 (IL-6), 
interleukin-11 (IL-11) and tumour necrosis factor-a (TNFa) act via promoter 1.4 of the aromatase gene to increase aromatase expression leading to 
the production of oestrogen. A pre-menopausal breast tumour therefore has oestrogen supply from the ovaries, adipose tissue as well as the tumour 
itself. A post-menopausal tumour is reliant on aromatase activity and oestrogen production from the surrounding adipose tissue as well as the breast 
tumour.
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1.2.2 Structure of the Oestrogen Receptor (ER)
The ER is a member of a nuclear receptor superfamily that includes the thyroid 
hormone receptor, the vitamin D receptor (VDR) and the retinoic acid receptors 
(RXR, RAR) (Mangelsdorf et al., 1995). There are two genes that encode the ER, a  
which was first isolated in the late 1950s (Jensen and Jacobson, 1960) and [3 which 
was identified almost thirty years later (Kuiper et al., 1996). ERa is organised in 
functional domains termed A-F encoded by 8 exons (see Figure 1.2). The A/B 
domain at the N-terminal exhibits the most variation in both sequence and length. 
Importantly it contains the hormone-independent transcription activation function-1 
(AF-1). The AF-1 contains several key serine phosphorylation sites (Ser 104, 106, 
118 and 167) which enhance the response to oestradiol binding or activation of 
growth factor tyrosine kinase signalling pathways (Lannigan, 2003). Compared to 
the understanding of co-accessory proteins involved in ligand dependent 
transcription, much less is known about the AF-1, where only two specific AF-1 co­
activators have been identified, p68 (Endoh et al.. 1999) and p72 RNA helicases 
(Watanabe et al., 2001). The DNA-binding domain (DBD) is centrally located in the 
C domain which is highly conserved among all of the nuclear receptors. Within this 
site there are eight cysteine residues, which are arranged in two zinc-finger motifs, 
each of which is followed by an extended a-helix, forming two sub-domains. 
Through the C domain (DBD), ER binds to DNA as dimers, at specific oestrogen 
response elements (EREs) located within the promoter of E2-responsive genes 
(Metivier et al.. 2002). Also in this domain is the serine residue 236, which can be 
directly phosphorylated by protein kinase A (PKA) (Chen et al.. 1999; Michalides et 
al.. 2004). The D domain appears to function as a hinge region, and may be an 
important binding site for co-accessory proteins. Finally, the E and F domains are 
less conserved among family members, and E contains the ligand-binding domain 
(LBD). Helix 12 is located in the LBD of the ER, but the composition and orientation 
of helix 12 differs depending on the ligand bound to the ER (Shiau et al.. 1998). 
Within the E domain near the hinge region is the serine 305 residue, which also seems 
to be a target of PKA activity (Chen et al.. 1999). Importantly, the ligand-dependent 
transcription activation function-2 (AF-2) is also contained in the E domain. The F 
domain is at the carboxy terminal end, which modulates transcriptional activation/ 
dimerization. The ER in its inactive state is bound to co-repressors, which recruit
9
CHAPTER 1 INTRODUCTION
histone deacetylases (HDACs) that maintain chromatin condensation (McKenna et 
al., 1999).
ER is expressed in the brain, bone, cardiovascular system and in a number of 
endocrine tissues including normal breast, uterus and vagina, as well as in the 
pituitary and hypothalamus (Osborne et al., 2004). A striking abnormal pathologic 
feature of many breast tumours is over-expression of ER.
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Figure 1.2 Structure of the Oestrogen Receptor
The ER has 5 domains each with specific function that lead to the complex function of the receptor. The A/B domain (N-terminus, -NH2) 
contains the AF-1 for transcriptional activity with its key serine phosphorylation sites (104/106, 118 and 167). The DNA binding domain 
which importantly binds ERE sequences is located in the C domain. The D domain contains the hinge region important for dimerization and 
Hsp90 binding. Within the E domain is the ligand binding domain which contains helix 12 and the AF-2 for transcriptional activation. The 
orientation of helix 12 is dependent on the ligand bound to the ER. The F domain is the carboxy terminus (-COOH) which modulates 
transcriptional activity and dimerization.
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1.2.3 Signalling via the Oestrogen Receptor-a (ERa)
It is now established that signalling mediated via the natural steroid hormone 
oestrogen through the oestrogen receptor has a mitogenic effect on many breast 
cancers, playing a key role in growth and development of this disease (Prall et al.,
1998). Unfortunately, there is not one straightforward mechanism in which oestrogen 
acts via oestrogen receptor to promote cell growth, proliferation and survival. The 
ERa is conventionally known as a nuclear receptor that, when oestradiol triggered, 
acts as a transcription factor promoting gene expression to drive growth. However, 
recent evidence suggests there is also a distinct rapid signalling mechanism not 
mediated by the activation of RNA or protein synthesis that has led to the discovery 
of receptor sub-fractions localised at the cell membrane (Simoncini and Genazzani, 
2003). The nuclear and plasma membrane ERa are quite complementary and do 
share some overlapping features, for example both bind oestradiol and interact with 
signalling kinases. Furthermore, it is has been suggested that membrane ERa 
signalling could amplify the actions of the nuclear receptor (Levin, 2002). Each form 
is separated by distinct mechanisms of action, which will be discussed in detail within 
the following sections.
1.2.3.1 Classical/ Ligand-Dependent Genomic Signalling
In the classical or ligand dependent ERa pathway of transcriptional control, the 
binding of oestradiol to the ERa initiates displacement of heat shock proteins from 
the ERa, followed by receptor dimerization (Osborne et al., 2004) (see Figure 1.3). 
The nuclear oestradiol/ ERa complex binds specifically to the oestrogen response 
elements (EREs), which are sequences situated in the regulatory regions of oestrogen 
sensitive genes. Transcription mediated via the ERa has direct and indirect 
involvement with a range of genes associated with survival, proliferation, 
angiogenesis, and invasion. The orchestrated concert of transcription is controlled by 
the AF-1 (phosphorylation at Seri 18 predominately) and AF-2 domains, with the aid 
of co-activator (CoA) proteins. Three important classes of CoA complex are 
subsequently recruited. The first promotes nucleosomal remodelling required for 
transcriptional activation and contains steroid receptor co-activator protein-1 (SRC-1, 
p i60), p300/CBP (CREB binding protein) and transcriptional intermediary factor-2 
(TIF-2) (Metivier et al., 2001). The next complex which forms a direct link to the 
transcriptional machinery apparatus is made up of SMCC/TRAP/DRIP (SRB and
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mediator-protein- containing complex, thyroid-hormone-receptor-associated protein 
and vitamin-D-receptor-interacting protein) and has been implicated in activation by 
several nuclear receptors (Font de Mora and Brown, 2000). The third co-activator 
complex includes AIB1 (amplified in breast cancer-1; also known as SRC-3, RAC3, 
TRAM-1, pCIP and ACTR) steroid hormone receptor co-activator which binds ER 
and enhances the expression of cyclin D1 (Planas-Silva et al., 2001). AIB1 has 
potential therapeutic predictive importance and has been implicated in enhancing 
anti-oestrogen resistance (Osborne and Schiff, 2003; Clarke et al., 2003). 
Furthermore, this co-activator is over-expressed in approximately 50% of breast 
tumours (Murphy et al., 2000), especially ERa positive breast cancers.
Once the CoA complex is recruited, stimulation of transcription begins via histone 
acetyl-transferase (HAT) activity which allows access to the transcriptional template 
by remodelling (or de-condensation) of the chromatin (McKenna et al., 1999). 
Phosphorylation within the AF-1 at serine 118 and to a lesser extent serine 104/106 
(Lannigan, 2003), completes the elements for the oestradiol/ERa complex to function 
maximally. The phosphorylation of serine 118 induced by oestradiol is mediated by 
CDK7, which is a cyclin kinase associated with the basal transcription factor TFIIH 
(Chen et al., 2000; Martin et al., 2003). The result of the machinery functioning 
properly is the transcription of oestrogen-responsive genes, such as c-myc, cyclin D, 
cathepsin D and transforming growth factor-a (TGF-a), all of which are known to 
stimulate mammary cell growth (Sun et al., 2001).
1.2.3.2 Non-Classical/Ligand-Dependent Genomic Signalling
ERs can modulate expression of target genes by indirectly interacting with further 
transcription factors such as AP-1 (activator protein-1) or Spl to facilitate expression 
in a tissue specific manner. Interestingly, despite some similar action at EREs, ERa 
and ER(3 have completely different effects at AP-1 sites. ERa activates and ERP 
inhibits transcription from an AP-1 site when receptors are complexed to oestradiol 
(Webb et al., 1999). The model for ER action at AP-1 sites is complicated. It has 
been proposed that ERa is present at AP-1 sites through contact with co-activators 
(SRC1, p i60) that have been recruited by Jun/Fos or Jun/Jun (Schiff et al., 2003) (see 
Figure 1.4). There is evidence to suggest that AP-1 transcription factors control 
survival and apoptosis by regulating the expression and function of cell cycle
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regulators, cyclin D, p21cip 1 /wafl5 p 19arf and p i6 (Shaulian and Karin, 2001). The 
difference between ER interactions at Spl sites versus AP-1 is ERa activates in a 
cell-specific manner and ERp is nearly inactive. It has been proposed that ERa 
binding to Spl increases the binding of Spl to its cognate element, thereby enhancing 
transcription (Delaunay et al., 2000).
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Figure 1.3 Classical/Ligand-Dependent Genomic Signalling
Oestrogen diffuses through the cell nuclear membrane binding into a hydrophobic region in the ER. There is conformational change in the ER so 
Helix 12 in the E domain seals the region. The Hsp90 molecules are lost and two oestrogen bound receptors dimerize leading to the binding to target 
sequences in the DNA of oestrogen sensitive genes, know as oestrogen response elements (ERE’s). This mechanism results in the transcription of 
genes known to stimulate mammary cell growth.
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Figure 1.4 Oestrogen Receptor Signalling via AP-1
First the binding of c-Jun and c-Fos takes place following the recruitment of the CBP/p300 associated proteins which also include the p i60 co-activators. 
The c-Jun/c-Fos heterodimer plus the co-activator complex binds to the ER triggering transcription from the AP-1 element. Transcription of genes that 
control survival and apoptosis occurs, such as cyclin D, p 21c‘P|/wafl, p i 9 ^  and pl6.
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1.2.3.3 Receptor Tyrosine Kinase Induced Oestrogen Receptor Genomic Signalling
Although in most cases both the functional domains AF-1 and AF-2 appear to act in 
conjunction to promote optimal transcriptional activity (Metivier et al., 2001), ERa 
mediated transcription can also be initiated in a ligand independent manner (Ali et al., 
1993; Kato etal., 1995; Lannigan, 2003). Crucial information has evolved describing 
receptor tyrosine kinase networks that are highly interactive with the ERa and breast 
cancer growth. Stimulation of signal transduction networks or activation of second 
messengers can directly phosphorylate serine residues, notably Ser 104, 106, 118 and 
167 (LeGoff et al., 1994; Martin et al., 2000), located within the AF-1 domain (see 
Figure 1.5). Perhaps one of the best described examples is the epidermal growth 
factor stimulation of the Ras/Raf/M APK pathway that can phosphorylate serine 118 
of ERa which allows both translocation of the receptor to the nucleus and 
transcription of transfected ERa regulated reporter genes (Kato et al., 1995). The 
phosphorylation of serine 167 has also been linked to EGFR/HER2 pathway; 
however involvement with a kinase downstream of MAPK, p90 ribosomal S6 kinase 
(RSK) is necessary to cause this activation (Joel et al., 1998). Alternatively, MAPK 
has the potential of activating the AF-2 co-activator AIB-1, which also regulates gene 
transcription and cell growth (Font de Mora and Brown, 2000).
The literature also contains supporting evidence of cross-talk between components of 
the ERa and insulin-like growth factor receptor (IGFR) signalling pathway in cells in 
vitro and in clinical disease (Yee and Lee, 2000; Lee et al., 2003). This consists of 
the IGF-I and IGF-II receptors (IGF-IR, IGF-IIR), the insulin receptor (IR), hybrid 
IGF/insulin receptor and IGF binding proteins (IGFBPs, six in total) (Sachdev and 
Yee, 2001). Signalling mediated via these receptors initiates a range of cellular 
functions by transmitting mitogenic signals, protecting cells from a variety of 
apoptotic insults, playing a critical role in transformation, regulating cell adhesion 
and cell motility, and inducing terminal differentiation (Yee and Lee, 2000). Key 
downstream signalling components include PKC5, which seems to be linked with 
anchorage-independent growth and AKT/ protein kinase B (PKB), which is believed 
to exert an anti-apoptotic effect (Kiley et al., 1999). There is strong evidence that ER 
Seri 67 can be phosphorylated by AKT (Figure 1.5) and also casein kinase II (Arnold 
et al., 1995; Sun et al., 2001). Clearly, the tyrosine kinase receptor pathways can lead 
to ligand independent activation of the oestrogen receptor by direct phosphorylation
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of the serine residues located in the AF-1 domain and/or by the phosphorylation of 
co-activators.
Within the AF-2 domain the protein kinase p21-activated kinase (Pakl), an effector 
of the small GTPases Cdc42 and Racl, has been shown to directly phosphorylate 
Ser305 (Wang et al., 2002). The study by Wang et al. (2002) was able to show Pak-1 
phosphorylates the AF-2 in the absence of oestrogen paralleled by an up regulation of 
MAPK activation.
18
Receptor Tyrosine Kinase
Cell Membrane
PTENP13KRas
Raf
AKTPDK-1 mTOR
MEK
p70 S6 KinaseRSK
ERK1/2
Ser 118 
Ser 104/106
Ser 167
TranscriptionE R / E R
= Phosphorylation
Figure 1.5 Receptor Tyrosine Kinase Induced ER Genomic Singailing
Stimulation of tyrosine kinase receptors therefore signal transduction network can lead to the phosphorylation of ER AF-1 serine residues. Ligand 
activation of the epidermal growth factor receptor (EGFR) results in the phosphorylation of the Ras/Raf/ERK (MAPK pathway) which can directly 
phosphorylate Seri 18 and indirectly through RSK phosphorylate Seri 67. Alternatively, ligand activation of the insulin-like growth factor receptor 
(IGFR) results in the phosphorylation of PI3K/AKT directly phosphorylating Seri67.
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1.2.3.4 Rapid Non-Genomic Signalling via Membrane Oestrogen Receptor 
The importance of functional ER associated with the plasma membrane remains 
somewhat controversial in breast cancer. Pietras and Szego (1977) first described the 
rapid generation of cyclic AMP (cAMP) in response to oestrogen which was bound to 
a receptor protein in the cell membrane of endometrial cells. It has also been 
demonstrated that oestrogen rapidly activates non-genomic signalling events 
including the second messengers calcium and nitric oxide (in endothelial cells), 
causes cAMP generation, activates phospholipase C and the generation of IP3 which 
leads to c-Src, PKC and PKA activation (Levin 1999; Shupnik 2004). This non- 
genomic signalling through the recruitment of G-protein-coupled receptors (GPCRs), 
in particular GPR30 (Filardo, 2002), can rapidly regulate multiple cellular functions. 
According to Simoncini et al. (2002), this rapid action can be classified by the 
following practical rules: (I) actions that are too rapid to be compatible with RNA and 
protein synthesis; (II) actions that steroid hormones induce in cells in which RNA and 
protein synthesis are nearly absent; (III) actions that can be reproduced in the 
presence of inhibitors of RNA or protein synthesis; (IV) actions that can be 
reproduced by using steroid hormones coupled to cell membrane-impermeable 
molecules. Although the primary action of such signalling is rapid, its consequences 
can modulate longer-term processes, such as gene expression and cell proliferation 
(Simoncini et al., 2002).
Significantly, it has been suggested that oestrogen deprivation can cause an oestrogen 
hypersensitive state, whereby significantly lower levels of oestrogen become 
sufficient for mitogenic cell growth (Santen et al., 2001, 2004a; Nicholson et al., 
2004b). This hypersensitivity has been linked to enhanced MAPK activity. Santen et 
al. (2004a) postulate that upon receptor activation by oestrogen, She (Src homology 
2-domain containing adaptor protein) is activated and binds to Grb2 and Sos. This 
results in activation of the Ras/Raf/MAPK pathway leading to a rapid 
phosphorylation of nuclear transcription factor Elk-1 (see Figure 1.6). Importantly, 
She is a key modulator of tyrosine kinase receptors including platelet-derived growth 
factor (PDGFR), IGFR and EGFR, and their triggering actively facilitates 
translocation of cytoplasmic ER to the plasma membrane and thus promotes MAPK 
signalling (Song et al., 2002; Nicholson et al., 2004b). Migliaccio et al. (1998, 2000) 
have shown that an ER/Src membrane complex may also lead to the rapid activation 
of signalling kinases. This is supported by the Santen et al (2004a) studies showing
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that both ER and Src are upstream of She and are required for its phosphorylation and 
subsequent MAPK activity. The ER/Src complex has also been linked physically and 
functionally to the p85 sub-unit of PI3K, catalyzing the synthesis of lipid mediators 
that act as second messengers transferring membrane signalling to intracellular 
protein kinases such as AKT (Castoria et al., 2001; Simoncini and Genazzani, 2003).
In summary, the membrane ER signalling mechanism in breast cancer represents a 
relatively new aspect within the understanding of oestrogen action, most notably in its 
contribution to oestrogen response versus genomic mechanism. Indeed, to date ER 
localised to the plasma membrane has not been isolated for detailed characterisation, 
although localisation of the receptor in this vicinity has been reported.
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Figure 1.6 Membrane Oestrogen Receptor Signalling
The Santen et al. (2003) membrane ER suggests E2 binds to ER near or in the cell membrane, followed by the initiation of She binding to the ER. 
Through Src kinase, She is phosphorylated. Then association with GRB2 and SOS leads to Ras (GDP to GTP) conversion activating Raf/MEK/ERKl/2 
enhancing cell proliferation through Elk and ERE transcription.
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1.3 ENDOCRINE THERAPY
The development of endocrine therapy has proved to be one of the major 
accomplishments in breast cancer and has resulted in much important translational 
research, including the discovery of the ER. It was the initial clinical discoveries with 
respect to Beatsons’ (1896) observations of oophorectomy causing a regression of 
breast tumours, followed by similar clinical results caused by adrenalectomy and 
hypophysectomy (Huggins and Bergenstal, 1952; Luft and Olivecrona, 1953), 
together with various additive therapy (i.e. androgens, oestrogens and progestins), 
that created the fundamental information underpinning our understanding of 
endocrine biology in breast cancer. The identification of the oestrogen receptor by 
Jensen and Jacobson (1960) prior to the isolation of the receptor by Toft and Gorski 
(1966), not only moved our understanding of oestrogen action to a molecular level, it 
gave us a predictive factor (Horwitz and McGuire, 1975) that enabled the rapid screen 
of ER as a specific therapeutic target. Throughout the 1960s, a number of anti- 
oestrogens were identified (e.g. ethamoxytriphetol and Clomiphene), although 
nothing was developed clinically for breast cancer therapy until ICI 46,474 (later to 
be renamed Tamoxifen) was developed (Cole et al., 1971). By 1977, tamoxifen had 
been granted approval for the treatment of metastatic advanced breast cancer in the 
United States (Cuzick and Baum, 1985).
During the same period, there were attempts to develop medical adrenalectomy by 
use of corticosteroids. This however, proved only partly successful until the 
adrenotoxic antiepileptic compound aminoglutethimide was introduced. Significantly 
Thompson and Siiteri (1974) found aminoglutethimide inhibited in vitro 
aromatization of androgens and subsequently extended this observation to 
postmenopausal women where it reduced oestrogen levels. A study by Geisler et al. 
(1997) additionally revealed treatment of postmenopausal women with 
aminoglutethimide decreased plasma levels of oestrone sulphate from a mean pre­
treatment value of 372.4 to 50.6 pmol/1 (74.5% inhibition), with plasma levels of 
oestrone and oestradiol being suppressed by 40.7% and 32.8% respectively. Since 
the 1970s endocrine therapy targeting the oestrogen receptor or inhibiting the 
production of oestrogen has been intensely investigated around the world, with such 
treatments promoting remission among patients with ER+ tumours. Currently, 
tamoxifen is the mainstay of endocrine therapy in ER+ disease, however recent 
advancement among oestrogen deprivation strategies, in particular the development
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of third generation aromatase inhibitors which reduce circulating oestrogen levels in 
postmenopausal women by upwards of 95%, is set to change this situation in the 
Western world.
1.3.1 Anti-oestrogens
1.3.1.1 Tamoxifen- Selective Oestrogen Receptor Modulator in ER+ Disease
It is now established that approximately 40% of breast cancer patients benefit from 
endocrine therapy, and most of those patients have been treated with the non-steroidal 
anti-oestrogen tamoxifen (Nolvadex, AstraZeneca Pharmaceuticals). The drug has 
been shown to be beneficial in both the adjuvant setting and in advanced ER+ disease. 
Tamoxifen is deemed to be a selective oestrogen receptor modulator (SERM), 
because it possesses mixed agonist and antagonist properties. Positioning of helix 12 
in the LBD seems to be a feature that allows discrimination between ER agonists and 
antagonists (Shiau et al., 1998). When the ER is occupied by an agonist the proper 
positioning of helix 12 generates AF-2 activity and allows a surface for the 
recruitment of co-activators (Pearce et al., 2003) thus leading to transcriptional 
activation. In contrast, tamoxifen does not allow the appropriate positioning of helix 
12 and indeed favours the recruitment of co-repressors that inhibit transcriptional 
activity (Shou et al. 2004). Despite this reduction in AF-2, a weak activation of AF-1 
does remain (Feng et al., 2001) and this can promote oestrogenic actions in a tissue 
specific manner. Clearly the antagonistic ability of tamoxifen to block ER AF-2 
driven breast cancer cell growth is beneficial, however the agonist effects are variable 
and have been linked to tumour flare as well as risk of uterine tumours (2-4 fold) in 
postmenopausal women (Early Breast Cancer Trialists’ Collaborative Group, 1998). 
Further side effects involved with tamoxifen treatment are similar to those 
experienced with hormone replacement therapy, which include thromboembolic 
disease, endometrial cancer, pulmonary embolus and stroke (ATAC Trialists’ Group, 
2002).
It has been shown that almost 50% of ER positive patients treated with the anti­
oestrogen tamoxifen will fail to respond despite having retained ER expression 
(Osborne and Fuqua, 1994; Schiff et al., 2003). Furthermore, many of the remaining 
patients who demonstrate an initial response, which is highly variable in magnitude, 
eventually acquire resistance leading to tumour progression (Cheung et al., 1997). 
The mechanisms of tamoxifen resistance have been well characterized by a number of
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groups including our own at the Tenovus Centre for Cancer Research. The consensus 
understanding is based on the large amount of evidence suggesting a retained 
importance of the ER and increased signalling via several growth factor tyrosine 
kinase receptor pathways and their downstream signalling components, promoting 
resistant in vitro/in vivo cell growth (Gross and Yee, 2003; Nicholson et al., 2001, 
2004a). The inability of tamoxifen to silence ER AF-1 activity gives a tumour cell 
the advantage or an avenue to overcome the stress of the treatment. This activity can 
be promoted by growth factor receptor pathways such as EGFR/HER2 and IGFR 
(Nicholson and Gee, 2000; Hutcheson et al., 2003; Knowlden et al., 2003a) to drive 
tamoxifen resistant growth. A number of gene transfer studies enhancing various 
elements involved in growth factor signalling (see Table 1.1) have been able to 
demonstrate the importance of their expression to proliferation, cell survival and 
ultimately anti-hormone resistance, as well as to invasiveness and angiogenesis.
Table 1.0 Reference list of gene transfer studies associated with resistance.
Target Gene Reference
IGF-II Abdul-Wahah et al., 1999; Daly et al., 1991
IGF-1R Guvakova & Surmacz, 1997, Kucab & Dunn, 2003
Heregulin-P Tang et al., 1996
EGFR van Agthoven et al., 1992; Miller et al., 1994
HER2 Benz et al., 1993; Liu et al., 1995; Pietras et al., 1995
VEGF Guo et al., 2003
Ras Kasid et al., 1985; Yu and Feig, 2002
R af El-Ashry et al., 1997; Oh et al., 2001
M APK Oh et al., 2001
| AKT Campbell et al., 2001
Moreover, to further illustrate this phenomenon without gene manipulation, there is a 
vast amount of both experimental and clinical evidence that indicates increased 
expression of EGFR (Tidow et al., 2003) and HER2 (Benz et al., 1993; Witters et al., 
1997; Dowsett, 2001; Shou et al., 2004) following treatment with tamoxifen can 
promote endocrine resistant states. In our own tamoxifen resistant models derived 
from MCF-7 and T47D cells there is increased expression and activity of these two 
tyrosine kinase receptors with a parallel increase in activity of their downstream 
signalling elements MAPK and AKT (Nicholson et al., 2001; Hutcheson et al., 2003; 
Knowlden et al., 2003a). A number of groups (Smith et al., 1997; Webb et al., 1998; 
Schiff et al., 2003) have suggested that the agonistic properties of tamoxifen are 
enhanced by increased levels in co-activators such as AIB1 or SRC1. This hypothesis
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is supported by the indication of increased MAPK activation, either by ER or growth 
factor signalling, leading to the direct phosphorylation of AIB1 which recruits p300 
and HAT activity to the AIB1 complex thereby regulating gene transcription and cell 
growth (Font de Mora and Brown, 2000; Osborne et al., 2003).
Parallel to these findings, is strong clinical evidence that suggests tumours expressing 
high co-activator AIB1 and HER2 have a poor outcome with anti-oestrogen 
treatment. In the malignant breast over-expression of HER2 occurs in 25-30% 
(Heldin, 2001; De Lorenzo et al., 2002) of patients and has been associated with a 
lack of response to endocrine therapy, that translates to an increase in metastatic 
disease and poor survival (Hutcheson et al., 2003). This supports the hypothesis that 
increased HER2 signalling yields increased MAPK signalling, which in turn activates 
ERa (primarily serine 118) and AIB1 (Osborne et al., 2003).
It has also been suggested both in vitro (Dumont et al., 1996; Kushner et al., 2000) 
and in vivo (Johnston et al., 1999; Schiff et al., 2000) that tamoxifen may act as an 
agonist on AP-1 regulated genes. Increased MAPK signalling and oxidative stress 
can cause increased AP-1 DNA binding associated with increased c-JUN NH2 
terminal kinase (JNK) activity in tamoxifen resistant breast cancer (Johnston and 
Dowsett, 2003). Interestingly, there is evidence that SERM induced AP-1 stimulation 
is more efficient with ERP than ERa and Webb et al. (1999) suggested that this 
mechanism was totally independent of the AF-2 function of ER(3. Since ERP has no 
constitutive AF-1 function, the tamoxifen (SERM)/ERp complex appears to activate 
AP-1 by an AF-independent action (Kushner et al., 2000).
Currently, there are several alternative SERMs being evaluated both in clinic and in 
the laboratory. Toremifene (Fareston, Shire US) was approved as a nonsteroidal anti­
oestrogen in the treatment of metastatic breast cancer. However, there were no added 
benefits of toremifene over tamoxifen in comparative studies on efficacy and 
tolerability and its use was still associated with undesirable oestrogenic effects (e.g. 
increased risk of thromboembolic disease, Bross et al., 2003). Raloxifene (Evista, Eli 
Lilly & Co) is a further class of SERM that possesses some oestrogenic activity on 
bone, although it has been suggested to lack the oestrogenic effects on the uterus 
(Clarke et al., 2003). Raloxifene is currently approved for the treatment of
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osteoporosis in postmenopausal women based on its ability to prevent bone 
degradation (Delmas et al., 1997) and has some inhibitory effects on breast cancer 
(Cummings et al., 1999).
1.3.1.2 Faslodex- Selective Oestrogen Receptor Down-regulator in ER+ Disease 
Faslodex (Fulvestrant, AstraZeneca Pharmaceuticals) is a 7a-alkylated analogue of 
oestradiol, which competitively inhibits binding of oestradiol to the oestrogen 
receptor (Wakeling, 1991). The binding of faslodex to the ER compromises receptor 
dimerization, and energy-dependent shuttling, thus not allowing nuclear localisation 
of the receptor (Dauvois et al., 1993). The simplified mechanism of faslodex action 
is it binds, blocks and accelerates degradation of the ER protein, and depletes activity 
of both AF-1 and AF-2 on any residual ER. This leads to complete inhibition of 
oestrogen signalling via the ER (Osborne et al., 1995). Faslodex therefore lacks the 
pivotal agonistic effects which limit the efficacy of tamoxifen, for example on 
endometrial cell growth.
The mechanisms of tamoxifen action both in treatment and resistance are reasonably 
understood, whereas those of faslodex are less well studied. In studies using the 
MCF-7 human breast cancer cell line, treatment with faslodex significantly reduces 
protein levels of oestrogen receptor, which is followed by suppression of the 
oestrogen regulated genes pS2 and cathepsin D as well as progesterone receptor 
(Nicholson et al., 1995; McClelland et al., 1996; Rajah et al., 1996). It has also been 
demonstrated in MCF-7 tumour xenograft models that faslodex is more effective than 
tamoxifen at suppressing both oestrogen and progesterone receptor proteins, as well 
as oestrogen responsive genes pS2 and pLIV 1 (Osborne et al., 1995). Significantly, 
faslodex shows anti-tumour activity in tamoxifen-resistant cell lines (McClelland et 
al., 1996), confirming a lack of cross-resistance between tamoxifen and faslodex 
models (Hu et al., 1993; Howell, 2002). This observation appears to be translated 
into the clinic with approximately 45% of tamoxifen-resistant breast cancer patients 
responding favourably to treatment with faslodex (Howell et al., 2002). Despite this, 
acquisition of resistance is still a fundamental issue. Moreover, emerging in vitro 
studies indicate an aggressive phenotype may ultimately result from the prolonged 
use of faslodex, associated with loss or silenced oestrogen receptor expression (Gee et 
al., 2004) with an increase in tumour cell motility and invasive capacity (personal 
communication with Dr. Steve Hiscox; Nicholson et al., 2005).
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1.3.2 Oestrogen Deprivation
1.3.2.1 Aromatase Inhibitors in ER+ Postmenopausal Disease 
The rationale behind targeting the synthesis of oestrogens is not new, however this 
strategy in breast cancer patient’s has recently gained in momentum for the treatment 
of both pre and postmenopausal women with the availability of the effective LHRH 
agonists and aromatase inhibitors (AIs) targeting the pituitary/ovarian axis and the 
P450 aromatase enzyme respectively. According to Buzdar and Howell (2001) it is 
knowledge of the peripheral route of oestrogen production in postmenopausal women 
that led to the development of aromatase inhibitors. Simplistically, aromatase 
inhibitors can be divided into two types based on their mechanism of action: steroidal 
and non-steroidal (see Table 1.2). The steroidal aromatase inhibitors (which are 
considered aromatase inactivators) bind to the substrate pocket of the enzyme causing 
irreversible inactivation, while the non-steroidal inhibitors bind competitively and 
reversibly to inhibit the P450 domain of the aromatase protein (Miller, 2004).
Table 1.2 Generations of aromatase inactivators and inhibitors
Type I: 
Inactivators (Steroidal)
Type II: 
Inhibitors (Non-Steroidal)
Generation I Testololactone Aminoglutethimide
Generation II Formestane
(4-hydroxyandrostenedione)
Fadrozole
Generation III Exemestane 
(Aromasin, Pfizer)
Anastrozole
(Arimidex, Astra Zeneca)
Letrozole
(Femara, Novartis) |
Aminoglutethimide (a phenobarbitone) was the first clinically available aromatase 
inhibitor and was used extensively as a second-line treatment of advanced breast 
cancer (Santen et al., 1978; Wells et al., 1978). Unfortunately, the use of 
aminoglutethimide inhibited the synthesis of all steroids yielding an extreme lack of 
selectivity with further limitations caused by its overall toxicity. It significantly 
influenced adrenocorticosteroid synthesis, therefore supplementation of 
corticosteroids, such as hydrocortisone, was necessary (Smith and Dowsett, 2003). 
Aminoglutethimide was associated with high incidence of side effects including skin 
rash, lethargy and orthostatic hypotension. One of the first steroidal aromatase 
inhibitors formestane, used during the early 1990s, caused fewer side effects and 
produced a degree of aromatase inhibition similar to aminoglutethimide (Coombes et
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al., 1992), but it failed to show increased clinical benefit over tamoxifen. Although 
fadrozole, a second-generation non-steroidal inhibitor, did demonstrate a more potent 
and selective inhibitory affect on aromatization than aminoglutethimide, it also 
influenced 11-deoxycorticosterone and aldosterone concentrations (Santen 1991; 
Dowsett et al., 1994).
Further development of aromatase inhibitors has now given us exemestane, 
anastrozole and letrozole, the so-called third generation of AIs. These compounds 
show a high degree of selectivity for the aromatase enzyme and they have improved 
tolerability. They do not have the same mode of action, with anastrozole and 
letrozole (triazole derivatives) interfering with the heme moiety of the P450 
aromatase enzyme thereby suppressing serum levels of oestrogen without affecting 
other steroidogenic pathways (Dixon, 2004), while exemestane is a compound 
structurally related to the natural substrate androstenedione which acts as a ‘suicide 
substrate’ for the aromatase enzyme. Anastrozole and letrozole have recently been 
evaluated in a crossover comparison study involving 12 postmenopausal women with 
metastatic breast cancer. The mean inhibition of whole body aromatization was 
97.3% for anastrozole and >99.1% for letrozole (Geisler et al., 2002). Exemestane 
significantly lowers circulating oestrogen concentration without affecting other 
enzymes involved in the steroidogenic pathway and has highly potent in vivo 
aromatase inactivation producing a >97.9% inhibition (Miller and Dixon, 2000).
Since the mid-1990s exemestane, anastrozole and letrozole have emerged as an 
alternative to tamoxifen in the treatment of postmenopausal women with ER+ 
advanced breast cancer and show a side-effect profile related to oestrogen 
withdrawal. This includes hot flushes, arthralgia, and bone demineralisation 
(Bonneterre et al., 2000). There is no association with an increase rate of vaginal 
discharge, vaginal bleeding, or increased risk of pathological endometrial changes, 
including endometrial cancer, upon treatment with aromatase inhibitors 
(Angelopoulos et al., 2004). Importantly, aromatase inhibitors do not appear to 
increase the risk of thromboembolic events (Baum et al., 2002), which has been one 
of the life-threatening side effects associated with tamoxifen treatment.
In summary, the third-generation of aromatase inhibitors/inactivators provide greater 
selectivity and increased suppression of oestrogens than earlier generations of
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compounds (Gershanovich et al., 1998). However, more information is needed to 
make the final judgment on which, if any of these drugs is superior and optimal 
duration of usage. This will emerge from comparative studies. Interestingly, there 
appears to be a lack of cross-resistance between the inhibitors and the inactivators of 
the aromatase enzyme, suggesting that patients demonstrating disease relapse on non­
steroidal compounds may benefit from additional treatment using a steroidal 
compound (Lonning et al., 2000; Dixon, 2004).
1.3.3 Aromatase Inhibitors/Inactivators versus Tamoxifen in the Clinic: In ER+ 
Postmenopausal Disease
In 1990 the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) 
recommended adjuvant endocrine therapy for women with breast tumours that 
expressed oestrogen or progesterone receptors. The overview of multiple adjuvant 
trials demonstrated that tamoxifen was associated with a highly significant 
improvement in relapse-free and overall survival of breast cancer patients. 8 years 
later it became general practice to treat hormone receptor-positive early breast cancer 
patients with 5 years of tamoxifen treatment irrespective of age, menopausal status or 
tumour stage (Early Breast Cancer Trialists’ Collaborative Group, 1998). In 
postmenopausal women a number of trials are currently investigating aromatase 
inhibitors (AIs) as alternatives to the gold standard tamoxifen.
1.3.3.1 Aromatase Inhibitors in Advanced Breast Cancer (First-line Therapy)
A patient with advanced disease unfortunately has a poor outlook as the breast cancer 
has already metastasized, and in this setting systemic therapies are only offered as 
palliative treatments to improve quality of life and hopefully to modestly improve 
survival. Recently, two large phase III trials have been set up to compare the efficacy 
and tolerability of the third-generation aromatase inhibitor anastrozole with 
tamoxifen, the TARGET (Tamoxifen and Arimidex Randomized Group Efficacy and 
Tolerability) trial and the NAT (North American Trial) trial. Significantly, both trials 
have shown that when the third-generation AIs are used as first-line therapy in 
postmenopausal women with advanced breast cancer they are at least equivalent to 
tamoxifen (Sainsbury, 2004). The primary end points of the TARGET trial were time 
to progression (TTP), objective response (OR) and tolerability, all of which 
demonstrated that anastrozole is equivalent to tamoxifen (Bonneterre et al., 2000). 
The NAT trial included postmenopausal women with ER and/or progesterone
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receptor (PR) positive or receptor unknown advanced disease. Patients were 
randomly assigned first-line treatment with either anastrozole or tamoxifen. Both 
treatments were well tolerated, with a significant increase in TTP among patients who 
received anastrozole versus those who received tamoxifen (11.1 vs. 5.6 months) 
(Nabholtz et al., 2000). In both trials more patients treated with tamoxifen reported 
vaginal bleeding in comparison with those treated with anastrozole (TARGET: 2.4% 
vs. 1.2%, NAT: 3.8% vs. 1.2% respectively), which may provide evidence that there 
is a lack of stimulation on the endometrium with anastrozole.
In a randomized phase II EORTC (European Organisation for the Research and 
Treatment of Cancer) study in either hormone receptor positive or unknown breast 
cancers (Paridaens et al., 2000), the overall response rate was higher for patients 
receiving exemestane than tamoxifen (44.6% vs. 14.3%) (Wong and Ellis, 2004). 
The phase III extension of the EORTC study, evaluated after a median follow-up of 
29 months, showed that exemestane significantly increased OR compared to 
tamoxifen (46% vs. 31%, respectively), and increased progression-free survival by 
approximately 4 months (exemestane 9.9 months vs. tamoxifen 5.8 months) 
(Paridaens et al., 2004). Letrozole has similarly demonstrated an increased clinical 
benefit as first-line therapy versus tamoxifen in a randomized phase III trial involving 
907 postmenopausal women with ER+ and/or PR+ or receptor unknown advanced 
breast cancer. Results from this trial demonstrate that letrozole (vs. tamoxifen) 
significantly prolonged the median TTP by 57% (9.4 months vs. 6.0 months), reduced 
the risk of progression by 30%, and showed that the OR rate was significantly higher 
in patients receiving letrozole versus tamoxifen (32% vs. 21%, respectively) 
(Mouridsen et al., 2003).
1.3.3.2 Adjuvant Trials: Early Breast Cancer
By definition early or primary breast cancer is operable and although the disease is 
confined to the breast (and potentially also axillary lymph nodes), adjuvant systemic 
therapy is necessary to combat micrometastatic deposits. Currently, in ER+ 
postmenopausal women adjuvant tamoxifen treatment is the standard treatment, 
administered with a potential curative aim. Emerging data from several ongoing 
clinical studies, including the ATAC (5 years of Arimidex and Tamoxifen Alone or in 
Combination) trial, the BIG FEMTA (Femara-Tamoxifen Breast International Group) 
trial and the MA-17 study, suggest AIs potentially offer a more effective first line
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therapy in comparison to tamoxifen in postmenopausal ER+ women with early breast 
cancer when used as an adjuvant to surgery. The ATAC trial included more than
9.000 postmenopausal patient’s (7839 hormone receptor positive, 768 negative, 759 
status unknown) who were randomly allocated to receive tamoxifen or anastrozole 
singly, or in combination, for a total treatment duration of five years (ATAC Trialists’ 
Group, 2002). The 47 month update analysis (Baum et al., 2003) indicated that 
disease-free survival (DFS) and time to recurrence (TTR) were significantly 
prolonged for the patients that received anastrozole alone compared to those who 
received tamoxifen. After evaluation of the data, it was reported anastrozole 
promoted a 97% inhibition of the aromatase enzyme and a 90% reduction in 
circulating oestrogen levels (Sainsbury, 2004). Furthermore, combination of 
tamoxifen and anastrozole was found to be no more effective than tamoxifen alone 
and less effective than anastrozole alone therefore discontinued from the trial. The 
recent 68 month update states anastrozole significantly reduced distant metastases and 
contralateral breast cancers in conjunction with the significant increase in DFS and 
TTR versus tamoxifen alone (ATAC Trialists’ Group, 2005).
The BIG-FEMTA trial has accrued over 5100 postmenopausal women with 
oestrogen/progesterone receptor positive disease treated with adjuvant letrozole 
and/or tamoxifen for 5 years (Goss, 1999). The trial is designed to compare a 
continuous course of each single agent for 5 years, as well as a randomization 
crossover study (3 years of tamoxifen followed by 2 years of letrozole or 3 years 
letrozole followed by 2 years of tamoxifen). The MA-17 trial included more than
5.000 post-menopausal patients, who were randomly allocated letrozole or placebo 
for five years following 4-6 years of adjuvant tamoxifen therapy. At the first interim 
analysis (~ 2.5 years), there was a significant benefit in terms of DFS for the women 
who had been prescribed letrozole following tamoxifen with an estimated four-year 
DFS rate of 93% compared with 87% in the placebo arm (Goss et al., 2003). This 
highly significant benefit resulted in the MA-17 trial being prematurely terminated. 
Further endpoints within this trial included an assessment of bone fracture incidence, 
bone mineral density (MA-17B), together with lipid profiles (MA-17L) (Buzdar and 
Howell, 2001). An assessment of these endpoints is essential in all Al trials as it was 
evident during the early anastrozole studies that there was an increased bone fracture 
risk (Wong and Ellis, 2004). Furthermore, Elisaf et al. (2001) have reported that 
aromatase inhibitors alter cholesterol and lipoprotein metabolism which could
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potentially cause detrimental effects on cardiovascular health, although to date there 
has been no substantial indication of such problems with AIs.
1.3.3.3 Neoadjuvant Trials
The aims of neoadjuvant hormonal therapy include reduction of tumour size prior to 
surgery to allow less extensive surgery, the avoidance of chemotherapy, and possible 
cure of the disease. In addition to improving breast conserving surgery, neoadjuvant 
therapy can provide an opportunity to explore drug development strategies in vivo 
(Ellis, 2004). Predictive biomarker studies can be carried out over a short period of 
time in order to gain insight into the molecular basis of endocrine therapy and 
intrinsic tumour resistance (Ellis, 2004). Furthermore, neoadjuvant therapy may be 
able to identify promising systemic strategies for additional testing in larger adjuvant 
trials, and finally neoadjuvant trials can allow new combinations and sequences of 
anti-cancer agents to be evaluated (Freedman et al., 2005). Concerns do remain in 
the neoadjuvant setting regarding many of the standard prognostic factors including 
axillary-node status which in this case is unknown at the time of initial treatment 
(Dixon, 2004).
There have been several randomized trials designed to make comparisons between 
tamoxifen and AIs in the ER+ neoadjuvant postmenopausal setting. The P024 trial 
compared 4 months of treatment with either letrozole or tamoxifen in 324 post­
menopausal women with oestrogen receptor positive and/or progesterone receptor 
positive disease (Eiermann et al., 2001). These patients were considered not eligible 
for breast conservation at the time of diagnosis. Following treatment, overall 
response rates were statistically improved in the letrozole group versus tamoxifen 
(55% vs. 36%). In addition 45% of the patients receiving letrozole (vs. 35% on 
tamoxifen) were, on completion of the study, eligible for breast conserving surgery 
(Eiermann et al., 2001). This study included assessment of EGFR and HER2 status 
and it was discovered that patients whose tumours were positive for EGFR and/or 
HER2 had an increased response rate in the letrozole arm (88% vs. 21% in the 
tamoxifen arm) (Eiermann et al., 2001). The IMPACT (Immediate Preoperative 
Arimidex Compared with Tamoxifen) trial commenced in 1997 with a target accrual 
of 330 patients residing in Germany and the UK. The PROACT (Pre-Operative 
Arimidex Compared to Tamoxifen) trial, which began in 2000 with a target accrual of 
440 patients is a multicenter trial being conducted in 10 different countries. The latter
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two trials involving anastrozole (Arimidex), report no significant difference in 
response rate compared with tamoxifen, however in both trials anastrozole was 
associated with more patients able to undergo breast conserving surgery versus 
tamoxifen (46% vs. 22% in the IMPACT trial) (Janicke, 2004). The IMPACT trial 
also reported that HER2 positive patient’s allocated anastrozole showed a higher 
response rate than those receiving tamoxifen (58% vs. 22%, respectively) (Freedman 
et al., 2005).
1.3.4 Ovarian Ablation/Suppression in Premenopausal Women
In premenopausal woman ovarian ablation (oophorectomy or ovarian irradiation) or 
suppression (LHRH analogues) are two oestrogen deprivation methods that promptly 
reduce circulating oestrogens to postmenopausal levels in nearly all treated women. 
AIs are not appropriate in this setting because they block the conversion of androgens 
(which are produced by the adrenal glands and ovaries) into oestrogens peripherally 
(in adipose, muscle, brain and breast tissue), a process by which the majority of 
postmenopausal oestrogen is produced. Surgical ablation of the ovaries is associated 
with irreversible premature menopause, increased risk of coronary artery disease, 
osteoporosis as well as permanent infertility (Goodwin et al., 1999). Ovarian 
chemical suppression is achieved by the administration of a LHRH analogue, such as 
goserelin (Zoladex, AstraZeneca Pharmaceuticals), which causes permanent 
internalisation of LHRH receptors in the pituitary gland due to its 100- to 200-fold 
higher binding affinity versus LHRH (Angelopoulos et al., 2004). Although 
goserelin causes an initial short-lived surge in LH/FSH and oestrogen levels, it 
rapidly promotes a decline in the levels of these hormones (Prowell and Davidson, 
2004). Goserelin is associated with menopausal symptoms and osteoporosis, 
however its clear advantage is its reversibility (Prowell and Davidson, 2004). This 
allows young women the possibility to preserve future fertility, as well as limit the 
effects of osteoporosis or coronary artery disease.
Important comparison data has come from the Zoladex Early Breast Cancer Research 
Association (ZEBRA) study which assessed the efficacy of goserelin versus the 
chemotherapy regime cyclophosphamide, methotrexate, and fluorouracil (CMF) as 
adjuvant therapy in premenopausal patients with node positive breast cancer (Jonat et 
al., 2002). The overall survival and disease-free survival between the treatments in 
ER+ patients were identical, suggesting the well-tolerated goserelin as an alternative
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to the highly toxic CMF (de Haes et al., 2003). In the ER negative patient population 
goserelin was inferior to the CMF regime (de Haes et al., 2003), supporting the 
importance of defining ER status in order to administer the appropriate therapeutic 
strategy. Klijn et al. (2001) have shown in a meta-analysis of four randomized 
clinical trials, that the combination of an LHRH agonist and tamoxifen had significant 
survival benefit in premenopausal women with advanced breast cancer versus 
endocrine monotherapy. The Austrian Breast and Colorectal Cancer Study Group 5 
(ABCSG) has enrolled 1,034 patients randomised to receive either 3 years of 
goserelin with 5 years of tamoxifen or 6 cycles of CMF. Significantly, the 6 year 
survival, relapse-free and local recurrence-free survival rates were all in favour of the 
endocrine treatments versus chemotherapy (Jakesz et al., 2002).
1.3.5 Future Development Studies and Research Considerations
Despite continued improvements in our capacity to alter the hormone environment of 
cancer cells, unfortunately, like the anti-oestrogen tamoxifen, it is known that 
treatment of breast carcinoma with AIs is also associated with the development of 
acquired resistance and patient relapse (Johnston and Dowsett, 2003). Moreover, to 
date no further improvement in overall survival has been reported with these agents 
versus tamoxifen. Thus there is not only an urgent need to consolidate the 
mechanisms by which anti-oestrogens fail to adequately impede breast tumour 
growth, but also to begin to understand how cells can adapt to a near total removal of 
endogenous oestrogen supply. Fortunately, there are experimental in vivo and in vitro 
oestrogen deprived breast cancer models that have already contributed significant 
information paralleling the findings in clinical disease.
1.4 DEVELOPMENT OF THE OESTROGEN DEPRIVATION RESISTANCE 
MODEL
Relatively little is known about the long-term effects of aromatase inhibitors and even 
less is known about the resistant phenotype that is emerging in the clinic compared to 
the information concerning the anti-oestrogen tamoxifen. Laboratories that have 
notably contributed to this area of research are those of Brodie, Martin/Dowsett, 
Santen and the Tenovus Centre for Cancer Research. Creating an in vitro oestrogen 
deprived model that mimics clinical acquired resistance has been difficult to achieve. 
Previous studies at the Tenovus Centre for Cancer Research (Helena Dunne,
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observations not published) have shown that the hormone sensitive MCF-7 cells are 
not responsive to the aromatase inhibitor anastrozole and this lack of effect concurs 
with the observations made by Brodie and Njara (2000). It has also been shown that 
hormone sensitive MCF-7 cells only poorly express the aromatase enzyme under 
basal growth conditions (Brodie and Njara, 2000). To overcome this experimental 
obstacle Brodie et al. (2001) developed a preclinical intra-tumoural aromatase model 
(MCF-7ca) using the MCF-7 breast cancer cell line stably transfected with the human 
placental aromatase gene which could be studied both in vitro and in vivo (Yue et a l., 
1994). The model has been used to investigate the effects of letrozole and 
anastrozole on tumour growth and has demonstrated their inhibitory activity (Lu et 
al., 1998). This model was also used to investigate combination anti-oestrogen and 
aromatase inhibitor treatments, which did not provide greater reductions in tumour 
growth than either letrozole or anastrozole alone (Lu et al., 1999), paralleling the 
recent clinical trial data from the MA-17 and the ATAC trials. In order to understand 
the phenomenon of acquired resistance to aromatase inhibitors, Brodies’ group has 
cultured the MCF-7Ca cell line for 8 months under steroid depleted conditions, and 
created the sub-line UMB-lCa. This sub-line is reported to have increased 
expression of ER (faslodex sensitive), HER2, and activation of AKT as well as 
increased invasive behaviour compared to the parental MCF-7Ca (Sabnis et al., 2005).
In vitro models of long-term oestrogen withdrawal have been developed from 
endocrine responsive cell lines, including MCF-7 (Santen et al., 2004a; Martin et al., 
2003; Jensen et al., 2003). For example, the model from Santen’s group was 
achieved by use of phenol-red-free medium containing charcoal-stripped serum, 
where the oestradiol concentration is reduced to 10'13 M. Following a growth 
inhibitory phase, the long-term oestrogen deprived (LTED) cells acquired resistance 
and resumed substantial proliferation. A unifying feature of these in vitro  models 
appears to be a retained mitogenic role for the oestrogen receptor. Such models 
commonly express increased ER and are growth sensitive to the pure anti-oestrogen 
faslodex. Long-term oestrogen deprivation has also been associated with the 
development of hypersensitivity to extremely low residual steroid hormone levels, 
which appear sufficient to support tumour cell growth in vitro and in vivo (Santen et 
al., 2004a). Thus, in such cells a 4-log lower concentration of oestradiol (1 O'14 M) has 
been reported to be able to stimulate the growth of the resistant cells in comparison 
with the parental MCF-7 cell line. In the Santen model, the aromatase enzyme is
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increased in response to oestrogen deprivation in parallel with the acquisition of 
oestrogen hypersensitivity (Yue et al., 2001; 2003), however this may not occur in 
invasive breast cancer and clinical endocrine resistance (de Jong et al., 2003). 
Interestingly, Fuqua et al., (2000) have demonstrated that an ERa mutation 
(Lys303Arg) can enable increased co-activator recruitment to the receptor, conferring 
hypersensitivity in the presence of reduced oestrogens. Once again the significance 
of this to clinical breast cancer is unknown.
However, a potentially key mitogenic contribution to resistance to oestrogen 
deprivation, as well as adaptive hypersensitivity, is increased growth factor signalling 
(Song et al., 2002; Santen et al., 2004a), mirrored by supportive evidence arising 
from other forms of anti-hormone resistance, notably anti-oestrogen resistant clinical 
disease and oestrogen receptor negative states, as well as acquired anti-oestrogen 
resistant models (Knowlden et al., 2003; Nicholson et al., 2004a). IGF-1R, HER2 
and downstream activation of MAPK and PI3K/AKT signalling have been implicated 
in the acquisition of resistance to oestrogen deprivation (Santen et al., 2004a; Martin 
et al., 2003) and anti-oestrogens (Nicholson and Gee, 2000; Hutcheson et al., 2003; 
Knowlden et al., 2003a). Long-term oestrogen deprived (LTED) cells from the study 
of Martin et al. (2003) revealed elevated MAPK activity that was suggested to be due 
to enhanced HER2 expression. These LTED cells also express elevated levels of 
IGF-1R and were sensitive to pharmacological inhibition of PI3K. In the Santen et 
al. (2004a) LTED model, MAPK is again up-regulated and there is also enhanced 
activation of AKT, p70 S6 Kinase and 4EBP-1 (all components of the PI3K 
pathway). In total these data suggest anti-growth factor therapies could find a clinical 
role in the treatment of resistance to oestrogen deprivation. However, there remains 
much to learn about the biology of this resistant state. Indeed, many of the models of 
oestrogen deprivation employed to date have been developed in the presence of serum 
growth factors, with in some cases further insulin, BSA and/or transferrin 
supplementation. It is thus possible that the availability of exogenous growth factors 
in these models may force an acquired resistance mechanism involving growth factor 
pathways and promote oestrogen hypersensitivity.
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1.5 AIM S AND OBJECTIVES
To broaden the understanding of potential mechanisms contributing to oestrogen 
deprived resistant cell growth, the Tenovus Centre for Cancer Research has created a 
unique in vitro model system in which ER+ endocrine responsive breast cancer MCF- 
7 cells are cultured under severe oestrogen and growth factor deprived conditions to 
create the resistant MCF-7X sub-line. The MCF-7X model represents an autocrine 
model not subject to the selective pressures of the previously reported in vitro models 
of long-term oestrogen deprivation (i.e. growth factor/serum supplementation).
The aims of the thesis centre around this MCF-7X model and are as follows:
> To determine whether resistance can still arise under the severe deprivation 
conditions and to characterise its associated cellular features.
> To determine if oestrogen receptor signalling still contributes to growth.
> To determine if this resistant phenotype has gained oestrogen hypersensitivity.
> To determine whether there is evidence for autocrine growth factor signalling 
pathways contributing to growth via i) receptor/ligands ii) intracellular kinases.
> To determine whether there is cross-talk between such signalling and the 
oestrogen receptor.
> To determine whether the identified growth mechanisms can be specifically 
targeted resulting in potential treatment strategies for resistance to oestrogen 
deprivation. Also to determine the phenotype of any resultant resistance, and to 
determine and evaluate intelligent combination treatments to prevent this state.
38
CHAPTER 2
OOMATERIALS AND METHODS oo
CHAPTER 2 MATERIALS AND METHODS
11 MATERIALS
.....™  ......... Product Supplier
Cell Culture Plastic T-Flasks: 25, 75 cm2 
Dishes: 35, 60, 100, 150 mm 
Plates: 12, 24 well
25 ml universal containers, 15 and 
50 ml Falcon tubes, 5 ml bijou 
tubes, pipettes (25 ml, 10 ml, 5 ml), 
tips (5 ml, 1 ml, 200 pi, 10 pi)
Nunc- Gibco Invitrogen 
Corporation 
Paisley, UK
Cell Culture Chemicals PD98059 Alexis Corporation 
Nottingham, UK
7a-[9(4,4,5,5,5
pentafluoropentylsulfinyl)nonyl]- 
oestra-1,3,5( 10)-triene-3,17P-diol 
(Faslodex, ICI 182,780, 
‘Fulvestrant’),
(4-3-chloro-4-fluoroanilino)-7-
methoxy-6-(3-
morpholinopropoxyquinazoline) 
(Iressa, ZD 1839, ‘Gefitinib’)
Astra-Zeneca 
Pharmaceuticals 
Cheshire, UK
Phenol-red free DCCM Biological Industries Ltd. 
Israel
Phenol-red RPMI 1640 medium, 
Phenol-red-free RPMI 1640 
medium, L-glutamine,
Penic i 11 in/streptomycin, 
Gentamycin, Fungizone, Dulbecco’s 
phosphate buffered saline (PBS), 
DCCM, Lipofectin® Reagent, 
Trypsin
Gibco Invitrogen 
Corporation 
Paisley, UK
SU6656, Vascular endothelial 
growth factor 121 (VEGF)
Merck Biosciences Ltd. 
Nottingham, UK
ADW742 Novartis
Basal, Switzerland
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Fibroblast growth factor (FGF)- 
acidic/ basic/ 7
R&D Systems 
Minnesota, USA
Herceptin (Trastuzumab) Roche Diagnostics 
Mannheim, Germany
17-(3 oestradiol (E2), 4-hydroxy 
tamoxifen, Amphiregulin, apo- 
Transferrin, Bis-indoylmaleimidine 
(Bis), Dimethyl sulphoxide 
(DMSO), Epidermal growth factor 
(EGF), Fetal Calf Serum (FCS), 
Glutaraldehyde, Heregulin cc/p, 
Insulin-like growth factor (IGF)-1/ 
II, LY294002 hydrochloride, 
Platelet derived growth factor 
(PDGF), Transforming growth 
Factor (TGF)- a/p, Wortmannin
Sigma-Aldrich 
Dorset, UK
Table 2.2 Product and supplier list for assays and procedures
Product Supplier
Anti-mouse horse-radish peroxidase 
(HRP)-linked antibody, Anti-rabbit 
HRP-linked antibody, Rainbow 
Marker (10-250 kDa), Random 
Hexamers- pd(N)6 dNTP Set 
(lOOmM solutions)
Amersham Biosciences 
UK Ltd.
Buckinghamshire, UK
Super Sensitive Concentrated 
Detection System (Mouse)
Biogenex 
California, USA
BIOTAQ® DNA Polymerase, 
HyperLadder IV
Bioline Ltd. 
London, UK
DC Protein Assay kit, Tris- 
Hydrochloride (HC1) pH 8.8, Tris- 
HC1 pH 6.8, Thin-wall PCR tubes
BioRad Laboratories 
Hemel Hempsted, UK
Rabbit polyclonal antibody specific 
for: total Src, phospho-Src (Y418)
BioSource International 
Inc.
California, USA
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Rabbit polyclonal antibody specific 
for: total p44/42 (ERK1/2) MAP 
kinase, phospho-p44/42 (ERK1/2) 
MAP kinase (Thr202/Tyr204), 
phospho- PKC5 (Thr505), phospho- 
PDK-1 (Ser241), total AKT, 
phospho-AKT (Ser473)
Mouse monoclonal antibody specific 
for: phospho-ER (Seri 18, 16J4)
Cell Signalling 
Technology Inc. 
Massachusetts, USA
Phosphorylated EGFR (Tyrl 173) 
mouse antibody
Chemicon Europe Ltd. 
Hampshire, UK
3,3’- diamoniobenzidine 
tetrahydrochloride (EnVision DAB), 
EnVision Mouse and Rabbit, Goat 
anti-mouse antibody (GAM), Mouse 
monoclonal ERa (ID5) antibody, 
Mouse peroxidase anti-peroxidase 
(PAP), Normal goat serum (NGS), 
Mouse monoclonal PgR (636) 
antibody
DAKO Ltd. 
Ely, UK
Acetone, Cylindrical test tubes (12 x 
75mm, 4 ml), Cell Scraper, Ethanol, 
Formaldehyde, Finntip Stepper (5.0 
ml), Magnesium Chloride, Methanol, 
Whatman Filter paper (grade 3,4), 
Transwell® Permeable Supports (6.5 
mm, 8.0 pm pore size), Xylene
Fisher Scientific 
Leicestershire, UK
Autoradiography Film Genetic Research 
Instrumentation 
Essex, UK
Normal human serum (NHS) Golden West Biologicals 
Inc.
California, USA
Rabbit polyclonal antibody specific 
for: total EGFR(1005)-G
Insight Biotechnology 
Wembley, UK
42
CHAPTER 2 MATERIALS AND METHODS
Alexa Flour 488-conjugated anti­
mouse antibody, Custom Primers, M- 
MLV Reverse Transcriptase, Texas 
Red -X phalloidin
Invitrogen 
Paisley, UK
Custom Primers MWG Biotechnology 
London, UK
Rabbit polyclonal antibody specific 
for: total AKT, phospho-AKT 
(Thr308)
New England Biolabs 
Ltd.
Hitchin, Herts.
Polyclonal pS2 antibody, 6F11 ER 
antibody
Novacastra Labs. 
Vision Biosystems 
Newcastle, UK
0.2 pm Sterile Vacuum Cap Filter Pal Corporation 
Lutterworth, UK
SuperSignal® West Femto, Dura, 
Pico Antibody Detection
Pierce (Perbio) 
Cheshire, UK
Luciferase Assay System with 
Reporter Lysis Buffer, MMLV, 
Recombinant RNasin® Ribonuclease 
Inhibitor, TAQ DNA Polymerase
Promega UK Ltd. 
Southampton, UK
Ehrlich Haematoxylin (10%), Eosin 
(1%)
Raymond A Lamb 
East Sussex, UK
Western Blocking Reagent Roche Diagnostics 
Mannheim, Germany
c-Fos (4) sc-52 g, rabbit polyclonal 
IGF-1R antibody N-20
Santa Cruz 
Biotechnology 
California, USA
Protran BA 85 Nitrocellulose 
membrane (0.45pm)
Schleicher and Schuell 
Dassel, Germany
Acrylamide 30%, Agar, Aprotinin, 
Bovine serum albumin (BSA), 5- 
Bromo,4-chloro,3-indolyl |3- 
galactopyranoside (X-gal), 
Bromophenol Blue, Chloroform, 
Dextran T-70, Dithiothreitol (DTT), 
Ethylenediamine tetra-acetic acid 
(EDTA), Ethylene glycol-bis (2-
Sigma-Aldrich 
Dorset, UK
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aminoethy lether)-N,N,N ’N ’ -tetra- 
acetic acid (EGTA), Gelatine 2%, 
Glycerol, Glycine, H20  Sterile, 
Isopropanol, Leupeptin, Macro­
disposable cuvettes (4 ml), Methyl 
Green, Paraplast Embedding Media, 
Phenol, Phenylarsine, 
Phenylmethylsulfonyl Fluoride 
(PMSF), Polaroid Black and White 
Print Film (Type 667), Potassium 
Ferricyanide, Potassium 
Ferrocyanide, Saponin, Sodium 
Chloride, Sodium Dodecyl Sulphate 
(SDS), Sodium Fluoride, Sodium 
Molybdate, Sodium Orthovanadate, 
Temed, Tri-reagent®
Triton X-100, Trizma Base, Trizma 
HC1
Rabbit polyclonal antibody specific 
for: phospho- ErbB2/HER2 (Y1248)
Upstate Biotechnology 
Buckingham, UK
Vectashield® Mounting Medium w/ 
DAPI
Vector Laboratories 
California, USA
2.2 CELL CULTURE
2.2.1 Routine Maintenance o f MCE- 7 Cells
The ER positive endocrine responsive MCF-7 human breast cancer cell line was 
routinely maintained in phenol-red RPMI medium supplemented with 5% (v/v) fetal 
calf serum (FCS), penicillin-streptomycin (100 U/ml) and fungizone (2.5 jug/ml). 
The cells were cultured as a monolayer in sterile T-75 cm2 culture flasks at 37°C in a 
humidified 5% CO2 atmosphere. Basal culture medium was replenished every 3-4 
days. Passaging (sub-culturing) occurred at approximately 80-90% confluency. 
Culture medium was removed, cells were trypsinised and incubated at 37°C for 3-5 
minutes. The detached cells were transferred to a sterile 25 ml universal container, 
while the remaining cells in the flask were washed with basal medium and transferred 
to the universal container. Cells were then centrifuged for 5 minutes at 1000 rpm
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(168 x g). The resultant cell pellet was re-suspended and seeded into new sterile T-75 
cm2 culture flasks at split ratios of 1:10 and 1:20. Passages used for experimentation 
were between 12-26 and in-house mycoplasma tests were performed every 6  months 
by the cell culture personnel.
2.2.2 Routine Maintenance o f MCF- 7X Cells
The severely oestrogen and growth factor deprived MCF-7X sub-line was established 
within the Tenovus Centre for Cancer Research from the parental MCF-7 cell line. 
This resistance model system evolved after 4 months of continuous culture in phenol- 
red-free RPMI medium containing 5% (v/v) heat-treated (65°C for 40 min) charcoal- 
stripped FCS (XFCS), penicillin-streptomycin (100 U/ml), fungizone (2.5 pg/ml) and 
L-glutamine (400 mM). This basal culture medium was replenished every 3-4 days 
and passaging occurred at approximately 80-90% confluency as above (split ratios of 
1:10 and 1:20). Passages used for experimentation were between 44-98 (15-28 
months), and in-house mycoplasma tests were performed every 6  months by the cell 
culture personnel.
2.2.3 Dose Response Assays
Dose response assays were set up with two different objectives, i) to determine the 
optimal concentration of a test compound to be used and ii) to determine if there was 
a shift or alteration in sensitivity of the breast cancer cells within a dose range. The 
hormone sensitive MCF-7 and multiple in house anti-hormonal resistant (MCF-7X, 
TAM-R, FAS-R, and TAM/TKI-R, see Appendix) cell lines were utilised when new 
compounds were under investigation. Cells were seeded into 24-well plates (~4 x 104 
cells/well) and allowed to adhere for 24 hours. The treatments were added in 
triplicate at each dose selected (see Table 2.3), replenished at day 3-4 and trypsin 
dispersed for Coulter (Multisizer II) whole cell counting on day 7 (experiments were 
performed in triplicate). The wide range of treatments and doses used are given in 
Table 2.3.
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Table 2.3 Compounds and cell lines utilised for dose response assays
Compound Cell Lines Carrier Dose Range
e2 MCF-7
MCF-7X
Ethanol 1015 M, 10'14 M, 10’13 M, 10' 12 M, 
10’11 M, 10’10 M, 10'9 M, 10'8 M, 
10’7 M, 10’6 M, 10‘5M
Faslodex MCF-7
MCF-7X
Ethanol 10' 13 M, 10'12M, 10'u M, 10'1oM, 
10'9 M, 10'8 M, 10‘7M
Transferrin MCF-7
MCF-7X
h2o 0.01 pM, 0.05 pM, 0.1 pM, 0.5 pM, 
1.0 fiM, 5.0 pM, 10.0 pM
Faslodex + Transferrin 
(4 pg/ml)
MCF-7
MCF-7X
Ethanol 10' 13 M, 10’12 M, 10' 11 M, 10' 10 M, 
10'9 M, 10'8 M, 10’7M
PD98059 MCF-7
MCF-7X
DMSO 25 pM, 50 pM
2.2.4 Growth Stimulation Assays
The Parental MCF-7 and MCF-7X cells in log-phase growth were dispersed by 
trypsinisation, re-suspended in experimental medium (see Appendix) and seeded into 
24-well plates (~4 x 104 cells/well). The cells were allowed 24 hours to adhere to the 
plastic before the following treatments were added (in triplicate wells):
> Control (containing carrier ethanol, > aFGF, lOng/ml
DMSO or H20) > bFGF, 10 ng/ml
> 17-P Oestradiol (E2), 1(T9M > FGF7, 10 ng/ml
> EGF, 10 ng/ml > IGF-I, 10 ng/ml
> TGF a, 10 ng/ml > IGF-II, 10 ng/ml
> Amphiregulin, 10 ng/ml ^  PDGF, 10 ng/ml
> Heregulin a, 10 ng/ml ^  VEGF, 10 ng/ml
> Heregulin p, 10 ng/ml ** Transferrin, 4 ng/ml
The experimental medium containing the various treatments was replenished every' 3- 
4 days. The cell growth was measured by trypsin dispersion followed by Coulter 
whole cell counting on day 7 (experiments were performed in triplicate).
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2.2.5 Growth Inhibition Assays
The parental MCF-7 and MCF-7X cells in log-phase growth were dispersed by 
trypsinisation, re-suspended in experimental medium and seeded into 24-well plates 
(~4 x 104 cells/well). The cells were allowed 24 hours to adhere to the plastic before 
the following treatments were added (in triplicate wells):
> Control (containing carrier ethanol, > ADW742, 1 pM
DMSO or H20) * > SU6656, 1 pM
> Faslodex (FAS), 1 O'7 M * > LY294002 (LY), 5 pM *
> Tamoxifen, 1 O'7 M > Wortmannin (Wortm), 1 pM
> Gefitinib, 1 pM pD 9 8 0 5 9  (PDy 25  pM *
> Herceptin, 100 nM > Bis? 0 5
> Gefitinib/ Herceptin, lpM/lOOnM * , , ~ r ,v ^ * +/- Transferrin, 4 pg/ml
The experimental medium containing the various treatments was replenished every 3- 
4 days. The cell growth was measured by trypsin dispersion followed by Coulter 
whole cell counting on day 7.
2.2.6 Growth Curve Assays
MCF-7 and MCF-7X cells in log-phase growth were dispersed by trypsin and re­
suspended in experimental medium and seeded into 24-well plates (~4 x 104 
cells/well). The cells were allowed 24 hours to adhere to the plastic before the 
following treatments were added (in triplicate wells):
> Control (containing carrier ethanol, > FAS/LY, 10'7 M/ 5 pM
DMSO or H20) * > FAS/Wortm, 10’7 M/ 1 pM
> E2, 10’9 M > LY/PD, 5 pM/ 25 pM
> Faslodex, 10'7 M * > Wortm/PD? j pM/25 pM
> LY294002,5 pM * ^  FAS/LY/PD,
> Wortmannin, 1 pM 10-7 M/ 5 ^  25
> PD98059,25 pM * > FAS/Wortm/PD,
* +/- Transferrin, 4 pg/ml 10-? M/ 1 pM/ 25 pM
The experimental medium containing the various treatments was replenished every 3- 
4 days. The cell growth was measured by trypsin dispersion followed by Coulter 
whole cell counting every 24 hours for 15 days.
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2.2.7 Development of MCF- 7XDrug-Resistant Sub-lines
The MCF-7X cell line (passage 74) was trypsin dispersed and seeded into 8  T-25 cm2 
flasks and grown to 70% confluency. The following treatments were added to each 
individual flask for long term culture:
> Control (basal medium) > FAS/LY, 1 O'7 M/ 5 pM
> Faslodex, 10'7 M > LY/PD, 5 pM/ 25 pM
> LY294002, 5 pM > FAS/LY/PD, 10'7 M/ 5 pM/ 25 pM
> PD98059, 25 pM
Cell growth was closely monitored and medium was replenished every 3-4 days. 
When increased tumour cell growth became evident, the cells were trypsinised, re­
suspended in medium and seeded into sterile T-25 cm2 flasks at a split ratio of 1:2. 
As tumour cell growth proceeded more rapidly, the cells were passaged at a split ratio 
of 1:10, 1:5 and 1:2. In general the T-25 cm2 1:5 flask was chosen for passaging, 
while the 1:10 and 1:2 flasks were kept for observation. Once the cells were in rapid 
log-phase growth (e.g. resistant to the drugs), cells were seeded into new sterile T-75 
cm2 flasks and passaged at a 1:10 split ratio. Resistant cell lines were derived from 
the MCF-7X cells treated with faslodex [X(FAS)], LY294002 [X(LY)], PD98059 
[X(PD)], faslodex/LY294002 combined [X(FAS/LY)], and LY294002/PD98059 
combined [X(LY/PD)].
2.3 RNA ANALYSIS
2.3.1 Total RNA Isolation
Cells were grown as monolayers on 100 mm culture dishes (-2.5 x 104 cells/dish 
initial seeding density) to 80% confluency. Table 2.4 describes the cell lines and 
treatments used prior to RNA isolation. Cell medium was replenished on day 3 or 4 
and on day 7 cells were lysed with Tri-Reagent® (Sigma-Aldrich). After 5 minutes 
at room temperature, phase separation was achieved by adding 0 .2  ml of chloroform 
per ml of TRI-Reagent®. Following a 10 minute incubation (at room temperature), 
the resulting mixture was centrifuged at 12,000 x g for 15 minutes at 4°C. The RNA 
remained in the aqueous phase (upper phase) which was transferred to a new tube for 
RNA precipitation. The aqueous phase was mixed with 0.5 ml of isopropanol per ml 
of TRI-Reagent® used, incubated at room temperature for 5 minutes and centrifuged 
at 12,000 x g for 10 minutes at 4°C. The supernatant was removed and the RNA
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precipitate was washed with 1 ml of 75% ethanol. Following gentle inverting of the 
tube, the mixture was centrifuged at 7,500 x g for 5 minutes at 4°C. After removal of 
the 75% ethanol wash, the RNA was dissolved in sterile water (50 pi) and stored at 
-80°C.
Table 2.4 Cell lines and treatments utilised for RNA analysis
Cell Line Medium Treatment
MCF-7
MCF-7X
wRPMI + 5% SFCS 
wRPMI + 5%XFCS
Control (ethanol, DMSO)*
Faslodex, 10'7 M*
LY294002, 5 pM*
PD98059, 25 pM*
FAS/LY, 10'7 M/5pM*
LY/PD, 5 pM/ 25 pM*
FAS/LY/PD, 10'7 M/ 5 pM/ 25 pM* 
* +/- Transferrin, 4 pg/ml
X(FAS) wRPMI + 5% XFCS + Faslodex 
(10'7 M)
N/A
X(LY) wRPMI + 5% XFCS + LY294002 
(5 pM)
N/A
X(PD) wRPMI + 5% XFCS + PD98059 
(25 pM)
N/A
X(FAS/LY) wRPMI + 5% XFCS + FAS/LY 
(10‘7 Ml 5 pM)
N/A
X(LY/PD) wRPMI + 5% XFCS + LY/PD 
(5 pM/ 25 pM)
N/A
2.3.2 Measurement o f Total RNA Concentration and Integrity
The concentration of the RNA isolated from each sample was measured using a 
spectrophotometer (CECIL 2000 series) at A 26o/28o, using a 1/100 dilution of RNA in 
sterile H20  using the formula 40 pg RNA @ 260 nm = optical density of 1.000. The 
RNA integrity was validated by electrophorating 1 pg of RNA (loading buffer, see 
Appendix) through a 2% agarose gel in IX tris acetate (TAE, see Appendix) buffer 
(80 volts for 35 minutes).
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Figure 2.1 Day 7 Basal MCF-7XRNA Integrity Gel (three separate RNA samples)
2.3.3 Reverse Transcription o f  RNA
The RNA was reverse transcribed into matching or complementary DNA (cDNA). 
First, 1 pg of RNA in a total volume of 7.5 pi of sterile H20  was added to 11 pi of 
RT master mix (see Appendix), this solution was then denatured at 95°C for 5 
minutes in a BioRad ICycler PCR machine and cooled immediately to 4°C. While on 
ice the reverse transcriptase enzyme M-MLV (Moloney Murine Leukemia Virus, 200 
U/pl) and the Recombinant RNasin® ribonuclease inhibitor (40 U/pl) was added to 
each tube of RNA being transcribed. The tubes were then placed in the PCR machine 
and reverse transcribed using the following parameters:
Annealing Time: 10 minutes @ 22°C 
RT Extension Time: 42 minutes @ 42°C 
Denaturing Time: 5 minutes @ 95°C 
To verity the reverse transcription of the RNA samples, an /?-Actin polymerase chain 
reaction (PCR) was performed. The resulting cDNA was stored at -20°C until 
further PCR assays were carried out.
Figure 2.2 Day 7 Basal MCF-7X Actin (204 bp) RT-PCR reaction at 25 cycles (three 
separate samples)
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2.3.4 Polymerase Chain Reaction (PCR)
A PCR reaction master mix (see Appendix), including the target primers, was 
prepared based on the number of samples that were being run. The mix was aliquoted 
into the appropriate number of sterile tubes and 0.5 pi of sample cDNA was added to 
each (a negative control contained master mix and sterile H20  only). The first cycle 
consists of heat denaturation to separate the double stranded DNA, annealing of the 
primers to their complementary sequences at a lower temperature, and extension of 
the annealed primers with stable DNA polymerase:
Denaturing Time: 2 minutes @ 95°C 
Annealing Time: 1 minute @ 55°C
Extension and Formation of PCR Product: 10 minutes @ 72°C 
This is followed by repeat cycles of heat denaturing, annealing and extension so that 
one cycle doubles the amount of DNA synthesized by the previous one. The 
annealing temperature* and cycle number** were optimised for each set of primers. 
Denaturing Time: 30 seconds @ 94°C 
Annealing Time: 1 minute @ 55°C* I  x n cycles**
Primer Extension: 1 minute @ 72°C
J
The final cycle consists of:
Denaturing Time: 1 minute @ 94°C 
Annealing Time: 1 minute @ 55°C 
Final Extension Time: 10 minutes @ 60°C 
A complete list of primer sequences and PCR parameters is presented in Table 2.5. 
The primer design was carried out in-house using Basic Local Alignment Search Tool 
(BLAST, http://www.ncbi.nlm.nih.gov/BLAST/). Each primer set was optimised 
against multiple cell lines, a series of cycle numbers were evaluated, and annealing 
temperature was varied, to ensure quality of the final product. Primer sets that 
required 29 cycles or less were run as co-amplifications with (3-Actin (to enable semi­
quantitation), in all other cases samples were subject to PCR once with /?-Actin (@ 25 
cycles) and again with the primer set under investigation. The combination (1:3 
volume ratio loaded) of the two products and a ladder marker (HyperLadder IV, 
1000-100 bp) was then run on a 2% agarose gel containing ethidium bromide (in TAE 
buffer).
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Table 2.5 Target primer sequences anc PCR parameters
Target Forward Sequence Reverse Sequence Cycles/
Annealing
Temperature
Size
(bp)
/?-Actin 5’GGAGCAATGATCTT
GATCTT-3’
5 ’ CCTTCCTGGGC ATG 
GAGTCCT-3’
25/55°C 204
AKT-1 5’ATGAGCGACGTGG
CTATTGTGAGG-3’
5’GAGGCCGTCAGCC 
AC AGTCTGGATG-3 ’
29/ 55°C 329
AK.T-2 5’ATGAATGAGGTGT
CTGTCATCAAAGAAG
GC-3’
5’TGCTTGAGGCTGTT 
GGCG ACC-3’
29/ 55°C 314
c-fos 5’GAGATTGCCAACCT
GCTGAA-3’
5 ’ AGACGAAGGAAGA 
CGTGTAA-3’
32/55°C 483
c-myc 5’CCAAGCTCGTCTCA 
GAG A AG-3’
5’CAGCAGGATAGTC
CTTCCGA-3’
29/ 55°C 549
c-src 5’CAGTGTCTGACTTC 
G AC A AC-3’
5’CTCCTCTGAAACCA
CAGCAT-3’
30/ 55°C 433
ER a 5 ’ GGAGACATGAGAG 
CTGCCAAC-3’
5’CCAGCAGCATGTC
GAAGATC-3’
25/55°C 432
HER2 5’CCTCTGACGTCCAT
CATCTC-3’
5’ATCTTCTGCTGCCG
TCGCTT-3’
35/55°C 98
IGF-1R 5’GAGCAGATGACAT
TCCTGGG-3’
5’CCTGGACATAGAA 
G A AC AC AG-3’
26/ 55°C 287
P21cipl/W3tl 5 ’ GTCTCAGTGTTGAG 
CCTTTTCC-3’
5’TCCGCTGCTAATCA
AAGTGC-3’
30/ 55°C 460
PKCa 5’AGTGCACCATGGT
AGAAAAGC-3’
5’TAGCTCGTCTTCAT 
CTTC ACC-3’
34/ 55°C 494
PKC5 5’CACCATCTTCCAGA
AAGAACG-3’
5’CTTGCCATAGGTCC
CGTTGTTG-3’
30/ 55°C 351
pS2 5’CATGGAGAACAAG
GTGATCTG-3’
5’CAGAAGCGTGTCT
GAGGTGTC-3’
25/55°C 336
Tf 5’CTGCACCAGGCTCT
ATCCTAG-3’
5’GTACCTAACTCTGC
ACAGGTG-3’
32/55°C 316
TfR 5 ’ TCTGCT ATGGG ACT 
ATTGCTG-3’
5’CTGTTGCAGCCTTA
CTATACG-3’
25/ 55°C 484
The PCR products were run on 2% agarose (TAE buffer) gels in the presence of 
ethidium bromide (5 mg/ml stock) at 80 volts for 35 minutes. The gel was then 
exposed to UV light to visualise bands and photographed. Using a BioRad GS-690 
Imaging Densitometer each PCR photographed result was scanned.
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2.4 TRANSIENT TRANSFECTION ASSAYS
2.4.1 Cell Culture and Transfection (18 hour)
The parental MCF-7 and MCF-7X cells in log-phase growth were dispersed by 
trypsinisation, re-suspended in experimental medium and seeded into 1 2 -well plates 
(-2.5 x 105 cells/well). After 24 hours, the following solutions were prepared for 
each transfection:
A) 3 pi of Lipofectin® Reagent (Gibco Invitrogen Corp.) plus 60 pi serum 
free/phenol-red free DCCM medium containing L-glutamine (400 mM) 
per well.
B) 1.1 fig plasmid DNA, consisting of 400 ng of the reporter construct of 
interest* or control construct plus 700 ng carrier plasmid DNA in 60 pi 
serum free/phenol-red free DCCM per well.
* of either ERE or AP-1 luciferase
Oestrogen Response Element (ERE)-firefly luciferase reporter plasmid. 
ERE is a dual reporter construct therefore the addition of a third 
construct, renilla luciferase reporter plasmid (150 ng) was included. The 
levels of carrier were adjusted to 550 ng so that the overall DNA load 
was maintained, 
or
Activating protein-1 luciferase reporter plasmid.
C) 5 pi DMSO diluted in 380 pi serum free/phenol-red free DCCM 
medium containing L-glutamine (400 mM) per well.
Solution A and B were left to equilibrate at 37°C. After 45 minutes, solution A and B 
were combined, gently mixed and returned to 37°C for a further 15 minutes. The A/B 
solution was then combined with C to produce the final transfection mixture. The 
cell culture medium was removed and the cell monolayers washed once with serum 
free/phenol-red free DCCM containing L-glutamine. The appropriate transfection 
mixture was added to each well and the plate was returned to incubate at 37°C for 6  
hours. The transfection medium was then removed and the wells were washed with 
experimental medium before treatments (in triplicate) were added for 18 hours. Table
2.6 has the complete list of treatments applied to each ERE and AP-1 transient 
transfection assay.
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Table 2.6 Transient transfection assays and treatment list
Reporter Construct
ERE + Renilla AP-1 /?-Galactosidase
The ERE construct is an ERE-tk-luc 
(firefly) reporter. Non-specific 
promoter transactivation (i.e. 
directly on the thymidine kinase 
promoter tk) is controlled by co­
transfection into the same well with 
a non-ERE bearing reporter tk-luc 
(renilla). Thus levels of non­
specific activation of this reporter 
are used to normalize the specific 
signal of ERE- driven luciferase 
production.
AP-1 system differs in that 
transfection of parallel wells is 
performed using two constructs, 
which produce firefly luciferase 
a) AP-l-pTal-luc, which 
represents total transactivation of 
the reporter, b) pTal-luc, which 
represents only the promoter 
driven activity. The 
normalization of b) against a) 
gives the specific activity.
Treatment
Control (ethanol, DMSO) * Control (ethanol, DMSO) N/A
E2 Dose Response, 10‘15 M- 10'8 M E2, 10'9M
E2, 10'9M Faslodex, 10'7 M
Faslodex, 10'7 M * LY294002, 5 pM
LY294002, 5 pM * PD98059,25 pM
PD98059, 25 pM * FAS/LY, 10'7 M/5 pM
FAS/LY, 1 O’7 M/ 5 pM * LY/PD, 5 pM/ 25 pM
LY/PD, 5 pM/ 25 pM FAS/LY/PD, 10‘7 M/ 5 pM/
FAS/LY/PD, 10'7 M/ 5 pM/ 25 pM * 25pM
2.4.2 Preparation o f Cell Lysates
Following 18 hours of treatment the medium was removed and the cells were washed 
with 1 ml PBS. The PBS was replaced with 200 pi of appropriate lysis buffer, IX 
Passive Lysis Buffer (Promega, diluted from 5X stock with sterile H20 )  for dual 
ERE- firefly/Ren ilia luciferase assay, or IX Reporter Lysis Buffer (Promega, diluted 
from 5X stock with sterile H20 ) for the AP-1 luciferase assay. The cells were gently 
scraped from the wells and transferred into 1.5 ml tubes, placed on ice (wet) until all 
tubes were collected. They were then stored at -80°C in order to perform a single 
freeze-thaw for complete lysis.
2.4.3 L uciferase Assay System
A dual-luciferase reporter assay kit (Promega UK Ltd.) was used to determine ERE- 
Renilla luciferase activity. To each sample luminometer tube 100 pi of assay reporter 
buffer was added, followed by the same volume of thawed sample lysate. This
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mixture was read over 10 seconds using a Lumat LB 9507 luminometer (GC+C 
Wallac, UK). The tube was then removed, 100 pi of Stop and Glo® (Promega UK 
Ltd.) reagent was added to terminate the first phase, ERE luciferase activity, and 
initiate the second phase of the assay, measurement of the renilla luciferase activity. 
The tube was then re-placed into the luminometer for the final reading. To calculate 
activity the renilla reading was subtracted from the ERE reading for each individual 
sample. In the case of the AP-1 assay only the first step was followed, as Stop and 
Glo® was not required for the one reading of AP-1 luciferase activity.
2.4.4 In-situ [3-Galactosidase Fixation, Staining and Quantitation
The /7-Galactosidase transfected wells (in triplicate) were washed with 1 ml PBS prior 
to a 15 minute 0.5% glutaraldehyde fixation (1 ml/well, room temperature). The 
fixation solution was removed, the wells washed with 1 ml PBS, replaced with 1 ml 
of X-gal staining solution (see Appendix) and placed in incubator overnight. The 
percentage of transfected cells (/^-Galactosidase positive stained) was used in the 
normalisation of each luciferase assay.
2.5 PROTEIN ANALYSIS: WESTERN BLOTTING
2.5.1 Cell Culture
Cells were seeded into 60 mm (~1 x 105 cells/dish) dishes and allowed to acclimatise 
for 24 hours. Monolayers were subsequently treated for 7 days with the agents that 
are listed in Table 2.7. Cell culture medium was replenished on day 3 or 4.
Table 2.7 Cell lines and treatments utilised for Western blotting
Cell Line Medium Treatment
MCF-7 wRPMI + 5%SFCS Control (ethanol, DMSO) 
Faslodex, 10*7 M 
LY294002, 5 pM 
PD98059, 25 pM 
FAS/LY, 10'7 M/ 5pM
MCF-7X wRPMI + 5%XFCS Control (ethanol, DMSO)
Faslodex, 10'7 M 
LY294002, 5 pM 
PD98059, 25 pM 
FAS/LY, 10'7 M/5pM 
LY/PD, 5 pM/ 25 pM 
FAS/LY/PD, 10'7 M/ 5 pM/ 25 pM
X(FAS) wRPMI + 5% XFCS + Faslodex 
(10’7 M)
N/A
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X(LY) wRPMI + 5% XFCS + LY294002 
(5 pM)
N/A
X(PD) wRPMI + 5% XFCS + PD98059 
(25 pM)
N/A
X(FAS/LY) wRPMI + 5% XFCS + FAS/LY 
(10‘7 M/5 pM)
N/A
X(LY/PD) wRPMI + 5% XFCS + LY/PD 
(5 pM/ 25 pM)
N/A
2.5.2 Preparation of Whole Cell Lysates
At day 7, dishes of cells were washed in PBS (x 3) followed by the addition of ice 
cold lysis buffer (see Appendix). The cells were scraped from the dishes, transferred 
to sterile 1.5 ml tubes and subject to 4°C centrifugation at 13,000 rpm (14,196 x g) 
for 15 minutes. The supernatant was removed and stored in aliquots of 50 and 100 pi 
at -20°C until required for Western blotting.
2.5.3 Protein Concentration Assay
Total protein concentrations were determined using the DC BioRad protein assay 
(BioRad Laboratories Ltd.). According to the suppliers’ recommendation, a standard 
curve was produced using the following dilutions of BSA (mg/ml) in lysis buffer in 
duplicate:
> 0  > 0.75
> 0.25 > 1.0
> 0.5 >  1.45
Protein samples were diluted 1:5 in lysis buffer to a volume of 50 pi (in duplicate). 
To each protein dilution 250 pi of reagent A (containing 20 pi reagent S/ 1 ml reagent
A) and 2 ml of reagent B was added (see Appendix for description of reagent A,S and
B). The samples were allowed to develop for 15 minutes before optical density was 
read at 750 nm on a spectrophotometer (CECIL 2000 series).
2.5.4 Sodium Dodecyl Sulphate (SDS)- PA GE
Electrophoresis was carried out using the Mini-Protein Slab II Electrophoresis Cell 
(BioRad Labs Ltd.,) and the apparatus was assembled to the manufacturers’ 
recommendations. The separating gel (see Appendix) was poured to reach a level just 
below the well-forming comb, and allowed to set for 10-20 minutes. A layer of 
distilled H2O was applied on top of the gel during this time to allow polymerization 
of the gel. The H20  was removed and the well-forming comb was inserted before the
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pouring of the stacking gel (see Appendix). Ready to use gels were then submerged 
in the electrophoresis tank containing IX running buffer (see Appendix) and the 
combs were removed. Protein samples from total cell lysates (20-40 pg) were mixed 
with 10 pi Laemmli sample loading buffer (see Appendix) containing 20 mM 
dithiothreitol (DTT) and heat denatured (100°C) for 10 minutes. Samples were 
loaded, including one sample of Rainbow Marker (5 pi, 10-250 kD) onto each gel, 
and electrophoresis was carried out at 200 volts for 45 minutes.
2.5.5 Western Blotting
Western blotting was carried out using the Trans-Blot Electrophoretic Transfer Cell 
(Bio-Rad). A nitrocellulose membrane (0.45 pm), Whatman filter paper (grade 3) 
and sponge pads were pre-soaked in transfer buffer (see Appendix). Once the 
electrophoresis was complete, the separating gel was briefly soaked in transfer buffer 
before it and the other components of the transfer cassette were loaded together. The 
cassette was placed into the transfer tank (containing transfer buffer and an ice block) 
and was subject to electroblotting for 1 hour at a constant voltage (100V). The 
nitrocellulose membrane was removed from the cassette and incubated in blocking 
solution for 1 hour at room temperature on a rocking platform. The membrane was 
then probed with primary specific antibodies for target proteins (see Table 2.8). 
Following the primary incubation the membrane was washed in Trizma Buffered 
Saline (TBS-T, see Appendix) ( 5 x 5  minutes) prior to the addition of the secondary 
antibody. The antibody concentration and incubation duration for each specific target 
is described in Table 2.8.
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Table 2.8 Western blotting antibody concentration and parameter list
Antibody Block Primary Antibody 
Concentration/ 
Duration
Secondary Antibody 
Concentration/ 
Duration
Film
Exposure
Time/
Detection
System
Total- ER Blocking
Reagent
1:2000 / O/N Anti-mouse 
1:10 ,0 0 0 / 1  hour
30 seconds/ 
Femto
p-ER 
(Seri 18)
Blocking
Reagent
1:10,000 / 4 hours Anti-mouse 
1:10,0 0 0 / 1 hour
2 0  seconds/ 
Femto
Total-
AKT
Blocking
Reagent
1:1,000 / 4 hours Anti-rabbit 
1:10,0 0 0 / 1 hour
5 minutes/ 
Dura
p-AKT
(Thr308)
Blocking
Reagent
1:1,000 / 4 hours Anti-rabbit 
1:10 ,0 0 0  / 1  hour
2.5 minutes/ 
Dura
Total- 
ERK 1/2
Blocking
Reagent
1:1,000 / 4 hours Anti-rabbit 
1:10,0 0 0 / 1 hour
2 minutes/ 
Femto
p-ERK
1/2
(Thr202/
Tyr204)
Blocking
Reagent
1:1,000 / 4 hours Anti-rabbit 
1:10,0 0 0 / 1  hour
4.5 minutes/ 
Dura
Total-
HER2
5% Marvel 
in TBS-T
1:1,000/O/N Anti-rabbit 
1:10,0 0 0 / 2  hours
10 seconds/ 
Dura
P-HER2
(Y1248)
5% Marvel 
in TBS-T
1:1,000/O/N Anti-rabbit 
1:10 ,0 0 0 / 2  hours
10 seconds/ 
Dura
Total-
PKC-5
Blocking
Reagent
1:1,000/O/N Anti-rabbit 
1:10,0 0 0 / 1  hour
30 seconds/ 
Dura
p-PKC-5
(Thr505)
5% Marvel 
in TBS-T
1:2,000/O/N Anti-rabbit 
1:10 ,0 0 0 / 1  hour
1 minute/ 
Dura
p-PDK-1
(Ser214)
Blocking
Reagent
1:4,000/O/N Anti-rabbit 
1:10,0 0 0 / 1 hour
2 0  seconds/ 1 
Femto
p-p70S6K
(Thr389)
Blocking
Reagent
1:1,000/O/N Anti-rabbit 
1:10 ,0 0 0 / 1  hour
30 seconds/ 
Femto
Total- Src Blocking
Reagent
1:1,000/O/N Anti-rabbit 
1:10 ,0 0 0 / 1 hour
30 seconds/ 
Dura
p-Src
(Y418)
Blocking
Reagent
1:2,000 / O/N Anti-rabbit 
1:10,0 0 0 / 1  hour
30 seconds/ 
Femto
Total-
EGFR
5% Marvel 
in TBS-T
1:1,000/O/N Anti-rabbit 
1:10 ,0 0 0  / 2 hour
5 minutes/ 
Dura
Total-
IGFR
Blocking
Reagent
1:2,000 / 3 hours Anti-rabbit 
1:10,0 0 0 / 1  hour
5 minutes/ 
Dura
/?-Actin Blocking
Reagent
1:10 ,0 0 0 /4  hour Anti-mouse 
1:10 ,0 0 0  / 1 hour
5 seconds/ 
Dura
2.5.6 Detection and A nalysis
The nitrocellulose membrane was washed in TBS-T ( 5 x 5  minutes) and placed into a 
plastic folder with a 1:1 dilution of chemiluminescent substrate (Super Signal West; 
Femto for strong signal enhancement, or Dura for moderate signal enhancement) for 
5 minutes. The membrane was then placed into a light proof X-ray cassette and 
exposed to autoradiography film for various time intervals. The film was then 
developed using an X-ray film processor (X-ograph Imagining Systems). Using a
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BioRad GS-690 Imaging Densitometer the results of each blot were scanned. Data 
was normalised against /?-Actin expression for each blot.
2.6 PROTEIN ANALYSIS: IMMUNOCYTOCHEMISTRY
2.6.1 Cell Culture
Cells in log-phase growth were subject to trypsin dispersion, re-suspended in 
experimental medium and seeded onto 3-aminopropyltriethoxysilane (APES) -coated 
glass coverslips ( ~ 8  x 104 cells /coverslip) in 35 mm culture dishes. The cells were 
allowed 24 hours to adhere to the coverslip before treatments were added (see Table 
2.9). Cell medium was replenished on day 3 or 4.
Table 2.9 Cell lines and treatments utilised for immunocytochemistry assays
Cell Line Medium T reatment
MCF-7 wRPMI + 5%SFCS Control (ethanol, DMSO) 
E2, 10'9M 
Faslodex, 10'7 M 
LY294002, 5 gM 
Wortmannin, 1 gM 
PD98059, 25 gM 
FAS/LY, 10'7 M/ 5gM 
AG 1024, 1 gM 
1GF-I, lOng/ml
MCF-7X wRPMI + 5%XFCS Control (ethanol, DMSO)
E2, 10’9M
E2/ Faslodex, 10'9 M/ 10‘7 M 
Faslodex, 10'7M 
LY294002, 5 gM 
Wortmannin, 1 gM 
PD98059, 25 gM 
FAS/LY, 10’7 M/5gM 
LY/PD, 5 gM/ 25 gM 
FAS/LY/PD, 10'7 M/ 5 gM/ 25 gM
TAM-R wRPMI + 5% SFCS + Tamoxifen 
(10'7 M)
Control (ethanol, DMSO) 
E2, 10'9M 
AG 1024, 1 gM 
IGF-I, lOng/ml
X(FAS) wRPMI + 5% XFCS + Faslodex 
(10'7 M)
N/A
X(LY) wRPMI + 5% XFCS + LY294002 
(5 gM)
N/A
X(PD) wRPMI + 5% XFCS + PD98059 
(25 gM)
N/A
X(FAS/LY) wRPMI + 5% XFCS + FAS/LY 
(10‘7 M/5 gM)
N/A
X(LY/PD) wRPMI + 5% XFCS + LY/PD 
(5 gM/ 25 gM)
N/A
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2.6.2 Coverslip Fixation
Optimal fixation immobilises the antigen, retains cellular structure while permitting 
antibody access to all cells and their cellular/sub-cellular compartments. Organic 
solvents such as alcohols and acetone remove lipids and dehydrate the cells, while 
precipitating protein architecture. Cross-linking reagents (such as paraformaldehyde) 
form intermolecular bridges, normally through a free amino acid groups, thus creating 
a network of linked antigens. These reagents preserve cell structure better than 
organic solvents, however may reduce the antigenicity of some cellular components 
and require a permeabilisation step to allow antibody access. Fixatives are selected 
based on the nature of the antigen being examined and on the properties of the 
antibody being used.
2.6.2.1 ERICA- (McClelland et aL, 1991)
Coverslips were removed from the 35 mm culture dishes and placed into a 
fixation rack. Coverslips were immersed into a 3.7% (v/v) formaldehyde (in 
phosphate buffered saline [PBS]) bath at room temperature for 15 minutes. 
They were then washed in a PBS bath at room temperature for 5 minutes, 
followed by 5 minutes in methanol (-10°C to -30°C) and 3 minutes in 
acetone (-10°C to -30°C). Finally coverslips were washed in PBS at room 
temperature for 5 minutes and then immersed in sucrose storage medium 
(SSM, see Appendix) and stored at -20°C.
2.6.2.2 Formal Saline (FS)-
Cell culture medium was removed from the 35 mm dishes and replaced with 
formal saline for 10 minutes. The formal saline (see Appendix) was removed 
and the coverslips were washed ( 2x5  minutes) in 70% ethanol followed by 2 
x 5 minute washes in PBS before storage at -20°C in sucrose storage 
medium.
2.6.23 Phenol Formal Saline (pFS)- (Knowlden et aL, 2005)
Cell culture medium was removed from the 35 mm dishes and replaced with 
phenol formal saline (see Appendix) for 10 minutes. The phenol formal 
saline was removed and the coverslips were washed in 70% ethanol ( 3 x 5
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minutes) followed by PBS washes ( 3 x 5  minutes) before storage at -20°C in 
sucrose storage medium.
2.6.2.4 Paraformaldehyde Vanadate (PFV)- (Britton et a t , 2006)
Cell culture medium was removed from the 35 mm culture dishes and 
replaced with 2% paraformaldehyde vanadate (see Appendix) for 20 minutes. 
The coverslips were subsequently washed with PBS ( 3 x 5  minutes) and 
stored in storage sucrose medium at -20°C.
2.6.2.5 Methanol Vanadate Acetone (MVA)- (Jones et aL, 2004)
Prior to fixation methanol and acetone baths were cooled to -10°C to -30°C. 
Cell culture medium was removed from the 35 mm culture dishes and 
replaced with methanol vanadate (see Appendix) for 5 minutes. The 
methanol vanadate was subsequently removed from the coverslips and 
replaced with methanol. At this time the coverslips were placed into a 
fixation rack, before being placed into an acetone bath for 5 minutes. The 
coverslips were then allowed to air dry for 30 minutes and stored dry at 
-80°C.
2.6.2.6 Acetone-
Coverslips were removed from the 35 mm culture dishes, placed into a 
fixation rack, then immersed in acetone (-10°C to -30°C) for 10 minutes. 
Coverslips were allowed to air dry for 30 minutes and stored dry at -80°C.
2.6.2.7 Chloroform Acetone (CA)-
Coverslips were removed from the 35 mm culture dishes and allowed to air 
dry for 2 hours before storing at -80°C. Prior to assay coverslips were 
immersed in a 1:1 chloroform/acetone solution at 4°C for 10 minutes. 
Coverslips were then allowed to air dry for 30 minutes before storing dry at 
-80°C.
2.6.2.8 Methanol Acetone (MA)-
Coverslips were removed from the 35 mm culture dishes, placed into a 
fixation rack and immersed into a methanol bath (-10°C to -30°C) for 5
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minutes. Immediately followed by an acetone bath (-10°C to -30°C) for 5 
minutes. Coverslips were then allowed to air dry for 30 minutes before 
storing at -80°C.
2.6.3 Immunocytochemistry
The following tables describe the immunocytochemistry assays according to which 
secondary detection system was utilised. Following two washes in PBS (5 minutes) 
and a blocking step the coverslips were incubated with a specific antibody. 
Coverslips were washed in PBS ( 3 x 3  minutes) followed by a PBS-T (phosphate 
buffered saline + 0.02% Tween 20) rinse before the addition of the secondary 
detection system. The coverslips were washed again in PBS ( 3 x 3  minutes) and 
again rinsed in PBS-T prior to the addition of the diaminobenzidine 
tetrahydrochloride and hydrogen peroxide (DAB) chromagen substrate. Tables 2.10 
to 2.13 describe the details of each assay performed, grouped according to the 
secondary detection system utilised.
Table 2.10 Assays utilising the DAKO EnVision® detection system
Antibody Fixation/
Block
Primary Antibody 
Concentration/ 
Duration
EnVision Detection 
Label Polymer HRP/ 
Duration
Chromagen
DAB
Duration
p-AKT
(Thr308)
ERICA/
PBS-T*
1:200 (PBS)/ 
120 min
Rabbit/ 60 min 10 min
p-ER 
(Seri 18)
PFV/
PBS-T
1:400 (PBS)/ 
O/N
Mouse/ 120 min 6 min
p-ER 
(Seri 67)
ERICA/
PBS-T
1:25 (PBS)/ 
O/N
Rabbit/120 min 10 min
p-IGFR
(Y1316)
PFV or 
MVA/ 
PBS-T
1:200 (PBS)/ 
O/N
Rabbit/ 120 min 8 min
p-MAPK
(Thr202/
Tyr204)
FS/
PBS-T
1:20 (PBS)/ 
60 min
Rabbit/ 60 min 10 min
p-PDK-1
(Ser214)
ERICA/
PBS-T
1:50 (5%BSA/PBS)/ 
O/N
Rabbit/ 60 min 10 min
p-PKC-6
(Thr505)
ERICA/
PBS-T
1:20 (PBS)/ 
O/N
Rabbit/ 120 min 8 min
pS2 ERICA/
PBS-T
1:500 (PBS)/ 
90 min
Rabbit/ 60 min 8 min
Total-
IGFR
pFS/
PBS-T
1:125 (PBS)/ 
O/N
Rabbit/ 120 min 6 min
* PBS-T, Phosphate buffered saline + 0.02 % Tween 20.
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Table 2.11 Assays utilising DAKO GAM/ 5AP detection system
I Antibody Fixation/
Block
Primary
Antibody
Concentration/
Duration
2° Goat 
anti-Mouse 
(Z0420) 
Cone/ 
Duration
3° Mouse 
PAP 
(P0850) 
Cone/ 
Duration
Chromagen
DAB
Duration
Total-ER
(ID5)
ERICA/ 
10% NGS* 
in PBS
1:100 (PBS)/ 
60 min
1:25 (PBS)/ 
30 min
1:250 (PBS)/ 
30 min
10 min
Total-ER
(6F11)
ERICA/
PBS-T
1:75 (PBS)/ 
90 min
1:25 (PBS)/ 
30 min
1:250 (PBS)/ 
30 min
10 min
p-EGFR 
(Tyrl 173)
MA/
PBS-T
1:5 (PBS)/ 
O/N
1:25 (PBS)/ 
30 min
1:250 (PBS)/ 
30 min
10 min
PgR
(636)
ERICA/ 
10% NGS* 
in PBS
1:200 (PBS)/ 
60 min
1:25 (PBS)/ 
30 min
1:250 (PBS)/ 
30 min
10 min
Total-
PKC-8
ERICA/
PBS-T
Pre-absorb w/ 
neat NHS** 
30 min 
1:50 (PBS)/ 
O/N
1:25 (PBS)/ 
30 min
1:250 (PBS)/ 
30 min
6  min
*NGS - normal goat serum, ** NHS - normal human serum.
Table 2.12 Assays utilising goat anti-rabbit secondary detection
| Antibody Fixation/
Block
Primary Antibody 
Concentration/ 
Duration
2° Goat anti-Rabbit 
Concentration/ 
Duration
Chromagen
DAB
Duration
c-fos (4) ERICA/ 
20% NHS 
in 0 .1% 
BSA/PBS
1:500 (40% NHS in 
5% BSA/PBS)/ 
O/N
1:40 (20% NHS in 
0.1% BSA/PBS)/ 
60 min
10 min*
I Total -  
HER2
ERICA/ 
5% NGS + 
5% NHS in 
PBS
1:100 (5% NGS+ 5% 
NHS in PBS)/
60 min
1:50 (5% NGS +5% 
NHS in PBS)/
60 min
6 min
P-HER2
(Y1248)
MVA/
PBS-T
1:20 (PBS)/ 
O/N
1:50(0.1% 
BSA/PBS)/ 
120 min
10 min
* An extra enhancement step is added to this assay: 0.5% copper sulphate in 0.85% sodium 
chloride solution, 5 min.
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Table 2.13 Assays utilising the Biogenex Super Sensitive Link Label system
Antibody Fixation/
Block
Primary
Antibody
Concentration/
Duration
2° Biogenex 
Mouse Link 
Cone/ 
Duration
3° Biogenex 
Mouse Label 
Cone/ 
Duration
Chromagen
DAB
Duration
CD71
(TfR)
pFS
PBS-T
1:100 (PBS)/ 
60 min
1:65(1% 
BSA/PBS)/ 
2 0  min
1:65(1% 
BSA/PBS)/ 
2 0  min
5 min DAB 
+ 3 min 
Haemo- 
toxylin 
+ 5 dH20
MIB-1 FS/
PBS-T
1:50 (PBS)/ 
60 min
1:65(1% 
BSA/PBS)/ 
2 0  min
1:65(1% 
BSA/PBS)/ 
2 0  min
10 min
Total-
EGFR
pFS or 
CM 
PBS-T
1:100 (PBS)/ 
O/N
1:65(1% 
BSA/PBS)/ 
2 0  min
1:65(1% 
BSA/PBS)/ 
2 0  min
10 min
2.6.4 Counterstain and Glass Slide Mounting
Following the DAB chromagen incubation, the coverslips were washed with distilled 
H20  ( 3 x 3 minutes) and 0.5% methyl green (aqueous) solution added for 20-30 
seconds to stain cell nuclei. After removal of the counterstain the coverslips were 
washed in distilled H20  and air dried. The coverslips were then mounted on glass 
slides using a xylene soluble mountant (Depex, Sigma-Alrich), labelled appropriately 
and stored until immunostaining analysis.
2.6.5 Immunostaining Analysis
Assessment of the immunostaining was determined at X20/ X40 magnification on a 
dual viewing Olympus BH-2 light microscope by two people. Comparative areas of 
confluency were located and given estimates of the percentage and intensity of cells 
positively stained. These data were used to calculate a semi quantitative H-Score on 
a scale of 0-300 (McClelland et aL, 1991). Assays were performed in triplicate, and 
two areas of each coverslip were assessed.
H-Score = I  (% of very weakly stained cells x 0.5)
+ (% of weakly stained cells x 1)
+ (% of moderately stained cells x 2 )
+ (% of strongly stained cells x 3).
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2.6.6 Haematoxylin & Eosin Staining
ERICA fixed coverslips were washed with PBS ( 3 x 3  minutes) prior to 10% Ehrlich 
Haematoxylin application for 10 minutes. The coverslips were then rinsed in tap H20  
for approximately 5 minutes prior to a VA hour application of 1% aqueous Eosin. 
The coverslips were washed in distilled H20  ( 3 x 3  minutes), allowed to air dry then 
mounted onto glass slides using xylene soluble mountant.
2.7 IMMUNOFLUORESCENCE
2.7.1 Cell Culture
MCF-7 and MCF-7X cells in log-phase growth were subject to trypsin 
dispersion, re-suspended in experimental medium and seeded onto 0.17 mm 
thick coverslips (~8 x 104 cells /coverslip) in 35 mm culture dishes. 
Experimental medium was replenished on day 3 or 4 and on day 7, a portion 
of the coverslips was treated with E2 (10’9 M) for 10 minutes prior to fixation 
with 3.7% (v/v) formaldehyde (in PBS) for 15 minutes. An equal portion of 
control and E2 treated coverslips were permeabilised with 0.4% saponin (in 
1% BSA/ PBS) for 15 minutes.
2.7.2 Total ER Assay
The fixed cells on the coverslips were blocked with 10% (v/v) normal goat serum and 
incubated for 1 hour with total ER (ID5, 1/20 in 1% BSA/ PBS +/- 0.4% saponin) 
antibody at room temperature. The secondary antibody utilized was Alexa Fluor 488- 
conjugated anti-mouse antibody (1/1000 in 1% BSA/ PBS +/- saponin) for 1 hour 
prior to 15 minute incubation in Texas Red phalloidin (6 .6  pM). Coverslips were 
mounted on to glass slides with Vectashield mounting medium (with DAPI). 
Assessment of the coverslips was done on a Leica RPE automatic microscope using a 
X I00 oil immersion lens. Fluorescent superimposed images were acquired by using a 
multiple band-pass filter set appropriately for DAPI (360 nm, blue), Alexa 488- 
fluorescein (488 nm, green) and Texas Red (594 nm, red).
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2.8 M OTILITY AND INVASION  
2.8.1 Insert Coating
2.8.1.1 Fibronectin Coating-
A fibronectin coating was applied to the bottom side of the Transwell® 
Permeable Support (6.5 mm, 8.0 pm pore size) inserts. For each insert that 
was being coated, a total volume of 300 pi was necessary to ensure that the 
bottom of the insert was properly submerged in the fibronectin solution ( 1 0  
pg/ml in PBS). The fibronectin solution was aliquoted into the outer wells 
(grey wells, Diagram 2.1) and the inserts from the inner 12 wells were placed 
into the liquid. The plate was placed in an incubator at 37°C for 2 hours. 
Each insert was then washed in sterile PBS, placed upside down to dry and 
returned to the empty inner wells (white wells, Diagram 2.1).
Diagram 2.1 Transwell® Permeable Support 24-well plate
oooooo
2.8.1.2 Matrigel Coating-
Matrigel coating was applied to the inside of the insert in order to form a 
barrier for cell invasion. Approximately 50 pg Matrigel (diluted in serum- 
free medium) was aliquoted on each insert utilising pre-cooled tips and 
allowed to set overnight at room temperature.
2.8.2 Cell Culture
MCF-7, MCF-7X and MCF-7X drug-resistant sub-lines in log-phase growth were 
subject to trypsin dispersion and re-suspended in appropriate experimental medium 
(see Table 2.14).
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Table 2.14 Cell lines and treatments utilised for motility and invasion assays
Cell Line Medium Treatment
MCF-7 wRPMI + 5%SFCS Control (ethanol, DMSO) 
Faslodex, 10'7 M 
LY294002, 5 gM 
PD98059, 25 gM 
FAS/LY, 10*7 M/5gM
MCF-7X wRPMI + 5%XFCS Control (ethanol, DMSO)
Faslodex, 10'7 M 
LY294002, 5 gM 
PD98059, 25 gM 
FAS/LY, 10’7 M/5gM 
LY/PD, 5 gM/ 25 gM 
FAS/LY/PD, 10’7 M/ 5 gM/ 25 gM
X(FAS) wRPMI + 5% XFCS + Faslodex 
(10'7 M)
N/A
X(LY) wRPMI + 5% XFCS + LY294002 
(5 m )
N/A
X(PD) wRPMI + 5% XFCS + PD98059 
(25 pM)
N/A
X(FAS/LY) wRPMI + 5% XFCS + FAS/LY 
(10‘7 M/5gM)
N/A
X(LY/PD) wRPMI + 5% XFCS + LY/PD 
(5 gM/ 25 gM)
N/A
2.8.3 Motility Assay
Treatment medium (-600 gl) was placed in the appropriate inner (white) wells with 
the inserts in place and the plate was placed in a 37°C incubator while cells were 
prepared for seeding. Approximately 5 x 10s cells/ml were re-suspended in serum 
free/phenol-red-free RPMI medium containing the appropriate treatment. Each cell 
suspension (5 x 104 /well) was added to the inside of duplicate inserts. The plate was 
returned to incubate at 37°C for 24 hours.
The medium was removed from the inside and the bottom side of the insert washed 
with PBS. The cells on the bottom side were then fixed in 4% formaldehyde for 15 
minutes at room temperature and then washed with PBS. After fixation the inserts 
were placed in the outer wells with a crystal violet solution for 15 minutes. Inserts 
were washed in PBS and excess stain was removed prior to air drying. Inserts were 
assessed by viewing at X I0 on a microscope. Cell counts were taken from 5 
representative fields of view on each insert.
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2.8.4 Invasion Assay (Jones et al., 2004; Hiscox et al., 2005)
The matrigel coating was rehydrated by adding serum-free phenol-red-free RPMI 
(-100 p.1) to each insert followed by an incubation period of 1 hour at 37°C. 
Approximately 5 x 104 cells/well in a volume of 200 pi (serum-free/phenol-red-free 
RPMI) containing the appropriate treatment was seeded to the upper compartment. 
The lower compartment was filled with 600 pi of phenol-red-free RPMI also 
containing the appropriate treatment.
Diagram 2.2 Transwell® Permeable Support insert
Transwell® insert
Upper compartment
Microporous membrane 
Lower com partment
http://www.corning.eom/lifesciences/technical information techdo 
cs/transwell euide.pdf
After the culture period of 72 hours, the medium was removed from the inside of the 
insert and its respective well. The matrigel layer on the inside of the insert was 
removed using a cotton bud (matrigel will stain thus making it difficult to assess). 
The cells on the reverse side were then fixed in 4% formaldehyde for 20 minutes at 
room temperature then washed with distilled H20 . The membrane of each insert was 
removed using a scalpel then placed onto a glass slide containing a drop of 
Vectashield (mounting medium with DAPI). The membrane was then covered with a 
coverslip, allowed to dry and stored at 4°C in the dark until analysis. Each slide was 
analysed (cell counts taken from 5 representative fields of view/ slide) using a Leica 
microscope at DAPI wavelength (360 nm).
68
CHAPTER 3
OORESULTS OO
CHAPTER 3 RESULTS
3.1 MCF-7 to MCF-7X: THE ACQUISITION OF RESISTANCE TO 
OESTROGEN DEPRIVATION
As with other endocrine strategies, the acquisition of resistance remains a significant 
problem with aromatase inhibitors. Sadly improvement in relapse-free survival in the 
adjuvant setting remains modest and relapse rates in advanced disease are still 
measured in months rather than years (Nicholson et al., 2004b). Studies focusing on 
this problematic development of resistance to oestrogen deprivation strategies are 
currently emerging, although model systems remain relatively sparse. An ER+ long­
term oestrogen deprived xenograft model has been described by Shim et al. (2000), 
while the laboratory of Brodie et al. (1999) describes a preclinical model system that 
used xenografts from die MCF-7 human breast cancer cell line stably transfected with 
the human placental aromatase gene (MCF-7Ca) to study both response and 
resistance. In addition long-term oestrogen deprived ERa positive in vitro models 
(Martin et al., 2003; Santen et al., 2004a) have also been developed from endocrine 
responsive cell lines, including MCF-7 cells (while a recent resistant model from 
Brodie/Sabnis has been developed from aromatase transfected cells, UMB-ICa, 
Sabnis et al., 2005). However, in most in vitro model systems to dale the cell cultures 
have been developed and even maintained in die presence of serum growth factors 
with in some cases further insulin supplementation. This exogenous growth factor 
rich environment could feasibly force die acquired resistance mechanism and even 
promote oestrogen hypersensitivity, therefore masking any inherent tumour 
capabilities to escape control by oestrogen deprivation.
In order to decipher resistance in vitro to oestrogen deprivation in the absence of high 
levels of growth factors, phenol-red-free RPMI (wRPMI) containing 5% charcoal 
stripped, heat-inactivated foetal calf serum (termed XFCS medium) was utilised in 
our system. Importantly this approach, which depletes oestrogens and exogenous 
growth factors, still ensures cell viability and attachment (van der Burg et al., 1988). 
The growth of the parental MCF-7 cell line subjected to these severely deprived 
conditions was inhibited by 74.3% compared to control MCF-7 cells grown in 5% 
charcoal stripped serum following 15 days of treatment This initial phase of 
substantial growth inhibition was subsequently maintained under such conditions for 
4 months. However, resistance was then acquired with proliferative activity of the 
resultant MCF-7X sub-line restored to that of the parental cell line prior to treatment 
(Figure 3.1). Later passages (44-98) of MCF-7X cells were utilised in the
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experimental characterisation and functional analysis involved in this project to 
ensure a stable phenotype had been achieved. The MCF-7X cell model clearly 
demonstrates that the acquisition of resistance to oestrogen deprivation can still arise 
in the absence of exogenous growth factors, with input from any residual steroid 
hormone and presumably predominately any autocrine growth factor signalling 
apparently adequate.
In order to compare the visual morphology of the MCF-7 parental control versus the 
MCF-7X cell line, phase contrast images (Figure 3.2A) and Haematoxylin & Eosin 
(Figure 3.2B) stained images were obtained. The MCF-7 parental cell line was a 
relatively homogenous population with respect to cell size and shape. The cell nuclei 
were ovoid in shape containing few prominent nucleoli. These cells had a nuclear to 
cytoplasmic area ratio of approximately 1 :4. In contrast, MCF-7X cells were a more 
heterogeneous population in size and shape with more prominent mitotic bodies. 
There were multiple nucleoli visible in the oestrogen deprived cells paralleled by a 
nuclear to cytoplasmic ratio of approximately 1.5 : 1. There was prominent 
attachment between MCF-7 cells when confluent, whereas the MCF-7X cells formed 
a loose ‘cobble stone’ structure where cell separation was evident (Figure 3.2A). In 
agreement with current literature (Sabnis et al., 2005), the parental MCF-7 cells had 
very low levels of measured motility and invasiveness, a profile indicative of a non- 
aggressive phenotype. This was also noted in MCF-7X cells, and although difficult 
to accurately quantify, there was some suggestion of a further reduction in these 
features within the resistant line versus MCF-7 cells (Figure 3.3A/B).
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Figure 3.1 Basal MCF-7 and MCF-7X cell growth. MCF-7 cells were 
grown and maintained in phenol-red-free RPMI media containing 5% SFCS or XFCS 
for 15 days on 24-well plates. MCF-7X cells were grown and maintained in phenol- 
red-free media containing 5% XFCS for 15 days on 24-well plates. Triplicate wells 
were subject to trypsin dispersion and Coulter cell counting at each time point 
indicated.
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Figure 3.2 Basal MCF-7 and MCF-7X cell visual morphology by phase 
contrast imaging (A) and H&E staining (B). MCF-7 and MCF-7 X cells were 
grown in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. (A) 
Cell phase contrast digital images were obtained during log phase growth (X20 
magnification). (B) MCF-7 and MCF-7X cells were grown under the same conditions 
previously described for 7 days on coverslips prior to ERICA fixation. The cells were 
H&E stained with 10% Ehrlich Haematoxylin (10 min) followed by 1% Eosin (214 hrs). 
The H&E digital images shown above are X40 magnification.
MCF-7 MCF-7X
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Figure 3.3 Basal MCF-7 and MCF-7X ceU motility (A) and invasive 
capacity (B). (A) MCF-7 and MCF-7X cells were seeded onto fibronectin coated 
Transwell® permeable supports fin* 24 hours prior to formaldehyde fixation and crystal 
violet staining. (B) MCF-7 and MCF-7X cells were seeded onto matrigel coated 
Transwell® permeable supports for 72 hours prior to formaldehyde fixation and 
mounting on glass slides with mounting medium containing DAPI. These data 
represent the mean number of cells/field of view +/- SD of triplicate inserts.
74
CHAPTER 3 RESULTS
3.1.1 O estrogen R eceptor (E R a) Expression
MCF-7 cells express oestrogen receptors (Horwitz et al., 1978) which allow 
investigation of the effects of hormone and anti-hormone sensitivity. Extensive 
characterisation of the MCF-7X oestrogen deprived cell line versus the parental 
MCF-7 cells revealed considerable evidence that the oestrogen receptors are retained 
and functional in die resistant model. Both the MCF-7 and MCF-7X cell lines were 
cultured for 7 days (log-phase growth) to compare die mRNA and protein levels of 
ERa, employing RT-PCR, Western blotting and immunocytochemistry. These 
approaches revealed that, like MCF-7 cells, MCF-7X cells expressed substantial 
levels of ERa (Figures 3.4,3.5 & 3.6). Moreover, a modest but significant increase in 
nuclear ERa was detected in MCF-7X versus the MCF-7 cells by 
immunocytochemistry (p<0.001 *). This small increase was due to enhanced intensity 
of nuclear staining rather than an increase in the percentage of positivity (Figure 3.6). 
Although only a small 25.8% increase was evident in MCF-7X cells, more substantial 
adaptive increases in ERa expression have been commonly described for models of 
long-term oestrogen deprivation (3-10 fold increases, Martin et al^ 2003; Santen et 
al., 2004a, Sabnis et al., 2005). Of note, in MCF-7X cells the immunocytochemical 
staining was entirely nuclear, observations certainly suggestive that any ERa function 
may be predominantly genomic in these cells.
3.1 .2  C lassical E R a/ Genom ic Signalling
To begin to assess if die nuclear ERa was transcriptionally active in the MCF-7X cell 
line and to evaluate comparatively versus the MCF-7 cell line, phosphorylation status 
of key AF-1 serine residues, 118 and 167 was first investigated by 
immunocytochemistry (Figure 3.7). Heterogeneous nuclear staining was apparent for 
Serll8ER phosphorylation in both MCF-7X and MCF-7 cells. Phosphorylated 
Serl67ER staining was also apparent in MCF-7 and MCF7X cells and was punctated 
within the nucleus. There was also cytoplasmic staining with the phospho-Serl 67ER 
antibody, but previous antibody absorption studies in the laboratory have suggested 
this staining component is unwanted background and so was not quantified in this 
study. Nuclear ERa phosphorylation activity at serine 118 (Serll8ER) was increased 
by 28.6% (p=0.037*) in MCF-7X cells, but not significantly altered at serine 167 
(Serl67ER) versus MCF-7 cells at day 7. The increase in Seri 18ER was due to an 
increase in the percentage of cells stained positive. Basal ERa transcriptional activity 
was subsequently measured using luciferase ERE (oestrogen response element)
75
CHAPTER 3 RESULTS
reporter gene construct assays in MCF-7X versus MCF-7 cells. There was a 5-fold 
increase in ERE reporter activity (Figure 3.8) in MCF-7X cells under basal growth 
conditions. In parallel with these reporter assays, basal expression of endogenous 
oestrogen regulated genes were monitored as a further indicator of ERa function. The 
oestrogen regulated gene pS2 was detectable in both MCF-7 and MCF-7X cells by 
RT-PCR (Figure 3.9) with pS2 mRNA expression significantly increased (65.5%, 
p=0.017*) in the resistant model. Furthermore, there was a parallel increase (44.4%, 
p<0.001*) in this cytoplasmic-localised protein expression by immunocytochemistry 
(Figure 3.10) at day 7. In MCF-7 cells progesterone receptor (a further oestrogen 
inducible gene) was heterogeneously detectable in the nuclei of approximately 30% 
of die cell population by immunocytochemistry but, in contrast to pS2 expression, in 
the MCF-7X cells there was a total loss (p<0.001*) o f this protein (Figure 3.11).
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Figure 3.4 Basal M CF-7X versus MCF-7 cell mRNA expression o f  
ERa by RT-PCR. MCF-7 and MCF-7X cells were grown on 100  mm dishes in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days before RNA was isolated and reverse transcribed. Co­
amplification RT-PCR of ERa (25 cycles/ 55°C annealing temperature, 432 bp) and /?- 
Actin (204 bp) was performed. The RT-PCR product was run on a 2% agarose gel 
containing ethidium bromide, subsequently photographed, scanned and normalised to fi- 
Actin. The digital image is representative of 3 experiments and the statistical analysis 
applied was an unpaired-T test (p=0.230) comparing mean ERa expression in MCF-7 
(0.37 +/- 0.08) and MCF-7X (0.45 +/- 0.04) cells.
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Figure 3,5 Basal MCF-7X versus MCF-7 cell expression o f  total ERa 
by Western blotting, MCF-7 and MCF-7X cells were grown on 60 mm dishes in 
phenol-red-free media containing 5% SFCS or XFCS respectively. Conditions were 
maintained for 7 days prior to whole cell lysis, SDS-PAGE (40 pg of sample 
protein/well) and Western blotting. The nitrocellulose membrane (0.45 pm) was 
probed for total ER (IDS, 60 kDa) and ^-Actin (42 kDa). The developed 
autoradiography film was scanned using densitometric imaging for each blot probed 
and ERa expression was normalised to /TActin. Data are presented as the mean (+/- 
SD) and the image above is representative of 3 experiments.
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Total Oestrogen Receptor (ERa)
MCF-7 MCF-7X
*  1
■ « , .___I
MCF-7 MCF-7X p-value
Total ERa
(Nuclear) 147.0(142.0-155.0) 185.0 (185.0-195.0) <0.001*
Figure 3,6 Basal MCF-7X versus MCF-7 cell ERa expression by 
immunocytochemistry, MCF-7 and MCF-7X cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days prior to ERICA fixation. The total nuclear ERa (6F11, 
antibody dilution 1:100) digital images shown above (X20 magnification) are 
representative of 3 experiments. H-Score data were obtained by dual assessment of 2 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in ERa expression between MCF-7 and MCF-7X 
cells.
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Phospho- 
ER Seri 18
Phospho- 
ER Seri 67
MCF-7 MCF-7X p-value
Phospho-ER Seri 18
(Nuclear) 70.0 (63.8-71.3) 90.0 (77.5-110.5) 0.037*
Phospho-ER Seri 67
(Nuclear) 82.5 (713-100.0) 50.0 (45.0-70.0) 0.170
Figure 3.7 Basal MCF-7X versus MCF-7 cell phosphorylation o f ERa 
at Seri 18 and Seri67 residues by immunocytochemistry. MCF-7  and 
MCF-7X cells were grown on coverslips in media containing 5% SFCS or XFCS 
respectively. Conditions were maintained for 7 days on coverslips prior to the 
appropriate fixation. The phospho-ER Seri 18 (antibody dilution 1:400) assay required 
coverslips paraformaldehyde vanadate fixed and the phospho-ER Serl67 (1:25) assay 
required coverslips ERICA fixed. The digital images shown above (X20 magnification) 
are representative of 6  experiments. H-Score data were obtained by dual assessment of 
2 representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in ERa phosphorylation at Seri 18/Ser 167 between 
MCF-7 and MCF-7X cells.
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Figure 3.8 Basal MCF-7X versus MCF-7 cell comparison of ER 
transcriptional activity by ERE reporter assay. MCF-7 and MCF-7X cells 
were grown on 12-well plates in phenol-red-free RPMI media containing 5% SFCS or 
XFCS respectively for 24 hours. Cells woe transfected in DCCM serum-free media 
containing transfection lipid (3 pl/well, Lipofectin), ERE reporter construct (400 
ng/well), Renilla (150 ng/ml), and ‘carrier’ DNA (550 ng/well, PCRscript) After 6 
hours, the transfection medium was replaced with phenol-red-free RPMI media for 18 
hours. A dual-hiciferase reporter assay kit was utilised fin* cell lysis and luminometer 
assessment Illustrated above is the basal reporter activity in MCF-7X versus MCF-7 
cell which has been normalised to /t-Galactosidase to account for variations in 
transfection efficiency.
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Figure 3.9 Basal MCF-7X versus MCF-7 cell mRNA expression o f  the 
endogenous oestrogen regulated gene pS2 by RT-PCR. MCF-7 and MCF- 
7X cells were grown on 100 mm dishes in phenol-red-free RPMI media containing 5% 
SFCS or XFCS respectively. Conditions were maintained for 7 days before RNA was 
isolated and reverse transcribed. Co-amplification RT-PCR of pS2 (25 cycles/ 55°C 
annealing temperature, 336 bp) and /?-Actin (204 bp) was performed. The RT-PCR 
product was run on a 2% agarose gel containing ethidium bromide, subsequently 
photographed, scanned and normalised to /?-Actin. The digital image is representative 
of 3 experiments and the statistical analysis applied was a unpaired-T test (p=0.017*) 
comparing mean pS2 expression in MCF-7 (2.9 +/- 0.6) and MCF-7X (4.8 +/- 0.6) cells.
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pS2
MCF-7 MCF-7X
M *
MCF-7 MCF-7X p-value
pS2
(Cytoplasmic) 90.0(81.3-98.8) 130.0 (1213-133.8) <0.001*
Figure 3.10 Basal MCF-7X versus MCF-7 cell pS2 expression by 
immunocytochemistry. MCF-7 and MCF-7X cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days prior to ERICA fixation. The pS2 (antibody dilution 1:500) 
digital images shown above (X20 magnification) are representative of 3 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in pS2 expression between MCF-7 and MCF-7X cells.
83
CHAPTER 3 RESULTS
Progesterone Receptor (PgR)
MCF-7 MCF-7X
*
* ♦
MCF-7 MCF-7X p-value
PgR
(Nuclear) 22.5 (13.8-27.8) o.o (o.o-o.o) <0 .0 0 1 *
Figure 3.11 Basal MCF-7X versus MCF-7 cell progesterone receptor 
expression by immunocytochemistry. MCF-7 and MCF-7X cells were grown 
on coverslips in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively. Conditions were maintained for 7 days prior to ERICA fixation. The 
progesterone receptor (636, antibody dilution 1:200) digital images shown above (X20 
magnification) are representative of 3 experiments. H-Score data were obtained by 
dual assessment of 2  representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant difference in progesterone 
receptor expression between MCF-7 and MCF-7X cells.
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3.1.3 ERa Contribution: Oestrogen and Faslodex E ffects
An obvious indicator of ERa function is growth sensitivity to oestrogens. A key 
feature under investigation by several groups in resistance to oestrogen deprivation is 
its apparent oestrogen hypersensitivity. In order to evaluate if this is a feature of our 
resistant model derived under conditions of exogenous growth factor/oestrogen 
deprivation, challenge with the ERa ligand oestradiol (E2) was investigated in MCF- 
7X cells. MCF-7X cells were substantially stimulated by exogenous oestradiol with a 
maximum 100% increase in growth when compared to untreated control achieved at a 
dose of 10*9 M. Maximum growth was also achieved in MCF-7 cells at this dosage. 
During a 10 day period MCF-7X cells also demonstrated an approximately equivalent 
bell-shaped concentration response profile to die MCF-7 cells over an extensive 10'15- 
10'5 M oestradiol range (Figure 3.12). Similarly, promotion of ERa transcriptional 
activity by the addition of oestradiol was assessed using ERE reporter gene constructs 
in MCF-7X versus MCF-7 cells and again an equivalent concentration curve profile 
was achieved (Figure 3.13), although higher levels were achieved in MCF-7X cells in 
relation to the stimulation achieved by oestradiol in MCF-7 cells. Collectively these 
data demonstrate ERa signalling is growth contributory in MCF-7X cells, but the 
dose response profiles indicate they are not growth hypersensitive to sub- 
physiological oestradiol levels. Therefore, severely depleted conditions (growth factor 
and oestrogen deprived) do not support oestrogen hypersensitivity in contrast to 
reported models where exogenous growth factors are available.
A further indication of ERa dependence is growth inhibition by the pure anti- 
oestrogen faslodex. MCF-7 and MCF-7X cells subject to a dose range of the pure 
anti-oestrogen faslodex (1013-10'7 M) for 7 days again demonstrated a broadly similar 
concentration response profile (Figure 3.14), although a large variability of response 
was seen in the parental cell line. MCF-7X cells were subsequently challenged with 
the anti-oestrogen at a significant inhibitory dose (10 7 M, p<0.001*) over a 15 day 
time course, with cell growth assessed every 48 hours. Faslodex significantly 
inhibited growth 37.2% (p<0.001*) at day 7, and by day 15 this inhibition was 
increased to 59.6% versus the untreated control (p=0.001*, Figure 3.15). In both 
MCF-7 and MCF-7X cells, faslodex treatment significantly decreased nuclear ERa 
(78.2%, p=0.001* and 63.5%, p=0.001* respectively) as measured by 
immunocytochemistry (Figure 3.16). Low levels of nuclear ERa remained 
subsequent to treatment in both MCF-7 and MCF-7X cells, with more occasional
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cells retaining a moderate nuclear intensity in the latter cell line. A decrease in ERa 
(60 kDa) with faslodex was also demonstrated by Western blotting in MCF-7X cells 
(Figure 3.17).
Treatment with the pure anti-oestrogen resulted in a significant MCF-7X cell 
reduction of Serll8ER phosphorylation (13.9%, p=0.030*, Figure 3.18) although 
there was no effect on the phosphorylation of Serl67ER (p=0.841, Figure 3.19). This 
result was contrary to faslodex producing some decrease in Seri 18ER 
phosphorylation but with a significant reduction in the phosphoiylation of Serl67ER 
(30.3%, p=0.019*) in MCF-7 cells by immunocytochemistry (Figures 3.18 & 3.19). 
Faslodex partially diminished ERE reporter activity after 18 hour treatment by 32.5% 
(p=0.007*) in MCF-7X cells (Figure 3.20). In parallel with these inhibitory effects 
on ERE reporter activity, RT-PCR of faslodex treated (7 days) MCF-7X cells 
revealed that level of the oestrogen regulated gene pS2 mRNA (336 bp) was 
significantly reduced (92.2%, p=0.002*, Figure 3.21). Immunocytochemistry 
demonstrated a significant 44.2% reduction in cytoplasmic localised endogenous pS2 
protein in MCF-7X cells (p=0.001*, Figure 3.22), a fall nearly equivalent to that 
revealed in MCF-7 cells (41.7%, p<0.001*).
3.1.4 Non-genomic ERa Signalling
In the long-term oestrogen deprived (LTED) model from Santen et al. (2003), 
confocal analysis displayed membrane-bound ERa in the ruffles and the peri- 
membrane region of the pseudopodia after short-term oestradiol treatment However, 
immunofluorescence studies (Figure 3.23) performed in MCF-7X cells failed to 
demonstrate obvious cytoplasmic or plasma membrane recruitment of ERa either 
before or after short-term (10 min.) E2 treatment, despite a prominent nuclear 
immunolocalisation (green). A strong level of actin polymerisation (red) was 
apparent by the colour merged digital images which importantly seemed to lack any 
evidence of co-localisation (yellow) with ERa. The lack of cytoplasmic or plasma 
membrane staining was also observed in the MCF-7 cells examined in this project 
both pre and post E2 treatment. This suggests that ERa signalling is unlikely to occur 
in a predominantly non-genomic manner in the MCF-7X model, cm* indeed 
substantially in die MCF-7 parental cell line in this study.
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Figure 3.12 Dose Response to Oestradiol in MCF-7X versus MCF-7 
cells. MCF-7 and MCF-7X cells wore grown on 24-well plates in phenol-red-free 
RPMI media containing 5% SFCS or XFCS respectively. Cells were exposed to a dose 
range of lfr15 M to 10*s M Ej including a control (ethanol lp l/10 ml). Conditions were 
maintained for 10 days prior to trypsin dispersion followed by Coulter counting 
(triplicate wells per dose). The data are displayed as the mean percentage of control 
cell growth +/- SD (n=4). The statistical analysis applied was an ANOVA Test 
followed by a Tamhane Post-Hoc Test
* and 0 Denotes a dose at which MCF-7 and MCF-7X cells were significantly growth 
promoted by oestradiol versus their respective controls at p<0.05.
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Figure 3.13 Oestrogen sensitivity of ERE transcriptional activity in 
MCF-7X versus MCF-7 cells. MCF-7 and MCF-7X cells were grown on 12- 
well plates in phenol-red-free media containing 5% SFCS or XFCS respectively for 24 
hours. Cells were transfected in DCCM serum-free media containing transfection lipid 
(3 pl/well, Lipofectin) ERE reporter construct (400 ng/well), Renilla (ISO ng/ml), and 
‘carrier’ DNA (550 ng/well, PCRscript) After 6 hrs, die transfection medium was 
removed and phenol-red-free RPMI media containing a dose range 10~1S M to 10** M Ej 
including a control (ethanol 1 pi/ 10 ml) was added (triplicate wells per treatment). 
Subsequent to 18 hour treatment incubation a dual-luciferase reporter assay kit was 
utilised for cell lysis and himinometer assessment (n=l). Data are displayed as a 
percentage of control ERE reporter activity for each cell line and has been normalised 
to /Hjalactosidase to account for variations in transfection efficiency.
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Figure 3,14 Dose response to the pure anti-oestrogen faslodex in MCF- 
7X versus MCF-7 ceils, MCF-7 and MCF-7X ceils wane grown on 24-well plates 
in phenol-red-free RPMI media containing 5% SFCS at XFCS respectively. Cells were 
exposed to a dose range of 10*13 M to 10~7 M faslodex including a control (ethanol 1 pi/ 
10 ml). Conditions were maintained for 10 days prior to trypsin dispersion followed by 
Coulter counting (triplicate wells per dose). The data are displayed as die mean 
percentage of cell growth +/- SD (n=3) fo r each cell line. The statistical analysis 
applied was an ANOVA Test followed by a Tamhane Post-Hoc Test.
* and 0 Denotes a dose at which MCF-7 and MCF-7X cells wane significantly growth 
inhibited by faslodex versus their respective controls at p<0.05.
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Figure 3.15 Growth o f MCF-7X cells challenged with the pure anti­
oestrogen faslodex. MCF-7X cells were grown on 24-well plates in phenol-red- 
free RPMI media containing 5% XFCS in the absence or presence of faslodex (10*7 M) 
for 15 days. At the time points indicated above, cells were subject to trypsin dispersion 
followed by Coulter counting (triplicate wells per time point). These data were log 
transformed to compare growth rate at day 7 and day 15. The statistical analysis 
applied was an ANOVA Test followed by a Bonferroni Post-Hoc Test. Data are 
displayed as the mean number of cells/well +/- SD (n=5).
0 Denotes faslodex treatment was significantly lower at day 7 (p<0.001) and day 15 
(p=0.001) versus untreated MCF-7X cells.
—♦ —Control - • - F A S
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Total ERa
Control
+ Faslodex 
(10'7M)
Total ERa (Nuclear)
Basal Control 147.0(142.0-155.0) 185.0 (185.0-195.0)
+ Faslodex (10*7M) 32.0(30.0-36.3) p=0.001* 67.5(60.0-71.3) p=0.001*
Figure 3.16 Effect o f the pure anti-oestrogen faslodex on ERa 
expression in MCF-7 and MCF-7X cells by immunocytochemistry.
MCF-7 and MCF-7X cells were grown on coverslips in phenol-red-free RPM1 media 
containing 5% SFCS or XFCS respectively in the absence or presence of faslodex (10-7 
M). Conditions were maintained for 7 days prior to ERICA fixation. The total nuclear 
ERa (6F11, antibody dilution 1:100) digital images shown above (X20 magnification) 
are representative of 3 experiments. H-Score data were obtained by dual assessment of 
2 representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in ERa expression following faslodex treatment.
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Figure 3.17 Effect o f the pure anti-oestrogen faslodex on ERa 
expression in MCF-7X cells by Western blotting. MCF-7X cells were 
grown on 60 mm dishes in phenol-red-free media containing 5% XFCS in the absence 
and presence of faslodex (10*7 M). Conditions were maintained for 7 days prior to 
whole cell lysis, SDS-PAGE (40 pg of sample protein/well) and Western blotting. The 
nitrocellulose membrane (0.45 pm) was probed for total ER (ID5, 60 kDa) and /?-Actin 
(42 kDa). The developed autoradiography film was scanned using densitometric 
imaging for each blot probed and ERa expression was normalised to ^ -Actin. Above is 
a representative experiment.
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Phospho-ER Seri 18
Control
+ Faslodex 
(10"7M)
MCF-7XMCF-7
MCF-7 MCF-7X
Phospho-ER Seri 18 (Nuclear)
Basal Control 70.0(63.8-71.3) 90.0(77.5-110.5)
+ Faslodex (10'7M) 57.5 (50.0-70.0) p=0.080 77.5(613-80.0) p=0.030*
Figure 3,18 Effect o f the pure anti-oestrogen faslodex on 
phosphorylation o f  ERa at Seri 18 residue in MCF-7 and MCF-7X 
cells by immunocytochemistry, MCF-7 and MCF-7X cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively 
in the absence or presence of faslodex (10*7M). Conditions were maintained for 7 days 
prior to paraformaldehyde vanadate fixation. The phospho-ER Seri 18 (antibody 
dilution 1:400) digital images shown above (X20 magnification) are representative of 4 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-ER Seri 18 level following faslodex treatment.
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MCF-7XMCF-7
Phospho-ER Seri67 (Nuclear)
Basal Control 82.5 (713-100.0) 50.0 (45.0-70.0)
+ Faslodex (10*7M) 57.5 (53.8-71.3) p=0.019* 55.0(40.0-70.0) p=0.841
Figure 3.19 Effect o f the pure anti-oestrogen faslodex on 
phosphorylation o f ERa at Seri67 residue in MCF-7 and MCF-7X 
cells by immunocytochemistry. MCF-7 and MCF-7X cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively 
in the absence or presence of faslodex (10'7M). Conditions were maintained for 7 days 
prior to ERICA fixation. The phospho-ER Seri67 (antibody dilution 1:25) digital 
images shown above (X20 magnification) are representative of 4 experiments. H-Score 
data were obtained by dual assessment of 2 representative areas of each coverslip 
followed by statistical analysis (Mann-Whitney U-Test). The median H-Score and Ql- 
Q3 values are displayed. A p-value <0.05(*) indicates a significant difference in 
phospho-ER Seri 67 level following faslodex treatment.
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Figure 3.20 Effect of the pure anti-oestrogen faslodex on ER 
transcriptional activity in MCF-7X cells after 18 hour treatment MCF- 
7X cells were grown on 12-well plates in phenol-red-free RPMI media containing 5% 
XFCS for 24 hours. Cells woe transfected in DCCM serum-free media containing 
transfection lipid (3 pl/well, Lipofectin), ERE reporter construct (400 ng/well), Renilla 
(150 ng/ml), and ‘carrier’ DNA (550 ng/well, PCRscript) After 6 hours, the 
transfection medium was replaced with phenol-red-free RPMI media in the absence or 
presence of faslodex (10*7 M) in triplicate wells. Subsequent to 18 hour treatment 
incubation, a dual-luciferase reporter assay kit was utilised for cell lysis and 
luminometer assessment (n=3). Data are displayed as percentage of control ERE 
activity +/- SD (triplicate wells) and has been ^-Galactosidase normalised in the 
absence and presence of faslodex (10*7 M). The statistical analysis applied was an 
ANOVA Test followed by a Bonferroni Post-Hoc Test
0 Denotes faslodex treatment (18 hrs) significantly decreased ERE activity in MCF-7X 
cells versus untreated control.
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Figure 3,21 Effect o f  the pure anti-oestrogen faslodex on pS2 mRNA in 
MCF-7X cells by RT-PCR, MCF-7X cells were grown on 100  mm dishes in 
phenol-red-free RPMI media containing 5% XFCS in the absence or presence of 
faslodex (10*7 M). Conditions were maintained for 7 days before RNA was isolated and 
reverse transcribed. Co-amplification RT-PCR of pS2 (25 cycles/ 55°C annealing 
temperature, 336 bp) and /?-Actin (204 bp) was performed. The RT-PCR product was 
run on a 2 % agarose gel containing ethidium bromide, subsequently photographed, 
scanned and normalised to /?-Actin. The digital image is representative of 3 
experiments and the statistical analysis applied was an unpaired-T test (p=0.002*) 
comparing mean pS2 expression in untreated MCF-7X cells (5.7 +/- 0.4) and faslodex 
treated MCF-7X cells (0.4 +/- 0.3).
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pS2
MCF-7 MCF-7X
Control
+ Faslodex 
(10'7M)
MCF-7 MCF-7X
pS2 (Cytoplasmic)
Basal Control 90.0 (81.3-98.8) 130.0 (121.3-133.8
+Faslodex (10‘7 M) 52.5 (42.5-58.8) p<0.001* 72.5 (58.8-80.0) p=0.001*
Figure 3.22 Effect o f the pure anti-oestrogen faslodex on pS2 
expression in MCF-7 and MCF-7X cells by immunocytochemistry.
MCF-7 and MCF-7X cells were grown on coverslips in phenol-red-free media 
containing 5% SFCS or XFCS respectively in the absence or presence of faslodex (10~7 
M). Conditions were maintained for 7 days prior to ERICA fixation. The pS2 
(antibody dilution 1:500) digital images shown above (X20 magnification) are 
representative of 3 experiments. H-Score data were obtained by dual assessment of 2 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in pS2 expression following faslodex treatment.
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Figure 3.23 ERa localisation in oestrogen stimulated MCF-7 and 
MCF-7X cells by immunofluorescence. MCF-7 and MCF-7X cell were grown 
on coverslips in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively. Conditions were maintained for 7 days prior to 10 minute E2 (10'9 M) or 
control (ethanol, 1 pi/ 10 ml) treatment followed by 3.7% formaldehyde fixation. The 
ERa (ID5, antibody dilution 1:20) superimposed digital images shown above were 
acquired using a multiple band-pass filter on a Leica RPE automatic microscope using a 
XI00 (magnification) oil immersion lens [DAPI (nuclear counter stain, blue, 360 nm), 
Alexa 488-fluorescein (ERa, green, 488 nm) and Texas Red phalloidin (actin fibers, 
red, 594 nm].
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3.1.5 AP-1 Signalling and Cell Cycle
In order to address whether non-classical/genomic ERa signalling via AP-1 was 
contributory in MCF-7X cells, AP-1 transcriptional activity was measured using an 
AP-1 reporter assay in both MCF-7 and MCF-7X cells. Basal AP-1 reporter activity 
was increased 4.6 fold in MCF-7 cells compared to the oestrogen deprived MCF-7X 
cells (Figure 3.24). In contrast to their obvious impact on ERE reporter gene 
construct activity and growth, there was no significant difference between untreated 
control and E2 (10'9 M) or faslodex (10‘7 M) treatment in MCF-7X cells (Figure 3.25). 
MCF-7 cells treated with E2 showed a small but significant reduction (11.0%, 
p=0.002*) in AP-1 activity while faslodex treatment had no effect versus untreated 
control. The protein c-fos binds to DNA by forming a stable heterodimer with the 
protein c-jun (Shaulian and Karin, 2001) that comprises die AP-1 transcription factor 
complex which targets the AP-1 response elements. RT-PCR revealed c-fos mRNA 
(483 bp) expression (Figure 3.26) in MCF-7X was significantly decreased with 
respect to the MCF-7 parental cell line (57.5%, p=0.001*). Fos protein expression 
was moreover significantly decreased 23.8% (p=0.004*) in MCF-7X versus MCF-7 
by immunocytochemistry (Figure 3.27). Cumulatively, these data suggest non- 
classical/genomic ERa signalling via AP-1 interactions is not a major contributory 
factor for ER-promoted growth in MCF-7X.
The transcriptional regulator c-myc is a strong inducer of proliferation and its role in 
cell cycle control is believed to be critical to oncogenesis (Nasi et al., 2001). RT- 
PCR of c-myc mRNA (549 bp) expression (Figure 3.28) revealed an increase in 
MCF-7X versus MCF-7 cells, although this did not reach significance (64.3%, 
p=0.087). Coder et al. (2000) has shown c-myc directly represses the expression of 
V2\c,pI wan during its promotion of growth. In MCF-7X cells p 2 \cipI/wafl mRNA (460 
bp) expression was significantiy decreased 47.8% (p=0.031 *) versus MCF-7 cells by 
RT-PCR (Figure 3.29).
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Figure 3.24 Basal MCF-7X versus MCF-7 cell comparison of AP-1 
transcriptional activity. MCF-7 and MCF-7X cells were grown on 12-well plates 
in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively fen* 24 
hours. Cells woe transfected in DCCM serum-free media containing lipid (3 pl/well, 
Lipofectin), AP-l-pTal reporter construct (400 ng/well), and ‘carrier’ DNA (700 
ng/well PCRscript). Control pTal luciferase reporter constructs were included for each 
treatment at the same construct and ‘carrier’ concentrations. After 6 hours, the 
transfection medium was removed and phenol-red-free RPMI for 18 hours. A 
luciferase repeater assay kit was utilised for cell lysis and luminometer assessment 
Illustrated above is basal repeater activity in MCF-7X versus MCF-7 cells which has 
been normalised to ^ -Galactosidase to account for variations in transfection efficiency.
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Figure 3,25 Treatment effects on AP-1 transcriptional activity in MCF- 
7X versus MCF-7, MCF-7 and MCF-7X cells were grown on 12-well plates in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively for 24 hours. 
Cells were transfected in DCCM serum-free media containing lipid (3 p 1/well, 
Lipofectin), AP-l-pTal reporter construct (400 ng/well), and ‘carrier’ DNA (700 
ng/well PCRscript). Control pTal luciferase reporter constructs were included for each 
treatment at the same construct and ‘carrier’ concentrations. After 6  hours, the 
transfection medium was removed and phenol-red-free RPMI media containing Ej (10‘ 
9 M), faslodex (10*7 M) or control (ethanol, lpl/ 10 ml) was added (triplicate wells per 
treatment). Subsequent to 18 hour treatment incubation, a luciferase reporter assay kit 
was utilised for cell lysis and luminometer assessment (n=3). Data are displayed as a 
percentage of control AP-1 activity for each cell line +/- SD and has been /?- 
Galactosidase normalised to account for variations in transfection efficiency. The 
statistical analysis applied was an ANOVA Test followed by a Dunnett-T Post-Hoc 
Test.
* Denotes Ej treatment significantly decreased AP-1 activity in MCF-7 cells versus 
untreated control.
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Figure 3.26 Basal MCF-7X versus MCF-7 cell mRNA expression o f  
C-fos by RT-PCR. MCF-7 and MCF-7X cells were grown on 100 mm dishes in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days before RNA was isolated and reverse transcribed. RT-PCR 
of c-fos (32 cycles/ 55°C annealing temperature, 483 bp) and /?-Actin (25 cycles/ 55°C 
annealing temperature, 204 bp) was performed. Product from each reaction was 
combined and run on a 2% agarose gel containing ethidium bromide, subsequently 
photographed, scanned and normalised to /?-Actin. The digital image above is 
representative of 3 experiments and the statistical analysis applied was an unpaired-T 
test (p=0.001*) comparing mean c-fos expression in MCF-7 (4.0 +/-0.2) and MCF-7X 
(1.7 +/- 0.4) cells.
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c-fos
MCF-7 MCF-7X
-----------------------
MCF-7 MCF-7X p-value
c-fos
(Nuclear) 52.5 (48.8-61.3) 40.0 (38.0-40.3) 0.004*
Figure 3.27 Basal MCF-7X versus MCF-7 c-fos expression by 
immunocytochemistry. MCF-7 and MCF-7X cells were grown on coverslips in 
phenol-red-free RPMI containing 5% SFCS or XFCS respectively. Conditions were 
maintained for 7 days prior to ERICA fixation. The c-fos (antibody dilution 1:500) 
digital images shown above (X20 magnification) are representative of 3 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in c-fos expression between MCF-7 and MCF-7X cells.
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Figure 3.28 Basal MCF-7X versus MCF-7 cell mRNA expression o f 
c-myc by RT-PCR. MCF-7 and MCF-7X cells were grown on 100  mm dishes in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days before RNA was isolated and reverse transcribed. Co­
amplification RT-PCR of c-myc (29 cycles/ 55°C annealing temperature, 549 bp) and fi- 
Actin (204 bp) was performed. The RT-PCR product was run on a 2% agarose gel 
containing ethidium bromide, subsequently photographed, scanned and normalised to /?- 
Actin. The digital image above is representative of 3 experiments and the statistical 
analysis applied was an unpaired-T test (p=0.087) comparing mean c-myc expression in 
MCF-7 (1.4 +/- 0.4) and MCF-7X (2.3 +/- 0.6) cells.
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Figure 3,29 Basal MCF-7X versus MCF-7 cell mRNA expression o f 
p21cipl/wby RT-PCR, MCF-7 and MCF-7X cells were grown on 100 mm dishes 
in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days before RNA was isolated and reverse transcribed. Co­
amplification RT-PCR of p21ciP1/wafl (30 cycles/ 55°C annealing temperature, 460 bp) 
and /?-Actin (204 bp) was performed. The RT-PCR product was run on a 2% agarose 
gel containing ethidium bromide, subsequently photographed, scanned and normalised 
to /?-Actin. The digital image above is representative of 3 experiments and the 
statistical analysis applied was a unpaired-T test (p=0.031*) comparing mean 
p2ic.pl/wan expression in MCF-7 (2.3 +/-0.5) and MCF-7X (1.2 +/- 0.2) cells.
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3.2 CLASSICAL GROWTH FACTOR RECEPTOR SIGNALLING
3.2.1 Insulin-like Growth Factor Receptor (IGF-1R) Signalling
The insulin-like growth factor-1 receptor (IGF-1R) is expressed to some degree in 
most cell types and its signalling promotes mitogenesis, apoptosis, cell adhesion and 
motility as well as terminal differentiation (Valentinis and Baserga, 2001). Both the 
MCF-7 and MCF-7X cell lines were cultured for 7 days to assess the mRNA and 
protein levels of IGFR. While readily detectable in MCF-7 cells, IGF-1R mRNA 
(287 bp) expression was significantly decreased 87.7% (p= 0.006*) in MCF-7X cells 
versus MCF-7 cells by RT-PCR (Figure 3.30). A decrease was also apparent by 
Western blotting (128 kDa) at the protein level (Figure 3.31). By 
immunocytochemistry a substantial decline in plasma membrane-localised receptor 
(86.7%, p=0.003*) along with a decrease (64.5%, p=0.003*) in cytoplasmic staining 
was also revealed versus the prominent staining in MCF-7 cells (Figure 3.32).
Using a specific antibody for phosphorylation of site Y1316 on die IGF-1R (a 
generous gift from M. Rubini, Ferrara University, Italy; where pY1316 
phosphorylation can contribute to IGF-1R mediated mitogenesis and tumourigenesis 
and does not cross-react with the corresponding moiety in activated insulin receptor, 
Rubini et al., 1999), immunocytochemistry demonstrated some parallel decrease in 
plasma membrane activation (37.5%, p=0.002*), although cytoplasmic activity was 
not depleted in MCF-7X versus MCF-7 cells (Figure 3.32). Cumulatively these 
MCF-7X cell results possibly suggest a diminished contribution for IGF-1R 
signalling versus the parental cell line. In accordance with this, although when 
challenged with the IGF-1R inhibitor ADW742 (1 pM) a 19.5% (p<0.001*) decrease 
in MCF-7X cell growth was observed (Figure 3.33), this was inferior to the 40.3% 
(p<0.001*) growth inhibitory effect in the MCF-7 cell line, where a dominant role for 
IGF-1R signalling prior to endocrine therapy has previously been established 
(Nicholson et al., 2004a). Finally there was no significant effect on MCF-7X cell 
growth when challenged with IGF-1R ligands IGF1 and -2 (Figure 3.34). In total, 
these data would suggest there is no dominant role for IGF-1R in MCF-7X growth, 
which is in contrast to some of the long-term oestrogen-deprived models generated in 
the presence of serum growth factors (Santen et al., 2004a; Martin et al., 2003).
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Figure 3.30 Basal MCF-7X versus MCF-7 cell mRNA expression o f 
IGF-1R by RT-PCR. MCF-7 and MCF-7X cells were grown on 100 mm dishes in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days before RNA was isolated and reverse transcribed. Co­
amplification RT-PCR of IGF-1R (26 cycles/ 55°C annealing temperature, 287 bp) and 
/?-Actin (204 bp) was performed. The RT-PCR product was run on a 2% agarose gel 
containing ethidium bromide, subsequently photographed, scanned and normalised to /?- 
Actin. The digital image above is representative of 3 experiments and the statistical 
analysis applied was an unpaired-T test (p=0.006*) comparing mean IGF-1R expression 
in MCF-7 (7.3 +/- 2.1) and MCF-7X (0.9 +/- 0.5) cells.
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Figure 3.31 Basal MCF-7X versus MCF-7 cell expression o f IGF-1R 
by Western blotting. MCF-7 and MCF-7X cells were grown on 60 mm dishes in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days prior to whole cell lysis, SDS-PAGE (30 pg of sample 
protein/well) and Western blotting. The nitrocellulose membrane (0.45 pm) was 
probed for total IGF-1R (125 kDa) and /?-Actin (42 kDa). The developed 
autoradiography film was scanned using densitometric imaging for each blot probed 
and IGF-1R expression was normalised to /?-Actin. The data is presented as die mean 
+/- SD and the image above is representative of 3 experiments.
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Total-
IGFR
Phospho-
IGFR
MCF-7 MCF-7X p-value
Total IGF-1R
(Membrane) 75.0 (68.8-82.5) 10.0 (10.0-12.8) 0.003*
(Cytoplasmic) 155.0 (151.3-161.3) 55.0 (50.0-61.3) 0.003*
Total 230.0 65.0
Phospho-IGFR
(Membrane) 32.0 (28.8-36.3) 20.0 (15.0-20.0) 0 .0 0 2 *
(Cytoplasmic) 125.0 (120.0-125.0) 135.0 (130.0-135.0) 0.028*
Total 157.0 155.0
Figure 3.32 Basal MCF-7X versus MCF-7 cell total and 
phosphorylated IGF-1R levels by immunocytochemistry. MCF-7 and 
MCF-7X cells were grown on coverslips in phenol-red-free RPMI media containing 5% 
SFCS or XFCS respectively. Conditions were maintained for 7 days prior to the 
appropriate fixation. The total IGF-1R (antibody dilution 1:125) and phosph-IGFR 
(1:150) assays required coverslips fixed in phenol formal saline and methanol vanadate 
acetone respectively. The digital images shown above (X20 magnification) are 
representative of 3 experiments. H-Score data was obtained by dual assessment of 2 
representative areas on each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in total/phospho- IGF-1R level between MCF-7 and 
MCF-7X cells.
MCF-7 MCF-7X
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Control ADW 742 luM
Figure 3.33 Effect of the IGF-1R inhibitor ADW 742 on the growth of 
MCF-7 and MCF-7X cells. MCF-7 and MCF-7X cells were grown on 24-well 
plates in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively in die 
absence or presence of ADW 742 (1 pM). Conditions were maintained for 7 days prior 
to trypsin dispersion and Coulter counting (triplicate wells per treatment). Data are 
displayed as a percentage of control cell growth and include 3 experiments +/- SD. The 
statistical analysis applied was an ANOVA Test followed by a Tamhane Post-Hoc Test.
* and 0 Denotes ADW 742 treatment significantly inhibited MCF-7 (p<0.001) and 
MCF-7X (p<0.001) cell growth versus their respective controls.
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HMCF-7X
Control
Figure 3.34 Effect of exogenous IGF ligands on the growth of MCF- 
7X cells. MCF-7X cells were grown on 24-well plates in phenol-red-free RPMI 
media containing 5% XFCS. Media was supplemented with IGF-1, -2 (10 ng/ml), Ej 
(10"9 M) or control (ethanol 1 pi/ 10 ml). Conditions were maintained for 7 days prior 
to trypsin dispersion and Coulter counting (triplicate wells per treatment). Data is 
displayed as percentage of control cell growth and include 4 experiments +/- SD. The 
statistical analysis applied was an ANOVA Test followed by a Tamhane Post-Hoc Test
0 Denotes Ej had a significant stimulatory effect on MCF-7X cell growth versus control 
(p<0.001).
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3.2.2 Epidermal Growth Factor Receptor (EGFR)/HER2 Signalling 
The over-expression of EGFR and HER2 has been found in a proportion of breast 
cancers and correlates with an adverse prognosis for survival. Implicated in our own 
acquired tamoxifen resistant cell line, there is evidence that the EGFR/HER2 pathway 
is involved in a cross-talk relationship with die ER that contributes to endocrine 
resistance (Knowlden et al., 2003b). Within the MCF-7X in vitro model detailed 
investigation of EGFR and HER2 tyrosine kinase signalling pathways was performed 
versus the parental MCF-7 cell line. Protein expression of total EGFR (175 kDa) by 
Western blotting (Figure 3.35) revealed low levels in both MCF-7X cells and MCF-7 
cells. While immunocytochemistry (Figure 3.36) revealed similar levels of plasma 
membrane EGFR expression in MCF-7X versus MCF-7 cells (p=0.866), cytoplasmic 
staining was significantly lower in the resistant line (65.7% fall, p=0.004*). 
Furthermore, while there was only a veiy low level of phosphorylated plasma 
membrane staining in both lines, again an obvious fall in cytoplasmic EGFR activity 
(42.9% fall, p=0.003*) using a pan-phospho-specific EGFR antibody was observed in 
MCF-7X cells.
RT-PCR indicated HER2 mRNA (98 bp) expression was equivalent in MCF-7X cells 
versus MCF-7 cells (p=0.275, Figure 3.37) with parallel Western blotting also 
indicating that total and phosphorylated HER2 (185 kDa) levels were similar in the 
two cell lines (Figure 3.38). There was similarly no significant change in expression 
of HER2 as detected by immunocytochemistry. However this technique did detect an 
apparent fall in MCF-7X cell membrane activity (33.3%, p=0.006*) versus MCF-7 
cells coupled with a significant fall in cytoplasmic activity (87.1%, p=0.003*, Figure 
3.39).
These EGFR/HER2 data suggest a diminished role for such signalling activity in 
MCF-7X versus MCF-7 cells. In agreement, there was a lack of obvious effect of 
inhibitors specifically targeting such signalling in MCF-7X cells (Figure 3.40). The 
selective EGFR tyrosine kinase inhibitor (TKI) gefitinib failed to significantly inhibit 
MCF-7X growth (p=0.102) using a 1 pM concentration. This has previously been 
demonstrated to be EGFR-selective and highly growth-inhibitory across our various 
anti-oestrogen resistant cell lines, versus the smaller significant effect on the parental 
MCF-7 cell line (32.9%, p<0.001*, Figure 3.40). Challenge with humanised HER2 
directed monoclonal antibody h^rceptin (100 nM) also failed to exert any growth
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inhibitory effect in MCF-7X cells (p=1.000) versus a modest significant effect in 
MCF-7 cells (21.5% fall, p=0.001*). Combination treatment was similarly 
ineffective in MCF-7X cells (Figure 3.40) however in MCF-7 cells the combination 
appeared equivalent to the significant effect of either herceptin or TKI alone (this arm 
of the experiment was only included once). Ligand challenge with an extensive range 
of peptide growth factors (10 ng/ml) for the erbB family of receptors (including 
HER3), notably epidermal growth factor (EGF), transforming growth factor-a 
(TGFa), heregulin- a, heregulin- P and amphiregulin, all failed to stimulate MCF-7X 
cell growth (Figure 3.41). There thus appears to be little EGFR/HER2 (and 
potentially HER3) signalling contribution to MCF-7X cell growth, contrasting several 
reported long-term oestrogen deprived cells developed in the presence of exogenous 
growth factors from Santen et al. (2004a), Martin et al. (2003) and Brodie et al. 
(1999).
Moreover, a range of ligands for further key growth factor receptors including 
fibroblast growth factors (FGFs), vascular endothelial growth factor (VEGF) and 
platelet derived growth factor (Figure 3.42) failed to exert any positive effect on 
growth in MCF-7X cells. These data cumulatively suggest no dominant role for 
classical growth factor receptor signalling in our long-term oestrogen deprived MCF- 
7X model derived in the absence of exogenous growth factors.
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MCF-7 MCF-7X
Total-EGFR 175 kDa
/?-Actin mmmm 42 kDa
MCF-7X
3.0+/-0.4
Figure 3.35 Basal MCF-7X versus MCF-7 cell expression o f EGFR by 
Western blotting. MCF-7 and MCF-7X cells were grown on 60 mm dishes in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days prior to whole cell lysis, SDS-PAGE (30 pg of sample 
protein/well) and Western blotting. The nitrocellulose membrane (0.45 pm) was 
probed for total EGFR (175 kDa) and )S-Actin (42 kDa). The developed 
autoradiography film was scanned using densitometric imaging for each blot probed 
and EGFR expression was normalised to /?-Actin. The data is presented as the mean +/- 
SD and the image above is representative of 3 experiments.
MCF-7
Total-EGFR 3.3+/- 0.8
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Total-
EGFR
Phospho-
EGFR
MCF-7 MCF-7X p-value
Total EGFR
(Membrane) 32.5 (30.0-40.3) 35.0 (30.0-40.0) 0 .8 6 6
(Cytoplasmic) 87.5 (78.8-100.0) 30.0 (28.0-35.0) 0.004*
Total 120.0 65.0
Phospho-EGFR
(Membrane) 3.0 (2.0-4.3) 1.5 (1.0-2.0) 0 .0 1 2 *
(Cytoplasmic) 70.0 (68.8-76.3) 40.0 (38.8-45.0) 0.003*
Total 73.0 41.5
Figure 3.36 Basal MCF-7X versus MCF-7 cell total and 
phosphorylated EGFR levels by immunocytochemistry. MCF-7 and MCF- 
7X cells were grown on coverslips in phenol-red-free RPMI media containing 5% 
SFCS or XFCS respectively. Conditions were maintained for 7 days prior to the 
appropriated fixation. The total EGFR (antibody dilution 1:100) and the phospho- 
EGFR (1:5) assays required coverslips fixed in phenol formal saline and methanol 
acetone respectively. The digital images shown above (X20 magnification) are 
representative of 3 experiments. H-Score data were obtained by dual assessment of 2 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in total/phospho- EGFR level between MCF-7 and 
MCF-7X cells.
MCF-7 MCF-7X
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•4 -/?-A ctin  (204 bp) 
•4-HER2 (98 bp)
I  MCF-7 SMCF-7X
Figure 3.37 Basal MCF-7X versus MCF-7 cell mRNA expression o f 
HER2 by RT-PCR. MCF-7 and MCF-7X cells were grown on 100 mm dishes in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days before RNA was isolated and reverse transcribed. 
Individual RT-PCR of HER2 (35 cycles/ 55°C annealing temperature, 98 bp) and /?- 
Actin (25 cycles/ 55°C annealing temperature, 204 bp) was performed. Product from 
each reaction was combined and run on a 2% agarose gel containing ethidium bromide, 
subsequently photographed, scanned and normalised to /?-Actin. The digital image 
above is representative of 3 experiments and the statistical analysis applied was an 
unpaired-T test (p=0.275) comparing mean HER2 expression in MCF-7 (0.7 +/- 0.1) 
and MCF-7X (0.6 +/- 0.1) cells.
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MCF-7 MCF-7X
Total- 185 kDaHER2
Phospho-
HER2
185 kDa
42 kDa/?-Actin
MCF-7 MCF-7X
Total-HER2 2.6+/-0.3 2.3+/-0.5
Phospho-HER2 2.5+/-0.5 2.7+/-0.4
Figure 3.38 Basal MCF-7X versus MCF-7 cell levels o f total and 
phosphorylated HER2 by Western blotting. MCF-7 and MCF-7X cells were 
grown on 60 mm dishes in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively. Conditions were maintained for 7 days prior to whole cell lysis, SDS- 
PAGE (30 pg of sample protein/well) and Western blotting. The nitrocellulose 
membrane (0.45 pm) was probed for total HER2 (185 kDa), phospho-HER2 (185 kDa) 
and /TActin (42 kD). The developed autoradiography film was scanned using 
densitometric imaging for each blot probed. Subsequently, both total and phospho- 
HER2 blots were normalised to ^ -Actin. The data is presented as the mean +■/- SD and 
the image above is representative of 5 experiments.
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MCF-7 MCF-7X
Total-
HER2
Phospho-
HER2
Total HER2
(Membrane)
(Cytoplasmic)
Total
Phospho-HER2
(Membrane)
(Cytoplasmic)
Total
MCF-7
57.5 (45.0-60.0)
30.0 (25.0-31.3)
87.5
22.5 (20.0-31.5)
77.5 (73.8-81J)
100.0
MCF-7X
67.5 (51.3-78.8) 
25.0 (20.0-30.0)
92.5
15.0 (13.8-16.3)
10.0 (10.0-15.0)
25.0
p-value
0.107
0.117
0.006*
0.003*
Figure 3.39 Basal MCF-7X versus MCF-7 cell total and 
phosphorylated HER2 levels by immunocytochemistry. MCF-7 and MCF- 
7X cells were grown on coverslips in phenol-red-free RPMI media containing 5% 
SFCS or XFCS respectively. Conditions were maintained for 7 days prior to the 
appropriate fixation. The total HER2 (antibody dilution 1:100) and the phospho-HER2 
(1:20) assays required coverslips fixed in ERICA and methanol vanadate acetone 
respectively. The digital images shown above (X20 original magnification) are 
representative of 3 experiments. H-Score data were obtained by dual assessment of 2 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in total/phospho- HER2 level between MCF-7 and 
MCF-7X cells.
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C o n tr o l  G e f i t in ib ( l u M )  H e rc e p t in ( lO O n M )  G e f i t in ib ( l u M )  +
H e r c e p t in ( 1 0 0  nM )
Figure 3.40 Effect o f the EGFR inhibitor gefitinib and the HER2 
monoclonal antibody herceptin singly and in combination on the 
growth o f MCF-7 and MCF-7X cells. MCF-7 and MCF-7X cells were grown 
on 24-well plates in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively in the absence and presence of gefitinib (1 pM), herceptin (100 nM) or 
gefitinih/herceptin co-treatement Conditions were maintained for 7 days prim’ to 
trypsin dispersion and Coulter counting (triplicate wells per treatment). Data are 
displayed as a percentage of control cell growth and include 4 experiments +/- SD, with 
the exception of the gefitinih/herceptin combination (1 experiment only). The statistical 
analysis applied was an ANOVA Test followed by a Tamhane Post-Hoc Test
* Denotes gefitinib (p<0.001) and herceptin (p=0.001) treatment significantly inhibited 
MCF-7 cell growth versus control.
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S M C F -7 X
Control EGF
Figure 3.41 Effect o f exogenous EGF-like ligands on the growth o f 
MCF-7X cells. MCF-7X cells were grown on 24-well plates in phenol-red-free 
RPMI media containing 5% XFCS. Media was supplemented (10 ng/ml) with EGF, 
TGFa, Heregulin-a, Heregulin-/?, amphiregulin, Ej (10*9 M) or control (1 pi/ 10 ml). 
Conditions were maintained for 7 days prior to trypsin dispersion and Coulter 
counting (triplicate wells per treatment). Data are displayed as a percentage of control 
cell growth and include 4 experiments +/- SD. The statistical analysis applied was an 
ANOVA Test followed by a Tamhane Post-Hoc Test
0 Denotes Ej had significant stimulatory effect on MCF-7X cell growth versus control 
(p<0.001).
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HMCF-7X
Control aFGF bFOF FGF7 VEGF PDGF E2
Figure 3.42 Effect o f exogenous FGF, VEGF, and PDGF ligands on 
the growth o f MCF-7X ceUs. MCF-7X cells were grown on 24-well plates in 
phenol-red-free RPMI media containing 5% XFCS. Media was supplemented (10 
ng/ml) with acidic FGF, basic FGF, FGF7, VEGF, PDGF, E2  (10-9 M) or control 
(ethanol 1 pi/ 10 ml). Conditions were maintained for 7 days prior to trypsin 
dispersion and Coulter counting (triplicate wells per treatment). Data are displayed as 
a percentage of control cell growth and include 4 experiments +/- SD. The statistical 
analysis applied was an ANOVA Test followed by a Tamhane Post-Hoc Test.
0 Denotes E2  had a significant stimulatory effect on MCF-7X cell growth versus 
control (pO.OOl).
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3.3 GROWTH FACTOR SIGNALLING PATHWAYS: INTRACELLULAR 
KINASES
3.3.1 Mitogen Activated Protein Kinase (MAPK) Signalling 
An adaptive increase in the activity of ERK1/2 mitogen activated protein kinase 
(MAPK) and recruitment to growth has been implicated from our own studies o f anti­
oestrogen resistance (McClelland et al., 2001; Gee et al., 2003). Parallel in vitro and 
in vivo evidence also suggests this adaptation occurs in long-term oestrogen 
deprivation (Jeng et al., 2000; Martin et al., 2003; Santen et al., 2004a). MAPK 
(42/44 kDa) was detectable in MCF-7X cells by Western blotting and its expression 
and activity was unchanged versus the parental MCF-7 cells known to exhibit quite 
low levels of such signalling using this detection procedure (Figure 3.43). 
Immunocytochemistry (Figure 3.46) revealed very little nuclear phosphorylated 
MAPK in either MCF-7 or MCF-7X cells, but was able to detect a significant 46.1% 
decrease (p=0.002*) in cytoplasmic-localised phosphorylated MAPK in the resistant 
line attributed predominantly to a reduction in the percentage of positive staining.
Challenge with the MAP kinase kinase (MEK1) inhibitor PD98059 was able to 
significantly reduced MCF-7 cell growth 35.0% (p<0.001*) by day 7 (Figure 3.44). 
In keeping with the reduced prominence o f MAPK activity in MCF-7X cells, 
PD98059 (25 pM) was unable to substantially inhibit cell growth. Moreover growth 
curve studies revealed PD98059 effect measured at day 7 or day 15 could not produce 
a significant growth inhibitory effect (Figure 3.45, p=1.000). This was despite the 
MEK1 inhibitor after 7 days significantly depleting the cytoplasmic phosphorylated 
MAPK in both MCF-7 and MCF-7X cells (53.1%, p=0.003* and 70.0%, p=0.001* 
respectively) as detected by immunocytochemistry (Figure 3.46). Western blotting in 
MCF-7X cells confirmed this reduction of phosphorylated MAPK with PD98059 
(Figure 3.47). Clearly, although there may be a small contribution for MAPK 
signalling in MCF-7 cells, this kinase does not appear to provide a dominant growth 
mechanism in MCF-7X cells.
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MCF-7 MCF-7X
Total-
MAPK
Phospho-
MAPK
/?-Actin
42/44 kDa
42/44 kDa
42 kDa
TotaLMAPK
Phospho-MAPK
MCF-7
1.9+/-0.4 
1.7+/-0.6
MCF-7X
1.6+/-03 
1.3+/-0.5
Figure 3.43 Basal MCF-7X versus MCF-7 cell levels o f  total and 
phosphorylated MAPK by Western blotting. MCF-7 and MCF-7X cells were 
grown on 60 mm dishes in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively. Conditions were maintained for 7 days prior to whole cell lysis, SDS- 
PAGE (30 pg of sample protein/well) and Western blotting. The nitrocellulose 
membrane (0.45 pm) was probed for total MAPK (42/44 kDa), phosphorylated MAPK 
(42/44 kDa) and /?-Actin (42 kDa). The developed autoradiography film was scanned 
using densitometric imaging for each blot probed. Subsequently, both total and 
phospho-MAPK blots were normalised to /?-Actin. The data is presented as the mean 
+/- SD and the image above is representative of 4 experiments.
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Control PD98059 (25 uM)
Figure 3.44 Effect o f the MEK-1 inhibitor PD98059 on the growth o f 
MCF-7 and MCF-7X cells. MCF-7 and MCF-7X cells were grown on 24-well 
plates in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively in the 
absence or presence of PD98059 (25 pM). Conditions were maintained for 7 days prior 
to trypsin dispersion and Coulter counting (triplicate wells per treatment). Data are 
displayed as a percentage of control cell growth and include 5 experiments +/- SD. The 
statistical analysis applied was an ANOVA Test followed by a Tamhane Post-Hoc Test
* Denotes PD98059 treatment significantly inhibited MCF-7 (p<0.001) cell growth 
versus control.
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Figure 3.45 Growth o f MCF-7X cells challenged with the MEK-1 
inhibitor PD98059. MCF-7X cells were grown on 24-well plates in phenol-red- 
free RPMI media containing 5% XFCS in the absence or presence of PD98059 (25 pM) 
for 15 days. At the time points indicated above, cells were subject to trypsin dispersion 
followed by Coulter counting (triplicate wells per time point). The data were log 
transformed to compare growth rate at day 7 and 15. The statistical analysis applied 
was an ANOVA Test followed by a Bonferroni Post-Hoc Test. The data is displayed as 
the mean number of cells/well +/- SD (n=5).
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Phospho-MAPK
MCF-7 MCF-7X
Control
+ PD98059 
(25 pM)
MCF-7 MCF-7X
Phospho-MAPK 
Basal Control
(Cytoplasm ic) 65.0 (63.8-72.5)
(Nuclear) 5.0 (3.0-5.0)
Total 70.0
+ PD98059 (25 pM)
(Cytoplasmic) 30.5(30.0-363) p=0.003# 10.5(5.0-10.0) p=0.001*
(Nuclear) 5.0(3.8-5.5) p=0.589 1.0(1.0-18) p=0.023*
Total 35.5 11.5
Figure 3.46 Effect o f the MEK-1 inhibitor PD980S9 on phosphorylated 
MAPK level in MCF-7 and MCF-7X cells by immunocytochemistry.
MCF-7 and MCF-7X cells were grown on coverslips in phenol-red-free RPMI media 
containing 5% SFCS or XFCS respectively in the absence or presence of PD98059 (25 
pM). Conditions were maintained for 7 days prior to formal saline fixation. The 
phospho-MAPK (antibody dilution 1:20) digital images shown above (X20 
magnification) are representative of 4 experiments. H-Score data was obtained by dual 
assessment of 2  representative areas of each coverslip followed by statistical analysis 
(Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are displayed. A p- 
value <0.05(*) indicates a significant difference in phospho-MAPK level following 
PD98059 treatment.
35.0 (35.0-48.8)
3.5 (13-5.0)
38.5
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MCF-7X
Control + PD98059
(25 pM)
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MAPK
42/44 kDa
/f-Actin
Figure 3.47 Effect o f the AfEK-1 inhibitor PD98059 on phosphorylated 
MAPK level in MCF-7X cells by Western blotting. MCF-7X cells were 
grown on 60 mm dishes in phenol-red-free media containing 5% XFCS in the absence 
and presence of PD98059 (25 pM). Conditions were maintained for 7 days prior to 
whole cell lysis, SDS-PAGE (40 pg of sample protein/well) and Western blotting. The 
nitrocellulose membrane (0.45 pm) was probed for phospho-MAPK (42/44 kDa) and /?- 
Actin (42 kDa). The developed autoradiography film was scanned using densitometric 
imaging for each blot probed and phospho-MAPK level was normalised to Actin. 
Above is a representative experiment
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3.3 .2  PI3K /A K T S ignalling
The AKT/PKB kinase lies downstream of PI3 kinase (PI3K) and controls a number of 
intracellular processes that have been implicated in the genesis and/or progression of 
breast cancer, mainly effector molecules involved in regulating cell survival and cell 
cycle progression (Zinda et al., 2001). Three isoforms of AKT have been identified, 
AKT-1, -2, and -3  which are expressed in a wide array of breast cancer cell lines. 
However AKT-3 expression is reported to be exclusive to ER negative cells 
(Nakatani et al., 1999). Investigation of mRNA by RT-PCR (Figure 3.48) revealed 
MCF-7X cells have equivalent AKT-1 (329 bp) and -2  (314 bp) expression to MCF-7 
cells and these cell lines lack AKT-3 expression (data not shown). Although, total 
and phosphoiylated AKT (60 kDa) levels were equivalent in MCF-7 versus MCF-7X 
cells by Western blotting (Figure 3.49), parallel monitoring of phosphorylated AKT 
by immunocytochemistry (Figure 3.52) revealed a differential staining pattern. MCF- 
7X cells had a significant increased level of membrane plus cytoplasmic signal due to 
increased stain intensity (170.7%, p=0.004*). In contrast, MCF-7 cells had a 
significant increased level (58.1%, p=0.004*) of nuclear AKT activity compared to 
MCF-7X cells. This differential pattern across the two cell lines is likely to explain 
the equivalent overall phosphorylated AKT levels observed by Western blotting. 
PDK-1 (phosphoinositide-dependent protein kinase-1) is also a downstream 
signalling element of PI3K and immunocytochemistry (Figure 3.54) demonstrated its 
activity in the cytoplasm, like AKT, was also significantly increased (34.9%) in 
MCF-7X cells compared to MCF-7 cells (p=0.004*). This increase was 
predominantly due to increased staining intensity in MCF-7X.
The PI3K inhibitor LY294002 (5 pM) was superior in reducing MCF-7X cell growth 
49.1% (p<0.001*) after 7 days of treatment versus a modest 21.6% (p<0.001*) 
inhibitory effect on MCF-7 cell growth (Figure 3.50). A growth curve subsequently 
monitoring the effect of LY294002 on MCF-7X cell growth revealed that the 
inhibitory response was further increased to 69.1% (p<0.001*) by day 15 versus the 
untreated control (Figure 3.51). PI3K/AKT signalling thus appears to be of increased 
importance to MCF-7X cell growth versus the parental line, in accordance with the 
increased cytoplasmic activity o f AKT and PDK-1. To ensure the agent was targeting 
the activity of die PI3K pathway in parallel with these growth effects in MCF-7X 
cells, immunocytochemistry and Western blotting were employed to evaluate the 
status of phosphorylated AKT and PDK-1 before and after 7 day treatment.
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LY294002 treatment resulted in a significant decrease of phosphorylated AKT, 
comprising a 66.0% (p=0.004*) decrease in membrane plus cytoplasmic activity 
coupled with a 32.1% (p=0.004*) decrease in nuclear activity by
immunocytochemical analysis o f MCF-7X cells (Figure 3.52). In contrast, there was 
a smaller significant decline in membrane plus cytoplasmic AKT activity alone 
detected with LY294002 in MCF-7 cells (17.3% fall, p=0.012*). Western blotting in 
MCF-7X cells confirmed an obvious reduction of phosphorylated AKT in MCF-7X 
cells treated with LY294002 (Figure 3.53). The activity of PDK-1 was also 
investigated following treatment challenge with the PBK inhibitor LY294002 by 
immunocytochemistry (Figure 3.54) in MCF-7 and MCF-7X cells. The results 
revealed a 31.0% (p=0.004*) inhibitory effect on the cytoplasmic activity of PDK-1 
in MCF-7X cells, largely due to a decreased intensity of positive staining, in contrast 
to the lack of inhibitory effect in MCF-7 cells. To further qualify the apparent growth 
contribution of PBK signalling in MCF-7X cells, the impact of the PBK inhibitor 
wortmannin (1 pM) was briefly examined in these cells. This agent partially 
inhibited growth 25.9% in MCF-7X cells (Figure 3.55) at 7 days, an event that was 
again associated with a significant depletion of AKT activity. Immunocytochemistry 
revealed a 31.0% (p=0.041*) reduction in membrane plus cytoplasmic activity and a 
32.6% (p=0.004*) decrease in nuclear activity in MCF-7X cells (Figure 3.56). 
Furthermore, unlike LY294002 treatment wortmannin treatment had no effect (Hi the 
phosphorylation of cytoplasmic localised PDK-1 (p=0.104, Figure 3.56).
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U-^-Actin (204 bp)
AKT-2 (314 bp) 
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AKT-1 AKT-2
Figure 3.48 Basal MCF-7 versus MCF-7X cell mRNA expression o f  
AKT-1 and AKT-2 by RT-PCR. MCF-7 and MCF-7X cells were grown on 100  
mm dishes in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. 
Conditions were maintained for 7 days before RNA was isolated and reverse 
transcribed. Co-amplification RT-PCR of AKT-1 (29 cycles/ 55°C annealing 
temperature, 329 bp) and /?-Actin (204 bp) was performed. Co-amplification RT-PCR 
of AKT-2 (29 cycles/ 55°C annealing temperature, 314 bp) and /?-Actin was performed. 
Product from each reaction was run on a 2% agarose gel containing ethidium bromide, 
subsequently photographed, scanned and normalised to /?-Actin. The digital images 
above are representative of 3 experiments (for each target sequence) and the statistical 
analysis applied was an unpaired-T test comparing mean AKT-1 expression (p=0.974) 
in MCF-7 (2.1 +/- 1.5) and MCF-7X (2.8 +/- 0.6) cells. An unpaired-T test was also 
applied to compare mean AKT-2 expression (p=0.758) in MCF-7 (2.5 +/- 1.7) and 
MCF-7X (2.2 +/- 0.6) cells.
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MCF-7 MCF-7X
Total-
AKT
Phospho-
AKT
/?-Actin
60 kDa
60 kDa
42 kDa
MCF-7 MCF-7X
Total-AKT 2.4+/-0.6 2.4 +/- 0.8
Phospho-AKT 2.1 +/-0.9 1.9+/- 0.6
Figure 3.49 Basal MCF-7X versus MCF-7 cell levels o f  total and 
phosphorylated AKT by Western blotting. MCF-7 and MCF-7X cells were 
grown on 60 mm dishes in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively. Conditions were maintained for 7 days prior to whole cell lysis, SDS- 
PAGE (40 pg of sample protein/well) and Western blotting. The nitrocellulose 
membrane (0.45 pm) was probed for total AKT (60 kDa), phosphorylated AKT (60 
kDa) and /f-Actin (42 kDa). The developed autoradiography film was scanned using 
densitometric imaging for each blot probed. Subsequently, both total and phospho- 
AKT blots were normalised to y5-Actin. The data is presented as the mean +/- SD and 
the image above is representative of 4 experiments.
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Figure 3.50 Effect of the PBK inhibitor LY294002 on the growth of 
MCF-7 and MCF-7X cells. MCF-7 and MCF-7X cells were grown on 24-well 
plates in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively in the 
absence or presence of LY294002 (5 pM). Conditions wore maintained for 7 days prior 
to trypsin dispersion and Coulter counting (triplicate wells per treatment). Data are 
displayed as a percentage of control cell growth and include 5 experiments +/- SD. The 
statistical analysis applied was an ANOVA Test followed by a Tamhane Post-Hoc Test
* and 0 Denotes LY294002 treatment significantly inhibited MCF-7 (p<0.001) and 
MCF-7X (p<0.001) cell growth versus their respective controls.
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Figure 3.51 Growth o f  MCF-7X cells challenged with the PI3K 
inhibitor LY294002. MCF-7X cells were grown on 24-well plates in phenol-red- 
free RPMI media containing 5% XFCS in the absence or presence of the PI3K inhibitor 
LY294002 (5 pM) for 15 days. At the time points indicated above, cells were subject 
to trypsin dispersion followed by Coulter counting (triplicate wells per time point). The 
data was log transformed to compare growth rate at day 7 and 15. The statistical 
analysis applied was an ANOVA Test followed by a Bonferroni Post-Hoc Test. The 
data is displayed as the mean number of cells/well +/- SD (n=5).
0 Denotes LY294002 treatment was significantly lower at day 7 (p<0.001) and day 15 
(p<0.001) versus untreated MCF-7X cells.
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Phospho-AKT
MCF-7 MCF-7X
Control
+ LY294002 
(5pM)
MCF-7 MCF-7X
Phospho-AKT 
Basal Control
(Memb. + Cyto.) 
(Nuclear)
Total
+ LY294002 (5 pM)
(Memb. + Cyto.) 
(Nuclear)
Total
37.5 (33.5-43.0)
170.0 (157.5-181.3)
207.5
101.5 (76.5-1193)
107.5 (95.0-112.5)
209.0
31.0(26.0-33.0) p=0.012* 34.5(32.0-57.0) p=0.004*
157.5(1513-168.8) p=0.197 73.0(61.0-813) p=0.004*
188.5 107.5
Figure 3.52 Effect o f  the PI3K inhibitor LY294002 on phosphorylated 
AKT level in MCF-7 and MCF-7X cells by immunocytochemistry.
MCF-7 and MCF-7X cells were grown on coverslips in phenol-red-free RPMI media 
containing 5% SFCS or XFCS respectively in the absence or presence of LY294002 (5 
pM). Conditions were maintained for 7 days prior to ERICA fixation. The phospho- 
AKT (antibody dilution 1:200) digital images above (MCF-7 cells X40 magnification 
and MCF-7X cells X20) are representative of 4 experiments. H-Score data were 
obtained by dual assessment of 2  representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in phospho-AKT 
level following LY294002 treatment
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Figure 3,53 Effect o f  the PI3K inhibitor on phosphorylated AKT level 
in MCF-7X cells by Western blotting, MCF-7X cells were grown on 60 mm 
dishes in phenol-red-free media containing 5% XFCS in the absence and presence of 
LY294002 (5 pM). Conditions were maintained for 7 days prior to whole cell lysis, 
SDS-PAGE (40 pg of sample protein/well) and Western blotting. The nitrocellulose 
membrane (0.45 pm) was probed for phospho-AKT (60 kDa) and /?-Actin (42 kDa). 
The developed autoradiography film was scanned using densitometeric imaging for 
each blot probed and phospho-AKT expression was normalised to /?-Actin. Above is a 
representative experiment.
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Phospho-PDK-1 
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(Cytoplasmic) 107.5 (103.8-1123) 145.0 (140.0-160.0)
+ LY294002 (5 pM)
(Cytoplasmic) 142.5 (1353-155.0) p=0.328 100.0 (93.8-101.3) p=0.004*
Figure 3,54 Effect o f  LY294002 on phosphorylated PDK-1 level in 
MCF-7 and MCF-7X by immunocytochemistry, MCF-7 and MCF-7X cells 
were grown for 7 days on coverslips in die presence of LY294002 (5 pM) prior to 
ERCLA fixation. The phosphorylated PDK-1 (antibody dilution 1:50) digital images 
shown above (X20 magnification) are representative of 2 experiments. H-Score data 
were obtained by dual assessment of 3 representative areas of each coverslip followed 
by statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in phosphp-PDK-1 
level following LY294002 treatment.
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Figure 3.55 Effect o f the PI3K inhibitor wortmannin on ceil growth in 
MCF-7X ceUs. MCF-7X cells were grown on a 24-well plate in phenol-red-free 
RPMI media containing 5% XFCS in die absence or presence of wortmannin (1 pM). 
Conditions were maintained for 7 days prior to trypsin dispersion and Coulter counting 
(triplicate wells per treatment). Data are displayed as a percentage of control cell 
growth and include 1 experiment
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Figure 3,56 Effect o f  the PI3K inhibitor wortmannin on 
phorsphorylated AKT and PDK-1 levels in MCF-7X cells by 
immunocytochemistry, MCF-7X cells were grown on coverslips in phenol-red- 
free RPMI media containing 5% XFCS in the absence or presence of wortmannin (1 
pM) prior to ERICA fixation. The phospho-AKT (antibody dilution 1:200) and 
phospho-PDK-1 (antibody dilution 1:200) digital images shown above (X20 
magnification) are representative of 2 experiments. H-Score data were obtained by 
dual assessment of 3 representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant difference in phospho-AKT level 
following wortmannin treatment in MCF-7X cells versus basal control.
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3.3.3 Protein K inase-C  (PKC) a  and 5
Protein kinase C (PKC) is composed of a family of serine/threonine protein kinases 
which have been implicated in a wide variety of signalling and regulatory events such 
as mitogenesis, tumourigenesis and differentiation (Blobe et al., 1996). PKCs can be 
associated with more aggressive forms of breast cancer (Patrick and Heimbrook, 
1996). Prominent among these are PKCS and PKCa, where associations are 
emerging with endocrine resistance and in the latter instance with ER negativity in 
vitro (Chisamore et al., 2001). Investigating these two PKC family members by RT- 
PCR revealed MCF-7X cell mRNA expression of PKCa was significantly decreased 
compared to MCF-7 cells (47.2% fall, p=0.030*, Figure 3.57), while PKCS 
expression was detected at a lower and apparently equivalent level in berth cell lines. 
While PKCa activity was not examined, Western blotting (Figure 3.58) demonstrated 
some increase in phosphorylated PKCS in MCF-7X cells (57.7%, 78 kDa). In 
parallel, immunocytochemistry demonstrated a 37.5% (p=0.003*) increase in nuclear 
staining for such activity in MCF-7X cells (Figure 3.59), although there were 
somewhat lower levels o f cytoplasmic staining (35.0, p=0.011 *). It was also revealed 
by immunocytochemistry that total PKCS expression was low in both cell lines, with 
this technique again showing significant decreases predominantly in the cytoplasmic 
staining in MCF-7X cells (48.7%, Figure 3.59) compared to MCF-7 cells. When 
challenged with the PKC inhibitor bisindolylmaleimide (Bis, 0.5 pM) there was no 
impact on growth suggesting that there is no substantial growth regulatory role for 
PKCs in MCF-7X (Figure 3.60). The contrasting MCF-7 cell growth data indicate 
there was some contribution for such signalling in these cells as the inhibitor was 
responsible for a significant 29.1% (p=0.001*) inhibitory effect at day 7.
3.3.4 Src
A number of growth factor receptor-driven responses have been functionally linked to 
Src, such as the activation of She followed by Grb2 and SOS recruitment leading to 
stimulation of the Ras-MAPK pathway (Blake et al., 2000). Recently, steroid 
hormones have been implicated in the rapid activation of intracellular signalling 
cascades, whereby membrane associated receptors interact directly with and activate 
Src and other molecules such as She, PI3K and pl30 Cas impacting on cell growth 
(Shupnik, 2004). RT-PCR revealed an equivalent level of mRNA expression of Src 
(433 bp) in MCF-7 and MCF-7X cells (Figure 3.61). While Src protein expression 
measured by Western blotting (Figure 3.62) paralleled the mRNA expression,
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phosphorylated Src (60 kDa) was increased in MCF-7X cells with respect to MCF-7 
cells. Despite this, when challenged with the specific Src inhibitor SU6656 (1.0 pM) 
MCF-7X cell growth was only reduced by 12.2% (p=0.011*), with a superior 
inhibition of 23.1% observed in MCF-7 cell (p=0.006*) after 7 days of treatment 
(Figure 3.63). Thus, Src signalling appears to make a diminished growth contribution 
in the resistant cells.
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Figure 3.57 Basal MCF-7 versus MCF-7X cell mRNA expression o f  
PKCa and PKCS by RT-PCR. MCF-7 and MCF-7X cells were grown on 100  
mm dishes in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. 
Conditions were maintained for 7 days before RNA was isolated and reverse 
transcribed. Individual RT-PCR of PKCa (34 cycles/ 55°C annealing temperature, 494 
bp) and /?-Actin (25 cycles/ 55°C annealing temperature, 204 bp) was performed. 
Product from each reaction was combined and run on a 2% agarose gel containing 
ethidium bromide, subsequently scanned, and normalised to /?-Actin. Co-amplification 
RT-PCR of PKC5 (30 cycles/ 55°C annealing temperature, 351 bp) and /9-Actin (204 
bp) was performed. RT-PCR product was run on a 2% agarose gel containing ethidium 
bromide, subsequently photographed, scanned and normalised to /?-Actin. The digital 
images above are representative of 3 experiments (for each target sequence) and the 
statistical analysis applied was an unpaired-T test comparing mean PKCa expression 
(p=0.030*) in MCF-7 (0.36 +/- 0.08) and MCF-7X (0.19 +/- 0.03) cells. An unpaired- 
T test was also applied to compare mean PKC5 expression (p=0.706) in MCF-7 (0.05 
+/- 0.03) and MCF-7X (0.04 +/- 0.01) cells.
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Phospho-PKCd 2.6 +/- 0.8 4.1 +/- 0.5
Figure 3.58 Basal MCF-7X versus MCF-7 cell level o f 
phosphorylated PKCS by Western blotting. MCF-7 and MCF-7X cells 
were grown on 60 mm dishes in phenol-red-free RPMI media containing 5% SFCS or 
XFCS respectively. Conditions were maintained for 7 days prior to whole cell lysis, 
SDS-PAGE (30 [Lg of sample protein/well) and Western blotting. The nitrocellulose 
membrane (0.45 pm) was probed for phosphorylated PKC-6  (78 kDa) and /?-Actin (42 
kDa). The developed autoradiography film was scanned using densitometric imaging 
for each blot probed and phospho-PKC5 level was normalised to /?-Actin. The data is 
presented as die mean +/- SD and the image above is representative of 5 experiments.
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Figure 3.59 Basal MCF-7X versus MCF-7 cell total and 
phosphorylated PKCS levels by immunocytochemistry. MCF-7 and MCF- 
7X cells were grown on coverslips in phenol-red-free RPMI media containing 5% 
SFCS or XFCS respectively. Conditions were maintained for 7 days prior to the 
appropriate fixation. The total PKC-8  (antibody dilution 1:50) and phosphorylated 
PKC-8  (1:20) assays required coverslips fixed in ERICA. The digital images shown 
above (X40 magnification) are representative of 3 experiments. H-Score data were 
obtained by dual assessment of 2  representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in total/phospho- 
PKC-5 level between MCF-7 and MCF-7X cells.
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Figure 3.60 Effect o f the PKC inhibitor bis-indoylmaleimidine (Bis) 
on the growth o f MCF-7 and MCF-7X cells. MCF-7 and MCF-7X cells were 
grown on 24-well plates in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively in the absence or presence o f Bis (0.5 pM). Conditions were maintained 
for 7 days prior to trypsin dispersion and Coulter counting (triplicate wells per 
treatment). Data are displayed as a percentage of control cell growth and include 5 
experiments +/- SD. The statistical analysis applied was an ANOVA Test followed by 
a Tamhane Post-Hoc Test
* Denotes Bis treatment significantly inhibited MCF-7 (p=0.001) cell growth versus 
control.
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Figure 3.61 Basal MCF-7X versus MCF-7 cell mRNA expression o f 
c-src by RT-PCR.. MCF-7 and MCF-7X cells were grown on 100  mm dishes in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. Conditions 
were maintained for 7 days before RNA was isolated and reverse transcribed. RT- 
PCR of c-src (30 cycles/ 55°C annealing temperature, 433 bp) was performed. RT- 
PCR product was run on a 2% agarose gel containing ethidium bromide and 
subsequently photographed. The digital image above is representative of 1 
experiment therefore no statistical analysis was applied.
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Figure 3.62 Basal MCF-7X versus MCF-7 cell levels o f total and 
phosphorylated Src by Western blotting. MCF-7 and MCF-7X cells were 
grown on 60 mm dishes in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively. Conditions were maintained for 7 days prior to whole cell lysis, SDS- 
PAGE (40 pg of sample protein/well) and Western blotting. The nitrocellulose 
membrane (0.45 pm) was probed for total Src (60 kDa), phosphorylated Src (60 kDa) 
and /TActin (42 kDa). The developed autoradiography film was scanned using 
densitometric imaging for each blot probed. Subsequently, both total and phospho- Src 
blots were normalised to /?-Actin. The data is presented as the mean +/- SD and the 
image above is representative of 3 experiments.
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Figure 3.63 Effect o f the specific Src inhibitor SU6656 on the growth 
of MCF-7 and MCF-7X cells. MCF-7 and MCF-7X cells were grown on 24- 
well plates in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively 
in die absence or presence of SU6656 (1 pM). Conditions were maintained for 7 days 
prior to trypsin dispersion and Coulter counting (triplicate wells per treatment). Data 
are displayed as a percentage of control cell growth and include 3 experiments +/- SD. 
The statistical analysis applied was an ANOVA Test followed by a Tamhane Post-Hoc 
Test
* and 0 Denotes SU6656 treatment significantly inhibited MCF-7 (p=0.006) and MCF- 
7X (p=0.011) cell growth versus control.
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3.4 GROWTH FACTOR SIGNALLING KINASES AND ERa CROSS­
TALK
In addition to their direct promotion of growth, the intracellular kinases MAPK and 
PI3K/AKT have been shown in anti-oestrogen resistant (Nicholson et al., 2004b) and 
long-term oestrogen deprived models (Santen et al., 2004a; Martin et al., 2003) to 
interact with die oestrogen receptor to drive growth. This can occur either via kinase 
activation of the key AF-1 residues Seri 18 or 167 on ER (or alternatively of its co­
activators), or through ligand-activated plasma membrane ER triggering downstream 
kinase activity. In the present study, it was important to investigate whether there 
was any evidence for kinase/ER cross-talk in MCF-7X cells, focusing on cross-talk at 
the level of nuclear ERa given the apparent absence of a significant non-genomic 
contribution either to MCF-7X or their parental cells.
3.4.1 The Influence o f  M APK Signalling on ER a Signalling
In both MCF-7 and MCF-7X cells while challenge with the MEK-1 inhibitor 
PD98059 diminished MAPK activation, modest inhibition of cell growth was only 
observed in the former cells. There was no significant effect o f this agent on total 
nuclear ERa (Figure 3.64) or on the phosphorylation status of the Seri 18ER (Figure 
3.65) or Serl67ER residues (Figure 3.66) in the two cells lines as detected using 
immunocytochemistry. Furthermore, die agent failed to inhibit ERE transcription or 
endogenous pS2 expression. The ERE reporter assays performed in MCF-7X cells 
indicated PD98059 inhibition of MAPK did not reduce ERE activity following 18 
hour treatment (Figure 3.67). RT-PCR performed on mRNA of MCF-7X cells treated 
with PD98059 for 7 days revealed no change in pS2 expression (Figure 3.68). There 
was similarly no significant effect on MCF-7X cell, or indeed MCF-7, pS2 protein 
expression by immunocytochemistry (Figure 3.69). In total, these data indicate there 
is no positive MAPK cross-talk with ERa signalling in MCF-7X cells, and similarly 
that the small growth contribution of MAPK in MCF-7 cells is independent of 
interplay of this kinase with nuclear ERa.
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+ PD98059 (25 pM) 155.0(147.5-1613) p=0.173 180.0(175.0-186.3) p=0.204
Figure 3.64 Effect o f the MEK-1 inhibitor PD98059 on ERa 
expression in MCF-7 and MCF-7X cells by immunocytochemistry.
MCF-7 and MCF-7X cells were grown on coverslips in phenol-red-free RPMI media 
containing 5% SFCS or XFCS respectively in the absence or presence of PD98059 (25 
pM). Conditions were maintained for 7 days prior to ERCIA fixation. The total ERa 
(6F11, antibody dilution 1:100) digital images shown above (X20 magnification) are 
representative of 3 experiments. H-Score data were obtained by dual assessment of 2 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed.
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MCF-7 MCF-7X
Phospho-ER Seri 18 (Nuclear)
Basal Control 70.0(63.8-713) 90.0(77.5-110.5)
+ PD98059 (25 pM) 65.0(57.5-70.0) p=0.209 82.5(78.8-101.3) p=0.757
Figure 3,65 Effect o f  the MEK-1 inhibitor PD98059 on 
phosphorylation o f  ERa at S e r ll8  residue in MCF-7 and MCF-7X 
cells by immunocytochemistry, MCF-7 and MCF-7X cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively 
in the absence or presence of PD98059 (25 pM). Conditions were maintained for 7 
days prior to paraformaldehyde vanadate fixation. The phospho-ER Seri 18 (antibody 
dilution 1:400) digital images shown above (X20 magnification) are representative of 4 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed.
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Figure 3.66 Effect o f  the MEK-1 inhibitor PD98059 on 
phosphorylation o f ERa at S eri67 residue in MCF-7 and MCF-7X 
cells by immunocytochemistry. MCF-7 and MCF-7X cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively 
in the absence or presence of PD98059 (25 pM). Conditions were maintained for 7 
days prior to ERICA fixation. The phospho-ER Seri 67 (antibody dilution 1:25) digital 
images shown above (X20 magnification) are representative of 4 experiments. H-Score 
data were obtained by dual assessment of 2  representative areas of each coverslip 
followed by statistical analysis (Mann-Whitney U-Test). The median H-Score and Ql- 
Q3 values are displayed.
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Figure 3.67 Effect on of the MEK-1 inhibitor PD98059 on ER 
transcriptional activity in MCF-7X cells after 18 hour treatment MCF- 
7X cells were grown on 12-well plates in phenol-red-free RPMI media containing 5% 
XFCS for 24 hours. Cells were transfected in DCCM serum-firee media containing 
transfection lipid (3 pl/well, Lipofectin), ERE reporter construct (400 ng/well), Renilla 
(150 ng/ml), and ‘carrier’ DNA (550 ng/well, PCRscript) After 6 hours, the 
transfection medium was replaced with phenol-red-fiee RPMI media in the absence or 
presence of PD98059 (25 pM) in triplicate wells. Subsequent to 18 hour treatment 
incubation, a dual-luciferase reporter assay kit was utilised for cell lysis and 
luminometer assessment (n=3). Data are displayed as percentage of control ERE 
activity +/- SD (triplicate wells) and has been /2-Galactosidase normalised in the 
absence and presence of PD98059 (25 pM). The statistical analysis applied was an 
ANOVA Test followed by a Bonferroni Post-Hoc Test
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Figure 3.68 Treatment effect o f  the MEK-1 inhibitor PD98059 on pS2  
mRNA in MCF-7X cells by RT-PCR. MCF-7X cells were grown on 100 mm 
dishes in phenol-red-free RPMI media containing 5% XFCS in the absence or presence 
of PD98059 (25 pM). Conditions were maintained for 7 days before RNA was isolated 
and reverse transcribed. Co-amplification RT-PCR of pS2 (25 cycles/ 55°C annealing 
temperature, 336 bp) and /?-Actin (204 bp) was performed. The RT-PCR product was 
run on a 2% agarose gel containing ethidium bromide, subsequently photographed, 
scanned and normalised to ^-Actin. The digital image above is representative of 3 
experiments and the statistical analysis applied was an unpaired-T test (p=1.000) 
comparing mean pS2 expression in untreated MCF-7X cells (5.7 +/- 0.4) and PD98059 
treated MCF-7X cells (5.4 +/- 0.5).
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Figure 3.69 Effect o f  the MEK-1 inhibitor PD98059 on pS2 expression 
in MCF-7 and MCF-7X cells by immunocytochemistry. MCF-7 and MCF- 
7X cells were grown on coverslips in phenol-red-free media containing 5% SFCS or 
XFCS respectively in the absence or presence of PD98059 (25 pM). Conditions were 
maintained for 7 days prior to ERICA fixation. The pS2 (antibody dilution 1:500) 
digital images shown above (X20 magnification) are representative of 3 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed.
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3.4.2 The Influence o f  PI3K/AK TSignalling on ERa Signalling 
MCF-7X cells revealed substantial growth inhibition in response to the PI3K inhibitor 
LY294002, paralleled by decreased expression of phosphorylated AKT and PDK-1. 
ERa protein levels were not significantly (p=0.539) influenced by LY294002 in 
MCF-7X cells (Figure 3.70) and there was no inhibitory effect on Serll8ER 
(p=0.186) activity (Figure 3.71). However, the inhibitor substantially decreased 
nuclear Serl67ER phosphorylation by 50.0% (p<0.001*, Figure 3.72). Brief parallel 
examination of wortmannin treatment in these cells confirmed the lack of inhibitory 
effect of PDK inhibition on total ERa (Figure 3.73) or phosphorylated Seri 18ER, but 
again substantially decreased phosphorylated Serl67ER (p=0.001*, Figure 3.74) 
activity in MCF-7X cells by immunocytochemistry (in parallel with its inhibitory 
effects on activity o f AKT and cell growth). Further studies in MCF-7X cells 
utilising LY294002 demonstrated a reduction in ERa transcriptional activity as 
monitored by ERE reporter activity (18 hour) and endogenous pS2 expression versus 
untreated control. ERE reporter activity measured after 18 hours was reduced by 
32.1% (p=0.049*, Figure 3.75). Parallel RT-PCR (Figure 3.76) of MCF-7X cells 
treated for 7 days with this PDK inhibitor demonstrated a significant decrease in 
endogenous oestrogen regulated gene pS2 (p=0.040*). Immunocytochemistry 
revealed a significant (30.8%, p=0.002*) decrease in pS2 protein expression (Figure 
3.77). Cumulatively, these data indicate PDK signalling contributes to MCF-7X via 
cross-talk with ERa in a genomic mechanism. This appears to involve AKT 
promotion of Seri 67 phosphorylation, thus influencing ER/ERE transcriptional 
activity and growth.
In MCF-7 cells, only a small growth inhibition had been achieved with die PDK 
inhibitor LY294002, and in parallel there was only a small depletion of downstream 
AKT and no impact on PDK-1 activity. In these cells ERa levels were very slightly 
decreased (8.2%, p=0.010*) following 7 day treatment with this inhibitor (Figure 
3.70). There was no impact on Serl67ER activity, but a significant decrease in their 
low levels of Serll8ER was observed (85.7%, p=0.003*, Figures 3.71 & 3.72). 
While impact on ERE reporter activity and pS2 as detected at the mRNA level was 
not monitored, immunocytochemical staining for pS2 in MCF-7 was partially 
decreased by LY294002 (8.3%, p=0.047*, Figure 3.77).
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MCF-7 MCF-7X
Total ERa (Nuclear)
Basal Control 147.0(142.0-155.0) 185.0(185.0-195.0)
+ LY294002 (5 pM) 135.0 (126.3-141.3) p=0.010* 192.5(183.8-200.0) p=0.539
Figure 3.70 Effect o f  the PI3K inhibitor LY294002 on ERa expression 
in MCF-7 and MCF-7X cells by immunocytochemistry. MCF-7 and MCF- 
7X cells were grown on coverslips in phenol-red-free RPMI media containing 5% 
SFCS or XFCS respectively in the absence or presence of LY294002 (5 pM). 
Conditions were maintained for 7 days prior to ERCIA fixation. The total ERa (6F11, 
antibody dilution 1:100) digital images shown above (X20 magnification) are 
representative of 3 experiments. H-Score data were obtained by dual assessment of 2 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in ERa expression following LY294002 treatment.
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Phospho- ER Seri 18
Control
+ LY294002 
(5 pM)
MCF-7 MCF-7X
Phospho-ER Seri 18 (Nuclear)
Basal Control 70.0 (63.8-71.3) 90.0 (77.5-110.5)
+ LY294002 (5 pM) 10.0(8.8-15.0) p=0.003* 105.0(93.8-112.5) p=0.186
Figure 3.71 Effect o f  the PI3K inhibitor LY294002 on phosphorylation 
o f ERa at S er llS  residue in MCF-7 and MCF-7X cells by 
immunocytochemistry. MCF-7 and MCF-7X cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% SFCS or XFCS respectively in the absence 
or presence of LY294002 (5 pM). Conditions were maintained for 7 days prior to 
paraformaldehyde vanadate fixation. The phospho-ER Seri 18 (antibody dilution 
1:400) digital images shown above (X20 magnification) are representative of 4 
experiments. H-Score analysis were obtained by dual assessment of 2 representative 
areas of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The 
median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a 
significant difference in phospho-ER Seri 18 level following LY294002 treatment.
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Phospho- ER Seri 67
MCF-7 MCF-7X
Control
•, d a
£
0 t f -
•
+ LY294002 
(5 pM)
MCF-7 MCF-7X
Phospho-ER Serl67 (Nuclear)
Basal Control 82.5 (71.3-100.0) 50.0 (45.0-70.0)
+ LY294002 (5 pM) 82.5 (73.8-92.5) p=0.935 25.0(20.0-25.0) p<0.001*
Figure 3.72 Effect o f  the PI3K inhibitor LY294002 on phosphorylation 
o f  ERa at S eri67 residue in MCF-7 and MCF-7X cells by 
immunocytochemistry. MCF-7 and MCF-7X cells were grown on coverslips in 
phenol-red-free RPM1 media containing 5% SFCS or XFCS respectively in the absence 
or presence of LY294002 (5 pM). Conditions were maintained for 7 days prior to 
ERICA fixation. The phospho-ER Seri 67 (antibody dilution 1:25) digital images 
shown above (MCF-7 X20, MCF-7X X40 magnification) are representative of 4 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-ER Seri67 level following LY294002 treatment.
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MCF-7X
Total ERa
(Nuclear) 185.0(185.0-195.0)
+ Wortmannin (1 pM)
180.0(167.5-190.0) p=0.491
Figure 3.73 Effect o f  the PI3K inhibitor wortmannin on ERa 
expression in MCF-7X cells by immunocytochemistry. MCF-7X cells were 
grown on coverslips in phenol-red-free RPMI media containing 5% XFCS in the 
absence or presence of wortmannin (1 pM). Conditions were maintained for 7 days 
prior to ERCIA fixation. The total ERa (6F11, antibody dilution 1:100) digital images 
shown above (X20 magnification) are representative of 3 experiments. H-Score data 
were obtained by dual assessment of 3 representative areas of each coverslip followed 
by statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed.
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Phospho-ER Seri 18
MCF-7X + Wortmannin (1 pM)
Phospho-ER Seri 67
MCF-7X + Wortmannin (1 pM)
MCF-7X + Wortmannin (1 pM)
Phospho-ER Seri 18
(Nuclear) 90.0(77.5-110.5) 117.5(1063-122.5) p=0.012*
Phospho-ER Serl67
(Nuclear) 50.0(45.0-70.0) 27.5(23.8-31.3) p=0.001*
Figure 3.74 Effect o f  the PI3K inhibitor wortmannin on 
phosphorylation o f  ERa at S e r ll8  and Serl67 residues in MCF-7X 
cells by immunocytochemistry. MCF-7X cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS in the absence or presence of 
wortmannin (1 pM). Conditions were maintained for 7 days prior to the appropriate 
fixation. The phospho-ER Seri 18 (antibody dilution 1:400) assay required coverslips 
paraformaldehyde vanadate fixed and the phospho-ER Seri67 (1:25) assay required 
coverslips ERICA fixed. The digital images shown above (X20 magnification) are 
representative of 2 experiments. H-Score data were obtained by dual assessment of 3 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in phospho-ER level following wortmannin treatment.
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Figure 3.75 Effect on of the PI3K inhibitor LY294002 on ER 
transcriptional activity in MCF-7X ceils after IS hour treatment MCF- 
7X cells were grown on 12-well plates in phenol-red-free RPMI media containing 5% 
XFCS for 24 hours. Cells were transfected in DCCM serum-free media containing 
transfection lipid (3 pl/well, Lipofectin), ERE reporter construct (400 ng/well), Renilla 
(ISO ng/ml), and ‘carrier’ DNA (550 ng/well, PCRscript) After 6 hours, the 
transfection medium was replaced with phenol-red-free RPMI media in the absence or 
presence of LY294002 (5 pM) in triplicate wells. Subsequent to 18 hour treatment 
incubation, a dual-lueiferase reporter assay kit was utilised for cell lysis and 
luminometer assessment (n=3). Data are displayed as percentage of control ERE 
activity +/- SD (triplicate wells) and has been ^-Galactosidase normalised in die 
absence and presence of LY294002 (5 pM). The statistical analysis applied was an 
ANOVA Test followed by a Bonferroni Post-Hoc Test
0 Denotes LY294002 treatment (18 hrs) significantly decreased ERE activity in MCF- 
7X cells versus untreated control.
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Control + LY294002 (5 pM)
Figure 3.76 Treatment effect o f  the PI3K inhibitor LY294002 on pS2  
mRNA in MCF-7X cells by RT-PCR. MCF-7X cells were grown on 100  mm 
dishes in phenol-red-free RPMI media containing 5% XFCS in the absence or presence 
of LY294002 (5 pM). Conditions were maintained for 7 days before RNA was isolated 
and reverse transcribed. Co-amplification RT-PCR of pS2 (25 cycles/ 55°C annealing 
temperature, 336 bp) and /?-Actin (204 bp) was performed. The RT-PCR product was 
run on a 2 % agarose gel containing ethidium bromide, subsequently photographed, 
scanned and normalised to ^-Actin. The digital image above is representative of 3 
experiments and the statistical analysis applied was an unpaired-T test (p=0.040*) 
comparing mean pS2 expression in untreated MCF-7X cells (5.7 +/- 0.4) and 
LY294002 treated MCF-7X cells (4.3 +/- 0.8).
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pS2
MCF-7 MCF-7X
Control
+ LY294002 
(5 pM)
MCF-7 MCF-7X
pS2 (Cytoplasmic)
Basal Control 90.0 (81.3-98.8) 130.0 (121.3-133.8)
+ LY294002 (5 pM) 82.5 (73.8-863) p=0.047* 90.0(85.0-112.0) p=0.002*
Figure 3.77 Effect o f the PI3K inhibitor LY294002 on pS2 expression 
in MCF-7 and MCF-7X cells by immunocytochemistry. MCF-7 and MCF- 
7X cells were grown on coverslips in phenol-red-free media containing 5% SFCS or 
XFCS respectively in the absence or presence of LY294002 (5 pM). Conditions were 
maintained for 7 days prior to ERICA fixation. The pS2 (antibody dilution 1:500) 
digital images shown above (X20 magnification) are representative of 3 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in pS2 expression following LY294002 treatment.
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3.4.3 The Influence o f  Sim ultaneous Targeting o f  the PI3K/AKT and ERa 
Signalling Pathways
As stated above, single agent treatment utilising the pure anti-oestrogen faslodex or 
the PI3K inhibitor LY294002 resulted in a significant and substantial reduction in 
MCF-7X cell growth. This was paralleled by faslodex or LY294002 reducing 
Serll8ER or Serl67ER activation respectively, revealing these sites have non- 
overlapping upstream regulatory pathways (presumably residual oestrogen/ERa and 
PI3K/AKT signalling respectively). However, responsiveness was incomplete in 
both instances, with ERa phosphorylation and transcriptional activity remaining and 
resistant growth subsequently emerging at 10 weeks (Figure 3.78). It was thus 
hypothesised that the phosphorylated ERa remaining when faslodex or LY294002 
was applied singly might provide an important compensatory cell survival 
mechanism, underlying the incomplete inhibitory effects on ERa transcriptional 
activity and growth of the single agents in MCF-7X cells. To test this hypothesis, co­
treatment of faslodex and LY294002 was performed for 7 days prior to extensive 
growth studies, immunocytochemistry for ERa phosphorylation, ERE reporter assays 
and RT-PCR for the oestrogen regulated gene pS2 being employed. As expected, co­
treatment specifically decreased ERa and PI3K/AKT signalling [(with no significant 
impact on pMAPK) (Figures 3.79, 3.80 & 3.81)] to equivalent levels achieved with 
each single agent. Total levels of nuclear ERa were decreased 59.5% (p=0.001*) 
with faslodex/LY294002 co-treatment, consistent with the significant (63.5%, 
p=0.001*) reduction observed following faslodex single treatment (LY294002 single 
treatment having no effect). Thus, ER levels were equivalent with faslodex or 
faslodex/LY294002 co-treatment (p=0.053). Co-treatment decreased membrane plus 
cytoplasmic and nuclear phosphoiylated AKT levels by 74.9% (p=0.004*) and 25.6% 
(p=0.012*) respectively. Again levels o f inhibition were similar to those reached 
following LY294002 single treatment (66.0% and 32.1% respectively; again faslodex 
single treatment exerting no significant effect).
However, co-treatment was successful at reducing phosphorylation of ERa at both 
Seri 18 and Serl67 residues (Figures 3.82 & 3.83). At both serine residues, 
faslodex/LY294002 treatment resulted in a reduced intensity of staining as well as a 
loss in the percentage of positive stained MCF-7X cells versus basal control. The 
combination treatment was responsible for a 41.7% (p=0.001*) inhibitoiy effect at 
nuclear Seri 18ER versus die basal control. This effect was not significantly superior
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to single treatment with faslodex (p=0.410), however was superior to LY294002 
(p=0.004*) that exerted no inhibitory effect on this parameter as a single agent by 
immunocytochemistry. Furthermore, the co-treatment was able to deplete Serl67ER 
activity 60.0% (p<0.001 *) versus the basal control. This result was significant versus 
faslodex treatment (p=0.002*), but was equivalent to LY294002 single treatment 
(p=0.603).
In parallel with the decreased phosphorylation of both ER AF-1 sites, ERE 
transcriptional activity measured following 18 hour faslodex/LY294002 treatment 
was decreased 47.1% (p<0.001*, Figure 3.84). This was a superior depletion 
compared to LY294002 as a single treatment (32.1% and 46.5% respectively) and 18 
hour faslodex treatment (32.5%). Parallel RT-PCR and immunocytochemical 
analysis of pS2 following co-treatment with faslodex/LY294002 revealed a 
significant 93.0% (p=0.003*) reduction in mRNA (Figure 3.85) that was again 
largely equivalent to faslodex alone (92.0%, Figure 3.21). However, the subsequent 
61.5% (p=0.001*) loss in cytoplasmic localised pS2 protein (Figure 3.86) proved 
superior to faslodex or LY294002 alone (44.2%, p=0.044* and 32.7%, p=0.004* 
respectively). These data were associated with a superior 90.0% (p<0.001*) anti- 
tumour response in MCF-7X cells by day 15 versus basal control (Figure 3.87), 
moreover resulting in a superior growth inhibitory effect versus faslodex or 
LY294002 alone (p<0.001* and p=0.001* respectively). There was also an extended 
time until resistant growth resumed at 25 weeks for the combination treatment versus 
10 weeks with faslodex or LY294002 alone, and furthermore the growth rate 
achieved remained lower with faslodex/LY294002
co-treatment (Figure 3.88). Again, preliminary growth studies utilising the 
alternative PI3K blocker wortmannin plus faslodex indicated the combination of a 
PI3K inhibitor and the pure anti-oestrogen comprises a superior strategy compared to 
single administration of either agent (Figure 3.89). Clearly, co-treatment resulted in a 
superior inhibition of ERa signalling and thus a more effective growth inhibition. 
However, disease progression did eventually resume with co-treatment, and some 
residual ERa phosphorylation (particularly on Serll8ER) and ERa transcriptional 
activity (~25%) was left with further profiling of these cells revealing that MAPK 
activity was not depleted (Figure 3.81). It was thus important to subsequently 
monitor if a triple inhibitory strategy using faslodex and LY294002 together with the
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MEK-1 inhibitor PD98059 was able to maximally block ERa signalling and 
completely subvert development of resistance.
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Figure 3.78 Cell culture time-line fo r long term faslodex and 
LY294002 treated MCF-7X cells. MCF-7X cells were grown in phenol-red- 
free RPMI media containing 5% XFCS in the presence of faslodex (10~7 M) or 
LY294002 (5 pM) for long term culture. The arrow signifies the time point at which 
the rate of cell growth began to increase. Based on the development of rapid log phase 
growth, there was need to increase the frequency of passaging by week 10. Data are 
displayed as the number of passages versus time (weeks).
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Total ERa
Control
MCF-7X 
+ Faslodex (10'7M) + LY294002 (5 pM)
I I
• ••
IV
+ FAS/LY
i
MCF-7X
Total ERa (Nuclear)
Basal Control 185.0 (185.0-195.0)
+ Faslodex 67.5(600-713) p=0.001*
+ LY294002 192.5 (183.8-200.0) p=0.539
+ Faslodex/LY294002 75.0 (70.3-87.5) p=0.001 *
Figure 3,79 Effect o f faslodex/LY294002 co-treatment on ERa 
expression in MCF-7X cells by immunocytochemistry, MCF-7X cells were 
grown on coverslips in phenol-red-free RPMI media containing 5% XFCS in the 
absence or presence of faslodex/LY294002 (10*7 M, 5 pM) co-treatment. Conditions 
were maintained for 7 days prior to ERCLA fixation. The total ERa (6F11, antibody 
dilution 1:100) digital images shown above (X20 original magnification) are 
representative of 3 experiments. H-Score data were obtained by dual assessment of 2 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant treatment effect versus MCF-7X basal control.
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Phospho-AKT
MCF-7X
Control + Faslodex (10'7M) + LY294002 (5 pM)
+ FAS/LY
MCF-7X
Phospho-AKT (Memb. + Cyto.) (Nuclear) Total
Basal Control 101.5 (76.5-1193) 107.5 (95.0-112.5) 209.0
+ Faslodex 78.5 (71.0-84.5) 102.5 (98.8-110.0) 181.0
p=0.127 p=0.680
+ LY294002 34.5 (32.0-57.0) 73.0 (61.0-81.3) 107.5
p=0.004* p=0.004*
+ Faslodex/LY294002 25.5 (21.8-29.0) 80.0 (73.8-93.8) 105.5
p=0.004* p=0 .0 1 2 *
Figure 3.80 Effect o f faslodex/LY294002 on phosphorylatedAKT level 
in MCF-7X cells by immunocytochemistry. MCF-7X cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS in the absence or 
presence of faslodex/LY294002 (10“7 M, 5 pM). Conditions were maintained for 7 
days prior to ERICA fixation. The phospho-AKT (antibody dilution 1:200) digital 
images shown above (X20 magnification) are representative of 4 experiments. H-Score 
data were obtained by dual assessment of 2  representative areas of each coverslip 
followed by statistical analysis (Mann-Whitney U-Test). The median H-Score and Ql- 
Q3 values are displayed. A p-value <0.05(*) indicates a significant treatment effect 
versus MCF-7X basal control.
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Phospho-MAPK
MCF-7X
Control + FAS/LY
MCF-7X
Phospho-MAPK (Cytoplasmic) (Nuclear) Total
Basal Control 35.0 (35.<M8.8) 3.5 (1.3-5.0) 38.5
+ Faslodex/LY294002 35.0(30.0-35.0) 1.5(1.0-20) 36.5
p=0.093 p=0.075
Figure 3.81 Effect o f faslodex/LY294002 on phosphorylated MAPK 
level in MCF-7X cells by immunocytochemistry. MCF-7X cells were grown 
on coverslips in phenol-red-free RPMI media containing 5% XFCS in the absence or 
presence of faslodex/LY294002 (lO-7 M, 5 pM). Conditions were maintained for 7 
days prior to formal saline fixation. The phospho-MAPK (antibody dilution 1:20) 
digital images shown above (X20 magnification) are representative of 4 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed.
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Phospho-ER Seri 18
MCF-7X
Control + Faslodex (10'7M) + LY294002 (5 pM)
+ FAS/LY
MCF-7X
Phospho-ER Seri 18 (Nuclear)
p=0.030*
p=0.186 
p=0 .0 0 1 *
Basal Control 90.0 (77.5-110.5)
+ Faslodex 77.5 (613-80.0)
+ LY294002 105.0 (93.8-112.5)
+ Faslodex/LY294002 52.5 (43.8-60.0)
Figure 3.82 Effect o f faslodex/LY294002 co-treatment on 
phosphorylation o f ERa at Serll8  residue in MCF-7X cells by 
immunocytochemistry. MCF-7X cells were grown on coverslips in phenol-red- 
free RPMI media containing 5% XFCS in the absence or presence of 
faslodex/LY294002 (10”7 M, 5 pM) co-treatment. Conditions were maintained for 7 
days prior to paraformaldehyde vanadate fixation. The phospho-ER Seri 18 (antibody 
dilution 1:400) digital images shown above (X20 magnification) are representative of 4 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
treatment effect versus MCF-7X basal control.
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Phospho-ER Seri 67
Control
MCF-7X 
+ Faslodex (10*7M) + LY294002 (5 pM)
+ FAS/LY
Phospho-ER Serl67 (Nuclear)
Basal Control 
+ Faslodex 
+ LY294002 
+ Faslodex/LY294002
MCF-7X
50.0 (45.0-70.0)
55.0 (40.0-70.0)
25.0 (20.0-25.0)
20.0 (12.0-30.0)
p=0.841
p<0 .0 0 1 *
p<0 .0 0 1 *
Figure 3,83 Effect o f faslodex/LY294002 co-treatment on 
phosphorylation o f ERa at Seri67 residue in MCF-7X cells by 
immunocytochemistry. MCF-7X cells were grown on coverslips in phenol-red- 
free RPMI media containing 5% XFCS in the absence or presence of 
faslodex/LY294002 (10‘7 M, 5 pM) co-treatment. Conditions were maintained for 7 
days prior to ERICA fixation. The phospho-ER Seri 67 (antibody dilution 1:25) digital 
images shown above (X40 magnification) are representative of 4 experiments. H-Score 
data were obtained by dual assessment of 2  representative areas of each coverslip 
followed by statistical analysis (Mann-Whitney U-Test). The median H-Sore and Ql- 
Q3 values are displayed. A p-value <0.05(*) indicates a significant treatment effect 
versus MCF-7X basal control.
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Figure 3.84 Effect on o f faslodex/LY294002 co-treatment on ER 
transcriptional activity in MCF-7X cells after 18 hour treatment MCF- 
7X cells woe grown on 12-well plates in phenol-red-free RPMI media containing 5% 
XFCS fin- 24 hours. Cells were transfected in DCCM serum-free media containing 
transfection lipid (3 pl/well, Lipofectin), ERE reporter construct (400 ng/well), Renilla 
(150 ng/ml), and ‘carrier’ DNA (550 ng/well, PCRscript) After 6 hours, die 
transfection medium was replaced with phenol-red-free RPMI media in the absence or 
presence of faslodex/LY294002 (10*7 M, 5 pM) in triplicate wells. Subsequent to 18 
hour treatment incubation, a dual-luciferase reporter assay kit was utilised for cell lysis 
and luminometer assessment (n=3). Data are displayed as percentage of control ERE 
activity +/- SD (triplicate wells) and has been /M3alactosidase normalised in the 
absence and presence of FAS/LY (10*7 M, 5 pM). The statistical analysis applied was 
an ANOVA Test followed by a Bonferroni Post-Hoc Test
0 Denotes FAS/LY treatment (18 hrs) significantly decreased ERE activity in MCF-7X 
cells versus untreated control.
173
CHAPTER 3 RESULTS
pS2 (336 bp)
/?-Actin (204 bp)
T3
O  V i  
V i 4>11 c >
o « e 5 c  «
z  1 2  2 
E g
CS J 3  
00 -T3o.
7.5
6
Q MCF-7 X4.5
3
1.5
+ FAS/LY
o
Control
Figure 3.85 Treatment effect o f faslodex/LY294002 co-treatment on 
pS2 rnRNA in MCF-7X cells by RT-PCR. MCF-7X cells were grown on 100  
mm dishes in phenol-red-free RPMI media containing 5% XFCS in the absence or 
presence of faslodex/LY294002 (10*7 M, 5 pM) co-treatment. Conditions were 
maintained for 7 days before RNA was isolated and reverse transcribed. Co­
amplification RT-PCR of pS2 (25 cycles/ 55°C annealing temperature, 336 bp) and /?- 
Actin (204 bp) was performed. The RT-PCR product was run on a 2% agarose gel 
containing ethidium bromide, subsequently photographed, scanned and normalised to /?- 
Actin. The digital image above is representative of 3 experiments and the statistical 
analysis applied was an unpaired-T test (p=0.003*) comparing mean pS2 expression in 
untreated MCF-7X cells (5.7 +/- 0.4) and faslodex/LY294002 co-treated MCF-7X cells 
(0.4 +/- 0.3).
174
CHAPTER 3 RESULTS
pS2
MCF-7X
Control + Faslodex (10-7M) + LY294002 (5 pM)
-
+ FAS/LY
MCF-7X
pS2 (Cytoplasmic) 
Basal Control 
+ Faslodex 
+ LY294002 
+ Faslodex/LY294002
130.0 (1213-133.8)
72.5 (58.8-80.0) p=0.001 *
87.5 (78.8-92.8) p=0.002*
50.0(45.0-70.0) p=0.001*
Figure 3.86 Effect o f  faslodex/LY294002 co-treatment on pS2 
expression in MCF-7X cells by immunocytochemistry. MCF-7X cells were 
grown on coverslips in phenol-red-free media containing 5% XFCS in the absence or 
presence of faslodex/LY294002 (10-7 M, 5 pM). Conditions were maintained for 7 
days prior to ERICA fixation. The pS2 (antibody dilution 1:500) digital images shown 
above (X20 magnification) are representative of 3 experiments. H-Score data were 
obtained by dual assessment of 2  representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant treatment effect versus MCF- 
7X basal control.
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Figure 3.87 Growth challenge with the pure anti-oestrogen faslodex or 
the PI3K inhibitor LY294002 singly or in combination in MCF-7X 
cells. MCF-7X cells were grown on 24-well plates in phenol-red-free RPMI media 
containing 5% XFCS in the absence or presence of faslodex (10*7 M), LY294002 (5 
pM) singly or in combination for 15 days. At the time points indicated above cells were 
subject to trypsin dispersion followed by Coulter counting (triplicate wells per time 
point). These data were log transformed to compare growth rate at day 7 and day 15. 
The statistical analysis applied was an ANOVA Test followed by a Bonferroni Post- 
Hoc Test. Data are displayed as the mean number of cells/well +/- SD (n=5).
0 Denotes faslodex/LY294002 treatment was significant lower at day 7 (p<0.001) and 
day 15 (p<0.001) versus untreated MCF-7X cells.
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Figure 3.88 Cell culture time-line fo r  long term faslodex/LY294002 
treated MCF-7X cells. MCF-7X cells were grown in phenol-red-free RPMI 
media containing 5% XFCS in the presence of faslodex/LY294002 (lfr7 M, 5 pM) for 
long term culture. The arrow signifies the time point at which the rate of cell growth 
began to increase. Based on the development of rapid log phase growth, there was need 
to increase the frequency of passaging at approximately week 25. Data are displayed as 
the number of passages versus time (weeks).
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Figure 3.89 Effect o f faslodexAvortmannin co-treatment on ceil growth 
in MCF-7X cells. MCF-7X cells woe grown on 24-well plates in phenol-red-free 
RPMI media containing 5% XFCS in the absence or presence of faslodex/wortmannin 
(10*7 M, 1 pM). Conditions were maintained for 7 days prior to trypsin dispersion and 
Coulter counting (triplicate wells per treatment). Data are displayed as a percentage of 
control cell growth and include 1 experiment
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3.4.4 The Influence o f  Sim ultaneous Targeting o f  the ERa, PI3K/AKT, and M APK  
Signalling Pathways
Considering the maintenance of MAPK activity in MCF-7X cells following faslodex 
plus LY294002 co-treatment, a triple combination strategy was employed which 
could identify if such signalling contributed to the incomplete blockade of ERa 
signalling and residual tumour growth response. After both 7 and 15 day treatment, 
the triple combination strategy markedly inhibited growth versus control (p<0.001* in 
both instances). While growth at 7 and 15 days was not significantly further inhibited 
versus faslodex/LY294002 co-treatment, triple challenge with the MEK1 inhibitor 
PD98059 in combination with faslodex and LY294002 by day 15 was associated with 
some indication of cell numbers beginning to fall below the initial seeding density 
[(indicative of cell loss) (Figure 3.90)]. This effect translated out into cultures that 
could not be maintained further past 16 weeks (Figure 3.91). This blockade of 
emergence of resistance contrasted the appearance of resistant growth with dual 
faslodex/LY294002 treatment by week 25. Triple treatment gave an equivalent 
blockade of total ERa, membrane plus cytoplasmic and nuclear pAKT (Figure 3.92 & 
3.93) to faslodex/LY294002 co-treatment (p=0.225 and p=0.162). Total levels of 
nuclear ERa were decreased 63.2% (p=0.001*) with faslodex/LY294002/PD98059 
triple treatment, consistent with the significant (59.5%, p=0.001*) reduction observed 
following faslodex/LY294002 co-treatment Monitoring of triple treatment on 
membrane plus cytoplasmic and nuclear phosphoiylated AKT levels revealed a 
68.5% (p=0.004*) and 16.3% (p=0.008*) respective fall, where again these levels of 
inhibition were similar to those reached following faslodex/LY294002 co-treatment 
(74.9% and 25.6% respectively). While co-treatment with feslodex/LY294002 had 
no significant impact on the phosphorylation of MAPK, triple treatment importantly 
reduced cytoplasmic (71.4%, p=0.001*) and fully depleted any nuclear (p=0.039*) 
localised activity (Figure 3.94).
Interestingly, the effectiveness of triple treatment in MCF-7X cells also equated with 
a superior 66.7% (pO.OOl*) inhibition of Serll8ER phosphorylation (Figure 3.95) 
versus basal control. However this was not a significant improvement versus the 
faslodex/LY294002 combination for Serl67ER (Figure 3.96), where triple treatment 
reduced phosphorylation 70.0% (p<0.001*) to a level equivalent to co-treatment with 
faslodex/LY294002 (p=0.795). ERa transcriptional activity was measured again 
following 18 hour (Figure 3.97) faslodex/LY294002/PD98059 treatment revealing a
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increased inhibitory effect versus faslodex/LY294002 co-treatment (66.8% vs. 
47.1%). Parallel immunocytochemical staining for endogenous pS2 following triple 
treatment inhibited cytoplasmic expression 59.6% (p=0.001*) which was a similar 
fall to dual treatment (61.5%, p=0.001*, Figure 3.98). As MAPK activity and ER 
have been associated with regulation of AP-1 transcriptional activity, AP-1 reporter 
assays (Figure 3.99) were also performed. These studies revealed PD98059, either 
applied singly (where no significant growth inhibitoiy effect was observed) or as a 
part of the highly growth-inhibitory triple treatment, was responsible for a -60% 
reduction in activity compared to basal MCF-7X cells (p=0.006* and p=0.003* 
respectively). Finally, preliminary growth studies using wortmannin together with 
faslodex and PD98059 was able to demonstrate a small superior treatment effect 
versus wortmannin/faslodex co-treatment (Figure 3.100).
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Figure 3,90 Growth challenge with the pure anti-oestrogen faslodex 
and the PI3K inhibitor LY294002 co-treatment or triple treatment with 
the addition o f the MEK-1 inhibitor PD98059 in MCF-7X cells, MCF- 
7X cells were grown on 24-well plates in phenol-red-free RPMI media containing 5% 
XFCS in the absence or presence of faslodex/LY294002 (10-7 M, 5 |iM) or 
faslodex/LY294002/PD98059 (lfr7 M, 5 pM, 25 pM) for 15 days. At the time points 
indicated above cells were subject to trypsin dispersion followed by Coulter counting 
(triplicate wells per time point). These data were log transformed to compare growth 
rate at day 7 and 15. The statistical analysis applied was an ANOVA Test followed by 
a Bonferroni Pos-Hoc Test. The data are displayed as the mean number of cells/well 
+/- SD (n=5).
0 Denotes faslodex/LY294002/PD98059 treatment was significant lower at day 7 
(p<0.001) and day 15 (p<0.001) versus untreated MCF-7X cells.
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Figure 3.91 Cell culture time-line fo r long-term 
faslodex/LY294002/PD98059 treated MCF-7X cells. MCF-7X cells were 
grown in phenol-red-free RPMI media containing 5% XFCS in the presence of 
faslodex/LY294002/PD98059 (lfr7 M, 5 pM, 25 pM) for long term culture. The arrow 
indicates the time point at which the culture could no longer be maintained due to total 
cell loss. Data are displayed as the number of passages versus time (weeks).
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Total ERa
MCF-7X 
+ FAS/LY + FAS/LY/PD
MCF-7X
Total ERa (Nuclear)
Basal Control 185.0 (185.0-195.0)
+ Faslodex/LY294002 75.0(70.3-87.5) p=0.001*
+ Faslodex/LY294002/PD98059 68.0(63.3-77.5) p=0.001*
Figure 3.92 Effect o f  faslodex/LY294002/PD98059 triple treatment on 
ERa expression in MCF-7X cells by immunocytochemistry. MCF-7X 
cells were grown on coverslips in phenol-red-free RPMI media containing 5% XFCS in 
the absence or presence of faslodex/LY294002/PD98059 (lfr7 M, 5 pM, 25 |iM) co­
treatment. Conditions were maintained for 7 days prior to ERCIA fixation. The total 
ERa (6F11, antibody dilution 1:100) digital images shown above (X10 original 
magnification) are representative of 3 experiments. H-Score data were obtained by 
dual assessment of 2  representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant treatment effect versus MCF-7X 
basal control.
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Phospho-AKT
MCF-7X
Control + FAS/LY + FAS/LY/PD
Phospho-AKT (Memb. + Cyto.)
Basal Control 101.5 (76.5-1193)
+ Faslodex/LY294002 25.5 (21.8-29.0)
p=0.004*
+ Faslodex/LY294002/PD98059 32.0 (29.5-33.8)
p=0.004*
MCF-7X
(Nuclear) Total
107.5 (95.0-112.5) 209.0
80.0 (73.8-93.8) 105.5
p=0 .0 1 2 *
90.0 (87.5-95.0) 122.0
p=0.008*
Figure 3,93 Effect o f  faslodex/LY294002/PD98059 on phosphorylated 
AKT level in MCF-7X cells by immunocytochemistry, MCF-7X cells were 
grown on coverslips in phenol-red-free RPMI media containing 5% XFCS in the 
absence or presence of faslodex/LY294002/PD98059 (10*7 M, 5 (iM, 25 pM). 
Conditions were maintained for 7 days prior to ERICA fixation. The phospho-AKT 
(antibody dilution 1:200) digital images shown above (X20 magnification) are 
representative of 4 experiments. H-Score data were obtained by dual assessment of 2 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant treatment effect versus MCF-7X basal control.
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Phospho-MAPK
MCF-7X
Control + FAS/LY + FAS/LY/PD
MCF-7X
Phospho-MAPK (Cytoplasmic) (Nuclear) Total
Basal Control 35.0 (35.0-48.8) 3.5 (1.3-5.0) 38.5
+ Faslodex/LY294002 35.0 (30.0-35.0) 1.5 (1.0-2.0) 36.5
p=0.093 p=0.075
+ Faslodex/LY294002/PD98059 10.0 (10.0-9.0) 1.0 (0.0-1.0) 11.0
p=0 .0 0 1 * p=0.007*
Figure 3.94 Effect o f  faslodex/LY294002/PD98059 on phosphorylated 
MAPK level in MCF-7X cells by immunocytochemistry. MCF-7X cells 
were grown on coverslips in phenol-red-free RPMI media containing 5% XFCS in the 
absence or presence of faslodex/LY294002/PD98059 (10*7 M, 5 |iM, 25 pM). 
Conditions were maintained for 7 days prior to formal saline fixation. The phospho- 
MAPK (antibody dilution 1:20) digital images shown above (X20 magnification) are 
representative of 4 experiments. H-Score data were obtained by dual assessment of 2 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant treatment effect versus MCF-7X basal control.
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Phospho-ER Seri 18
MCF-7X
Control + FAS/LY + FAS/LY/PD
MCF-7X
Phospho-ER Seri 18 (Nuclear)
Basal Control 90.0 (77.5-110.5)
+ Faslodex/LY294002 52.5 (43.8-60.0)
+ Faslodex/LY294002/PD98059 30.0 (25.0-36.3)
p=0 .0 0 1 *
p<0 .0 0 1*
Figure 3,95 Effect o f  faslodex/LY294002/PD98059 triple treatment on 
phosphorylation o f  ERa at S e r ll8  residue in MCF-7X cells by 
immunocytochemistry, MCF-7X cells were grown on coverslips in phenol-red- 
free RPMI media containing 5% XFCS in the absence or presence of 
faslodex/LY294002/PD98059 (10-7 M, 5 pM, 25 pM). Conditions were maintained for 
7 days prior to paraformaldehyde vanadate fixation. The phospho-ER Seri 18 (antibody 
dilution 1:400) digital images shown above (X20 magnification) are representative of 4 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
treatment effect versus MCF-7X basal control.
186
CHAPTER 3 RESULTS
Phospho-ER Seri67
MCF-7X
Control + FAS/LY + FAS/LY/PD
MCF-7X
Phospho-ER Serl67 (Nuclear)
Basal Control 50.0 (45.0-70.0)
+ Faslodex/LY294002 20.0 (12.0-30.0)
+ Faslodex/LY294002/PD98059 15.0 (10.0-35.0)
p<0 .0 0 1 *
p=0 .0 0 1 *
Figure 3,96 Effect o f  faslodex/LY294002/PD98059 triple treatment on 
phosphorylation o f  ERa at S eri67 residue in MCF-7X cells by 
immunocytochemistry. MCF-7X cells were grown on coverslips in phenol-red- 
free RPMI media containing 5% XFCS in the absence or presence of 
faslodex/LY294002/PD98059 (10*7 M, 5 pM, 25 pM). Conditions were maintained for 
7 days prior to ERICA fixation. The phospho-ER Seri 67 (antibody dilution 1:25) 
digital images shown above (X20 magnification) are representative of 4 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
treatment effect versus MCF-7X basal control.
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Figure 3.97 Effect on o f faslodex/LY294002/PD980S9 triple treatment 
on ER transcriptional activity in MCF- 7X cells after 18 hour treatment
MCF-7X cells were grown on 12-well plates in phenol-red-free RPMI media containing 
5% XFCS fin* 24 hours. Cells woe transfected in DCCM serum-free media containing 
transfection lipid (3 pl/well, Lipofectin), ERE reporter construct (400 ng/well), Renilla 
(150 ng/ml), and ‘carrier’ DNA (550 ng/well, PCRscript) After 6 hours, die 
transfection medium was replaced with phenol-red-free RPMI media in the absence or 
presence of faslodex/LY294002/PD98059 (10~7 M, 5 pM, 25 pM) in triplicate wells. 
Subsequent to 18 hour treatment incubation, a dual-luciferase reporter assay kit was 
utilised for cell lysis and luminometer assessment (n=3). Data are displayed as 
percentage of control ERE activity +/- SD (triplicate wells) and has been 
Galactosidase normalized in the absence and presence of FAS/LY/PD (10*7 M, 5 pM, 
25 pM).
0 Denotes FAS/LYPD treatment (18 hrs) significantly decreased ERE activity in MCF- 
7X cells versus untreated control
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pS2
MCF-7X
Control + FAS/LY + FAS/LY/PD
MCF-7X
pS2 (Cytoplasmic)
Basal Control 130.0 (121.3-133.8)
+ Faslodex/LY294002 50.0 (45.0-70.0) p=0 .0 0 1 *
+ Faslodex/LY294002/PD98059 52.5 (50.0-58.8) p=0 .0 0 1 *
Figure 3,98 Effect o f  faslodex/LY294002/PD98059 triple treatment on 
pS2 expression in MCF-7X cells by immunocytochemistry. MCF-7X cells 
were grown on coverslips in phenol-red-free media containing 5% XFCS in the absence 
or presence of faslodex/LY294002/PD98059 (10*7 M, 5 (iM, 25 pM). Conditions were 
maintained for 7 days prior to ERICA fixation. The pS2 (antibody dilution 1:500) 
digital images shown above (X20 magnification) are representative of 3 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
treatment effect versus MCF-7X basal control.
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Figure 3.99 Treatment effect offaslodex/LY294002/PD98059 on AP-1 
transcriptional activity in MCF-7X cells. MCF-7X cells were grown on 12- 
well plates in phenol-redrfree RPMI media containing 5% XFCS for 24 hours. Cells 
were transfected in DCCM serum-free media containing lipid (3 pl/well, Lipofectin), 
AP-l-pTal reporter contract (400 ng/well) and 'carrier* DNA (700 ng/well PCRscript). 
Control pTal luciferase reporter constructs were included fa* each treatment at the same 
construct and ‘carrier’ concentrations. After 6 hours, the transfection medium was 
replaced with phenol-red-free RPMI media in the presence of control (ethanol, 1 pi/ 10 
ml), feslodex/LY294002/PD98059 (lfr7 M, 5 pM, 25 pM) or PD98059 (25 pM) in 
triplicate wells. Subsequent to 18 hour treatment incubation, a luciferase reporter assay 
kit was utilised for cell lysis and luminometer assessment (n=3). Data are displayed as 
a percentage of control AP-1 activity +/- SD and has been /^ Galactosidase normalised 
for transfection efficiency.
0 Denotes FAS/LY/PD and PD98059 treatment (18 hrs) significantly decreased AP-1 
activity in MCF-7X cells versus untreated control.
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Figure 3,100 Effect o f faslodex/wortmannin or 
faslodexAvortmannin/PD98059 combination treatment on cell growth 
in MCF-7X cells, MCF-7X cells were grown on 24-well plates in phenol-red-free 
RPMI media containing 5% XFCS in die absence or presence of faslodex/wortmannin 
(10*7 M, 1 pM) or faslodex/w<Htmannin/PD980S9 (10*7 M, 1 pM, 25 pM). Conditions 
were maintained fen 7 days prim’ to trypsin dispersion and Coulter counting (triplicate 
well per treatment). Data are displayed as a percentage of control cell growth and 
includes 1 experiment
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3.4.5 The Influence o f  Co-targeting o f  the PI3K/AKT and M APK Signalling 
Pathways
Further confirmation that the inhibition of ERa and its phosphorylation was required 
for the catastrophic effects o f triple treatment came from profiling MCF-7X cells co­
treated with the PBK inhibitor LY294002 plus the MEK-1 inhibitor PD98059. This 
combination treatment was certainly superior in inhibiting growth (75.0%, p<0.001*) 
compared with LY294002 (69.1%, p<0.001*) or PD98059 alone (29.0%, p=1.000) 
(Figure 3.101) by day 15. This superior combination effect has also been observed by 
Martin et al. (2003), Yue et al. (2003) and Santen et al. (2004a) in their long-term 
oestrogen deprived models. However, in contrast to triple treatment that included 
faslodex, co-treatment with LY284002/PD98059 in MCF-7X cells did not prevent 
resistance from emerging, in this instance at 12 weeks (Figure 3.102). Subsequent 
studies indicated that LY294002/PD98059 co-treatment in die absence of faslodex 
was capable of maximally decreasing MAPK activity. Immunocytochemistry 
revealed this co-treatment decreased MAPK cytoplasmic staining by 74.3% 
(p=0.001*), in parallel with a significant 51.7% (p=0.004*) depletion of membrane 
plus cytoplasmic phosphoiylated AKT and a 12% (p=0.016*) fall in nuclear AKT 
activity (Figure 3.103). However, LY294002/PD98059 was without significant 
inhibitory effect on total ERa (p=0.757) or Serll8ER phosphorylation (p=0.197), 
versus the basal control level, although Seri 67 was significantly depleted as with 
LY294002 alone (50.0%, p<0.001*, Figure 3.104). These data were confirmation 
that inhibition of ER and its Seri 18 phosphorylation was required for die catastrophic 
effects o f triple treatment on MCF-7X cell growth in preventing resistance, rather 
than any direct effect o f MAPK depletion cm growth.
192
CHAPTER 3 RESULTS
900000
— 800000 - 
%Z  700000 
o  600000 -
PD98059  LY/PDControl LY294002
V -O
SJoE3
C
§
500000 -
400000
300000
200000 -
100000 -
Day 1 Day 3 Day 5 Day 7 Day 9 Day 11 Day 13 Day 15
Figure 3.101 Growth challenge with the PI3K inhibitor LY294002 or 
the MEK-1 inhibitor PD98059 singly or in combination in MCF-7X 
cells. MCF-7X cells were grown on 24-well plates in phenol-red-free RPMI media 
containing 5% XFCS in the absence or presence of LY294002 (5 pM), PD98059 (25 
pM) singly or in combination for 15 days. Every 48 hours cells were subject to trypsin 
dispersion followed by Coulter counting (triplicate wells per time point). These data 
were log transformed to compare growth rate at day 7 and 15. The statistical analysis 
applied was an ANOVA Test followed by a Bonferroni Pos-Hoc Test. Data are 
displayed as the mean number of cells/well +/- SD (n=5).
0 Denotes LY294002/PD98059 treatment was significantly lower at day 7 (p<0.001) 
and day 15 (p<0.001) versus untreated MCF-7X cells.
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Figure 3,102 Cell culture time-line fo r long-term LY294002/PD98059 
treated MCF-7X cells. MCF-7X cells were grown in phenol-red-free RPMI 
media containing 5% XFCS in the presence of LY294002/PD98059 (5 pM, 25 pM) for 
long term culture. The arrow signifies the time point at which the rate of cell growth 
began to increase. Based on the development of rapid log phase growth, there was need 
to increase the frequency of passaging at approximately week 12. Data are displayed as 
the number of passages versus time (weeks).
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MCF-7X
Control +LY/PD
Phospho-MAPK
Phospho-AKT
MCF-7X
Phospho-MAPK
Basal Control 
+ LY294002/PD98059
Phospho-AKT
Basal Control 
+ LY294002/PD98059
(Cytoplasmic)
35.0 (35.0-48.8)
9.0 (6.0-10.0)
p=0 .0 0 1 *
(Memb. + Cyto.)
101.5(76.5-1193)
49.0 (46.0-55.3) 
p=0.004*
(Nuclear)
3.5 (13-5.0) 
1.0(03-1.8) 
p=0.016* 
(Nuclear)
107.5 (95.0-112.5)
95.0 (88.8-95.0)
p=0.016*
Total
38.5
10.0
Total
209.0
144.0
Figure 3,103 Effect o f LY294002/PD98059 on phosphorylated MAPK 
and AKT levels in MCF-7X cells by immunocytochemistry, MCF-7X 
cells were grown on coverslips in phenol-red-free RPMI media containing 5% XFCS in 
the absence or presence of LY294002/PD98059 (5 pM, 25 pM). Conditions were 
maintained for 7 days prior to the appropriate fixation. The phospho-MAPK (antibody 
dilution 1:20) assay required coverslips formal saline fixed and the phospho-AKT 
(1:200) assay required coverslips ERICA fixed. The digital images shown above (X20 
magnification) are representative of 4 experiments. H-Score data were obtained by 
dual assessment of 2  representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant treatment effect versus MCF-7X 
basal control.
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MCF-7X
Total ERa
Phospho-ER 
Seri 18
Phospho-ER 
Seri 67
+LY/PDControl
■ • . . .*  ' • • • • ' A -  - .
J* -V  i 5-: -
»
Total ERa (Nuclear)
Basal Control 
+ LY294002/PD98059 
Phospho-ER Seri 18 (Nuclear) 
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Figure 3.104 Effect o f LY294002/PD98059 co-treatment on total ERa 
and the phosphorylation o f ERa at Seri 18 and Seri67 residues in 
MCF-7X cells by immunocytochemistry. MCF-7X cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS in the absence or 
presence of LY294002/PD98059 (5 pM, 25 pM). Conditions were maintained for 7 
days prior to the appropriate fixation. The total nuclear ERa (antibody dilution 1:100) 
and the phospho-ER Seri 67 (1:25) assays required coverslips ERICA fixed. The 
phospho-ER Seri 18 (antibody dilution 1:400) assay required coverslips 
paraformaldehyde vanadate fixed. The digital images shown above (X20 
magnification) are representative of 3 experiments. H-Score data were obtained by 
dual assessment of 2  representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant treatment effect versus MCF-7X 
basal control.
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3.5 DEVELOPMENT O F RESISTANCE TO SINGLE AND CO­
TREATMENT STRATEGIES
3.5.1 Faslodex Resistance in the MCF-7XModel
Faslodex sensitivity is a feature retained by many of die acquired resistance models, 
including the MCF-7X model where this project has shown the agent partially down- 
regulated ERa, lowered Serll8ER activity, diminished ERE reporter activity and 
reduced endogenous pS2 expression. The pure anti-oestrogen inhibited growth by 
nearly 60% and this response was maintained for approximately 10 weeks (Figure 
3.78). However, faslodex failed to block Serl67ER activity and residual ERa 
transcriptional activity remained, culminating in emergence of resistance to the agent 
with the resultant proliferative activity of these cells restored to that of the untreated 
MCF-7X cells.
Visual characterisation of the subsequent faslodex resistant MCF-7X phenotype 
[X(FAS)j by phase contrast imaging (Figure 3.105A) and Haematoxylin & Eosin 
staining (Figure 3.105B) revealed small irregular colonies, where cells were 
heterogeneous with more elongated pseudopodia and a ‘kite-like’ cellular shape. The 
nuclear to cytoplasmic ratio was equal and the nuclei were heterogeneous ovoid or 
round with prominent nucleoli. These morphological features of the culture became 
evident during initial faslodex treatment of MCF-7X cells and were retained 
throughout the development of X(FAS) cell resistance. Studies in the Tenovus 
Centre for Cancer Research (Nicholson et al., 2005) suggest an increase in aggressive 
behaviour on acquisition of faslodex resistance by breast cancer cells, and in 
accordance with this an increase in motility and, to a lesser extent, invasiveness was 
detected in the X(FAS) sub-line compared to the MCF-7X parental cells (Figure 
3.106A/B).
This resistance to faslodex was associated with diminished ERa expression (45.9%, 
p=0.001*, Figure 3.107) and Serll8ER activity (44.4%, p=0.001*, Figure 3.108) 
versus the basal control. While ERa expression was slightly recovered in X(FAS) 
cells versus the responsive phase (48.0%, p=0.004*, X(FAS) vs. faslodex treated), 
this Serll8ER phosphorylation observed in X(FAS) cells was further significantly 
lowered (p=0.017*) versus treatment of MCF-7X cells with faslodex for 7 days 
primarily due to an increased percentage of cells negative for Serll8ER 
phosphoiylation. In contrast, however, a significant 95.0% (p=0.0035,[) increase in
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Serl67ER activity on the residual ER was observed in the resistant cells versus the 
basal control as well as versus faslodex treatment (p=0.003*, Figure 3.108). In 
parallel, while ER transcriptional activity was not measured in these studies, 
evaluation of pS2 protein by immunocytochemistry revealed considerable recovery in 
expression in the resistant cells by 62.1% versus faslodex treatment (p=0.001*) 
nearing basal levels in the parental MCF-7X cells (Figure 3.109).
7 day faslodex treatment failed to alter MAPK cytoplasmic or nuclear activity 
(p=0.418 and p=0.708 respectively) in MCF-7X cells by immunocytochemistry, and 
there was also no significant influence on AKT activity (membrane plus cytoplasmic 
p=0.127, or nuclear p=0.680) suggesting the inhibitoiy effect o f this agent on ERa 
activity and growth was independent of these kinases. However, the resistant 
phenotype exhibited a substantial 207.1% (p=0.001*) increase in cytoplasmic- 
localised MAPK phosphorylation versus basal MCF-7X cells and a 152.9% rise 
versus faslodex treatment (p=0.003*) while nuclear levels were maintained (Figure 
3.110). Some increases were also achieved for AKT activity (Figure 3.111), although 
increases were more modest in the X(FAS) resistant cells. Thus while there was no 
significant effect on membrane plus cytoplasmic activity (p=0.109), there was a 
20.9% (p=0.004*) increase in nuclear AKT activity versus MCF-7X cell control 
equating to a 26.8% (p=0.003*) increase versus faslodex treatment. These kinases 
could thus be contributory towards ERa activity (alongside the modest increases in 
ERa expression level) and growth in the X(FAS) cells.
Our established in vitro breast cancer cell lines that have acquired anti-oestrogen 
resistance have clearly demonstrated a pivotal role for autocrine EGFR/HER2/IGF1R 
signalling in promoting increased activation of downstream elements MAPK and 
PBK/AKT that drive ERa phosphorylation and transcriptional activity, resistant cell 
growth and also increased invasiveness (McClelland et al., 2001; Knowlden et al., 
2003b). It is thus feasible that the residual Seri 18ER, increased Serl67ER activity, 
and ERa transcriptional activity driven by increases in MAPK and AKT 
phosphorylation (alongside some increases in ERa expression level) may also lie 
downstream of such receptor signalling in the X(FAS) cells and be of potential 
importance in promoting their increased aggressive behaviour and growth. While 
investigation of the parental MCF-7X cell line had revealed only low expression 
levels of IGF-1R, EGFR and HER2, observations made on acquisition of faslodex
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resistance indicated such signalling was significantly altered. Thus, increases in 
EGFR expression were observed in X(FAS) cells versus the parental line. The 
X(FAS) cells exhibited a substantial 235.7% (p=0.004*) increase in membrane 
localised EGFR paralleled by a 125.0% (p=0.004*) increase in cytoplasmic 
expression compared to the low levels in MCF-7X cells (Figure 3.112). HER2 
expression levels were also increased significantly in die X(FAS) resistant phenotype 
by 63.0% (p=0.001*) for membrane localised HER2, coupled with a 120.0% 
(p=0.003*) rise in cytoplasmic expression versus the parental line (Figure 3.113). In 
addition, IGF-1R membrane and cytoplasmic expression was increased by 155.0% 
(p=0.003*) and 77.3% (p=0.004*) respectively once resistance occurred (Figure 
3.114).
Interestingly, while HER2 and IGF-1R expression was unchanged, EGFR levels 
began to increase during early faslodex treatment of MCF-7X cells, with membrane 
and cytoplasmic expression increasing by 50.0% (p=0.004*) and 100% (p=0.004*) 
respectively versus basal control (Figure 3.112). More modest increases were also 
observed in HER2 membrane (22.2%, p=0.056) and cytoplasmic staining (20.0%, 
p=0.016*). Following die faslodex responsive phase in MCF-7X cells, the membrane 
EGFR level increased 123.8% (p=0.004*) Anther once the resistance phenotype 
developed. While EGFR/HER2 does not appear to contribute substantially to MCF- 
7X cells under basal conditions, such signalling may contribute to the MAPK, AKT, 
substantial levels o f Serl67ER and the residual Seri 18ER activity detectable during 
faslodex response, as we have observed previously in association with cell survival 
during anti-oestrogen treatment of MCF-7 cells (Gee et al., 2003).
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A.
B.
MCF-7X MCF-7X + Faslodex (10"7 M) x  (FAS)
Figure 3.105 The visual morphology o f MCF-7X versus X(FAS) 
phenotype by phase contrast (A) and H&E staining (B). MCF-7X and the 
X(FAS) resistant cells were grown in phenol-red-free RPMI media containing 5% 
XFCS in the appropriate absence or presence of faslodex (10*7 M). (A) Cell phase
contrast digital images were obtained during log phase growth (X20 magnification). 
(B) MCF-7X and X(FAS) cells were grown under the same conditions as previously 
described for 7 days on coverslips prior to ERICA fixation. The cells were H&E 
stained with 10% Ehrlich Haematoxylin (10 min) followed by 1% Eosin (2 !/2 hrs). The 
H&E digital images shown above are X40 magnification.
MCF-7X MCF-7X +Faslodex (10-7 M) X(FAS)
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Figure 3.106 MCF-7X and X(FAS) cell motility (A) and invasive 
capacity (B). (A) MCF-7X and X(FAS) cells were seeded onto fibronectin coated 
Transwell® permeable supports for 24 hours prior to formaldehyde fixation and crystal 
violet staining. (B) MCF-7X and X(FAS) cells were seeded onto matrigel coated 
Trans well® permeable supports for 72 hours prior to formaldehyde fixation and 
mounting to glass slides with mounting medium containing DAPI. These data above 
represent the mean number if cells/field of view +/- SD of triplicate inserts.
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Figure 3.107 MCF-7X versus X(FAS) cell ERa expression by 
immunocytochemistry. MCF-7X and X(FAS) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of faslodex (10*7 M). Conditions were maintained for 7 days prior to ERICA 
fixation. The total nuclear ERa (6F11, antibody dilution 1:100) digital images shown 
above (X10 original magnification) are representative of 3 experiments. H-Score data 
were obtained by dual assessment of 2  representative areas of each coverslip followed 
by statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in ERa expression 
versus MCF-7X basal control.
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MCF-7X X(FAS)
Control 
Phospho-ER Seri 18
+ Faslodex (10'7 M)
Phospho-ER Seri67
MCF-7X + Faslodex X(FAS)
Phospho-ER Seri 18
(Nuclear) 90.0(77.5-110.5) 77.5(61.3-80.0) 50.0(47.5-55.0)
p=0.030* p=0.001*
Phospho-ER Seri 67
(Nuclear) 50.0 (45.0-70.0) 50.0 (40.0-60.0) 97.5 (81.3-102.5)
p=0.841 p=0.003*
Figure 3.108 MCF-7X versus X(FAS) cell phosphorylation o f ERa at 
Seri 18 and S eri67 residues by immunocytochemistry. MCF-7X and 
X(FAS) cells were grown on coverslips in phenol-red-free RPMI media containing 5% 
XFCS with the appropriate absence or presence of faslodex (10*7 M). Conditions were 
maintained for 7 days prior to the appropriate fixation. The phospho-ER Seri 18 
(antibody dilution 1:400) assay required coverslips paraformaldehyde vanadate fixed. 
The phospho-ER Seri 67 (antibody dilution 1:25) assay required coverslips ERICA 
fixed. The digital images shown above (X20 magnification) are representative of 4 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-ER Seri 18 or Seri67 level versus MCF-7X basal control.
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pS2
MCF-7X X(FAS)
+ Faslodex (10*7 M)Control
M C F -7X  + F aslodex X (F A S)
pS2
(Cytoplasmic) 130.0(1213-133.8) 72.5 (58.8-80.0) 117.5(105.0-125.0)
p=0.001* p=0.034*
Figure 3.109 MCF-7X versus X(FAS) cell pS2 expression by 
immunocytochemistry. MCF-7X and X(FAS) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence of 
presence of faslodex (10*7 M). Conditions were maintained for 7 days prior to ERICA 
fixation. The pS2 (antibody dilution 1:500) digital images shown above (X20 
magnification) are representative of 3 experiments. H-Score data were obtained by 
dual assessment of 2  representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant difference in pS2 expression 
versus MCF-7X basal control.
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Figure 3.110 MCF-7X versus X(FAS) cell phosphorylated MAPK level 
by immunocytochemistry. MCF-7X and X(FAS) cells were grown on coverslips 
in phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of faslodex (10-7 M). Conditions were maintained for 7 days prior to formal 
saline fixation. The phospho-MAPK (antibody dilution 1:20) digital images shown 
above (X20 magnification) are representative of 4 experiments. H-Score data were 
obtained by dual assessment of 2  representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in phospho-MAPK 
level versus MCF-7X basal control.
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Phospho-AKT
MCF-7X X(FAS)
Control + Faslodex (10*7 M)
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(Nuclear) 107.5 (95.0-112.5) 102.5 (98.8-110.0) 130.0 (128.8-135.0)
p=0.680 p=0.004*
Total 209.0 181.0 245.0
Figure 3.111 MCF-7X versus X(FAS) cellphosphorylated AKT level by 
immunocytochemistry. MCF-7X and X(FAS) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with die appropriate absence or 
presence of faslodex (10*7 M). Conditions were maintained for 7 days prior to ERICA 
fixation. The phospho-AKT (antibody dilution 1:200) digital images shown above 
assay photographed (X20 original magnification) are representative of 3 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-AKT level versus MCF-7X basal control.
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Figure 3.112 MCF-7X versus X(FAS) cell total EGFR expression by 
immunocytochemistry. MCF-7X and X(FAS) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of faslodex (10*7 M). Conditions were maintained for 7 days prior to phenol 
formal saline fixation. The total EGFR (antibody dilution 1:100) digital images shown 
above (X20 magnification) are representative of 2 experiments. H-Score data were 
obtained by dual assessment of 3 representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in total EGFR 
expression versus MCF-7X basal control.
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Figure 3.113 MCF-7X versus X(FAS) cell total HER2 expression by 
immunocytochemistry. MCF-7X and X(FAS) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with die appropriate absence or 
presence of faslodex (10*7 M). Conditions were maintained for 7 days prior to ERICA 
fixation. The total HER2 (antibody dilution 1:100) digital images shown above (X20 
magnification) are representative of 2 experiments. H-Score data were obtained by 
dual assessment of 3 representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant difference in total HER2 
expression versus MCF-7X basal control.
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Figure 3.114 MCF-7X versus X(FAS) cell total IGF-1R expression by 
immunocytochemistry. MCF-7X and X(FAS) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of faslodex (10*7 M). Conditions were maintained for 7 days prior to phenol 
formal saline fixation. The total IGF-1R (antibody dilution 1:125) digital images shown 
above (X20 magnification) are representative of 2 experiments. H-Score data were 
obtained by dual assessment of 3 representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in total IGF-1R 
expression versus MCF-7X basal control
209
CHAPTER 3 RESULTS
3.5.2 LY294002 Resistance in the MCF-7XModel
This project has shown that PI3K inhibitor LY294002 decreased AKT and PDK-1 
activity, and by day 15 inhibited MCF-7X growth by nearly 70%. In contrast to the 
pure anti-oestrogen faslodex, the agent substantially decreased Serl67ER 
phosphorylation leaving Serll8ER activity unchanged. LY294002 subsequently 
partially reduced ERa transcriptional activity both with regards to ERE reporter 
activity and endogenous pS2 expression. However like faslodex the treatment only 
delayed (10 weeks, Figure 3.78) the progression of cell growth, in parallel with die 
incomplete blockade of ERa phosphoiylation and transcriptional activity. There was 
subsequent emergence of an LY294002 resistant MCF-7X sub-line [X(LY)] and 
preliminary investigation (passages 13-15) was performed to better understand the 
mechanism underlying the development of resistance.
The visual morphology of the X(LY) cells by phase contrast imaging and 
Haematoxylin & Eosin staining revealed these cells were a homogeneous population 
mostly round in shape (Figure 3.115A/B). Similar to X(FAS) cells the nuclear to 
cytoplasmic ratio was equal; there were prominent nucleoli in the nuclei however in 
this case the nuclei were large and ovoid. Again these morphological features 
became evident during die initial treatment of MCF-7X cells with the agent and were 
retained as the X(LY) resistant phenotype emerged. Motility and invasion studies 
showed that these LY294002 resistant cells did not show increased aggressive 
behaviour versus the parental MCF-7X cell line, and indeed motility was somewhat 
reduced (Figure 3.116A/B).
Resistance to LY294002 was not associated with any change in total ERa (p=0.279, 
Figure 3.117) or phosphorylated Serll8ER (p=0.596, Figure 3.118) versus basal 
control consistent with the high levels maintained during the responsive phase. 
Phosphoiylation at Serl67ER, however was recovered to a level comparable to MCF- 
7X cell control (p=0.790) and significantly elevated (150%, p=0.021*) versus the 
decreased levels observed in the LY294002 responsive phase (Figure 3.118). Parallel 
evaluation of the oestrogen regulated gene pS2 revealed that levels were also 
increased significantly versus the LY294002 responsive phase of MCF-7X cells 
(80.0%, p<0.001*), resulting in a 21.2% (p=0.001*) increase versus basal control 
(Figure 3.119).
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During LY294002 treatment phosphorylated MAPK was unchanged versus the basal 
control; however, once resistance was established cytoplasmic MAPK activity was 
significantly increased 107.0% (p=0.016*, Figure 3.120) versus basal MCF-7X cells 
and (p=0.002*) versus the LY294002 responsive phase. Phosphorylated AKT was 
also investigated and while LY294002 treatment could inhibit a significant portion of 
AKT activity in MCF-7X cells, immunocytochemistry revealed X(LY) cell 
membrane plus cytoplasmic localised AKT activity was significantly recovered 
(p=0.004*) to a level equal to that of the untreated MCF-7X parental line (Figure 
3.121), as was nuclear staining (37.0%, p=0.003*). Thus, increases in these kinases 
are also apparent where there are obvious increases in Serl67ER phosphorylation and 
ERa transcriptional activity recovery in the X(LY) resistant cells (alongside the 
maintained levels of Seri 18ER activity).
Parallel studies monitoring growth factor receptors in the X(LY) resistant model 
revealed no change in EGFR cytoplasmic expression. However, there was a modest 
35.7% (p=0.006*) increase in membrane EGFR versus MCF-7X cells by 
immunocytochemistry (Figure 3.122). Furthermore, X(LY) cell EGFR membrane 
expression was increased 137.5% (p=0.004*) versus MCF-7X cells treated with 
LY294002. Total HER2 expression followed a similar pattern o f modest increases on 
development of LY294002 resistance (Figure 3.123). Thus, the X(LY) sub-line 
revealed a 26.7% (p=0.004*) increase in membrane staining with a more substantial 
70.0% (p=0.001*) increase in cytoplasmic HER2 expression versus the basal MCF- 
7X control. Membrane and cytoplasmic HER2 expression again increased 
significantly 56.1% (p=0.004*) and 29.4% (p=0.003*) from LY294002 treated cells 
to the resistant phenotype. Immunocytochemistry revealed membrane IGF-1R 
expression in the LY294002 resistant cells was equivalent to the low level o f basal 
MCF-7X cell expression (Figure 3.124), although there were modest increases in 
cytoplasmic staining (22.0%, p=0.013*). It is thus feasible that the Serl67ER activity 
and recovered ERa transcriptional activity may be driven by phosphorylated MAPK 
and AKT downstream of modestly increased growth factor receptor signalling. 
Together with the maintained Seri 18ER activity, this may promote growth of X(LY) 
cells (but appears insufficient to promote invasive behaviour).
In this instance, however, neither EGFR nor HER2 were increased substantially 
during early LY294002 treatment of MCF-7X cells (Figures 3.122 & 3.123; only
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20.0% increase for cytoplasmic HER2, p=0.003*), and indeed EGFR and HER2 
membrane localisation were reduced by such treatment (42.9%, p=0.003* and 44.4%, 
p=0.001* respectively). As such, these particular receptors may not be major 
contributors to the remaining ERa activity (predominately pSerll8ER) and 
associated cell survival during the phase of partial LY294002 response. Early 
LY294002 treatment also did not effect membrane localisation of IGF-1R although 
cytoplasmic expression was increased 45.5% (p=0.009*) versus untreated MCF-7X 
cells (Figure 3.124).
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A.
MCF-7X MCF-7X + LY294002 (5 pM)
B.
MCF-7X MCF-7X + LY294002 (5 pM) x  (LY)
Figure 3.115 The visual morphology o f MCF-7X versus X(LY) 
phenotype by phase contrast (A) and H&E staining (B). MCF-7X and 
X(LY) resistant cells were grown in phenol-red-free RPMI media containing 5% XFCS 
in the appropriate absence or presence of LY294002 (5 pM). (A) Cell phase contrast 
digital images were obtained during log phase growth (X20 magnification). (B) MCF- 
7X and X(LY) cells were grown under the same conditions as previously described for 
7 days on coverslips prior to ERICA fixation. The cells were H&E stained with 10% 
Ehrlich Haematoxylin (10 min) followed by 1% Eosin (2'A hrs). The H&E digital 
images shown above are X40 magnification.
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Figure 3.116 MCF-7X and X(LY) cell motility (A) and invasive 
capacity (B). (A) MCF-7X and X(LY) cells were seeded onto fibronectin coated 
Trans well® permeable supports for 24 hours prior to formaldehyde fixation and crystal 
violet staining. (B) MCF-7X and X(LY) cells were seeded onto matrigel coated 
Transwell® permeable supports for 72 hours prior to formaldehyde fixation and 
mounting to glass slides with mounting medium containing DAPI. These data above 
represent the mean number if cells/field of view +/- SD of triplicate inserts.
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MCF-7X + LY294002 X(LY)
Total ERa
(Nuclear) 185.0 (185.0-195.0) 192.5 (183.8-200.0) 192.5 (185.0-202.5)
p=0.539 p=0.279
Figure 3.117 MCF-7X versus X(LY) cell ERa expression by 
immunocytochemistry. MCF-7X and X(LY) cells were grown on coversiips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of LY294002 (5 pM). Conditions were maintained for 7 days prior to ERICA 
fixation. The total nuclear ERa (6F11, antibody dilution 1:100) digital images shown 
above (X10 original magnification) are representative of 3 experiments. H-Score data 
were obtained by dual assessment of 2  representative areas of each coverslip followed 
by statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed.
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MCF-7X X(LY)
Control + LY294002 (5 pM)
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MCF-7X + LY294002 X(LY)
Phospho-ER Seri 18
(Nuclear) 90.0(77.5-110.5) 105.0(93.8-112.5) 95.0(90.0-106.3)
p=0.186 p=0.596
Phospho-ER Seri 67
(Nuclear) 50.0(45 0-70.0) 25.0(20.0-25.0) 62.5 (42.5-71.3)
p<0.001* p=0.790
Figure 3.118 MCF-7X versus X(LY) cell phosphorylation o f  ERa on 
Seri 18 and S eri67 residues by immunocytochemistry. MCF-7X and 
X(LY) cells were grown on coverslips in phenol-red-free RPMI media containing 5% 
XFCS with the appropriate absence or presence of LY294002 (5 pM). Conditions were 
maintained for 7 days prior to the appropriate fixation. The phospho-ER Seri 18 
(antibody dilution 1:400) assay required coverslips paraformaldehyde fixed. The 
phospho-ER Ser 167 (antibody dilution 1:25) assay required coverslips ERICA fixed. 
The digital images shown above (X20 magnification) are representative of 4 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-ER Serl67 versus MCF-7X basal control.
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pS2
MCF-7X X(LY)
Control + LY294002 (5 pM)
MCF-7X + LY294002 X(LY)
pS2
(Cytoplasmic) 130.0 (121.3-133.8) 87.5 (78.8-92.8) 157.5 (146.3-160.0)
p=0.002* p=0.002*
Figure 3,119 MCF-7X versus X(LY) cell pS2 expression by 
immunocytochemistry, MCF-7X and X(LY) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence of 
presence of LY294002 (5 pM). Conditions were maintained for 7 days prior to ERICA 
fixation. The pS2 (antibody dilution 1:500) digital images shown above (X20 
magnification) are representative of 3 experiments. H-Score data were obtained by 
dual assessment of 2  representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant difference in pS2 expression 
versus MCF-7X basal control.
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Phospho-MAPK
MCF-7X X(LY)
Control + LY294002 (5 pM)
MCF-7X
Phospho-MAPK
(Cytoplasmic) 35.0 (35.0-48.8)
(Nuclear)
Total
3.5 (1.3-5.0)
38.5
+ LY294002
35.0 (21.3-38.8) 
p=0.187
2.0  (1.3-2.8) 
p=0.275
37.0
X(LY)
72.5 (50.0-107.5)
p=0.016*
5.0 (2.0-5.0) 
p=0.777
77.5
Figure 3,120 MCF-7X versus X(LY) cell phosphorylated MAPK level 
by intmunocytochemistry, MCF-7X and X(LY) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of LY294002 (5 pM). Conditions were maintained for 7 days prior to formal 
saline fixation. The phospho-MAPK (antibody dilution 1:20) digital images shown 
above (X20 magnification) are representative of 4 experiments. H-Score data were 
obtained by dual assessment of 2  representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in phospho-MAPK 
level versus MCF-7X basal control.
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Phospho-AKT
MCF-7X X(LY)
Control + LY294002 (5 pM)
MCF-7X + LY294002 X(LY)
Phospho-AKT
(Memb. + Cyto.) 101.5 (76.5-119.3) 34.5 (32.0-57.0) 107.0(99.0-113.0)
p=0.004* p=0.520
(Nuclear) 107.5 (95.0-112.5) 73.0(61.0-81.3) 100.0 (98.8-101.3)
p=0.004* p=0.284
Total 209.0 107.5 207.0
Figure 3.121 MCF-7X versus X(LY) cell phosphorylated AKT level by 
immunocytochemistry. MCF-7X and X(LY) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of LY294002 (5 pM). Conditions were maintained for 7 days prior to ERICA 
fixation. The phospho-AKT (antibody dilution 1:200) digital images shown above 
(X20 magnification) are representative of 3 experiments. H-Score data were obtained 
by dual assessment of 2  representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant difference in phospho-AKT level 
versus MCF-7X basal control.
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Total EGFR
MCF-7X X(LY)
Control + LY294002 (5 pM)
•
-*
MCF-7X + LY294002 X(LY)
Total EGFR
(Membrane) 35.0 (30.0-40.0) 20.0 (18.8-25.0) 47.5 (43.8-55.0)
p=0.003* p=0.006*
(Cytoplasmic) 30.0 (28.0-35.0) 30.0 (28.8-34.3) 32.5 (28.8-40.0)
p=0.933 p=0.365
Total 65.0 50.0 80.0
Figure 3.122 MCF-7X versus X(LY) cell total EGFR expression by 
immunocytochemistry. MCF-7X and X(LY) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of LY29002 (5 pM). Conditions were maintained for 7 days prior to phenol 
formal saline fixation. The total EGFR (antibody dilution 1:100) digital images shown 
above (X20 magnification) are representative of 2 experiments. H-Score data were 
obtained by dual assessment of 3 representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in total EGFR 
expression versus MCF-7X basal control.
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Total HER2
MCF-7X X(LY)
Control + LY294002 (5 pM)
MCF-7X + LY294002 X(LY)
Total HER2
(Membrane) 67.5 (51.3-78.8) 37.5 (35.0-41.3) 85.5 (82.5-91.3)
p = 0 .0 0 1 * p = 0 .0 0 4 *
(Cytoplasmic) 25.0 (20.0-30.0) 30 .0 (28 .8 -36 .0 ) 42.5 (40.0-513)
p = 0 .0 3 3 * p=o .ooi*
Total 92.5.0 67.5 128.0
Figure 3.123 MCF-7X versus X(LY) cell total HER2 expression by 
immunocytochemistry. MCF-7X and X(LY) cells were grown on coverslips in 
phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of LY29002 (5 pM). Conditions were maintained for 7 days prior to ERICA 
fixation. The total HER2 (antibody dilution 1:100) digital images shown above (X20 
magnification) are representative of 2 experiments. H-Score data were obtained by 
dual assessment of 3 representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant difference in total HER2 
expression versus MCF-7X basal control.
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Total IGF-1R
MCF-7X X(LY)
Control + LY294002 (5 uM)
MCF-7X + LY294002 X(LY)
Total IGF-1R
(Membrane) 10 .0  (10.0-12..8) 12.5 (10.0-15.0) 10.0 (10.0-14.3)
p=0.411 p=0.924
(Cytoplasmic) 55.0 (50.0-61.3) 80.0(71.3-86.3) 67.5 (63.8-70.0)
p=0.009* p=0.013*
Total 65.0 92.5 77.5
Figure 3.124 MCF-7X versus X(LY) cell total IGF-1R expression by 
immunocytochemistry. MCF-7X and X(LY) cells were grown on coverslips in 
phenol-red-free RPM1 media containing 5% XFCS with the appropriate absence or 
presence of LY29002 (5 pM). Conditions were maintained for 7 days prior to phenol 
formal saline fixation. The total IGF-1R (antibody dilution 1:125) digital images shown 
above (X20 magnification) are representative of 2 experiments. H-Score data were 
obtained by dual assessment of 3 representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in total IGFR 
expression versus MCF-7X basal control.
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3.5.3 Faslodex/LY294002 R esistance in the M CF -7X M odel 
Co-treatment of MCF-7X cells with faslodex plus LY294002 was able to 
significantly decrease ERa expression, ERa phosphorylation at both Seri 18 and 
Seri67 residues, promote some further decrease ERa transcriptional activity using 
ERE reporter constructs and monitoring of pS2 protein expression, as well as 
inhibiting growth substantially by 90% at day 15. However, although this 
combination was associated with a superior anti-tumour response in MCF-7X cells in 
comparison with the single agents, it again was only able to delay resistance. The 
resistant cells were much slower growing than those emerging with the single agents 
as they did not emerge until after 25 weeks of treatment (Figure 3.88). Phase contrast 
imaging and Haematoxylin & Eosin staining was performed on MCF-7X cells before 
and after treatment with faslodex/LY294002 in comparison with the resistant 
X(FAS/LY) sub-line to investigate the alteration in morphological features (Figure 
3.125A/B). The X(FAS/LY) cells were a heterogeneous cell population with more 
frequent apoptotic bodies, and nuclear appearance and nuclear/cytoplasmic ratio was 
approximately 1 : 1 .  The colony appearance of the faslodex/LY294002 resistant 
cells, X(FAS/LY), was very irregular and these cells appeared to be more loosely- 
adherent to each other than the X(FAS) or X(LY) cells. The cells resembled the 
X(FAS) cells to some degree in that they were elongated in shape with some 
pseudopodia, characteristics that developed during die treatment phase and persisted 
in resistance. Despite these morphological changes however, there was little change 
in motility versus MCF-7X cells, and invasion was only slightly increased (Figure 
3.126A/B).
Faslodex/LY294002 co-treatment significantly reduced ERa expression and ERa 
phosphorylation versus the MCF-7X cell basal control. The resistant X(FAS/LY) 
cells also had a reduction in ERa expression (47.3%, p=0.001*) compared to the 
MCF-7X cells, although this level was slightly elevated versus the responsive phase 
(30.0%, p=0.013*, Figure 3.127). In parallel, there was a significant recovery of 
activity at both Seri 18 and Serl67 ER sites (Figure 3.128). Thus, X(FAS/LY) 
Serll8ER activity was increased 147.6% (p=0.004*) and Serl67ER activity 
increased 325.0% (p=0.003*) compared to the short-term combination treatment, 
furthermore equating to a significant 44.4% (p=0.004*) and 70.0% (p=0.013*) 
increase respectively versus MCF-7X cell control. Moreover, while co-treatment 
resulted in a marked inhibitory effect on ERa transcriptional activity as measured by
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monitoring the oestrogen regulated protein pS2, the X(FAS/LY) cells recovered this 
expression by 120.0% (p=0.001*) versus short-term treatment to a level only 15.4% 
lower (p=0.017*) than in the MCF-7X cells pre-treatment (Figure 3.129).
In parallel with these gains in ERa phosphorylation and transcriptional activity, 
MAPK cytoplasmic activity was significantly increased by 100.0% (p=0.002*) in the 
X(FAS/LY) cells versus the untreated MCF-7X cells and versus response to FAS/LY 
co-treatment (p=0.001*, Figure 3.130). For MAPK activity, changes observed on 
resistance to FAS/LY co-treatment thus equated with the patterns noted on 
development of resistance to each single agent. With regards to AKT activity that 
was inhibited during the responsive phase with faslodex/LY294002, membrane plus 
cytoplasmic levels were significantly increased versus response (278.4%, p=0.004*) 
and restored to the MCF-7X pre-treatment level, while nuclear activity was increased 
by 68.8% versus treatment (p=0.004*) and further increased by 25.6% (p=0.005*,) 
once the resistant phenotype emerged (Figure 3.131). This pattern mirrored the 
increases in kinase activity observed on development of resistance versus the 
responsive phase with faslodex or LY294022 as single agents. Such increases in 
kinase activity may promote the recoveiy o f ERa phosphoiylation and ERa 
transcriptional activity in X(FAS/LY) cells.
Investigation of growth factor receptor expression in the X(FAS/LY) cells revealed 
(as in resistance to faslodex as a single agent) significant increases in EGFR (Figure 
3.132), with membrane expression increased by 242.9% (p=0.003*) and cytoplasmic 
localised expression increased by 125.0% (p=0.004*) versus the parental MCF-7X 
cells. Total IGF-1R membrane and cytoplasmic levels were also increased 
substantially by 250.0% (p=0.003*) and 81.8% (p=0.003*) respectively in the 
X(FAS/LY) cells versus MCF-7X cells (Figure 3.133) where increases had also been 
noted in faslodex resistance. In the case of membrane staining, there was also a 
significant increase in the X(FAS/LY) resistant cells versus the FAS/LY responsive 
phase (p=0.003*). These substantial increases in EGFR and IGF-1R may lie 
upstream of kinase and ERa activity on both Seri 18 and Serl67 in the X(FAS/LY) 
cells, and may contribute to resistant growth. However in contrast to resistance to 
faslodex alone (and as noted in resistance to LY294002), there were only small 
increases in HER2 expression (18.0%, p=0.015*, membrane and 20.0%, p=0.042*, 
cytoplasmic; Figure 3.134). This lack of substantial increase HER2, together with the
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recoveiy of both serine 118 and 167 activity, may in some way preclude substantially 
increased aggressive invasive behaviour in die X(FAS/LY) cells.
In contrast to treatment with faslodex as a single agent, there was no change in 
membrane EGFR staining during faslodex/LY294002 treatment of MCF-7X cells, 
although a 66.7% (p=0.003*) increase in cytoplasmic expression was noted versus 
basal MCF-7X control (Figure 3.132). There was some increase in HER2 membrane 
and particularly cytoplasmic staining during the responsive phase with this co­
treatment (25.9%, p=0.034* and 60.0%, p=0.002*; Figure 3.134), with increases in 
cytoplasmic staining only for IGF-1R observed (118.2%, p=0.003*; Figure 3.133). 
While the relevance o f cytoplasmic staining for such receptors remains unknown, 
they may in some way contribute to residual kinase/ERa activity and cell survival 
during the responsive phase with co-treatment.
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A.
MCF-7X MCF-7X + FAS/LY
B.
MCF-7X MCF-7X +FAS/LY X (FAS/LY)
Figure 3.125 The visual morphology o f MCF-7X versus X(FAS/LY) 
phenotype by phase contrast (A) and H&E staining (B). MCF-7X and the 
X(FAS/LY) resistant cells were grown in phenol-red-free RPM1 media containing 5% 
XFCS in the appropriate absence or presence of faslodex/LY294002 (10*7 M, 5 pM). 
(A) Cell phase contrast digital images were obtained during log phase growth (X20 
original magnification). (B) MCF-7X and X(FAS/LY) cells were grown under the 
same conditions as previously described for 7 days on coverslips prior to ERICA 
fixation. The cells were H&E stained with 10% Ehrlich Haematoxylin (10 min) 
followed by 1% Eosin (IVi hrs). The digital images shown above are X40 
magnification.
X (FAS/LY)
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Figure 3.126 MCF-7X and X(FAS/LY) cell motility (A) and invasive 
capacity (B). (A) MCF-7X and X(FAS/LY) cells were seeded onto fibronectin 
coated Trans well® permeable supports for 24 hours prior to formaldehyde fixation and 
crystal violet staining. (B) MCF-7X and X(FAS/LY) cells were seeded onto matrigel 
coated Transwell® permeable supports for 72 hours prior to formaldehyde fixation and 
mounting to glass slides with mounting medium containing DAPI. These data above 
represent the mean number if cells/field of view +/- SD of triplicate inserts.
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Total ERa
MCF-7X X(FAS/LY)
Control + FAS/LY (lO*7 M, 5 pM)
MCF-7X + FAS/LY X(FAS/LY)
T ota l E R a
(Nuclear) 185.0 (185.0-195.0) 75.0 (70.3-87.5) 97.5 (90.0-112.5)
p=0.001* p=0.001*
Figure 3.127 MCF-7X versus X(FAS/LY) cell ERa expression by 
immunocytochemistry. MCF-7X and X(FAS/LY) cells were grown on coverslips 
in phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of faslodex/LY294002 (lfr7 M, 5 pM). Conditions were maintained for 7 
days prior to ERICA. The total nuclear ERa (6F11, antibody dilution 1:100) digital 
images shown above (X10 original magnification) are representative of 3 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in ERa expression versus MCF-7X basal control.
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MCF-7X X(FAS/LY)
Control + FAS/LY (10'7 M, 5 pM)
Phospho-ER Seri 18
Phospho-ER Ser 167
MCF-7X + FAS/LY X(FAS/LY)
Phospho-ER Seri 18
(Nuclear) 90.0(77.5-110.5) 52.5 (43.8-60.0) 130.0 (111.3-150.0)
p=0 .0 0 1 * p=0.004*
Phospho-ER Serl67
(Nuclear) 50.0 (45.0-70.0) 20.0 (12.0-30.0) 85.0 (77.5-92.5)
p<0 .0 0 1 * p=0.013*
Figure 3.128 MCF-7X versus X(FAS/LY) cell phosphorylation o f ERa 
on Serll8  and Serl67 residues by immunocytochemistry. MCF-7X and 
X(FAS/LY) cells were grown on coverslips in phenol-red-free RPMI media containing 
5% XFCS with the appropriate absence or presence of faslodex/LY294002 (10~7 M, 5 
pM). Conditions were maintained for 7 days prior to the appropriate fixation. The 
phospho-ER Seri 18 (antibody dilution 1:400) assay required coverslips 
paraformaldehyde fixed. The phospho-ER Ser 167 (antibody dilution 1:25) assay 
required ERICA fixed coverslips. The digital images shown above (X20 magnification) 
are representative of 4 experiments. H-Score data were obtained by dual assessment of 
2 representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in phospho-ER Seri 18 or Seri 67 level versus MCF- 
7X basal control.
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pS2
MCF-7X X(FAS/LY)
Control + FAS/LY (1 O'7 M, 5 pM)
h  v .4 .,
* ' 0
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MCF-7X + FAS/LY X(FAS/LY)
pS2
(Cytoplasmic) 130.0(1213-133.8) 50.0(45.0-70.0) 110.0(1013-123.8)
p=0.001* p=0.017*
Figure 3,129 MCF-7X versus X(FAS/LY) cell pS2 expression by 
immunocytochemistry, MCF-7X and X(FAS/LY) cells were grown on coverslips 
in phenol-red-free RPMI media containing 5% XFCS with die appropriate absence of 
presence of faslodex/LY294002 (10*7 M, 5 pM). Conditions were maintained for 7 
days prior to ERICA fixation. The pS2 (antibody dilution 1:500) digital images shown 
above (X20 magnification) are representative of 3 experiments. H-Score data were 
obtained by dual assessment of 2  representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value <0.05(*) indicates a significant difference in pS2 expression 
versus MCF-7X basal control.
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Phospho-MAPK
MCF-7X
Control + FAS/LY (10'7 M, 5 pM)
X(FAS/LY)
MCF-7X
Phospho-MAPK
(C ytoplasm ic) 35.0 (35.0-48.8)
(Nuclear)
Total
3.5 (13-5.0)
38.5
+ FAS/LY
35.0 (30.0-35.0) 
p=0.093
1.5 (l.0-2.0) 
p=0.075
36.5
X(FAS/LY)
70.0 (55.0-100.0)
p=0 .0 0 2 *
3.5 (1.3-5.0) 
p=0.824
73.5
Figure 3,130 MCF-7X versus X(FAS/LY) cell phosphorylated MAPK  
level by immunocytochemistry, MCF-7X and X(FAS/LY) cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS with the appropriate 
absence or presence of faslodex/LY294002 (10-7 M, 5 pM). Conditions were 
maintained for 7 days prior to formal saline fixation. The phospho-MAPK (antibody 
dilution 1:20) digital images shown above (X20 magnification) are representative of 4 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-MAPK level versus MCF-7X basal control.
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Phospho-AKT
MCF-7X X(FAS/LY)
Control + FAS/LY (10‘7 M, 5 pM)
MCF-7X + FAS/LY X(FAS/LY)
Phospho-AKT
(Memb. + Cyto.) 101.5 (76.5-119.3) 25.5 (21.8-29.0) 96.5 (93.8-101.0)
p=0.004* p=0.575
(Nuclear) 107.5 (95.0-112.5) 80.0 (73.8-93.8) 135.0 (123.8-141.3)
p=0 .0 1 2 * p=0.005*
Total 209.0 105.5 231.5
Figure 3,131 MCF-7X versus X(FAS/LY) cell phosphorylated AKT  
level by immunocytochemistry. MCF-7X and X(FAS/LY) cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS with the appropriate 
absence or presence of faslodex/LY294002 (10*7 M, 5 pM). Conditions were 
maintained for 7 days prior to ERICA fixation. The phospho-AKT (antibody dilution 
1:200) digital images shown above (X20 magnification) are representative of 3 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-AKT level versus MCF-7X basal control.
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Total EGFR
MCF-7X X(FAS/LY)
Control + FAS/LY (10*7 M, 5 pM)
f V  *
*
*
$  '
MCF-7X + FAS/LY X(FAS/LY)
Total EGFR
(Membrane) 35.0 (30.0-40.0) 35.0 (33.8-37.0) 120.0 (108.8-120.0)
p=0 .8 6 6 p=0.003*
(Cytoplasmic) 30.0 (28.0-35.0) 50.0 (48.8-51 J) 67.5 (60.0-71.3)
p=0.003* p=0.004*
Total 65.0 85.0 187.5
Figure 3.132 MCF-7X versus X(FAS/LY) cell total EGFR expression 
by immunocytochemistry. MCF-7X and X(FAS/LY) cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS with the appropriate 
absence or presence of faslodex/LY29002 (10*7 M, 5 pM). Conditions were maintained 
for 7 days prior to phenol formal saline fixation. The total EGFR (antibody dilution 
1:100) digital images shown above (X20 magnification) are representative of 2 
experiments. H-Score data were obtained by dual assessment of 3 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in total EGFR expression versus MCF-7X basal control.
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Total IGF-1R
Control
MCF-7X X(FAS/LY)
+ FAS/LY (10*7 M, 5 pM)
=
MCF-7X + FAS/LY
Total IGF-1R
(Membrane) 10.0 (10.0-12.8) 5.0 (5.0-6.3)
p=0.006*
(Cytoplasmic) 5 5 .0  (50.0-61.3) 120 .0(112 .5 -121 .3 )
Total 65.0
p=0.003*
125.0
X(FAS/LY)
35.0 (30.0-45.0) 
p=0.003*
100.0 (90.0-110.0) 
p=0.003*
135.0
Figure 3,133 MCF-7X versus X(FAS/LY) cell total IGF-1R expression 
by immunocytochemistry. MCF-7X and X(FAS/LY) cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS with the appropriate 
absence or presence of faslodex/LY294002 (10'7 M, 5 pM). Conditions were 
maintained for 7 days prior to phenol formal saline fixation. The total IGF-1R 
(antibody dilution 1:125) digital images shown above (X20 magnification) are 
representative of 2 experiments. H-Score data were obtained by dual assessment of 3 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in total IGF-1R expression versus MCF-7X basal 
control.
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Total HER2
MCF-7X X(FAS/LY)
Control + FAS/LY (10 7 M, 5 pM)
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____________________
Total HER2
(Membrane)
(Cytoplasmic)
Total
MCF-7X
67.5 (513-78.8)
25.0 (20.0-30.0)
92.5
+ FAS/LY
85.0 (68.8-96.3) 
p=0.034*
40.0 (33.8-41.3)
p=0 .0 0 2 *
125.0
X(FAS/LY)
79.5 (75.0-85.0) 
p=0.015*
30.0 (30.0-35.0) 
p=0.042*
109.5
Figure 3,134 MCF-7X versus X(FAS/LY) cell total HER2 expression 
by immunocytochemistry. MCF-7X and X(FAS/LY) cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS with the appropriate 
absence or presence of faslodex/LY29002 (10-7 M, 5 pM). Conditions were maintained 
for 7 days prior to ERICA fixation. The total HER2 (antibody dilution 1:100) digital 
images shown above (X20 magnification) are representative of 2 experiments. H-Score 
data were obtained by dual assessment of 3 representative areas of each coverslip 
followed by statistical analysis (Mann-Whitney U-Test). The median H-Score and Ql- 
Q3 values are displayed. A p-value <0.05(*) indicates a significant difference in total 
HER2 expression versus MCF-7X basal control.
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3.5.4 LY294002/PD98059 Resistance in the Oestrogen Deprived Model 
The LY294002 plus PD98059 combination was superior in inhibiting growth (75% at 
day 15) versus these agents applied singly. However long-term exposure still 
produced a resistant sub-line [X(LY/PD)] following 12 weeks of co-treatment (Figure 
3.102), in parallel with retention of significant ERa activity, primarily serine 118 
phosphorylation. As stated previously, this contrasted the catastrophic effects of a 
triple treatment of LY294002 and PD98059 together with faslodex that was able to 
promote superior depletion of ERa activation on both serine 118 and serine 167.
Phase contrast imaging and Haematoxylin & Eosin staining revealed these cells were 
mostly round in shape, contained very large nuclei with prominent nucleoli and the 
majority of cells were multi-nuclear (Figure 3.135A/B). As observed during the 
LY294002/PD98059 response, there was no impact on ERa expression (Figure
3.136) or Seri 18ER phosphorylation in the X(LY/PD) resistant phenotype versus the 
parental MCF-7X cells (Figure 3.137). Serl67 activity which was reduced 50.0% 
during LY294002/PD98059 treatment recovered to basal MCF-7X level (Figure
3.137). While the co-treatment did not affect endogenous pS2 expression, once 
resistance occurred pS2 cytoplasmic localised staining increase 23.1% (p=0.001*) 
versus basal control by immunocytochemistiy (Figure 3.138).
While LY294002/PD98059 co-treatment significantly reduced MAPK cytoplasmic 
and nuclear activity, the X(LY/PD) resistant cells demonstrated some recoveiy 
(127.8%, p=0.001*) in the low level of cytoplasmic activity and a detectable increase 
(p=0.001*) in nuclear staining. X(LY/PD) cytoplasmic staining remained 41.4% 
(p=0.001*) less than basal control, but there was a rise (p=0.015*) in nuclear MAPK 
activity (Figure 3.139) in the resistant phenotype. The combination treatment was 
also successful at reducing membrane plus cytoplasmic (51.7%, p=0.004*) and 
nuclear (11.6%, p=0.016*) AKT activity in MCF-7X cells (Figure 3.140). Once 
again, characterisation of the resistance phenotype revealed substantial recoveiy of 
both membrane plus cytoplasmic (206.1%, p=0.004*) and nuclear (31.6%, p=0.003*) 
compared to the responsive phase. This measured recovery was in fact a significant 
increase from die basal control levels of membrane plus cytoplasmic and nuclear 
staining (47.8%, p=0.004* and 16.3%, p=0.019* respectively).
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These recovery observations o f MAPK, AKT and ERa activity were paralleled by 
modest immunocytochemical increases in EGFR expression following emergence of 
LY294002/PD98059 resistance (Figure 3.141). While co-treatment for 7 days 
reduced both membrane as well as cytoplasmic EGFR 42.9% (p=0.003*) and 33.3% 
(p=0.006*) respectively in MCF-7X cells, the resistant phenotype modestly recovered 
total EGFR expression reaching increased expression levels of 57.1% (p=0.003*, 
membrane) and 33.3% (p=0.003*, cytoplasmic) versus basal control. This result 
equates to a 175.0% (p=0.003*) and 100.0% (p=0.003*) increase in membrane and 
cytoplasmic X(LY/PD) expression respectively, versus the MCF-7X cell responsive 
phase. MCF-7X cell HER2 membrane and cytoplasmic localised expression was 
unaffected by LY294002/PD98059 combination treatment, and while once resistance 
developed there was a 23.8% increase in membrane staining significant versus the 
responsive phase (p=0.019*, Figure 3.142), there was little change versus the basal 
control.
Once die X(LY/PD) resistant phenotype emerged immunocytochemistry revealed a 
significant increase in membrane and cytoplasmic localised IGF-1R expression 
(100.0%, p=0.004* and 68.2%, p=0.004* respectively) versus basal control (Figure 
3.143). The data suggest the increase in IGF-1R began during the responsive phase 
as membrane and cytoplasmic staining did rise during 7 day treatment significantly 
(50.0%, p=0.016* and 145.5%, p=0.003* respectively) versus basal control and so 
may contribute to cell survival at this time.
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A.
MCF-7X MCF-7X + LY/PD X(LY/PD)
B.
Figure 3,135 The visual morphology o f  MCF-7X versus X(LY/PD) 
phenotype by phase contrast (A) and H&E staining (B). MCF-7X and the 
X(LY/PD) resistant cells were grown in phenol-red-free RPMI media containing 5% 
XFCS in the appropriate absence or presence of LY294002/PD98059 (5 pM, 25 pM). 
(A) Cell phase contrast digital images were obtained during log phase growth (X20 
original magnification). (B) MCF-7X and X(LY/PD) cells were grown under the same 
conditions as previously described for 7 days on coverslips prior to ERICA fixation. 
The cells were H&E stained with 10% Ehrlich Haematoxylin (10 min) followed by 1% 
Eosin (2*/i hrs). The digital images shown above are X40 magnification.
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MCF-7X + LY/PD X(LY/PD)
Total ERa
(Nuclear) 185.0(185.0-195.0) 187.5 (183.8-205.0) 187.5 (183.8-206.3)
p=0.797 p=0.757
Figure 3,136 MCF-7X versus X(LY/PD) cell ERa expression by 
immunocytochemistry, MCF-7X and X(LY/PD) cells were grown on coverslips 
in phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of LY294002/PD98059 (5 pM, 25 pM). Conditions were maintained for 7 
days prior to ERICA fixation. The total nuclear ERa (6F11, antibody dilution 1:100) 
digital images shown above (X10 original magnification) are representative of 3 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed.
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MCF-7X
Control + LY/PD (5 pM, 25 pM)
X(LY/PD)
Phospho-ER Seri 18
___
Phospho-ER Seri67
MCF-7X + LY/PD X(LY/PD)
Phospho-ER Seri 18
(Nuclear) 90.0(77.5-110.5) 92.5(78.8-112.5) 80.0(68.8-92.5)
p=0.197 p=0.807
Phospho-ER Seri 67
(Nuclear) 50.0(45.0-70.0) 25.0(10.0-35.0) 75.0(62.5-82.5)
p=0 .0 0 1 * p==0 .1 2 2
Figure 3.137 MCF-7X versus X(LY/PD) cell phosphorylation o f  ERa 
on Seri 18 and S er i67 residues by immunocytochemistry. MCF-7X and 
X(LY/PD) cells were grown on coverslips in phenol-red-free RPMI media containing 
5% XFCS with the appropriate absence or presence of LY294002/PD98059 (5 pM, 25 
pM). Conditions were maintained for 7 days prior to the appropriate fixation. The 
phospho-ER Seri 18 (antibody dilution 1:400) assay required coverslips 
paraformaldehyde fixed and the phospho-ER Seri67 (1:25) assay required coverslips 
ERICA fixed. The digital images shown above (X20 magnification) are representative 
of 4 experiments. H-Score data were obtained by dual assessment of 2 representative 
areas of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The 
median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a 
significant difference in phospho-ER level versus MCF-7X basal control.
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pS2
MCF-7X X(LY/PD)
Control + LY/PD (5 pM, 25 pM)
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(Cytoplasmic)
M C F -7X
130.0(121.3-133.8)
+  L Y /P D
135.0 (106.3-148.8) 
p=0.671
X (L Y /P D )
160.0 (152.5-168.8)
p=0 .0 0 1 *
Figure 3.138 MCF-7X versus X(LY/PD) cell pS2 expression by 
immunocytochemistry. MCF-7X and X(LY/PD) cells were grown on coverslips 
in phenol-red-free RPMI media containing 5% XFCS with the appropriate absence of 
presence of LY294002/PD98059 (5 pM, 25 pM). Conditions were maintained for 7 
days prior to ERICA fixation. The pS2 (antibody dilution 1:500) digital images shown 
above (X20 magnification) are representative of 3 experiments. H-Score data were 
obtained by dual assessment of 2  representative areas of each coverslip followed by 
statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are diaplayed. A p-value <0.05(*) indicates a significant difference in pS2 expression 
versus MCF-7X basal control.
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Phospho-MAPK
MCF-7X X(LY/PD)
Control + LY/PD (5 pM, 25 pM)
MCF-7X
Phospho-MAPK
(C ytoplasm ic) 35.0 (35.0-48.8)
(Nuclear)
Total
3.5 (l.3-5.0)
38.5
+ LY/PD
9.0 (6.0-10.0)
p=0 .0 0 1 *
1.0 (03-1.8)
p=0.016*
10.0
X(LY/PD)
20.5 (20.0-25.0)
p=0 .0 0 1 *
9.5 (4.0-13.8) 
p=0.015* 
30.0
Figure 3.139 MCF-7X versus X(LY/PD) cell phosphorylated MAPK 
level by immunocytochemistry. MCF-7X and X(LY/PD) cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS with the appropriate 
absence or presence of LY294002/PD98059 (5 pM, 25 pM). Conditions were 
maintained for 7 days prior to formal saline fixation. The phospho-MAPK (antibody 
dilution 1:20) digital images shown above (X20 magnification) are representative of 4 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-MAPK level versus MCF-7X basal control.
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Phospho-AKT
MCF-7X X(LY/PD)
Control + LY/PD (5 pM, 25 pM)
Phospho-AKT
(Memb. + Cyto.)
(Nuclear)
Total
MCF-7X
101.5 (76.5-119.3) 
107.5(95.0-112.5)
209.0
+ LY/PD
49.0 (46.0-553) 
p=0.004*
95.0 (88.8-95.0) 
p=0.016*
144.0
X(LY/PD)
150.0 (145.0-160.0) 
p=0.004*
125.0 (120.0-130.0) 
p=0.019*
275.0
Figure 3.140 MCF-TX versus X(LY/PD) cellphosphorylated AKT level 
by immunocytochemistry. MCF-7X and X(LY/PD) cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS with the appropriate 
absence or presence of LY294002/PD98059 (5 pM, 25 pM). Conditions were 
maintained for 7 days prior to ERICA fixation. The phospho-AKT (antibody dilution 
1:200) digital images shown above (X20 magnification) are representative of 3 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-AKT level versus MCF-7X basal control.
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Total EGFR
MCF-7X XCLY/PD)
Control + LY/PD (5 pM, 25 pM)
Total EGFR
(Membrane)
(Cytoplasmic)
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MCF-7X
35.0 (30.0-40.0)
30.0 (28.0-35.0)
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+ LY/PD
20.0 (15.0-21.3) 
p=0.003*
20.0 (15.0-25.0)
p=0.006*
40.0
X(LY/PD)
55.0 (53.8-56.3) 
p=0.003*
40.0 (40.0-46.3) 
p=0.003*
95.0
Figure 3.141 MCF-7X versus X(LY/PD) cell total EGFR expression by 
immunocytochemistry. MCF-7X and X(LY/PD) cells were grown on coverslips 
in phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of LY29002/PD98059 (5 pM, 25 pM). Conditions were maintained for 7 days 
prior to phenol formal saline fixation. The total EGFR (antibody dilution 1:100) digital 
images shown above (X20 magnification) are representative of 2 experiments. H-Score 
data were obtained by dual assessment of 3 representative areas of each coverslip 
followed by statistical analysis (Mann-Whitney U-Test). The median H-Score and Ql- 
Q3 values are displayed. A p-value <0.05(*) indicates a significant difference in total 
EGFR expression versus MCF-7X basal control.
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Total HER2
MCF-7X X(LY/PD)
Control + LY/PD (5 pM, 25 pM)
MCF-7X + LY/PD X(LY/PD)
Total HER2
(Membrane) 67.5 (513-78.8) 52.5 (48.8-60.0) 65.0 (58.8-72.5)
p=0.099 p=0.964
(Cytoplasmic) 25.0 (20.0-30.0) 25.0 (18.8-30.0) 20.0 (18.8-25.0)
p=0.770 p=0.076
Total 92.5 77.5 85.0
Figure 3.142 MCF-7X versus X(LY/PD) cell total HER2 expression by 
immunocytochemistry. MCF-7X and X(LY/PD) cells were grown on coverslips 
in phenol-red-free RPMI media containing 5% XFCS with the appropriate absence or 
presence of LY29002/PD98059 (5 pM, 25 pM). Conditions were maintained for 7 days 
prior to ERICA fixation. The total HER2 (antibody dilution 1:100) digital images 
shown above (X20 magnification) are representative of 2 experiments. H-Score data 
were obtained by dual assessment of 3 representative areas of each coverslip followed 
by statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed.
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Total IGF-1R
MCF-7X X(LY/PD)
Control + LY/PD (5 pM, 25 pM)
---------.
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MCF-7X
Total IGF-1R
(Membrane) 10.0(10.0-12.8)
(Cytoplasmic) 55.0 (50.0-61.3)
+ LY/PD X(LY/PD)
Total 65.0
15.0 (14.0-17.5) 20.0 (18.8-21.3)
p=0.016* p=0.004*
135.0(134.8-140.0) 92.5(87.5-96.3)
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150.0 112.5
Figure 3.143 MCF-7X versus X(LY/PD) cell total IGF-1R expression 
by immunocytochemistry. MCF-7X and X(LY/PD) cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% XFCS with the appropriate 
absence or presence of LY29002/PD98059 (5 pM, 25 pM). Conditions were 
maintained for 7 days prior to phenol formal saline fixation. The total IGF-1R 
(antibody dilution 1:125) digital images shown above (X20 magnification) are 
representative of 2 experiments. H-Score data were obtained by dual assessment of 3 
representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in total IGF-1R expression versus MCF-7X basal 
control.
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3 .6  A F F Y M E T R IX H U M A N  G E N O M E  U 133A  G E N E C H IP ® A R R A Y S
3.6.1 M icroarray A nalysis o f  M C F -7X  versus M C F -7 cells
In an attempt to decipher any alternative receptor input that may be contributing to 
MCF-7X cell growth signalling (notably promoting the PI3K/AKT pathway and ER 
signalling), Asymetrix microarray technology was utilised (UWCM). MCF-7 versus 
MCF-7X cell expression profiles were investigated from triplicate cell preparations 
using web-based GeneSifter® microarray analysis software. Statistical analysis was 
performed to reveal the spectrum o f genes altered in the resistant cell line employing 
a threshold o f 2-fold change and a significance cut-off of p<0.05. The altered genes 
were subsequently classified according to ontology provided through GeneSifter® 
software.
3126 genes related to molecular function matched the applied criteria in MCF-7X 
cells. O f the 3126 genes matching the parameters set, 349 (11.16%) were described 
as being related to signal transducer activity (Figure 3.144). As there were 1852 genes 
in total on the Afiymetrix arrays associated with such an ontology, approximately 
20% (349/1852) o f genes in this signalling category were altered in MCF-7X cells. 
Further ontological sub-grouping revealed the majority (207/349 genes; 60%) of the 
signal transducer activity genes altered in MCF-7X were implicated specifically in 
receptor activity (Figure 3.145). O f these 207 genes, approximately 63% were 
induced in MCF-7X versus MCF-7. O f particular interest among these induced 
receptor activity genes were FGFR4, EphA3 receptor, and transferrin receptor.
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Totals
Ontology List Array
binding 1348 6782
catalytic activity 770 3695
signal transducer activity 349 1852 ^
transporter activity 218 1158
transcription regulator activity 203 1022
structural molecule activity 101 572
enzyme regulator activity 93 460
motor activity 20 118
translation regulator activity 17 84
antioxidant activity 4 26
chaperone regulator activity 2 5
chaperone activity 1 1
nutrient reservoir activity 0 1
Figure 3,144 Asym etrix Human Genome U133A Genechip® Array 
molecular function ontology clustering. The web-based Genesifter® 
microarray software was utilised for the data analysis of the Affymetrix microarray 
results. Ontology clustering was employed to identify genes involved in molecular 
function revealing out of 15,776 genes on the array, 3,126 were altered in MCF-7X 
cells versus MCF-7 cells. Parameter settings included a 2-fold threshold change and 
significance cut-off of p<0.05 for statistical analysis. This ontology profile revealed 
349 signal transducer activity genes significantly altered in MCF-7X cells.
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Figure 3,145 Affymetrix Human Genome U133A Genechip® Array 
signal transducer activity ontology clustering. The web-based Genesifter® 
microarray software was utilised for the data analysis of the Affymetrix microarray 
results. Ontology clustering was employed to identify genes involved in signal 
transducer activity revealing out of 1,767 genes on the array, 349 were altered in MCF- 
7X cells versus MCF-7 cells. Parameter settings included a 2-fold threshold change and 
significance cut-off of p<0.05 for statistical analysis. This ontology profile revealed 
207 receptor activity genes significantly altered in MCF-7X cells.
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3.6.2 R eceptor Input P otentially Contributory to M CF -7X Cell Signalling and  
Growth R evealed by A ffym etrix A nalysis
3.6.2.1 FG FR-4 and EphA3 R eceptor
The fibroblast growth factor receptor-4 (FGFR-4, Accession No. AF202063, Figure 
3.146) was among the 207 receptor activity genes significantly induced in MCF-7X 
cells. The FGFR family consists of at least four members that contain an 
extracellular ligand binding domain, an intracellular tyrosine kinase domain and a 
single transmembrane domain (Johnson & Williams 1993). FGFR-4 is a highly 
specific receptor for acidic FGF, although basic FGF will bind with a lower affinity 
(Ron et al.9 1993). FGFR-4 is over expressed in 30% of breast cancers and can 
contribute to cell proliferation, cell survival and migration, and can trigger kinase 
signalling and co-operate with HER2 (Koziczak & Hynes 2004).
According to the parameter settings used in the Affymetrix analysis (threshold of 2 
fold change, significance cut-off of p<0.05), FGFR-4 expression was markedly 
increased in MCF-7X cells versus an absent call in the parental MCF-7 cells (-3- 
fold). While the project has previously observed a lack of stimulatory effect of 
exogenous FGFs on MCF-7X cell growth (Figure 3.42), a role for such signalling is 
still feasible in the absence of challenging MCF-7X cells with a selective FGFR-4 
inhibitor (unavailable for this project). However, since the Affymetrix data also 
revealed the natural ligands for the FGFR-4, FGF1 (acidic FGF, Accession No. 
NM_013394) and FGF2 (basic FGF, Accession No. NM 002006) were absent in 
both the oestrogen deprived and parental cell lines (Figure 3.147), the data imply that 
FGFR4 signalling is unlikely to provide a major receptor input in these cells.
A further gene identified by Affymetrix as significantly increased (4.5-fold) in MCF- 
7X cells compared to the parental cell line was the EphA3 receptor (HEK, Accession 
No. AF213459, Figure 3.148). Ephrin receptors comprise the largest family of 
receptor tyrosine kinases and are divided into two sub-categories based on ligand and 
binding differences (Heroult et al., 2006). There are at least five ephrin A ligands 
with eight corresponding EphA receptors, where ephrin A3 receptor binds to ephrin- 
A2, -A3, -A4 and -A5 (Accession No’s. NM_001405, AW189015, NM_005227 and 
NM 001962 respectively). Interestingly, the profiles for each of these ligands 
indicate that MCF-7X cells do not over express an endogenous ligand stimulus for die 
EphA3 receptor (Figure 3.149). Ephrin A2 and A5 called as absent in MCF-7X cells.
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However, MCF-7X cells do produce ephrin A3 and A4, albeit at a much lower level 
compared to MCF-7 cells (~l-fold and 2-fold less respectively). It is feasible that 
these ephrins may exert a more prominent effect in MCF-7X cells via the increased 
EphA3 receptor. EphA3 receptor has previously been linked with tumour progression 
and so may positively contribute to growth; however since it has also been described 
as a tumour suppressor in some cell contexts, its role remains unclear in MCF-7X 
cells (Brantley et al., 2002).
3.6.2.2 Transferrin R eceptor
A further receptor whose expression was significantly increased (~2-fold) in MCF-7X 
cells compared to the parental MCF-7 cells within the list of genes involved in 
receptor activity from Affymetrix analysis was the transferrin receptor (CD71, TFR1, 
Accession No. NM 003234, Figure 3.150). The transferrin receptor (TfR) is a 
transmembrane homodimer consisting of two identical monomers with a molecular 
weight o f 90 kDa located in the plasma membrane that bind iron-loaded transferrin 
with a very high affinity. Maintained iron uptake is pivotal for energy metabolism, 
DNA synthesis, cell survival and proliferation [where CD71 immunostaining 
invariably equates with proliferative capacity in clinical disease (Wrba et al., 1989)]. 
Indeed transferrin supplementation is an essential component of defined media for in 
vitro studies, and TfR increases in breast cancer cells (e.g. T47D) occur in response to 
reduced concentrations of fetal calf serum in media. Breast cancer cell models have 
previously been shown to produce transferrin and express transferrin receptor to 
maximise their iron delivery and enable proliferative activity (Vandewalle et al., 
1989). Moreover, transferrin/TfR over expression has also been equated with 
metastastic growth in rat breast cancer model systems (Cavanaugh et al., 1999) and 
progression in the clinic (Agarwal et al., 2001). It was therefore hypothesised that 
increases in TfR may also play a vital contributoiy role in MCF-7X cell growth by 
maintaining iron delivery under the severe oestrogen and growth factor depleted 
conditions, thereby aiding mitogenic signalling pathways (e.g. AKT/ER) and 
conferring a selective growth advantage.
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Fibroblast Growth Factor Receptor 4
MCF-7X (XFCS)MCF-7 (SFCS) MCF-7 (XFCS)
Figure 3.146 Affymetrix fibroblast growth factor receptor 4 (FGFR4) 
log intensity profile and heat map fo r  MCF-7 and MCF-7X cells. 
MCF-7 and MCF-7X cells were grown in phenol-red-free RPMI media containing 5% 
SFCS or XFCS respectively. Conditions were maintained for 7 days before RNA was 
isolated for Affymetrix microarray analysis (U133A Genechip® arrays). The web- 
based Genesifter® microarray software was utilised to generate the intensity profile 
and heat map for FGFR4 (Accession No. AF202063) shown above. A negative 
intensity value denotes an affymetrix call of absent
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Figure 3.147 Affymetrix fibroblast growth factor -1 (A) and -2 (B) log 
intensity profiles and heat maps fo r MCF-7 and MCF-7X cells. MCF-7 
and MCF-7X cells were grown in phenol-red-free RPMI media containing 5% SFCS 
or XFCS respectively. Conditions were maintained for 7 days before RNA was 
isolated for Affymetrix microarray analysis (U133A Genechip® arrays). The web- 
based Genesifter® microarray software was utilised to generate the intensity profile 
and heat map for FGF-1 and -2 (Accession No. NM 013394 and NM 002006) shown 
above. A negative intensity value denotes an affymetrix call of absent.
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Ephrin A3 Receptor (EphA3)
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Figure 3.148 Affymetrix ephrin A3 receptor log intensity profile and 
heat map fo r MCF-7 and MCF-7X cells. MCF-7 and MCF-7X cells were 
grown in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. 
Conditions were maintained for 7 days before RNA was isolated for Affymetrix 
microarray analysis (U133A Genechip® arrays). The web-based Genesifter® 
microarray software was utilised to generate the intensity profile and heat map for 
EphA3 receptor (Accession No. AF213459) shown above. A negative intensity value 
denotes an affymetrix call of absent.
254
CHAPTER 3 RESULTS
Ephrin-A2
o
059  «  - 2 - +c --
- 3 - \
MCF-7 (SFCS) MCF-7 (XFCS) MCF-7X (XFCS)
Ephrin-A3
A  -
£
S3 3 -
Js 2 - t
1 -
MCF-7 (SFCS) MCF-7 (XFCS) MCF-7X (XFCS)
Ephrin-A4
 ^ i^ -
3 -
C/3
S  -g 2 -C +
1 - F
MCF-7 (SFCS) MCF-7 (XFCS) MCF-7X (XFCS)
Ephrin-A5
4 J1
Cfl -1  -s
♦
4 5  - 2  -a
- 3 -  
- A  - 1
MCF-7 (SFCS) MCF-7 (XFCS) MCF-7X (XFCS)
Figure 3.149 Affymetrix ephrin -A2 (A), -A3(B), -A4(C) and -A5(D) 
log intensity profiles and heat maps fo r MCF-7 and MCF-7X cells. 
MCF-7 and MCF-7X cells were grown in phenol-red-free RPMI media containing 5% 
SFCS or XFCS respectively. Conditions were maintained for 7 days before RNA was 
isolated for Affymetrix microarray analysis (U133A Genechip® arrays). The web- 
based Genesifter® microarray software was utilised to generate the intensity profile 
and heat map for the ephrin ligands -A2, -A3, -A4 and -A5 (Accession No. 
NM 001405, AW 189015, NM_005227 and NM_001962 respectively) shown above. 
A negative intensity value denotes an affymetrix call of absent.
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Figure 3.150 Affymetrix tranferrin receptor log intensity profile and 
heat map fo r  MCF-7 and MCF-7X cells. MCF-7 and MCF-7X cells were 
grown in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively. 
Conditions were maintained for 7 days before RNA was isolated for Affymetrix 
microarray analysis (U133A Genechip® arrays). The web-based Genesifter® 
microarray software was utilised to generate the intensity profile and heat map for 
transferrin receptor (Accession No. NM 003234) shown above. Affymetrix call is 
present for MCF-7 and MCF-7X.
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3.7 IMPACT OF TRANSFERRIN/TRANSFERRIN RECEPTOR 
SIGNALLING INM CF-7X CELLS
Based on the promising transferrin receptor Affymetrix profile, several experiments 
including growth studies, RT-PCR and immunocytochemistry were employed to 
investigate transferrin/transferrin receptor signalling in further detail in MCF-7X 
cells. RT-PCR confirmed the above described Affymetrix data, demonstrating a 
marked 241.2% (p<0.001*) increase in MCF-7X cell TfR mRNA expression versus 
MCF-7 cells (Figure 3.151). RT-PCR also revealed equivalent MCF-7 and MCF-7X 
cell production of low, but detectable, levels of transferrin (Figure 3.151). Protein 
level assessed by immunocytochemistry revealed prominent TfR staining with a 
substantial 77.8% (p=0.003*) increase in plasma membrane expression and increased 
cytoplasmic staining (90.5%, p=0.004*) in MCF-7X cells compared to the parental 
cell line (Figure 3.152). These data were paralleled by 7 day growth studies, where 
the addition of transferrin (4 pg/ml) stimulated MCF-7X cell growth substantially by 
100% (p<0.001*) compared with a more modest impact on MCF-7 cells (50.0%, 
p<0.001*) (Figure 3.153). Immunocytochemical analysis o f die TfR receptor 
following transferrin treatment revealed a modest increase in cytoplasmic localised 
staining in occasional MCF-7 cells (47.6%, p=0.012*). In contrast, there was a large 
significant decrease in both plasma membrane (87.5%, p=0.003*) and cytoplasmic 
(65.0%, p=0.003*) immunostaining (Figure 3.154) in MCF-7X cells following 
transferrin treatment.
3.7.1 E ffect o f  Transferrin/Transferrin Receptor Input on K inase A ctivity in M CF- 
7X Cells
Growth studies performed over 15 days supported the concept of significant positive 
TfR/PDK interplay in MCF-7X cells, since LY294002 was able to fully abrogate 
transferrin-induced growth in these cells (p=0.002*, Figure 3.155). Surprisingly, 
however, further investigation of the interplay between transferrin and the PI3K 
pathway revealed some negative impact o f transferrin treatment on AKT activity 
observed by immunocytochemistry (Figure 3.156). Thus, transferrin treatment 
significantly reduced nuclear phosphoiylated AKT by 46.5% in MCF-7X cells 
(p=0.004*), also with some decline in cytoplasmic activity. Further growth studies 
indicated that the MEK1 inhibitor PD98059 was substantially less effective in 
abrogating transferrin-induced growth of MCF-7X cells (p=1.000, Figure 3.157) at 
day 15, in contrast to the PI3K inhibitor. Again, immunocytochemistry revealed that
257
CHAPTER 3 RESULTS
transferrin exerted some negative impact on MAPK phosphorylation in MCF-7X cells 
(Figure 3.158). Transferrin treatment reduced MCF-7X cell cytoplasmic MAPK 
activity by 28.6% (p=0.026*), and the low levels of nuclear localised activity in these 
cells were abrogated.
In total, these data do not appear to advocate the concept that increased transferrin 
receptor is an upstream positive regulator o f kinase signalling activity in MCF-7X 
cells. Indeed, there appears to be significant negative cross-talk following transferrin 
challenge that may in some way serve to limit excessive growth responses in the 
presence of transferrin. However, since LY294002 clearly abrogates transferrin- 
induced growth, it does seem that transferrin/transferrin receptor signalling effects in 
MCF-7X cells are in some way positively regulated by PI3K. Interestingly, PI3K 
signalling has been shown to be able to regulate trafficking of transferrin/transferrin 
receptor, where PDK inhibitors deplete cell surface TfR levels (Jess et al., 1996). It is 
thus possible that LY294002 may interfere with transferrin-induced growth via such a 
mechanism. As such, expression of transferrin receptor was examined following 
treatment with LY294002 in MCF-7X cells. This showed LY294002 treatment had 
no effect on membrane expression, but the compound was responsible for a small 
significant 10% (p=0.011*, Figure 3.159) reduction in cytoplasmic localised staining.
3.7.2 The E ffect o f  Transferrin/Transferrin Receptor Input on ERa Signalling in  
M C F -7X  Cells
Growth studies over 15 days with faslodex revealed that transferrin-stimulated growth 
could be significantly inhibited by this pure anti-oestrogen (Figure 3.160). These data 
suggest interplay between ERa and transferrin/TfR signalling in MCF-7X cells. In 
order to further decipher this potential positive cross-talk, immunocytochemistry was 
utilised to investigate the effect of transferrin treatment on nuclear ERa, 
phosphorylation of Serll8ER  and Serl67ER and expression of the oestrogen 
regulated gene pS2. Again, surprisingly total nuclear ERa was slightly reduced by 
13.9% (p=0.002*) in MCF-7X cells (Figure 3.161). Moreover, while there was no 
significant change in Serll8ER phosphorylation (Figure 3.162), Serl67ER activity 
was reduced significantly by 50.0% (pO.OOl*) following transferrin treatment 
(Figure 3.162). In parallel there was a significant 34.6% (p=0.002*) loss of pS2 
cytoplasmic localised expression in MCF-7X cells (Figure 3.163).
258
CHAPTER 3 RESULTS
These data do not appear to advocate die increased transferrin receptor as an upstream 
positive regulator of ERa signalling activity in MCF-7X cells, and indeed again there 
appears to be significant negative cross-talk following transferrin challenge, where 
potentially its depletion o f kinase activity (alongside a modest decline in ERa level) 
contributes to decreases in Serl67ER phosphorylation and ER-regulated gene 
expression. Such inhibitory effects may again serve to limit excessive growth 
responses in the presence o f transferrin. However, since faslodex can abrogate 
transferrin-induced growth, it does seem that transferrin/TfR signalling is in some 
way positively regulated by ERa (and indeed oestrogens have previously been shown 
to positively regulate transferrin/transferrin receptor expression [Vandewalle & 
Lefebvre, 1989]). As such, immunocytochemistry was used to examine if there was 
any influence of faslodex on TfR expression in MCF-7X cells. However, in this case 
the anti-oestrogen had no significant effect on membrane or cytoplasmic localised 
TfR (p=1.000 and p=0.150 respectively, Figure 3.164).
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Figure 3.151 Basal MCF-7X versus MCF-7 mRNA expression o f 
transferrin receptor and transferrin by RT-PCR. MCF-7 and MCF-7X cells 
were grown on 100 mm dishes in phenol-red-free RPMI media containing 5% SFCS or 
XFCS respectively. Conditions were maintained for 7 days before RNA was isolated 
and reverse transcribed. Co-amplification RT-PCR of transferrin receptor (25 cycles/ 
55°C annealing temperature, 484 bp) and y9-Actin (204 bp) was performed. Individual 
RT-PCR of transferrin (32 cycles/ 55°C annealing temperature, 316 bp) and /?-Actin (25 
cycles/ 55°C annealing temperature, 204 bp) was performed. Product from each 
reaction was run a 2 % agarose gel containing ethidium bromide, subsequently 
photographed, scanned and normalised to /?-Actin. The digital images above are 
representative 3 experiments (for each target sequence) and the statistical analysis 
applied was an unpaired-T test (transferrin receptor p<0.001*, transferrin p=0.932) 
comparing mean MCF-7 cell expression to mean MCF-7X cell expression.
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Transferrin Receptor
MCF-7 MCF-7X
MCF-7 MCF-7X p-value
TfR CD71
(Membrane) 22.5 (18.8-26.3) 40.0 (37.5-45.0) p=0.003*
(Cytoplasmic) 52.5 (48.8-60.0) 100.0 (98.8-101.3) p=0.004*
Total 75.0 140.0
Figure 3.152 Basal MCF-7X versus MCF-7 cell transferrin receptor 
(TfR, CD71) expression by immunocytochemistry. MCF-7 and MCF-7X 
cells were grown on coverslips in phenol-red-free RPMI media containing 5% SFCS or 
XFCS respectively. Conditions were maintained for 7 days prior to phenol formal 
saline fixation. The CD71 (antibody dilution 1:100) digital images shown above (X20 
magnification) are representative of 4 experiments. H-Score data were obtained by 
dual assessment of 2  representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant difference in transferrin receptor 
expression between MCF-7 and MCF-7X cells.
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+ Transferrin (4 |ig/ml)Control
Figure 3.153 Effect o f transferrin on growth of MCF-7 versus MCF- 
7X cells. MCF-7 and MCF-7X cells were grown on 24-well plates in phenol-red-free 
RPM3 media containing 5% SFCS or XFCS respectively in the absence or presence of 
transferrin (4 jig/ml). Conditions were maintained for 7 days [Him’ to trypsin dispersion 
followed by Coulter counting (triplicate wells per treatment). Data are displayed as a 
percentage of control cell growth and include 3 separate experiments +/- SD.
* and 0 Denotes transferrin significantly stimulated MCF-7 (p<0.001) and MCF-7X 
(p<0.001) cell growth versus their respective controls.
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Transferrin Receptor (CD71)
MCF-7 MCF-7X
Control
+ Transferrin 
(4 pg/ml)
—
MCF-7
TfR CD71 
Basal Control
(Membrane) 22.5 (18.8-26.3)
(Cytoplasmic) 52.5 (48.8-60.0)
Total 75.0
+ Transferrin (4 jig/ml)
(Membrane) 22.5 (17.5-25.0) p=0.735
(Cytoplasmic) 77.5 (66.3-86.3) p=0.012*
Total 100.0
MCF-7X
40.0 (37.5-45.0)
100.0 (98.8-101.3)
140.0
5.0 (5.0-10.0) p=0.003*
35.0 (28.8-40.0) p=0.003*
40.0
Figure 3.154 Effect o f  transferrin on transferrin receptor (CD71) 
expression in MCF-7 and MCF-7X cells by immunocytochemistry.
MCF-7 and MCF-7X cells were grown on coverslips in phenol-red-free RPMI media 
containing 5% SFCS or XFCS respectively in the absence or presence of transferrin (4 
Hg/ml). Conditions were maintained for 7 days prior to phenol formal saline fixation. 
The CD71 (antibody dilution 1:100) digital images shown above (X20 magnification) 
are representative of 3 experiments. H-Score data were obtained by dual assessment of 
2 representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value of <0.05(*) 
indicates a significant difference in transferrin receptor expression following transferrin 
treatment.
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Figure 3.155 Growth challenge with transferrin singly or in 
combination with the PI3K inhibitor LY294002 in MCF-7X cells. MCF- 
IX  cells were grown on 24-well plates in phenol-red-free RPMI media containing 5% 
XFCS in the presence of transferrin (4 (ig/ml) or transferrin/LY294002 (4 pg/ml, 5 pM) 
for 15 days. Every 48 hours cells were subject to trypsin dispersion followed by 
Coulter counting (triplicate wells per time point). These data were log transformed to 
compare growth rate at day 15. The statistical analysis applied was an ANOVA Test 
followed by a Bonferroni Post-Hoc Test. The data are displayed as die mean number of 
cells/well +/- SD (n=3).
0 Denotes transferrin/LY294002 treatment was significantly lower at day 15 (p=0.002) 
versus transferrin treatment control.
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Phospho-AKT (Control)
(Memb. + Cyto.) 101.5 (76.5-119.3)
(Nuclear) 107.5 (95.0-112.5)
Total 209.0
+ Transferrin (4 pg/ml)
(Memb. + Cyto.) 77.0 (70.5-80.3) p=0.077
(Nuclear) 57.5 (55.0-61J ) p=0.004*
Total 134.5
Figure 3.156 Effect o f transferrin on phosphorylated AKT level in 
MCF-7X cells by immunocytochemistry. MCF-7 and MCF-7X cells were 
grown on coverslips in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively in the absence or presence of transferrin (4 pg/ml). Conditions were 
maintained for 7 days prior to ERICA fixation. The phospho-AKT (antibody dilution 
1:200) digital images shown above (X20 magnification) are representative of 3 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicate a significant 
difference in phospho-AKT level following transferrin treatment.
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Figure 3,157 Growth challenge with transferrin singly or in 
combination with the MEK-1 inhibitor PD98059 in MCF-7X cells, 
MCF-7X cells were grown on 24-well plates in phenol-red-free RPMI media containing 
5% XFCS in the presence of transferrin (4 pg/ml) or transferrin/PD98059 (4 pg/ml, 25 
pM) for 15 days. Every 48 hours cells were subject to trypsin dispersion followed by 
Coulter counting (triplicate wells per time point). These data were log transformed to 
compare growth rate at day 15. The statistical analysis applied was an ANOVA Test 
followed by a Bonferroni Post-Hoc Test. The data are displayed as the mean number of 
cells/well +/- SD (n=3).
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Phospho-MAPK
Control + Transferrin (4 pg/ml)
I
Phospho-MAPK
Control
(Cytoplasmic)
(Nuclear)
Total
+ Transferrin (4 pg/ml)
(Cytoplasmic)
(Nuclear)
Total
MCF-7X
35.0 (35.0-48.8)
3.5 (1.3-5.0)
38.5
25.0 (20.0-32.5) 
0.5 (0.0-2 .0)
25.5
p=0.026*
p=0.024*
Figure 3.158 Effect o f  transferrin on phosphorylated MAPK level in 
MCF-7X cells by immunocytochemistry. MCF-7 and MCF-7X cells were 
grown on coverslips in phenol-red-free RPMI media containing 5% SFCS or XFCS 
respectively in the absence or presence of transferrin (4 pg/ml). Conditions were 
maintained for 7 days prior to formal saline fixation. The phospho-MAPK (antibody 
dilution 1:20) digital images shown above (X20 magnification) are representative of 3 
experiments. H-Score data were obtained by dual assessment of 2 representative areas 
of each coverslip followed by statistical analysis (Mann-Whitney U-Test). The median 
H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in phospho-MAPK level following transferrin treatment.
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Transferrin Receptor (CD71)
Control + LY294002 (5 pM)
TfR CD71 
Basal Control
(Membrane)
(Cytoplasmic)
Total
+ LY294002 (5 pM)
(Membrane)
(Cytoplasmic)
Total
MCF-7X
40.0 (37.5-45.0)
100.0 (98.8-101.3)
140.0
40.0 (35.0-41.3) p=0.589
90.0(86.3-92.5) p=0.011*
130.0
Figure 3,159 Effect o f  LY294002 on transferrin receptor (CD71) 
expression in MCF-7X cells by immunocytochemistry. MCF-7X cells were 
grown on coverslips in phenol-red-free RPMI media containing 5% XFCS in the 
absence or presence of LY294002 (5 pM). Conditions were maintained for 7 days prior 
to phenol formal saline fixation. The CD71 (antibody dilution 1:100) digital images 
shown above (X20 original magnification) are representative of 3 experiments. H- 
Score data were obtained by dual assessment of 2 representative areas of each coverslip 
followed by statistical analysis (Mann-Whitney U-Test). The median H-Score and Ql- 
Q3 values are displayed. A p-value of <0.05(*) indicates a significant difference in 
transferrin receptor expression following LY294002 treatment.
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Figure 3.160 Growth challenge with transferrin singly or in 
combination with the pure anti-oestrogen faslodex in MCF-7X cells. 
MCF-7X cells were grown on 24-well plates in phenol-red-free RPMI media containing 
5% XFCS in the presence of transferrin (4 pg/ml) or transferrin/faslodex (4 jig/ml, 10*7 
M) for 15 days. Every 48 hours cells were subject to trypsin dispersion followed by 
Coulter counting (triplicate wells per time point). These data were log transformed to 
compare growth rate at day 15. The statistical analysis applied was an ANOVA Test 
followed by a Bonferroni Post-Hoc Test. The data are displayed as the mean number of 
cells/well +/- SD (n=3).
0 Denotes transferrin/faslodex treatment was significantly lower at day 15 (p=0.012) 
versus transferrin treatment control.
269
CHAPTER 3 RESULTS
Total ERa
Control + Transferrin (4 pg/ml)
•  .  M  ^ fit
* -  # », * »»’
* •  *• I
••  :%*• ' » •   ?!_______________
Total ERa (Nuclear)
Basal Control 
+ Transferrin (4 jig/ml)
MCF-7X
185.0 (185.0-195.0) 
152.5 (141.3-161.3) p=0.002*
Figure 3.161 Effect o f  transferrin on ERa protein expression in MCF- 
7X cells by immunocytochemistry. MCF-7 and MCF-7X cells were grown on 
coverslips in phenol-red-free RPMI media containing 5% SFCS or XFCS respectively 
in the absence or presence of transferrin (4 pg/ml). Conditions were maintained for 7 
days prior to ERICA fixation. The total nuclear ERa (6F11, antibody dilution 1:100) 
digital images shown above (X20 magnification) are representative of 3 experiments. 
H-Score data were obtained by dual assessment of 2 representative areas of each 
coverslip followed by statistical analysis (Mann-Whitney U-Test). The median H- 
Score and Q1-Q3 values are displayed. A p-value <0.05(*) indicates a significant 
difference in ERa expression following transferrin treatment.
270
CHAPTER 3 RESULTS
Control 4- Transferrin (4 pg/ml)
Phospho-ER Seri 18
Phospho-ER Seri67
V
MCF-7X
----------
Phospho-ER Seri 18 (Nuclear)
Basal Control 90.0 (77.5-110.5)
+ Transferrin (4 pg/ml) 77.5 (68.8-91.3) p=0.102
Phospho-ER Seri67 (Nuclear)
Basal Control 50.0 (45.0-70.0)
+ Transferrin (4 pg/ml) 25.0 (20.0-30.0) p<0.001*
Figure 3.162 Effect o f  transferrin on phosphorylation o f  ERa on 
Seri 18 and S eri67 residues in MCF-7X cells by immunocytochemistry.
MCF-7 and MCF-7X cells were grown on coverslips in phenol-red-free RPMI media 
containing 5% SFCS or XFCS respectively in the absence or presence of transferrin (4 
pg/ml). Conditions were maintained for 7 days prior to the appropreiate fixation. The 
phospho-ER Seri 18 (antibody dilution 1:400) assay required coverslips 
paraformaldehyde fixed. The phospho-ER Seri67 (antibody dilution 1:25) assay 
required coverslips ERICA fixed. The digital images shown above (X20 magnification) 
are representative of 3 experiments. H-Score data were obtained by dual assessment of 
2 representative areas of each coverslip followed by statistical analysis (Mann-Whitney 
U-Test). The median H-Score and Q1-Q3 values are displayed. A p-value <0.05(*) 
indicates a significant difference in phospho-ER Seri 18 or Seri67 level following 
transferrin treatment.
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Control Transferrin (4 pg/ml)
. <v
pS2 (Cytoplasmic)
Basal Control 
+ Transferrin (4 pg/ml)
MCF-7X
130.0 (121.3-133.8)
85.0 (813-91.3) P=0.002*
Figure 3.163 Effect o f  transferrin on pS2 expression in MCF-7X cells 
by immunocytochemistry. MCF-7 and MCF-7X cells were grown on coverslips 
in phenol-red-free media containing 5% SFCS or XFCS respectively in the absence or 
presence of transferrin (4 pg/ml). Conditions were maintained for 7 days prior to 
ERICA fixation. The pS2 (antibody dilution 1:500) digital images shown above (X20 
magnification) are representative of 3 experiments. H-Score data were obtained by 
dual assessment of 2 representative areas of each coverslip followed by statistical 
analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values are 
displayed. A p-value <0.05(*) indicates a significant difference in pS2 expression 
following transferrin treatment.
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Transferrin Receptor (CD71)
Control + Faslodex (10*7 M)
TfR CD71 
Basal Control
(Membrane)
(Cytoplasmic)
Total
+ Faslodex (10*7 M)
(Membrane)
(Cytoplasmic)
Total
MCF-7X
40.0 (37.5-45.0) 
100.0(98.8-101.3)
140.0
40.0(37.5-45.0) p=1.000
102.5(100.0-106.3) p=0.150 
142.5
Figure 3,164 Effect o f  faslodex on transferrin receptor (CD71) 
expression in MCF-7X cells by immunocytochentistry. MCF-7X cells were 
grown on coverslips in phenol-red-free RPMI media containing 5% XFCS in the 
absence or presence of faslodex (10'7 M). Conditions were maintained for 7 days prior 
to phenol formal saline fixation. The CD71 (antibody dilution 1:100) digital images 
shown above (X20 magnification) are representative of 3 experiments. H-Score data 
were obtained by dual assessment of 2 representative areas of each coverslip followed 
by statistical analysis (Mann-Whitney U-Test). The median H-Score and Q1-Q3 values 
are displayed. A p-value of <0.05(*) indicates a significant difference in transferrin 
receptor expression following faslodex treatment.
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4.1 RESISTANCE TO OESTROGEN DEPRIVATION
Oestrogen deprivation as a therapeutic strategy is not a new concept in the 
experimental or clinical setting. However, with good cause this type of therapy has 
gained significant clinical momentum within the last few years. Due to the 
development of potent third generation aromatase inhibitors and LHRH agonists 
which block oestrogen production, pivotal changes in endocrine treatment strategies 
for breast cancer have taken shape. An increasing body of clinical data indicate 
oestrogen deprivation strategies are superior to the gold standard tamoxifen in 
postmenopausal advanced and early disease (Mouridsen et al., 2003; Paridaens et al., 
2004; AT AC Trialists’ Group, 2005). In clinical studies concerning premenopausal 
disease, the combination of an LHRH agonist and tamoxifen is also favoured over 
CMF chemotherapy in ER+ advanced breast cancer (Jakesz etal., 2002). Furthermore 
it was found that the addition of an LHRH agonist to standard tamoxifen therapy was 
more effective than tamoxifen alone in early premenopausal disease (Baum et al., 
2006). While such clinical studies have been underway, parallel experimental studies 
have been initiated to better understand mechanisms o f action. Unfortunately, 
however, the development o f resistance yet again remains a disruptive obstacle with 
respect to the treatment o f hormone sensitive breast cancer. There has been an 
encouraging surge of research focused on the resistance mechanisms involved in 
oestrogen deprivation strategies from the various in vivo and in vitro cell model 
systems, notably the Brodie/Sabnis (UMB-ICa), Martin/Dowsett (LTED), Stephen, 
Jensen (MCF-7/S9), Santen (LTED) and our own MCF-7X models. Among these 
models, there are obvious complementary results, but also contradictory data, where 
basic explanation to these issues may lie in the conditions employed for model 
development notably encompassing the presence of growth factors in the charcoal- 
stripped serum used in the media to maintain the cells, and in some instances addition 
of further exogenous growth factors such as insulin.
4.1.1 Severe Oestrogen and Growth Factor D eprived M CF -7X M odel
The in vitro MCF-7X model developed during long-term culture in phenol red-free 
medium with 5% stripped, heat-inactivated medium clearly demonstrates a sobering 
example of the adaptability ER+ breast cancer cells are capable o f achieving (Figure 
4.1A/B, the elements o f this figure will be discussed in further detail as this chapter 
proceeds). This model was created to evaluate the absolute capability that breast 
cancer cells severely deprived o f oestrogen and exogenous growth factors may
275
CHAPTER 4 DISCUSSION
possess to ultimately enable resistant growth (while ensuring the culture conditions 
still maintain the necessary attachment factors and viability; van der Burg et ah, 
1988). Remaining inputs for MCF-7X cells would presumably be predominantly 
autocrine growth factors, and exquisitely low levels of any residual steroid hormone 
(where the exogenous oestradiol concentration is depleted to 10‘13M in stripped 
serum). Importantly, without an exogenous growth factor-rich environment, these 
cells were not potentially forced to utilise one particular mitogenic signalling pathway 
to initiate resistant growth, and in this regard MCF-7X cells contrast many previous 
models of resistance to oestrogen withdrawal. Furthermore, this model revealed just 
how complex cell survival and adaptive mitogenic signalling is once an 
oestrogen/growth factor resistant phenotype develops. The MCF-7X cell data also 
demonstrate that a resilient cell line does not necessarily have to involve the 
development of a more aggressive motile/invasive phenotype. The MCF-7X sub-line 
appeared to have a non-invasive profile compared to the parental MCF-7 cell line. 
This contrasts the Sabnis et al. (2005) model. The UMB-ICa cells demonstrate a 
significant increase in their ability to migrate when compared to the MCF-7Ca 
parental cell line. The UMB-ICa cells are routinely grown in steroid depleted 5% 
dextran-coated charcoal-treated serum, which may contain residual exogenous growth 
factors perhaps causing the altered phenotype compared to MCF-7X cell. In 
particular, UMB-ICa cells are reported to employ significant HER2 signalling, a 
feature absent in MCF-7X cells, and previously linked with aggressive cellular 
behaviour in models of anti-oestrogen resistance (Nicholson et al., 2005; Hiscox et 
al., 2005) as well as with poor prognosis in the clinic (Gee et al., 2005). While MCF- 
7X cells showed some increase in c-Myc expression and significantly decreased 
p21apl/wafl, features that may promote increased cell proliferation, MCF-7X have 
merely recovered their growth to that o f the parental cells, again contrasting the more 
highly proliferative phenotypes that can be associated with anti-oestrogen resistant 
models where there can be marked increases in EGFR/HER2 receptors.
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A. MCF-7: Basal Expression
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Figure 4.1 Schematic illustration o f  basal characterisation fo r  MCF-7 
(A) versus MCF-7X (B) cells. Above illustrates the basal characterisation of the 
parental MCF-7 cell line (A) versus the oestrogen growth factor deprived MCF-7X (B) cell 
line.
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4.1.2 R etained Im portance o f  the Oestrogen Receptor
Among the long-term oestrogen deprived (in vivolin vitro) models including the 
MCF-7X, an undeniable unifying feature is retained and functional oestrogen 
receptors. Like the parental MCF-7 cells, MCF-7X cells retain high levels o f ERa. 
Indeed, there is some increase in expression in the resistant model. This increase in 
ERa expression was modest (—20%) in the MCF-7X model compared to previous 
models with residual/added exogenous growth factors, which report on average a 3- 
10 fold increase in ERa expression (Martin e t cd., 2003; Santen e t a l., 2004a; Sabnis 
et cd., 2005). The oestrogen deprived model from Martin e t cd. (2003) is also in 
agreement with MCF-7X cells with regards to the increase in ERa activity at the AF- 
1 residue serine 118 (-30%  in MCF-7X cells), and elevated basal ERa transcriptional 
activity measured by ERE reporter assays. We also observed a rise in expression of 
the endogenous oestrogen-regulated gene pS2 in MCF-7X cells. The only oestrogen 
deprived model to reveal a loss of progesterone receptor (PR) to date is MCF-7X, a 
characteristic that has been linked to sustained activation of growth factor signalling 
pathways (Osborne et cd., 2005). A study by Cui e t cd. (2003) provides evidence that 
IGF-1 down-regulates PR independent o f ER activity through sustained PI3K/AKT 
mTOR signalling in MCF-7 cells (where interestingly PI3K/AKT signalling is a 
prominent feature of MCF-7X cells, as will be discussed later). Similarly, transient 
transfection experiments o f constitutively active HER2 (Liu e t cd., 1995), MAPK (Oh 
et cd., 2001), Rafl (El-Ashry e t cd., 1997) or EGFR (Miller e t cd., 1994) into MCF-7 
cells demonstrate ERa mRNA reduction paralleled by loss o f ER-regulated gene PR  
In addition, prolonged blockade o f ER signalling can promote epigenetic loss of ER- 
regulated genes like PR (Leu e t al., 2004). In this instance, however, preliminary 
experiments following completion of this project examining oestrogen challenge in 
MCF-7X cells have indicated that PR expression can be substantially stimulated, 
suggesting lack o f irreversible silencing of this ER-regulated gene.
Long-term oestrogen deprivation has been associated with the phenomenon of 
adaptive oestrogen hypersensitivity. Two models that give a detailed illustration of 
oestrogen action from a genomic and non-genomic point o f view are the LTED 
models o f Martin/Dowsett and Santen respectively. The Martin/Dowsett model 
suggests the adaptation in ERa function and the hypersensitive state are primarily a 
result o f increased genomic ERa/growth factor signalling cross-talk (Johnston & 
Dowsett, 2003), although more recently some non-genomic contribution has been
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suggested. The characterisation of this model includes elevated ERa expression, 
increased phosphorylation o f serine 118 level, increased expression of die ER- 
regulated gene c-Myc and parallel increased ERE transcriptional activity. These 
LTED cells reportedly are oestrogen hypersensitive and maximally growth stimulated 
at doses of oestradiol as low as 1013 M versus 10'9 M for the parental MCF-7 cells. 
In contrast, Santen (2004a) explains the LTED model oestrogen hypersensitivity by a 
non-genomic mechanism involving increased cell membrane-localised ERa. In this 
instance, the binding o f oestrogen to this membrane ERa was observed to rapidly 
recruit a network of classical growth factors signalling elements. Similar to the 
LTED model of Martin/Dowsett, these cells have adapted to low levels of residual 
oestrogens again as low as 10'13 M. However, while significant growth stimulation 
by exogenous oestradiol was achieved, MCF-7X cells were not growth hypersensitive 
to sub-physiological oestradiol levels. Similar results were revealed by measuring 
ERE transcriptional activity, data collectively inferring that exogenous growth factors 
(signalling through increased growth factor receptors such as EGFR and IGF-1R that 
are notably depleted in MCF-7X cells) are critical in the development o f oestrogen 
hypersensitivity.
While not fully addressed (still requires detailing of any rapid signalling activity 
initiated by E2 ), the data in the present project do suggest that a genomic ERa 
mechanism is dominant in MCF-7X cells (i.e. nuclear ERa event resulting in 
increased ERE transcriptional activity). Thus, immunofluorescence studies revealed 
MCF-7X cells lack membrane ERa basally and subsequent to 10 minute E2  challenge, 
and also the membrane growth factor receptors required for such a mechanism. Such 
events hallmark non-genomic signalling in LTED cells (Santen et al., 2003; 2004a) 
and some tamoxifen resistant cells (Schiff & Osborne, 2005). There also seemed to 
be an apparent lack o f importance for non-classical nuclear ER signalling in MCF-7X 
cells i.e. ER interplay with AP-1 priming AP-1 transcriptional activity. This is an 
unlikely growth mechanism in MCF-7X cells since AP-1 basal activity and Fos 
expression was depleted versus the parental MCF-7 line, while ERa manipulation 
(using oestradiol or faslodex) that promoted obvious changes in MCF-7X growth 
were not associated with any rational changes in AP-1 transcriptional activity.
Finally, despite the mechanistic ERa signalling differences, a feature shared by all 
the models of resistance to oestrogen deprivation, including MCF-7X cells, is
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substantial growth sensitivity to the ER down regulator faslodex (60% inhibition in 
MCF-7X cells). Maximal faslodex inhibitory responses wore achieved at an 
equivalent dosage (10‘7 M) to MCF-7 cells. The growth inhibitory response to 
faslodex in MCF-7X cells was long-lived, lasting 10 weeks in culture before 
resistance emerged. These data provide powerful evidence that there remains a 
substantial contribution for ERa signalling following acquisition of this resistant 
state. In keeping with its mechanism of action (Wakeling, 1991), faslodex depleted 
ERa by 80%, promoted some depletion in Seri 18ER activity on the residual ERa and 
substantially depleted ERE transcriptional activity and hence pS2 expression in MCF- 
7X cells. Data from the MCF-7X cell and other oestrogen deprived resistance models 
(including the MCF-7/S9 cell line recently developed by Jensen et cd. (2003) under 
serum-free culture conditions) cumulatively support the use o f faslodex in targeting 
the prominent ERa signalling. Recent in vitro studies from Martin et cd. (2005) 
demonstrating LTED sensitivity to faslodex have resulted in a phase HI randomised 
trial (SOFEA) among postmenopausal women with ER+ and/or PR+ locally 
advanced/metastatic breast cancer following progression on non-steroidal aromatase 
inhibitors (Johnston et al., 2005). Comparing progression-free survival o f patients 
treated with faslodex plus anastrozole versus faslodex alone, as well as the 
progression-free survival of patients treated with faslodex alone versus those treated 
with the steroidal aromatase inactivator exemestane are the primary aims o f the trial. 
Brodie et al. (2005) has recently investigated in their MCF-7ca model the use of 
letrozole and faslodex combined, which revealed the combination was more effective 
than either treatment alone. These experimental and clinical data collectively suggest 
ERa remains an important growth contributor and therefore an appropriate target 
during or following an oestrogen deprivation strategy to prolong a treatment response.
4.1.3 Classical Growth Factor Receptor StgmaUimg im the MCF-7XModel 
Aberrant growth factor signalling has been implicated in both de novo and acquired 
resistance of breast cancer cells subject to endocrine manipulation. Experimental and 
clinical de novo endocrine resistance, whether ER' or ER+, is invariably associated 
with increased levels o f EGFR, HER2 and in some instances transforming growth 
factor-a (TGF-a) (Normanno et al., 1994; Tusda 2001; Gee et cd., 2005). 
Inappropriate activation of these growth factor pathways either through an increase in 
natural ligand supply and/or up-regulation o f their respective growth factor receptors 
can alternatively promote failure during anti-oestrogen treatment, yielding acquired
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resistance (Nicholson e t cd., 2004a). Our in vitro  acquired anti-oestrogen (both 
tamoxifen and faslodex) resistant models demonstrate as much as a 40-fold increase 
in EGFR immunostaining paralleled by significant increased HER2 immunostaining 
(Knowlden e t cd., 2003b; Nicholson e t cd., 2001; McClelland e t cd., 2001). Accepting 
this concept o f receptor over expression having such {nofound influence cm both de 
novo endocrine resistance and acquired anti-oestrogen resistance, these growth factor 
receptors were explored in our oestrogen deprived resistant model. However, 
extorsive profiling o f die MCF-7X in vitro  cell model for receptor expression and 
phosphorylation status revealed no dominant role for several classical plasma 
membrane receptors, notably including EGFR, HER2 or IGF-1R in promoting 
growth. These studies included challenge with an extensive range o f peptide growth 
factors paralleled by specific receptor inhibitors (i.e. gefitinib, herceptin and 
ADW742 for EGFR, HER2 and IGF-1R respectively). All failed to achieve any 
obvious impact on growth. These data contrast observations in many anti-oestrogen 
resistant models, including our own TAMR cells that demonstrate effective inhibition 
utilising the EGFR tyrosine kinase inhibitor gefitinib (1 pM) or the humanised HER2 
monoclonal antibody herceptin [(100 nM) (Knowlden e t cd., 2003b; Hutcheson e t cd., 
2003; Nicholson e t cd., 2004a)} and thus a substantial dependency on mitogenic 
growth factor receptor signalling. Furthermore, Massarweh e t cd. (2003) illustrate in 
vivo  studies where challenged of HER2 transfected MCF-7 cells with gefitinib was 
able to delay resistance to tamoxifen resistance therefore confirming a growth 
contribution for such signalling. The lack of effect o f such agents in the MCF-7X 
model is also in contrast to the oestrogen hypersensitive models, of particular note the 
Martin e t cd. (2003) model, where growth contributory HER2 activity is significantly 
reduced with high dose gefitinib (5 pM). UMB-ICa cells are also reported to be 
responsive to gefitinib at doses targeting HER2 signalling (Sabnis e t cd., 2005). The 
unifying feature shared by these resistant models whether de novo/acquired tamoxifen 
resistant, LTED resistant or in vivo manipulated (transfection studies) is a marked 
increase in EGFR and/or HER2 receptor expression, an increase that clearly was not 
observed in the MCF-7X model. Indeed, receptor activity was further depleted versus 
the parental MCF-7 cells whose growth is already established as hugely independent 
of such signalling. These MCF-7X data suggest that targeting of EGFR/HER2 
signalling could prove to have limited success in effectively treating resistance to 
oestrogen deprivation. Questionable EGFR/HER2 relevance is not the only data 
revealed in die MCF-7X model. In addition there was little indication that IGF-1R
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signalling participates in a dominant growth promoting role for these cells. Again 
multiple studies suggest a prominent function of this receptor independent and in 
cooperation with EGFR/HER2, ultimately contributing to anti-oestrogen resistance 
(Coppola et a/., 1994; Balana et al., 2001; Knowlden et al.9 2003a). Again, models of 
LTED resistance developed in the presence of serum growth factors or exogenous 
insulin indicate prominent significance of IGF-1R mediated signalling (Stephen et al. 
2001; Martin et al., 2003; Santen et al., 2004a) paralleled by gene transfer studies 
over expressing IGF-II, IGF-1R or insulin substrate-1 also suggesting a causative 
relationship with oestrogen independence (Guvakova & Surmacz 1997). Martin et al. 
(2005) report a 2-3-fold increase in IGF-1R, suggesting the significant increase is a 
result o f the marked elevation in ERa signalling. The LTED model o f Santen et al. 
(2004a; Song et al., 2004) has shown that She and non-genomic membrane ERa co- 
immunoprecipitate using an anti-IGF-lR antibody, and the binding of ERa to the 
IGF-1R occurs in minutes o f the addition of oestradiol orchestrating a downstream 
kinase cascade. Stephen et al. (2001) have revealed in their long-term oestrogen 
deprived model increased IGF-1R correlating with cell density, and also suggest that 
this increase may enable the cells to respond to the reduced IGF levels present in the 
culture medium and/or endogenously produced. Meanwhile, the MCF-7X model 
(stripped of exogenous growth factor input) displayed decreased expression/activation 
of IGF-1R in accordance with no response to IGFs and an inferior response to 
ADW742 IGF-1R selective inhibitor challenge compared to the MCF-7 parental cell 
line, where IGF-1R comprises a dominant pathway that interplays with and enhances 
the E2/ER pathway. Thus, there seems to be a markedly diminished role for the IGF- 
1R in MCF-7X cells versus MCF-7 cells, and could indicate that IGF-1R blockade 
may not prove folly effective in resistance to oestrogen deprivation.
In summary, the collective MCF-7X data indicate that neither exogenous growth 
factor ligands nor any autocrine signalling through their classical receptors are 
essential to maintain growth in an oestrogen deprived environment However, this 
growth factor ligand/receptor relationship appears to be o f some importance in 
facilitating the growth and oestrogen hypersensitivity in vitro models derived in the 
presence o f serum growth factors, as evidenced by the emerging relevance of HER2 
and IGF-1R described for such cells. These data cumulatively indicate that while 
future use o f inhibitors targeting such pathways may have some value, they are
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unlikely to provide completely effective treatments in acquired resistant to oestrogen 
deprivation.
4.1.4 K inase Prom otion o f  Growth in the M CF-7X M odel
Within previous models o f acquired resistance to oestrogen deprivation there are clear 
implications o f roles for EGFR/HER2 and IGF-1R receptor signalling which in turn 
influence the activation o f downstream signalling pathways. It is widely accepted 
that these growth factor receptors can initiate activity o f such intracellular elements 
like ERK1/2 MAP kinase (MAPK), phosphatidylinositol-3-OH kinase (PI3K)/AKT 
and protein kinase C isofonns (PKC). Activation o f these kinases simplistically can 
lead to a number o f key cellular functions, notably cell proliferation and cell survival 
(and in some instances gain o f aggressive invasive behaviour) eventually contributing 
to the resistant phenotype.
4.1.4.1 M APK
O f particular interest is MAPK, as increased activity o f this kinase is an established 
component o f anti-oestrogen resistant intracellular signalling (Knowlden et al., 
2003b) and recent findings suggest this kinase also contributes to adaptive growth 
changes observed in oestrogen deprived breast cancer cells and their oestrogen 
hypersensitivity. Increased MAPK activity is a common feature o f many models that 
have adapted to long-term oestrogen deprivation both in vitro and in vivo (Jeng et al., 
2000; Martin et al., 2003; Santen et cd., 2004a). Invariably this has been associated 
with increased upstream input from elevated growth factor receptors (i.e. 
EGFR/HER2; IGF-1R). There appears to date to be only one exception to this rule, 
where UMB-ICa cells which show a 4.1-fold increase in HER2 expression do not 
show increased phosphorylation o f MAPK and are unaffected by the MEK-1 inhibitor 
PD98059 (Sabnis et al., 2005).
The long-term oestrogen deprived in vitro model from Martin/Dowsett showed 
significantly elevated HER2 activity and they concluded this alteration could explain 
the rise (8-fold) in MAPK activity within their cells (Martin et al., 2003) that 
subsequently facilitates genomic ERa signalling. However, in an updated study, they 
have also shown a 2-3-fold increase in IGF-1R (with elevated IRS-2) and suggest this 
scenario as a possible non-genomic adaptation, augmenting any membrane ERo/IGF- 
1R interaction resulting in enhanced MAPK activity that contributes to oestrogen
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hypersensitivity in their LTED cells (Martin et al., 2005). This possible interaction is 
strikingly similar to the Santen/Song explanation for increased MAPK activity in 
conjunction with plasma membrane ERa associated oestrogen hypersensitivity. Song 
et al. (2004) suggest die intimate relationship o f She and IGF-1R in their LTED cells 
serves two functions; the first is to lead to ERa membrane translocation, and the 
second is to markedly activate downstream MAPK in an IGF-1 R-dependent manner. 
Previous studies including those by Lee et al. (1999) have shown that oestrogen/ER 
signalling can promote a rise in IGF-1R, IRS-1 and IRS-2 expression and expression 
o f IGF-1R can be regulated by faslodex in the LTED cells from Martin et al. (2005). 
However, E2 /ER signalling can also directly enhance IGF-1R activity and 
subsequently IRS phosphorylation, which can lead to increased MAPK activity via 
the non-genomic mechanism. Cumulatively, these data suggest a positive feed back 
loop, where membrane ERa binds to the 1GF-1R and activates the IGF-1R signalling 
cascade including MAPK which in turn stimulates the genomic activity o f nuclear 
ERa to promote expression o f components o f the IGF-1R cascade. Based on this 
information any available growth factor ligands in exogenous serum would feasibly 
enhance this signalling loop therefore providing a reasonable mechanism underlying 
increases in MAPK activity and its contribution to long-term oestrogen deprived cell 
growth. Furthermore, in the LTED resistant model o f Martin/Dowsett, insulin 
supplementation during the development and maintenance o f this cell line could have 
substantially primed the IGF-1R pathway leading to a prominent MAPK signalling 
mechanism that provides a potential contribution to the observed oestrogen 
hypersensitivity. However, in the MCF-7X model endogenous growth factors are 
depleted, and increases in the classical growth factor receptor/activity are not 
apparent (coupled with an apparent absence o f non-genomic ER contribution). Not 
surprisingly, therefore, the MCF-7X model fails to demonstrate increased MAPK 
activity versus the parental MCF-7 ER+ cell line and the resistant cells are not 
oestrogen hypersensitive. Indeed some MAPK activity decreases were observed 
compared to MCF-7 cells, in parallel with a decline in expression and/or activity o f 
the classical growth factor receptors. These data were paralleled by the MEK-1 
inhibitor PD98059 having a markedly reduced inhibitoiy effect in the 
oestrogen/growth factor deprived cells versus die parental MCF-7 line (despite being 
able to further deplete the low levels o f MAPK activity in such cells), and no 
significant duration o f response with this agent. Clearly, although there is some 
contribution for MAPK signalling in MCF-7 cells, this kinase does not provide a
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dominant mechanism in MCF-7X cells, markedly contrasting the contribution for the 
substantial MAPK increases in previous models generated in die presence of 
exogenous growth factors and a key factor contributory towards their oestrogen 
hypersensitivity. O f note, however, such signalling w as reported to not be the 
only growth contribution in LTED cells. Cumulatively, the MCF-7X cell data 
suggest that resistance to oestrogen deprivation is unlikely to be fully-treated using a 
MAPK inhibitory approach.
4.1.4.2 PI3K/AKT
Activation o f IGF-1R is known to recruit the p85 regulatory domain o f phosphatidyl- 
inositol-3-OH kinase (PBK) initiating a cascade o f signalling events in MCF-7 cells 
(Castoria et al., 2001). The serine/threonine protein kinase AKT is one o f the 
downstream targets o f PBK and its activation generally promotes cell growth and 
proliferation, as well as cell survival. Interestingly, AKT activity is significantly 
enhanced in several anti-oestrogen resistance models, notably including our own 
TAMR cells (Jordan et al., 2004), where in this instance activity is also regulated by 
enhanced EGFR/HER2 signalling. Enhanced AKT activity similarly equates with 
tamoxifen resistance and poorer outlook in clinical disease (Perez-Tenorio et al.,
2002). It has also been repented that, like MAPK, PI3K/AKT activity can be 
triggered by a non-genomic ERa mechanism (Song et al., 2002; 2004; Wessler et al., 
2006).
With regards to oestrogen deprivation, th a t is evidence from some previous models 
o f enhanced PI3K/AKT signalling. Brodie/Sabnis have repented that UMB-ICa cells 
showed increased levels o f phosphorylated AKT at serine 473 (3.3-fold) and 
threonine 308 (2.7-fold) versus the MCF-7ca parental cells (Salmis et al., 2005). 
There is similarly elevated AKT activity in the Santen LTED model. Once activated, 
AKT can phosphorylate a number o f proteins leading to regulation o f metabolism 
(glycogen synthase kinase 3) and translational control, for example, via p70 S6 kinase 
(Kandel and Hay, 1999; Fry, 2001). Amplification o f the p70 S6 kinase gene is 
associated with a poor prognosis in breast cancer (van der Hage et al., 2004). AKT 
can influence cell survival through the forkhead family o f transcription factors, 
including inactivation o f BAD, a bcl-2 family member and inhibition o f cell death 
pathway enzyme caspase-9 (Cardone et al., 1998; Fry, 2001). Furthermore, AKT can 
influence mTOR (mammalian target o f rapamycin), facilitating the regulation o f the
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cell cycle through cyclin D, E2F and c-Myc (Kandel and Hay, 1999; Johnston et al., 
2003). Santen/Yue recently confirmed alongside significantly enhanced AKT 
activation, elevated mTOR, p70 S6 kinase and eukaryotic translation initiation factor- 
4E binding protein in their LTED cell line (Yue et al,, 2003) resulting in increased 
cell cycle progression and proliferation. While Martin et al. (2003) observed levels 
o f AKT equivalent to MCF-7 cells this was paralleled by significant altered p90 
ribosomal S6 kinase (RSK) in their model.
In the present study, characterisation o f the MCF-7X cell line revealed that while 
AKT activity was equivalent overall to MCF-7 cells, there was enhanced 
cytoplasmic/membrane activation in the resistant model. Interestingly in parallel, the 
PBK inhibitor LY294002 caused a marked reduction in AKT activity and displayed a 
substantial growth inhibitory effect (70% by day 15) on the oestrogen/growth factor 
deprived cells. This anti-tumour response was prolonged, lasting 10 weeks before 
resistance emerged. Some significant inhibitory effects on growth and AKT activity 
w o e also apparent with a further PBK inhibitor wortmannin. PBK can also activate 
phosphoinositide-dependent protein kinase-1 (PDK-1) whereby, upon activation it 
can influence both AKT and RSK (Williams et al., 2000). Like AKT, cytoplasmic 
PDK-1 activity was increased in the MCF-7X model (versus MCF-7 cellsX which 
was also shown to be sensitive to LY294002 treatment Growth, AKT and PDK 
signalling inhibition with LY294002 proved superior in MCF-7X versus MCF-7 
cells. Clearly, PI3K/AKT is a likely contributor to resistant MCF-7X cell growth and 
o f increased importance versus the parental cell line. Since it was observed that 
PDK-1 activity was refractory to wortmannin, the MCF-7X data suggest that it is 
AKT, rather than PDK, that is the major downstream PBK signalling element 
promoting growth o f the MCF-7X cells. Challenge with PBK inhibitors in the LTED 
models from the Santen and Martin laboratories has also revealed PBK signalling is 
(in addition to MAPK) contributory to their oestrogen hypersensitivity, thus it appears 
that PBK signalling comprises a universal growth signalling input, independent o f 
any requirement for exogenous growth factor/classical receptor input, in oestrogen 
deprivation resistance, contrasting the more limited impact o f MAPK inhibition 
implied from these MCF-7X studies.
286
CHAPTER 4 DISCUSSION
4.1.4.3 PKC Isoforms andSrc
Protein kinases are an integral part o f die network o f intracellular signalling, critical 
to growth, differentiation, motility and survival. PKCs have been implicated as 
regulatory steps o f the PBK pathway and in enhancement o f AP~1 promotor activity 
(Moscat et al., 2001). PKCs have again been associated with anti-oestrogen failure 
(Chisamore et al., 2001) and more aggressive forms o f breast cancer (Patrick & 
Heimbrook, 1996). Among these PKC5 and PKCa have been shown to be elevated 
in tamoxifen resistance (Kruger & Reddy, 2003; Fournier et al., 2001)) and are both 
increased in our TAMR model, while PKCa has also been linked with ER negativity 
(Chisamore et al., 2001). Interestingly, PKC5 has also been shown to promote 
phosphorylation o f serine 122 o f the mouse (Lahooti et al., 1998) (equivalent to 
serine 118 in human). However, despite a small increase in PKCS activity in the 
MCF-7X cells (versus MCF-7 cells) predominantly within the nuclei [a localisation 
increasingly linked to promoting therapeutic resistance (Jones et al. 2004)], the PKC 
inhibitor bis-indolylmaleimide (Bis) was without impact on resistant cell growth, in 
contrast to an inhibitory effect in MCF-7 cells. Furthermore, PKCa was at a lower 
level in MCF-7X cells versus the parental line. In total, these data suggest that there 
is no obvious growth regulatory role o f PKCs in MCF-7X cells growth, although 
continued exploration in the future could encompass further PKC isoforms not 
influenced by this inhibitor.
Downstream kinase recruited in growth facto  pathways and contributes to the non- 
genomic mechanism from Santen et al. (2003; 2004a). Also contributes to anti­
oestrogen resistant growth signalling and invasive behaviour (part o f EGFR/IGF-1R 
cross talk mechanism in TAMR cells Knowlden et al., 2003a; Hiscox et al., 2005X 
and can also cross-talk with ERa activity at serine 118. However, despite increased 
Src activity in MCF-7X, a diminished growth contribution was evidenced by the lack 
o f effect o f SU6656, and there was moreover no increase in invasiveness versus the 
parental line. Collectively, suggesting that Src did not provide a dominant signalling 
mechanism for MCF-7X cells.
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4.2 KINASE DEPENDENT REGULATION OF ERa PHOSPHORYLATION 
The human ERa is a phosphoprotein that is hyperphosphorylated in response to 
steroid binding and associated receptor conformational changes. Phosphorylation 
residues including the AF-1 residues serine 167 (Serl67ER) and 118 (Serll8ER) 
have been implicated, but these appear to vary according to cell context (Lannigan 
2003). ERa phosphorylation acts to regulate aspects o f steroid receptor function, 
notably transcriptional activation o f ER-regulated genes. A number o f studies 
following anti-oestrogen failure have demonstrated growth factor induced kinase 
ability to target and activate the key regulatory sites on the ERa protein, notably Ser 
118 and 167. Previously shown within our own acquired tamoxifen resistant cells is a 
correlation between substantially increased AF-1 ERa phosphorylation (Seri 18ER 
and Serl67ER) and elevated MAPK and AKT phosphorylation regulated by 
increased upstream EGFR/HER2/IGF-1R activity (Nicholson et al., 2004a). The 
growth factor receptor signalling acts via this ligand independent activation o f the 
ERa to enhance coactivator recruitment and subsequently the transcriptional activity 
o f the tamoxifen/ER complex to promote growth. It is conceivable that such kinases 
might also induce nuclear ERa phosphorylation and thereby transcriptional activity in 
a ligand-independent manner, facilitating the action o f ER as a transcription factor in 
the steroid-depleted environment. Indeed, transcriptional activity induced by 
substantial kinase activation o f nuclear ERa on Seri 18ER (3-fold increase) has been 
implicated by the Maitin/Dowsett model as a mechanism in promoting oestrogen 
hypersensitivity (Martin et al., 2003). A study by Font de Mora and Brown (2000) 
revealed MAPK was not only a prime kinase candidate for Serll8ER  
phosphorylation, but the kinase was involved in transcriptional activity mediated by 
the coactivator AIB1. In addition they found the ALB 1/MAPK relationship increased 
the recruitment o f p300/CBP and its associated historic acetyl tnmsferase (HAT) 
activity. Reported potential kinase mediators o f Serl67ER phosphorylation are AKT, 
casein kinase II and also MAPK-activated RSK (Arnold et al., 1994; Lannigan,
2003). Again kinase/ER cross-talk reaches another level o f complexity. MAPK 
phosphorylates RSK where in the nucleus it forms a stable complex with p300/CBP 
which has been shown to regulate transcription (Nakajima et al., 1996). However, 
Joel et al. (1998) have provided data that suggest RSK can also directly 
phosphorylate Serl67ER thereby mediating transcription. Although coactivator 
involvement was not measured in the MCF-7X model, this project was able to 
decipher the impact kinase activity had on the phosphorylation at Seri 18ER and
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Serl67ER. Using immimocytochemistry, MCF-7X cells were shown to have 
detectable levels o f nuclear ERa AF-1 phosphorylation on Serl67ER and Seri 18ER 
and in parallel with the adaptive increase in ERa expression, there was a -30%  
increase in Seri 18ER phosphorylation versus die parental MCF-7 cells, although 
Serl67ER activity was unchanged. The lack o f substantial increases in such ERa 
AF-1 phosphorylation noted in MCF-7X may be a consequence o f relatively modest 
ERa expression and growth factor kinase activity in these cells, as well as the 
apparent absence o f any classical growth factor ligand/receptor input under conditions 
o f oestrogen and serum growth factor depletion.
4.2.1 Absence ofMAPK Regulation o f ERa Phosphorylation m MCF-7X Model 
Challenge with MEK-1 inhibitor PD98059 blocked the phosphorylation o f MAPK 
but barely inhibited MCF-7X cell growth. It was also without inhibitory effect on 
Seri 18ER or Serl67ER activity. There was further indication that any very small 
contribution for MAPK to growth in MCF-7X cells was direct rather than via nuclear 
ERa signalling, as PD98059 failed to inhibit ERE transcriptional and endogenous pS2 
expression. Moreover, ERa phosphorylation was also not MAPK regulated in MCF- 
7 cells, alongside lack o f impact on ER transcriptional activity and pS2 expression, 
indicating that the growth contribution o f MAPK in MCF-7 cells is again independent 
o f interplay o f this kinase with nuclear ERa. In this regard, Seri 18ER is reported to 
be a dominant ligand phosphorylated site in MCF-7 that may occur independently of 
MAPK (Martin et al. 2003) and can perhaps be promoted by CDK7/TFIIH (Joel et 
al., 1998; Chen et al., 2002; Lannigan, 2003), and so it is feasible that activity o f this 
site may also be promoted by residual steroid hormone in the MCF-7X cells. The 
Martin/Dowsett oestrogen hypersensitive model has also failed to show any 
involvement o f MAPK activity o f Seri 18ER phosphorylation. However, contrary to 
the MCF-7X model the LTED resistant cells did demonstrate a partial contribution 
from increased MAPK activity to ER transcriptional and growth, an event that they 
suggest may occur via MAPK regulating ER coactivator activity or additional AF-1 
phosphorylation sites (Martin et al., 2003). On a final note, a long-term oestrogen 
deprived model by Santen describes the basal growth regulation o f their cells by 
MAPK occurs independently o f any impact on ER transcriptional activity, although 
growth stimulation o f their cells by exogenous oestrogen appears in part to involve 
such interplay (Jeng et al., 2000).
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4.2,2 PI3K/AKT D ependent Regulation o f  E R a Phosphorylation a t S erl67  
Collectively the data revealed in this study demonstrate a prominent contribution for 
PI3K/AKT signalling in MCF-7X cells. The PDK inhibitors LY294002 and 
wortmannin were clearly effective at reducing growth as well as decreasing AKT 
activity and, in the case o f the former inhibitor PDK>1 activity. In parallel they 
demonstrated a significant inhibitory effect on ERa activity. MCF-7X cells subject to 
PDK inhibition showed decreased phosphorylation o f ERa by 50% at serine 167 
(where total ERa expression and Seri 18ER were unaffected). It also partially reduced 
ERa transcriptional activity with respect to ERE reporter activity and endogenous 
pS2 expression. It is acknowledged and important to note that studies have 
previously suggested LY294002 (1-25 pM) may, in equivalence to the anti-oestrogen 
faslodex, be able to act as a competitive inhibitor o f oestrogen binding to the ERa and 
thereby subvert ERa transcriptional activity. This is in addition to its ability to 
decrease PDK/AKT signalling that can influence ERa phosphorylation status and 
transcriptional activity (Pasapera Limon e t a l., 2003). However, studies in the present 
project utilising wortmannin support the latter PDK/AKT cross-talk with ERa as 
significant inhibition was again achieved at Serl67ER. Interestingly, an 
AKT/Serl67ER mechanism has also been reported to contribute to tamoxifen 
resistance (Campbell e t al. 2001; Nicholson e t al. 2004a). Moreover, Martin/Dowsett 
report LY294002 impacts adversely on ERa transcriptional activity in their LTED 
model (Martin e t a l., 2003). Brodie/Sabnis also report their increase in AKT activity 
shown in UMB-ICa cells was sensitive to wortmannin treatment and that 
concomitant immunoprecipitation studies (immunoprecipitation with anti-AKT 
followed by immunoblot for total ERa) revealed an increased association o f AKT/ER 
(Sabnis e ta l., 2005) that could also be decreased somewhat by wortmannin, although 
Serl67ER activity was not measured in this study, in total, these data demonstrate 
that there is a prominent cross-talk between PDK/AKT and genomic ERa in MCF- 
7X cells, where PDK/AKT regulation o f Serl67ER activity appears to play a leading 
role in undermining the inhibitory effects o f oestrogen deprivation on ERa 
transcriptional activity and growth.
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4.3 M APK A N D  A K T  INDEPENDENT REGULATION O F ER a  
PH OSPH ORYLATION
As noted with the PDK inhibitor LY294002, Faslodex was substantially growth 
inhibitory in MCF-7X cells, an event paralleled by significant inhibition o f ERE 
activity as measured using reporter gene construct studies, and o f endogenous ER- 
regulated gene expression (pS2). However, in contrast to LY294002, faslodex 
treatment was associated with reduced nuclear ERa, and a decrease in Seri 18ER 
phosphorylation. This effect was observed while the anti-oestrogen caused no 
alteration in Serl67ER activity on the remaining ERa in the cells.
The lack o f impact o f faslodex on Serl67ER is paradoxical given the partial decrease 
in ERa protein level achieved with this agent. Thus, faslodex may even be enabling 
Seri67 activity on the residual ERa in MCF-7X cells. In this regard, Faslodex, and a 
further pure anti-oestrogen, ICI 164,384, have been previously reported to be able to 
promote ERa serine phosphorylation, although it is uncertain which AF-1 sites are 
targets for its action and this may also be cell context specific (Le Goff e t a/., 1994; 
Joel e t a l., 1998; Chen e t a l., 2002). Potential kinase mediators o f Serl67ER 
phosphorylation in MCF-7X cells are AKT, MAPK-promoted p90 ribosomal S6 
kinase (RSK), and casein kinase II (Lannigan 2003). As stated above, the lack o f 
effect o f PD98059 and inhibitory impact o f LY294002 on Serl67ER phosphorylation 
(paralleled by inhibitory effects with wortmannin) indicate AKT is the kinase driving 
Serl67ER activity in MCF-7X cells in the presence o f faslodex How this is achieved 
remains unknown, since faslodex treatment does not obviously increase AKT 
activity: perhaps there is in some way improved accessibility o f this kinase to the 
Seri 67 residue in the presence o f faslodex Importantly, the observations with 
faslodex challenge suggest an additional growth importance for phosphorylation o f 
Seri 18ER in MCF-7X cells. In the MCF-7X model Serll8ER phosphorylation 
appears to be independent o f MAPK and AKT since faslodex treatment did not alter 
activity o f these kinases. It is possible that activity if  this site may be promoted by 
residual steroid hormone in this model. Seri 18ER can comprise a ligand 
phosphorylated site, and we have previously observed in MCF-7X cells substantial 
further Seri 18ER (but not Serl67ER) activation following oestrogen challenge (data 
not shown). Martin et al. (2003) have also shown ligand stimulated Seri 18ER 
phosphorylation to occur independently o f MAPK and PDK/AKT and others suggest 
activation o f the serine residue may be mediated via CDK7/TFIIH (Joel e t a l., 1998;
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Chen et al., 2002; Lannigan, 2003). Interestingly, the Affymetrix list o f induced 
genes in MCF-7X revealed some increase in TFIIH and CDK7 expression which may 
facilitate such activity. Since MCF-7X cells nuclear ERa and Seri 18ER 
phosphorylation increased by approximately 20%, it is also feasible that faslodex- 
driven decreases in ERa protein may be a contributory factor to the reduced 
Seri 18ER phosphorylation observed with this agent
4.4 TARGETING RESIDUAL ERa PHOSPHORYLATION 
The MCF-7X model data indicate that activation o f both Seri 18ER and Seri 67ER 
contributes to ERa transcriptional activity and growth. Furthermore, non-overlapping 
regulatory pathways for these ER activity sites have been revealed through treatment 
challenge with o f the pure anti-oestrogen faslodex and the PDK inhibitors LY294002 
and wortmannin. It was thus hypothesised that any phosphorylated ERa remaining 
when faslodex or LY294002 are applied singly might provide an important 
compensatory cell survival mechanism, underlying incomplete inhibitory effects on 
ERa transcriptional activity and growth in MCF-7X cells and ultimately enabling 
emergence o f resistance to each agent after 10 weeks.
In parallel with its depletion o f both ERa level and PDK/AKT signalling, the co- 
treatment data o f faslodex plus LY294002 clearly displayed a decrease in both 
Seri 18ER and Serl67ER phosphorylation. In parallel, there was a superior depletion 
o f ERa transcriptional activity measured by ERE reporter assays after 18hr treatment 
(although by 7 days this appeared to be equivalent to faslodex), and a superior 
depletion o f pS2 protein. Moreover the combination was associated with a superior 
(90%) anti-tumour response versus the single agents and an extended duration of 
growth inhibitory response (25 weeks), where resistant cells were subsequently 
slower growing than those emerging with the single agents. Again the preliminary 
growth studies with wortmannin substituted for LY294002 complemented these data. 
In agreement, studies from Brodie/Sabnis have also shown this latter combination to 
be an effective growth inhibitory strategy. Their UMR-ICa cells demonstrated a 40% 
reduction in proliferation to both wortmannin and faslodex as single agents, however 
when combined these two compounds imposed an 80% growth inhibitory effect 
(Sabnis et al., 2005). Clearly, this strategy may have considerable potential for 
therapeutic exploration in patients who have become resistant to oestrogen 
deprivation. However, while co-treatment with faslodex plus LY294002 proved a
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superior approach compared to the single agents in MCF-7X cells, this strategy was 
unable to prevent the development o f therapeutic resistance (cell growth resumed 
following 25 weeks continuous culture), heralding that such strategies may not prove 
maximally effective in the clinic.
Extensive profiling o f MCF-7X cells treated with the above combination revealed the 
cells retained MAPK activity, alongside residual ERa phosphorylation (particularly 
on Seri 18) and ERa transcriptional activity. It was therefore possible that the low 
levels o f MAPK activity unchanged by faslodex or LY294002 treatment were now 
able to trigger Seri 18ER phosphorylation (or coactivator activation initiating 
transcriptional activity). To assess if  it was possible to improve upon the 
faslodex/LY294002 combination, therefore, the MEK-1 inhibitor PD98059 was 
added to this strategy which resulted in an improved anti-tumour effect for the triple 
treatment (again also shown with wortmannin substitution for LY294002). There was 
marked growth inhibition, and interestingly following approximately 2 weeks of 
treatment, cell numbers fell below the initial seeding density and by week 16 the 
culture could no longer be maintained. Thus, this triple treatment had efficiently 
abrogated emergence o f therapeutic resistance. The triple treatment was associated 
with decreases in ERa expression and AKT activity, as observed with faslodex and 
LY294002 alone. However, the addition o f PD98059 as predicted also targeted 
MAPK activity. While the decrease in Serl67ER activity was as observed with dual 
faslodex/LY294002 treatment, importantly there was a superior depletion of 
Seri 18ER. This effect was again associated with marked depletion o f ERE activity 
and endogenous pS2 expression.
Thus, while MAPK activity does not contribute to basal ERa phosphorylation in 
MCF-7X, it does appear that this kinase interplays with ERa via Seri 18ER 
phosphorylation under conditions o f faslodex plus LY294002 co-treatment, an event 
that contributes to cell survival. The mechanism underlying this new coupling 
remains unknown. However, it is feasible that the low levels o f MAPK activity are 
now sufficient to trigger Seri 18ER phosphorylation because there is effective 
blockade o f the basal ER phosphorylation regulators by faslodex plus LY294002 co­
treatment, or alternatively that MAPK access to this site is now enabled because o f 
ERa conformational changes occurring with co-treatment (Lannigan 2003). 
However, the present study does not appear to advocate a link between growth of
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MCF-7X cells and activity o f the AP-1 response element in MCF-7X cells. Indeed, 
both PD98059 alone and triple treatment w o e equally effective in reducing AP-1 
activity in reporter assays, despite a lack o f growth inhibitory effect o f the former 
agent Nevertheless, it remains possible that there is interplay with further response 
elements though interplay between ER and other transcription factors, perhaps 
including SP-1 which is a key regulatory element in the cell survival gene bcl-2 
(DeNaido et al., 2005).
The project was subsequently able to confirm that inhibition o f Serll8ER  
phosphorylation was required for the catastrophic effects o f triple treatment on MCF- 
7X. Dual treatment with LY294002 plus PD98059 again reduced MAPK and AKT 
activity and significantly inhibited MCF-7X cell growth. This combination treatment 
was certainly superior in inhibiting growth versus LY294002 or PD980S9 alone. This 
combination strategy has also been investigated in the LTED models from 
Santen/Yue and Martin/Dowsett. The Santen/Yue studies revealed in their LTED 
cells that adaptive hypersensitivity involved the dual activation o f PBK and MAPK 
signalling pathways, and showed the combination o f LY294002/PD98059 shifted the 
level o f oestradiol sensitivity dramatically more than 2 logs to the right (Yue et al., 
2003; Santen et al., 2004a). The LTED model o f Martin/Dowsett also revealed 
PBK/MAPK dual inhibition results in a 70% reduction in basal transcription which 
was susceptible to partial rescue by high doses o f oestradiol (Martin et al. 2003). 
Importantly, this combination applied to the MCF-7X non-oestrogen hypersensitive 
model confirmed that inhibition o f Seri 18ER phosphorylation is required for the 
catastrophic effects o f the triple treatment. However, in MCF-7X cells, Seri 18ER 
phosphorylation was unaffected and the cells survived LY294002 phis PD98059 co­
treatment, resulting in resistance emerging following 12 weeks o f continuous 
treatment in marked contrast to the triple treatment where faslodex that targets ER. 
These studies in MCF-7X demonstrate that combination therapy to target all 
regulators o f ER AF-1 phosphorylation (i.e. PBK/AKT inhibitor plus MAPK 
inhibitor plus faslodex in MCF-7X) may be required to eradicate the cell survival 
mechanism in cells refractory to oestrogen deprivation, and prevent subsequent 
emergence o f therapeutic resistance.
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4.5 MCF-7X RESISTANT SUB-LINES: RATIONAL FOR COMBINATION 
THERAPY
4.5.1 F aslodex R esponse and D evelopm ent o f  Resistance
The pure anti-oestrogen faslodex is involved in several clinical trials as a single 
strategy following tamoxifen or aromatase inhibitors (NCCTG and SAKK) or in 
combination with aromatase inhibitors (FACT, SOFEA, and SWOG 226) (Johnston 
et al., 2005)]. There is an abundance o f experimental data that suggest the substantial 
retained ERa following oestrogen deprivation is faslodex sensitive, and therefore this 
agent is a logical choice o f treatment following or concurrent with an aromatase 
inhibitor/inactivator. Investigation o f the MCF-7X cells similarly revealed significant 
faslodex growth sensitivity. This was paralleled by the drug decreasing nuclear ERa 
and its phosphorylation at Seri 18 (via influencing a kinase other than MAPK or 
AKT), coupled with a reduction in ERa transcriptional activity and endogenous pS2 
expression. These are all reasonable alterations considering the compound binds ERa 
to adversely impact on its activity as a nuclear transcription factor and leads to 
receptor degradation (Figure 4.2A). Other in vitro models o f long-term oestrogen 
deprivation have also been used to investigate short-term faslodex treatment and 
again suggest it as a viable therapeutic intervention. However, based on the MCF-7X 
cell data reported here, there is strong indication that such a strategy will not be fully- 
effective in tumours resistant to oestrogen deprivation. Indeed, breast cancer cells 
resistant to oestrogen deprivation seem able to ultimately evade the substantial ERa 
inhibitory effects o f faslodex and furthermore promote an adverse phenotype in the 
presence o f this agent. Thus, while the faslodex responsive phase in MCF-7X cells 
lasted 10 weeks, a cohort o f tumour cells survived this strategy and subsequently 
became faslodex resistant. The incomplete inhibition was associated with a failure to 
deplete AKT-driven Serl67ER phosphorylation and thus incomplete block o f ERa 
transcriptional activity. Characterisation o f the faslodex resistant oestrogen deprived 
X(FAS) phenotype showed a disconcerting increase in aggressive behaviour 
[(increased cellular motility and to a lesser extent invasive capacity) (Figure 4.2B)]. 
It seems likely that the emergence o f faslodex resistance and the associated disease 
progression was driven by the substantial gains in expression o f the classical growth 
factor receptors EGFR, HER2 and IGF-1R observed in the X(FAS) cells and 
subsequent increased downstream kinase activity, in particular MAPK that is known 
to promote growth and motility o f ceils (Kruger & Reddy, 2003).
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The increases in EGFR (coupled with more modest HER2 increases) began early 
during targeting o f ERa in MCF-7X cells with faslodex during response. These 
increases had become very substantial by the time o f emergence o f X(FAS) resistant 
cells. Such increases have also been previously repeated (Gee et al., 2003) to arise 
during treatment with anti-oestrogens such as tamoxifen and faslodex in ER+ 
endocrine responsive cells such as MCF-7 that express only low levels of 
EGFR/HER2 prior to treatment The event has been linked with anti-oestrogen- 
mediated de-repression o f an oestrogen/ER inhibitory effect at the first intron in the 
promoters o f these genes (Chrysogelos et al., 1994), where the EGFR/HER2 
expression gain is maximised and growth contributory by the time o f emergence o f 
anti-oestrogen resistance (Knowiden et al., 2003b). The observation that 
EGFR/HER2 expression are not elevated in MCF-7X cells basally indicates that the 
ER blockade in MCF-7 cells as a consequence o f steroid hormone depletion in the X 
medium, in contrast to the effect o f the pure anti-oestrogen faslodex, is insufficient 
for this de-repressive event. The mechanism o f anti-oestrogen induction o f genes 
normally repressed by oestrogen/ER signalling remains poorly-characterised, but may 
not involve influences at ERE-like sites in the EGFR or HER2 genes. One proposed 
explanation is that anti-oestrogen treatment prevents non-classical ER 
protein/transcription factor interactions that normally transiepress gene expression 
from response elements such as NFkB (Zhou et al., 2005). A second is that anti­
oestrogen treatment may free-up coactivators normally promoted to the ERE in the 
presence o f oestrogen, so these are now available to activate alternative response 
elements (Oestemeich et al., 2001). Whatever the undedying molecular mechanism, 
the EGFR/HER2 gains during anti-oestrogen treatment, including faslodex, can 
provide a cell survival mechanism that limits maximal anti-tumour response and 
maintains the cohort o f cells from which resistance (TAMR or FASR cells) 
subsequently emerge (Gee et al., 2003; Yarden et al., 2001). These events appear 
likely to be equally contributory to acquisition o f resistance by the MCF-7X line and 
subsequent maintenance o f X(FAS) cells.
As we have observed in the acquired TAMR and FASR cells developed from MCF-7 
(Knowiden et al., 2003b; McClelland et al., 2001), the substantial gain in 
EGFR/HER2 signalling in X(FAS) was also paralleled by a very marked rise in 
phosphorylated MAPK and some increase in AKT activity, presumably downstream 
of the elevated growth factor receptors. Interestingly, these alterations were
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associated with a substantial increase in Serl67ER activity in X(FAS) cells versus 
untreated MCF-7X cells, and while Serll8ER  activity remained lower it was 
nevertheless also detectable. In parallel with this re-activation o f ER, there was 
substantial recovery in ER-regulated gene (pS2) expression. It seems likely that the 
recovery in ER signalling seen in X(FAS) cells is driven by the increased growth 
factor receptor-promoted kinases triggering ER phosphorylation. In support o f this 
concept, we have previously noted that in acquired TAMR cells, increased 
EGFR/HER2 drives phosphorylation o f MAPK and AKT that in turn reactivate ER 
on both Seri 18 and Serl67 to promote ER-regulated EGF-like ligand expression 
(Britton et al., 2006). This supports an autocrine mitogenic EGFR signalling loop in 
such cells that may also prove relevant in X(FAS) cells (Britton et al., 2006). In 
addition, re-activation o f ER results in expression o f IGF-1R signalling components 
that in turn further enhance the EGFR pathway (Knowiden et al., 2003a). Similarly, 
in our acquired FASR model developed from MCF-7 cells, we have seen increases in 
EGFR/HER2 signalling (McClelland et al., 2001) that again promote downstream 
kinase activity to maintain phosphorylation on residual ERa in such cells, and IGF- 
1R signalling is also detectable in such cells. It is again possible that the reactivation 
o f ERa in X(FAS) cells underlies their substantial gain in IGF-1R. The observation 
that EGFR/HER2 is not subsequently repressed on re-instigation o f substantial ERa 
activity in the X(FAS) cells suggests the mechanism o f expression o f these receptors 
is indeed independent o f an ERE mechanism.
Encouragingly, in both our acquired TAMR and FASR models, growth can be 
substantially inhibited by targeting the increased growth factor receptor signalling 
loop, for example using gefitinib (Knowiden et al., 2003b, McClelland et al., 2001) 
that is currently being explored in endocrine resistance through several clinical trials 
(Johnston et al., 2003; 2005). While not examined in the present study, one might 
similarly envisage that targeting o f the increased EGFR/HER2/IGF-1R (and 
MAPK/AKT kinase signalling) could provide an inhibitory strategy for X(FAS) cells, 
where this project suggests this should be o f superior benefit compared with the 
oestrogen deprived-resistant (MCF-7X) phase. Excitingly, our studies in TAMR cells 
indicate that such depletion o f the elevated growth factor receptor signalling also has 
potential to decrease aggressive cellular behaviour. Targeted growth factor receptor 
or MAPK/AKT inhibition could similarly prove useful in limiting this adverse feature 
in oestrogen deprived cells that have acquired resistance to faslodex. Interestingly, a
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further key element to growth and invasive behaviour in TAMR (and possibly FASR) 
cells that can be targeted is Src (Hiscox et al., 2005), and it thus it would be 
interesting to examine in the future if  the contribution o f this non-receptor tyrosine 
kinase is also enhanced on acquisition o f faslodex resistance by MCF-7X cells. 
Finally, since EGFR/HER2 increases begin early during faslodex treatment and may, 
via MAPK and AKT, sustain die residual Seri 18ER and also the substantial levels of 
Serl67 in the presence o f this agent, it is possible that combined treatment o f faslodex 
plus agents such as gefitinib (or relevant kinase inhibitors as shown in this project) 
will provide a superior strategy to faslodex alone in oestrogen deprivation resistance 
and could subvert emergence o f the more aggressive X(FAS) phenotype. Certainly, 
we have observed that in MCF-7 such co-treatment can block the increased EGFR 
and residual kinase activity during anti-oestrogen treatment, more effectively deplete 
ERa activity and subsequent ER-regulated cell survival gene expression (i.e. bcl-2), 
and improve anti-proliferative and pro-apoptotic effects versus tamoxifen or faslodex 
alone. There is consequently an enhanced anti-tumour response and a delay 
in/prevention o f emergence o f resistance (Gee et al., 2003). Similarly, in our TAMR 
cells we have shown that a combined treatment o f faslodex with gefitinib is again 
more effective than either single agent in depleting ER phosphorylation, exciting an 
improved anti-tumour response and preventing subsequent acquisition o f resistance 
(Nicholson et al., 2005).
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A. MCF-7X: Faslodex Responsive
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Figure 4.2 Schematic illustration offaslodex responsive (A) and faslodex  
resistant (B) MCF-7X cells. Above illustrates the changes MCF-7X cells undergo 
during short term faslodex treatment (A) and when MCF-7X cells become resistant to 
faslodex (B).
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4.5.2 LY294002 R esponse and D evelopm ent o f  Resistance
PI3K/AKT has been shown to comprise an important signalling pathway in cancer 
and is being explored as a therapeutic target in breast cancer (Kim et al., 2005). 
While PBK inhibitors are emerging for clinical exploration there have been problems 
with selective targeting (Granville et al., 2006), and hence the general clinical focus 
to date has been to inhibit mTOR, which is downstream o f AKT, with mTOR 
inhibitors or faroesyltransferase inhibitors (FTIs) that influence both MAPK and 
mTOR signalling (Yue et al., 2005; Johnston et al., 2005). Such agents are currently 
being examined through clinical trials both in the endocrine responsive and resistant 
phases o f breast cancer (Johnston et al., 2005). In the present study, the PI3K/AKT 
inhibitors wortmannin or LY294002 could reduce phosphorylated AKT levels in 
MCF-7X cells and were significant inhibitors o f growth, data confirmatory o f the 
dominance o f AKT signalling and relevance o f its targeting in resistance to oestrogen 
deprivation.
There is also strong indication from the literature that PDK/AKT can directly 
phosphorylate Serl67ER (Campbell et al., 2001) to promote ERa transcriptional 
activity. This is again consistent with the t findings in the MCF-7X cell model where 
the PBK inhibitors depleted Serl67ER phosphorylation (Figure 4.3AX reduced ERE 
activity and decreased endogenous pS2 expression. However, like faslodex, 
LY294002 proved incomplete in its inhibitory effects both at the level o f ER 
transcriptional activity and growth, and resistant growth emerged following 10 weeks 
of treatment [X(LY) cells]. In this instance, incomplete blockade was associated with 
failure o f LY294002 to deplete Serll8ER activity. Studies using combination 
treatment with LY294002/PD98059 to deplete both AKT and MAPK (and also 
Serl67ER), like PBK blockade alone failed to block Seri 18ER activation or 
resistance emerging in MCF-7X cells, indicating phosphorylation o f this ERa site is 
PDK/AKT and MAPK independent Sadly, therefore, these data reveal that breast 
cancers resistant to oestrogen deprivation may again ultimately be able to bypass 
therapeutic inhibition o f the key mitogenic pathway PDK/AKT, as well as any agent 
that blocks both PDK/AKT signalling and MAPK, to reinstate resistant growth. The 
survival mechanism in both instances appears to involve residual 
oestrogen/Serl 18ER signalling and the data thus support combination strategies that 
include faslodex for maximal depletion o f ERa activity.
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Interestingly, during the LY294002 responsive phase in MCF-7X cells there was no 
increase in HER2 or EGFR expression. Thus, despite decreased Serl67ER and ER 
transcriptional activity during P13K inhibition, this appears insufficient to de-repress 
expression o f the growth factor receptor genes, in contrast to faslodex treatment. This 
may indicate that depletion o f ligand-promoted Serll8ER activity, or alternatively 
functional PDK signalling, is essential for increases in EGFR/HER2 to arise during 
treatment, and also suggests only limited value o f inclusion o f anti-growth factor 
receptor agents in this phase in the absence o f faslodex.
While apparently o f limited relevance to cell survival during the LY294002 
responsive phase, it seems likely that maintenance o f X(LY) resistant growth was at 
least in part due to increased EGFR and HER2, and their promotion o f kinase activity. 
Although the increase in EGFR and HER2 expression were modest in X(LY) cells no 
comparative increase in IGFR membrane staining was noted. However, X(LY) cells 
showed a significant increase in phosphorylated MAPK versus the parental cell line. 
However, there were much larger changes observed for all three receptors and MAPK 
in X(FAS) cells, possibly explaining why the X(LY) cells failed to exhibit increased 
aggressive behaviour. Interestingly, X(LY) cells also recovered their AKT activity, a 
somewhat surprising observation given that LY294002 should deplete such 
signalling. Hence increased MAPK activity in X(LY) cells, perhaps EGFR/HER2- 
driven, may underlie their apparently PDK inhibitor-refractory phosphorylation of 
AKT and growth. (Figure 4.3B). This appears to contrast the basal input for AKT 
activity in MCF-7X cells, which is not driven by classical growth factor receptor or 
MAPK since such receptors are only at very low levels in untreated MCF-7X cells 
while PD98059 exerts no impact on this kinase or growth under basal conditions. In 
parallel with the gains in MAPK and recovery o f AKT in X(LY) cells, there was 
recovery in Serl67ER activity, alongside retained levels o f Seri 18ER presumably 
driven by ligand-promoted ERa. This reinstating o f ERa activity in resistance was 
associated with recovery (and marginal increase) in pS2 expression. It thus seems 
that oestrogen deprivation resistant cells can ultimately fully re-activate their ERa 
signalling and growth following treatment with a PDK inhibitor, although it remains 
unclear why this does not in turn promote substantial expression o f the ER-regulated 
IGF-1R (other than small cytoplasmic increases).
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The data suggest that treatment with agents targeting EGFR/HER2 may be o f some 
value in established oestrogen deprived, PDK resistant cells if  such signalling does 
indeed lie upstream o f the recovered MAPK/AKT and Serl67ER activity in X(LY) 
cells. Addition o f MAPK inhibition may also be valuable. However, LY294002 in 
combination with PD98059 again failed to block Seri 18ER activation in MCF-7X 
cells and could not prevent resistance from ultimately emerging. Moreover, the 
resultant phenotype, X(LY/PD), was in many ways comparable with that o f cells 
resistant to PBK inhibitor alone (i.e. modestly increased EGFR, little effect on HER2, 
some recovery in MAPK and increased AKT activity, retained Seri 18ER 
phosphorylation, recovered Serl67ER activity and a marginal increase in pS2 
expression versus untreated MCF-7X cells). These data reiterate the necessity to 
include faslodex in any combination treatment strategy for resistance to oestrogen 
deprivation in order to eliminate ligand-promoted Seri 18ER phosphorylation for 
more effective growth inhibition.
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Figure 4.3 Schematic illustration o f  LY294002 responsive (A) and 
LY294002 resistant (B) MCF-7X cells. Above illustrates the changes MCF-7X 
cells undergo during short term LY294002 treatment (A) and when MCF-7X cells 
become resistant to LY294002 (B).
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4.5.3 Faslodex/L Y294902 Co-treatment Response ami Development ofResistance 
The combination o f a PBK inhibitor with pure anti-oestrogen has proven a superior 
treatment strategy for several models resistant to oestrogen deprivation, as observed 
through growth studies in the Brodie/Sabnis model as well as in the MCF-7X model. 
In the latter model, faslodex/LY294002 treatment decreased nuclear ERa mid AKT 
activity, inhibited much o f the ERa activity at both Seri 18 mid Seri 67 ER sites, and 
promoted superior reduction in ERE activity mid pS2 protein expression versus the 
agents applied singly (Figure 4.4A). Clearly co-treatment prolongs growth blockade 
compared to either treatment alone and most noteworthy once resistance emerged the 
cells maintained a lower proliferative index compared to the parental MCF-7X cells. 
However, the development o f the resistant phenotype after 25 weeks exposure to the 
combination therapy demonstrated marked plasticity within this model. This suggests 
any residual AF-1 phosphorylation is sufficient to overcome the anti-proliferative 
blockade as evidenced in this model here potential MAPK-driven phosphorylation o f 
Seri 18 ER when inhibited by the triple treatment with FAS/LY/PD negates growth.
Short term (7 day) studies with FAS/LY co-treatment revealed cytoplasm, but no 
plasma membrane, increases in EGFR, also with only small increases in HER2. 
These modest and predominantly cytoplasmic increases m EGFR/HER2, alongside 
cytoplasmic increases in IGF-1R, may be sufficient to promote the MAPK activity we 
have shown (through the FAS/LY/PD triple treatment studies) drives residual 
Seri 18ER activity and cell survival. Since FAS/LY co-treatment, like faslodex 
applied singly, depleted Seri 18ER activity, yet failed to induce substantial expression 
o f the growth factor receptors, maintenance o f functional PBK signalling and its 
cross-talk with ER may be important to the mechanism whereby increases in 
EGFR/HER2 expression can arise during early treatment While MAPK blockade 
was clearly a powerful addition in the triple treatment strategy that prevented 
emergence o f resistance, growth factor receptor inhibition could perhaps also improve 
FAS/LY response. However, the rational for this latter strategy is perhaps not as 
obvious as in improving response to faslodex alone, where more significant increases 
in growth factor receptor expression arise during treatment with this anti-oestrogen. 
Subsequent profiling o f the faslodex/LY294002 MCF-7X resistant cells 
[X(FAS/LY)j revealed some similarity to the X(FAS) cells in that there were large 
increases in the classical growth factor receptors EGFR and IGF-1R. However, HER2 
increases were minor and the X(FAS/LY) cells did not exhibit aggressive behaviour,
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in obvious contrast to the X(FAS) cells, an observation implying that it is increased 
HER2 that is particularly required for disease progression during treatment of 
oestrogen deprivation resistant cells. Thus concept is in keeping with observations 
made by Sabnis et al. in UMBl-Ca cells (2005) and clinical links between increased 
HER2 and poor prognosis (De Lorenzo et al., 2002; Gee et al., 2005). In parallel 
with the marked increases in EGFR and IGF1R, both phosphorylated MAPK and 
AKT (presumably again MAPK/RSK-driven) were increased in X(FAS/LY) cells 
versus MCF-7X, and there was similarly recovery o f both Seri 18ER and Serl67ER 
phosphorylation so that their levels exceeded MCF-7X cells. There was clearly also a 
gain in ERa transcriptional activity as measured by substantial recovery o f pS2 
expression. Thus, ERa signalling has again been fully reactivated on emergence of 
resistance to co-treatment, perhaps underlying the substantial increases in 1GF-1R 
expression also noted in such cells (Figure 4.4B). Cumulatively, the data suggest that 
treatment with a MAPK inhibitor, or perhaps blockade o f upstream EGFR or IGF-1R, 
would be valuable after long-term FAS/LY treatment.
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Figure 4.4 Schematic illustration o f  faslodex/LY294002 responsive (A) 
and faslodex/LY294002 resistant (B) MCF-7X cells. Above illustrates the 
changes MCF-7X cells undergo during short term faslodex/LY294002 treatment (A) 
and when MCF-7X cells become resistant to faslodex/LY294002 (B).
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4.6 POTENTIAL RECEPTOR CONTRIBUTION TO M CF-7X CELL GROW TH  
Ultimately, by further understanding inherent resistance mechanisms, we can 
determine effective treatment strategies for cells that have acquired resistance to 
oestrogen deprivation. Classical growth factor signalling via EGFR, HER2 and IGF- 
1R has clear importance in both hormone sensitive and insensitive breast cancer. 
However, it is emerging from clinical studies with anti-growth factors targeting such 
pathways that resistance again develops, indicating there are further factors 
contributory to therapeutic resilience o f the disease. Alongside elegant use of 
signalling studies to decipher pathway activity, the development o f array technology 
is beginning to reveal the previously unrecognised breadth o f potential contributory 
elements by profiling at a transcriptional level. Excitingly, it has to be mentioned that 
within the genetic profile lists currently being generated, often the classical receptors 
and/or associated intracellular kinases are significant however not at the top o f the 
lists. This should be rather encouraging, as alongside continued study o f classical 
signalling pathways, future research can now also begin to piece in the new elements 
ultimately optimising and integrating any emerging novel targeting strategies together 
with those already established for the candidate pathways.
With regards to deciphering resistance oestrogen deprivation, the studies from 
MCF-7X cells indicate our quest for receptors promoting significant PI3K/AKT and 
ER signalling should indeed sweep much further than the candidate pathways, since 
these cells were notably growth refractory to inhibition o f the growth factor receptors 
EGFR/HER2 and IGF-1R and also to many growth factor receptor ligands (i.e. EGF- 
like ligands, IGFs, VEGF, PDGF). It is envisaged that uncovering any dominant 
upstream receptor inputs in MCF-7X cells may not only reveal new contributors to 
PI3K/AKT and ER signalling regulation but furthermore quite novel therapeutic 
angles, since these cells employ growth mechanisms apparently totally divorced from 
serum growth factors/autocrine signalling inputs through all the classical receptors 
examined in this project. As such, the observation that 207 o f the gene probes 
representing aspects o f receptor activity were induced in MCF-7X using Affymetrix 
with GeneSifter® analysis clearly should provide a valuable future resource to 
uncover such novel mechanisms and to evaluate their targeting potential. In this 
regard, the present project has initially focussed around examining 3 interesting 
induced receptors, FGFR-4, EphA3 receptor and transferrin receptor.
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4.6.1 Contribution o f  FGFR-4 Signalling to  M CF-7X Cell Growth
The Asymetrix data revealed a marked, significant increase in fibroblast growth 
factor receptor-4 (FGFR-4) expression in MCF-7X cells. This is interesting since 
over expression o f FGFR-4 has been detected in approximately 30% o f breast 
cancers, correlates to a pom* patient prognosis and can contribute to cell proliferation, 
cell survival and migration (Penault-Llorca e t a l., 1995). Studies have shown 
activation o f FGFR-4, like EGFR, HER2 and IGF-1R, initiates MAPK and 
PI3K/AKT downstream signalling (Klint & Claesson-Welsh, 1999). A current study 
by Koziczak and Hynes (2004) suggests increased FGFR-4 and HER2 control both 
MAPK and PI3K signalling which enhance S6K1 and 4E-BP1 phosphorylation, 
thereby cooperatively regulating the activity o f the mTOR pathway. In this study, it 
was shown that either targeting FGFR-4/HER2 (PD173074 and PKI166 respectively) 
or MAPK/PI3 K/AKT (U 0126 and wortmannin respectively) simultaneously caused a 
complete block o f S6K1 activity. These data are complementary o f the Santen/Yue 
data which indicate mTOR as the nodal point o f MAPK and PD K/AKT signalling 
and therefore a strategic therapeutic target (Yue et al., 2005).
Unfortunately, however, die MCF-7X cell Asymetrix data revealed very little 
expression o f the natural ligands FGF1 or -2, and moreover growth o f MCF-7X cells 
could not be stimulated by exogenous addition o f these growth factors. In the 
absence o f a selective inhibitor few FGFR-4 in this study, it is hard to definitively rule 
out a growth contribution for such signalling and this is clearly required in the future. 
Nevertheless, if  MAPK and PDK/AKT are the predominant signalling kinases 
involved following activation o f FGFR-4, the MCF-7X oestrogen deprived model 
already suggests residual ERa activity at Seri 18 would remain a critical concern if 
treating cells with an FGFR-4-selective agent, and thus again that combination 
treatment with faslodex to maximally deplete ERa activity would be required.
4.6.2 Contribution o f  EpkA3 Receptor Signalling to M CF-7X Cell Growth
It was not completely naive to consider at least one member o f die ephrin receptor 
family would be singled out as induced by the MCF-7X cell Asymetrix analysis as 
this does comprise the largest receptor tyrosine kinase group. The group are 
transmembrane receptors, activated by clustered, membrane-bound ligands, where 
activation relies on cell-cell interactions. Their signalling is complex, but many o f 
the downstream signalling pathways from such receptors converge on the
308
CHAPTER 4 DISCUSSION
cytoskeleton (Kul lander & Klein, 2002). Interestingly, the Affymetrix array data 
revealed ephrin A3 receptor (EphA3) was markedly and significantly increase in 
MCF-7X cells (versus MCF-7 cells). Ephrin A3 receptor has been linked with tumour 
progression and so has potential to positively contribute in MCF-7X cells, although it 
has also been described as a tumour/invasion suppressor (Fox & Kandpal, 2004). 
Unfortunately, the observation o f increases in this receptor were paralleled by 
virtually no expression o f ephrin AS and A2, and while detectable, in MCF-7X cells 
there were lower levels versus the parental MCF-7 cells for the further natural ligands 
o f this receptor, ephrin-A3 and ephrin-A4. Nevertheless, since these data are the first 
demonstrating increased EphA3 receptor in oestrogen deprived resistant breast 
cancer, and since the various ephrin receptors themselves can also act as ligands and 
their signalling is likely to depend cm the tumour cellular microenvironment 
(Kullander & Klein, 2002), more detailed deciphering, including selective inhibition, 
remains important for the future to investigate if  there is indeed any contribution to 
this resistant state. There has certainly been some interest in further members o f this 
receptor family in breast cancer, where emerging data indicates some associations 
with aggressive cellular behaviour and pom- outlook. For example, there are a 
number o f in vitro studies implicating over expression o f EphA2 in non-neoplastic 
epithelia (Paine et cd., 1992; Pauley et al., 1993) and metastatic breast cancer cells 
(Price 1996). Furthermore a more recent in vivo study from Zelinski et al. (2001) 
revealed over expression o f the EphA2 receptor in approximately 40% o f their breast 
cancer clinical specimens. EphA2 has been shown to interact and/or enhance cell 
signalling via FAK, SHP-2 and PDK (Miao et al., 2000; Pandey et al., 1994). 
Suggested factors that can contribute to increases o f EphA2 include Ras oncogene, E- 
cadherin (Zantek et al., 1999), members o f the p53 family o f transcriptional 
regulators, DNA damage, and interestingly loss o f oestrogen receptors and c-Myc 
(Zelinski et al., 2002). The latter association might explain why EphA2 also did not 
appear in our Affymetrix profiling as oestrogen receptor and c-Myc were both 
increased somewhat in MCF-7X cells.
4.6.3 Contribution of Transferrin Receptor Signalling to MCF-7X CeU Growth
Characterised fifty years ago, transferrin (Tf) is an important iron-transport protein 
and therefore an essential component for iron metabolism. Iron is essential for cell 
growth and metabolic processes including enzyme function, oxygen transport, DNA 
synthesis and electron transport and in turn proliferation and also cell survival. Iron
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is taken into cells by high-affinity binding o f iron-loaded transferrin to its receptor 
(TfR) with receptor-mediated endocytosis of monoferric and diferric transferrin. 
Thus, after binding to its receptor on the cell surface, transferrin is rapidly 
internalised by invagination o f clathrin- coated pits with formation o f endocytic 
vesicles (Elliott et al., 1993). TfR expression is controlled by the amount o f iron 
required by the cell to maintain its metabolism. This receptor is expressed on rapidly 
dividing cells, with 10,000 to 100,000 molecules per cell, commonly found on highly 
proliferative tumour cells or cells in culture (Inoue et cd., 1993). Interestingly, breast 
cancer cells have previously been shown to produce Tf and express TfR an event that 
in improving iron delivery may facilitate proliferative events (Vandewalle et cd., 
1989), and again TfR correlates with proliferative capacity in clinical breast cancer 
(Wrba et al., 1989). Antisense inhibition o f TfR or selective antibodies to this 
receptor inhibit cell survival and proliferation in breast cancer models showing its 
fundamental growth importance to such cells (Yang et cd., 2001) and there has been 
some interest in this avenue for cancer therapeutics.
Interestingly, the MCF-7X model revealed significantly increased transferrin receptor 
levels by Affymetrix analysis, verified at the PCR level and subsequently at the 
protein level, coupled with detectable autocrine production o f transferrin (also 
observed in MCF-7 cells; Vandewalle et cd., 1989). There was a markedly superior 
mitogenic response to exogenous transferrin challenge (associated with down 
regulation o f transferrin receptor) in the MCF-7X cells. We surmised, therefore, that 
it is feasible that increased TfR may facilitate MCF-7X resistant ceil growth under 
oestrogen and growth factor depleted conditions by improving iron delivery and 
thereby aiding mitogenic signalling pathways in such cells (i.e. AKT/ER), ultimately 
conferring a selective growth advantage. While not examined at the protein level, the 
increase in TfR mRNA expression appeared to begin during exposure o f the parental 
MCF-7 cells with oestrogen/growth factor depleted medium, an observation that has 
been previously reported in other cell models in response to very low concentrations 
o f fetal calf serum in media. The finding o f increased TfR in MCF-7X cells may have 
clinical relevance, since TfR has been shown to alter during disease progression 
(Elliott et cd., 1993; Inoue et cd., 1993), and the Tenovus laboratories have obtained 
preliminary data showing increase TfR mRNA associates with elevated proliferative 
activity and poorer patient survival in clinical disease.
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Growth studies supported the concept o f significant positive TfR/PI3K interplay in 
MCF-7X cells (a feature clearly not apparent for MAPK since there was no 
significant impact o f the MEK-1 inhibitor PD98059). The MCF-7X model revealed 
that PI3K inhibition by LY294002 could fully interfere with transferrin-induced 
growth, so growth was depleted to a level equivalent to that following LY294002 
treatment o f MCF-7X cells under control conditions. However, transferrin treatment 
imposed a negative effect on AKT as well as MAPK activity in MCF-7X cells as 
measured by immunocytochemistry. The pure anti-oestrogen faslodex was also able 
to fully abrogate transferrin stimulated growth, again suggesting positive cross talk 
between TfR and ERa. However, transferrin treatment imposed a negative effect on 
nuclear ERa, causing slightly reduced ERa levels, diminished Serl67ER activity 
(with no impact on Seri 18ER) and reduced pS2 expression.
In total, these data suggest that transferrin receptor is not the positive upstream 
regulator o f kinase or ERa signalling in MCF-7X cells. Indeed, some negative cross 
talk is suggested, where depletion o f AKT activity (alongside a modest decline in 
ERa level) is likely to result in the depleted Serl67ER activity and reduce ER- 
regulated gene expression, effects that in total may serve to limit excessive growth 
responses in the presence o f transferrin. TransfeiTin/transferrin receptor trafficking 
has been closely associated with the intracellular kinase PI3K (Jess et al., 1996), 
where inhibitors o f the kinase can deplete cell surface TfR level, and this observation 
may explain the apparent interplay with PB K/AKT revealed using LY294002. 
Similarly, oestrogen signalling has been shown to regulate transfemn/TfR (Vyhlidal 
& Safe, 2002; Vandewalle et al., 1989), although this was not apparent at the level of 
TfR expression using faslodex in the present study.
4.7 CONCLUSIONS, THERAPEUTIC IMPLICATIONS AND OPTIONS FOR 
INTELLIGENT THERAPY
These studies in MCF-7X cells reveal the high level o f flexibility o f the breast cancer 
cell when key growth-promoting pathways are blocked. Thus, breast cancer cells can 
clearly survive the rigors o f oestrogen deprivation and o f a severely reduced growth 
factor environment. However, while resistance to oestrogen deprivation can evolve 
in the absence o f exogenous growth factors in MCF-7X cells, their primarily
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autocrine input appears insufficient to support development o f oestrogen 
hypersensitivity. This feature may relate to the lack o f input from classical growth 
factor receptors and only modestly altered kinase signalling versus the parental cells. 
There does not seem to be a significant dominant contribution o f EGFR, HER2 or 
IGF-1R to the basal growth o f MCF-7X cells, and so these findings would suggest 
that agents targeting these pathways would not be fully effective as treatments when 
used singly in tumours resistant to oestrogen deprivation, or indeed when used in 
combination with oestrogen deprivation strategies. Moreover, while there may be 
some role for the significantly increased FGFR-4, EphA3 and transferrin receptors, 
further investigation (i.e. ligand profiling/challenge studies) has suggested these 
inputs are unlikely to be the key upstream positive growth regulators under basal 
conditions. Thus, future detailed investigation o f any further receptors identified by 
Affymetrix microarray analysis remains important to fully decipher this resistant state 
and design improved tyrosine kinase inhibitory approaches.
Importantly, the MCF-7X model has consolidated the central importance o f increased 
ERa signalling (in this instance, apparently classical genomic) in resistance to 
oestrogen deprivation, alongside several previous LTED models generated in the 
presence of serum growth factors. The data cumulatively are supportive o f use o f 
faslodex in acquired resistance to oestrogen deprivation, where in MCF-7X cells this 
agent depletes nuclear ERa, decreases Seri 18ER phosphorylation (maintained by as 
yet unknown kinases triggered by residual oestrogen) and ERa transcriptional 
activity, and inhibits growth for a reasonably long duration in culture. Excitingly, 
faslodex responses following clinical acquisition o f resistance to aromatase inhibitors 
are now being described (Johnston, 2004). The Martin/Dowsett LTED in vitro model 
(Martin et cd., 2003; 2005) has already inspired the SOFEA clinical trial which is 
comparing progression-free survival in patients who have progressed on a non­
steroidal aromatase inhibitor and subsequently treated with faslodex plus anastrozole 
or faslodex alone. The study will also address the comparison o f the steroidal 
aromatase inactivator exemestane versus faslodex examining biological markers o f 
response (Johnston et cd., 2005) and given the promising faslodex responses noted in 
MCF7-X cells, the results o f this clinical study are eagerly anticipated.
Deciphering o f MCF-7X cells has furthermore identified a key contribution for 
intracellular kinase signalling, primarily PI3K/AKT rather than MAPK to the growth
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of cells dial have acquired resistance to oestrogen deprivation. As stated above, die 
identity of the upstream receptor activators of this kinase basally remains as yet 
unknown. Again, nuclear ERa plays a central role in this growth mechanism, with 
PI3K/AKT cross-talking closely with this receptor via phosphorylation of its AF-1 
Seri67 residue to influence ERa transcriptional activity. The studies from 
Brodie/Sabnis similarly support PDK/AKT cross-talk with ERa in their UMB-ICa 
cell line. MCF-7X cells reveal the significant potential for PD K/AKT blockade to 
treat resistance to oestrogen deprivation, where impact on ERa phosphorylation (in 
this instance the AKT-driven Serl67 site) again appears central to subsequent 
inhibitory effects on growth. Excitingly agents adversely influencing PDK pathways 
are now emerging for experimental and clinical evaluation. Moreover, Santen/Yue 
have challenged their LTED model with famesylthiosalicylic acid (FTS) which 
encouragingly has shown inhibition of proliferation and enhancement o f apoptotic 
cell death. They have shown that FTS not only subverts MAPK activity but also 
partially blocks AKT (McMahon et cd., 2005; Santen et cd., 2006), although 
subsequent impact on ERa phosphorylation status remains unknown.
However, the various monotherapies examined, although having considerable merit, 
all proved incomplete inhibitors of MCF-7X cell growth and as such allowed 
subsequent emergence of resistance. Importantly, this project has revealed that the 
oestrogen-deprived phenotype is extremely flexible in its recruitment o f signalling 
pathways during these various treatments, and can also maintain residual ERa 
phosphorylation and hence ERa function. These events provide the initial 
compensatory mechanism that limits therapeutic efficacy of the single agents and 
subsequently drive resistance. Thus, challenge with faslodex that depletes ligand/ER 
signalling is associated with a de-repression of EGFR/HER2 expression, maintained 
downstream MAPK and PI3K/AKT signalling, and ultimately significant increases in 
these various signalling elements culminating in resistant growth. In the case o f PDK 
blockade, while there is little change in expression during response, die cells again 
exhibit increased EGFR/HER2 (albeit more modest) by the time resistance emerges 
that may promote MAPK and recovery of AKT activity via RSK. Such observations 
indicate that growth factor receptor inhibitors such as gefitinib or MAPK inhibitors 
may be of some value in treating established resistance to faslodex or PDK inhibitors, 
although this project has shown that combination treatment of MAPK inhibitor plus 
PDK inhibitor is unable to prevent subsequent development of resistance. A
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significantly more rewarding avenue has been to consider the role for ERa 
phosphorylation. With faslodex or PI3K inhibitor treatment, phosphorylation of ERa 
remains a crucial element both in limiting maximal drug response and maintaining 
resistance. Thus, during the responsive phase faslodex fails to inhibit AKT-driven 
Serl67ER activity and blockade of Seri 18ER is incomplete, while PI3K inhibitors do 
not subvert ERa ligand-promoted Seri 18ER activation. The resultant resistant 
growth mechanism is associated with further re-activation of ERa by kinase-driven 
phosphorylation (including MAPK and AKT downstream of the increased growth 
factor receptors), substantial recovery of ERa transcriptional activity and thereby 
expression of ERa regulated genes (such as the growth signalling element 1GF-1R).
Encouragingly, an improved quality and longer duration of growth inhibition can be 
achieved by combining faslodex with PI3K signalling inhibitor in order to promote a 
superior depletion of the compensatory mechanism that involves residual ERa AF-1 
phosphorylation. Furthermore, the resultant cells do not show substantial increases in 
their aggressive behaviour, in contrast to treatment with faslodex alone. However, 
there again remains some residual ERa phosphorylation during the responsive phase 
not surprisingly resistance does emerge and is associated with full ERa re-activation. 
Again, these events may involve recruitment of increased EGFR (and 1GF-1R) that 
triggers downstream kinases (although in contrast HER2 remains at low levels 
perhaps explaining the lack of aggressiveness). Importantly, this thesis has been able 
to show that intelligent, simultaneous blockade of all the dominant regulators of ERa 
AF-1 phosphorylation can completely abrogate the compensatory cell survival 
mechanism that relies on functional ERa. In the MCF-7X cells, this can be achieved 
using a simultaneous treatment with faslodex plus PDK/AKT inhibitor plus a MAPK 
inhibitor in MCF-7X cells, where the central importance o f ERa knockdown is 
revealed by the somewhat inferior effect noted with PI3 K/AKT plus MAPK inhibitor 
alone. The triple treatment approach not only maximises initial anti-tumour activity 
but also promotes cell loss, thus preventing emergence of therapeutic resistance. 
Clearly, therefore, the aim in designing clinical combinations treatments should be to 
achieve “total depletion of ERa phosphorylation” for maximal inhibitofy effect to 
improve patient outlook. This may, of course, be difficult to achieve if we are to 
avoid potential unwanted side-effects of complex “cocktails” of signal transduction 
inhibitors. However, intelligent combination strategies of faslodex together with the 
upstream regulators of the various kinase activity remaining during ERa blockade
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(i.e. gefitinib) could prove of future value in this regard, where such combinations are 
excitingly currently under clinical evaluation. In contrast, it is envisaged that 
sequential use o f single agents following development of resistance could prove less 
effective, since in the case of faslodex, the drug resistant phenotype was also more 
aggressive (probably promoted by increased HER2), wonying observations if 
translated into prognostic impact in the clinic.
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2.2.3 (pg. 45) MCF-7 Resistant Sub-lines Culture Conditions and Maintenance: 
TAM-R, FAS-R and TAM/TKI-R
The TAM-R (tamoxifen resistant), FAS-R (faslodex resistant), and TAM/TKI-R 
(tamoxifen and gefitinib resistant) cell lines are all derivatives of the MCF-7 hormone 
sensitive breast cancer cell line and have been established within the Tenovus Centre 
for Cancer Research. The TAM-R is an acquired resistant stable cell line that 
evolved from the MCF-7 cells following a long-term exposure to tamoxifen (10'7 M). 
These cells were continually cultured in the presence of tamoxifen (10'7 M). After an 
initial inhibition of 50-60% the cells developed a resistant phenotype and log phase 
growth began after 4 months.
The FAS-R cell line was acquired in a similar fashion to the TAM-R cell line. MCF- 
7 cells were routinely cultured in the presence of the pure anti-oestrogen faslodex (10" 
7 M) with 60-70% initial inhibition for 5 months, before log phase growth resumed.
The TAM/TKI-R cells were TAM-R (6 months) cells exposed to subsequent 
treatment with the tyrosine kinase inhibitor, gefitinib (TKI, 1 pM) followed by an 
initial sensitivity to the compound of about 60%. Approximately 3 months later the 
cells, in the continued presence of both tamoxifen (10"7 M) and gefitinib (1 pM) 
began log phase growth as a ‘double’ resistant cell line.
2.2.4 (pg. 46) Experimental MCF-7 Culture Medium
For experimental purposes MCF-7 cells were seeded into phenol-red-free RPMI 
(wRPMI) + 5% charcoal stripped fetal calf serum (SFCS). In order to charcoal strip 
serum a charcoal solution was first made containing: 18 ml distilled H20, 2 g Norit A, 
0.01 g Dextran T-70. This solution was set to stir for at least 1 hour. The FCS (100 
ml) was pH adjusted to 4.2 with 5 M HC1 and allowed to equilibrate for 30 minutes at 
4°C. The charcoal solution (5 ml) was added to the FCS and incubated for 
approximately 16 hours at 4°C with gentle agitation. The charcoal was removed by 
centrifugation at 12,000 x g for 40 minutes, followed by coarse filtration (Whatman 
filter paper grade, 4). The pH was readjusted to 7.2 followed by sterile filtration (0.2 
pm sterile vacuum cap filter), and stored at -20°C until utilised.
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2.3.2 (pg. 49) RNA and PCR Product Loading Buffer and TAE Running Buffer
Loading buffer was stored at 4°C until use and contained: 6 g sucrose in 10 ml of 
sterile H20. A very small amount of bromophenol blue was added prior to filtration 
(0.2 pm filter paper) of the buffer followed by storage.
A stock 50X TAE running buffer contains:
242 g Tris base
57.1 ml glacial acetic acid
18.6 g EDTA
1 L distilled H20
When making a 2% agarose gel or running a gel the stock 50X TAE was diluted to 
IX.
2.3.3 (pg. 50) RTMaster Mix
The RT master mix was made up immediately before reverse transcription on ice 
(wet). For each sample subject to reverse transcription, an 11 jul aliquot of RT master 
mix was placed in a thin wall PCR tube.
5 pi dNTP’s (2.5 mM)
2 pi PCR Buffer (1 OX)*
2 pi DTT(O.IM)
2 pl Random Hexamers (100 pM)
* PCR Buffer (10X): 100 mM Tris-HCl pH 8.3, 500 mM KC1, 15 mM MgCl2, 0.01% 
w/v gelatin.
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2.3.4 (pg. 51) PCR master mix
The PCR master mix was made up immediately before PCR reaction on ice (wet). 
The master mix was made according to the number of samples being run. For each 
sample subject to PCR, a 24.5 pi aliquot of the PCR master mix was placed in a thin 
wall PCR tube:
18.625 pi Sterile H20  
2.5 pi PCR Buffer (1 OX)
2.0 pi dNTP’s (2.5 mM)
0.2 pi BIOTAQ DNA Polymerase
0.625 pi Primer set of target sequence (20 pM)
0.156 pi y^ -Actin primer set (20 pM) NB: only if PCR is being run as a co­
amp.
0.5 pi cDNA equivalent to 0.025 pg starting material
2.4.4 (pg. 55) X-gal Staining Solution
The staining solution was made prior to 0.5% glutaraldehyde fixation of the /3- 
Galactosidase transfected cells.
Solution A contained:
1.0% potassium ferricyanide (300 mM/130 mM MgCl2 in PBS) and 
1.0% potassium ferrocyanide (300 mM/ 130 mM MgCl2 in PBS) in PBS.
Solution B (X-gal solution) contained:
3.125 pi of X-gal (40 mg/ml) /ml of solution A
These solutions were made and kept in the dark to avoid degradation.
2.5.2 (pg. 56) Protein Lysis Buffer (pH 7.5)
A stock solution containing the following was stored at 4°C until protein lysis buffer 
was needed: 50 mM Trizma HC1, 5 mM EGTA, 150 mM Sodium Chloride, 1% 
Triton X-100. Prior to lysis the following reagents were added to the stock protein 
lysis buffer solution: 2 mM Sodium Vanadate, 50mM Sodium Fluoride, 1 mM
Phenylmethylsulphonyl Fluoride, 20 pM Phenylarsine Oxide, 10 mM Sodium 
Molybdate, 10 pg/ml Leupeptin, 2 mg/ml Aprotinin.
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2.5.3 (pg. 56) Protein Concentration Assay Reagents 
DC BioRad protein assay reagents contain:
Reagent A- 1-5% Sodium Hydroxide, 1% sodium tartrate and less than 0.1% copper 
sulfate.
Reagent S- 5-10% Sodium dodecyl sulfate (SDS)
Reagent B- a diluted FOLIN reagent containing less than 1% of each the following, 
lithium sulfate, tungstic acid sodium salt, molybolic acid sodium salt, hydrochloric 
acid and phosphoric acid.
2.5.4 (pg. 56) Separating Gel, Stacking Gel, Running Buffer IX
The separating gel was made according to the molecular size of the target protein:
7.5% gel for protein range 70-200 (kDa)- 30% Acrylamide (2.5 ml), distilled 
H20  (4.8 ml), 1.5 M Tris-HCl (pH 8.8, 2.5 ml), 10% SDS (0.1 ml), 10% APS 
(0.1 ml), Temed (10 jxl).
10% gel for protein range 20-100 (kDa)- 30% Acrylamide (3.3 ml), distilled 
H20  (4.0 ml), 1.5 M Tris-HCl (pH 8.8, 2.5 ml), 10% SDS (0.1 ml), 10% APS 
(0.1 ml), Temed (10 p,l).
The 5% stacking gel contained: 30% Acrylamide (1.7 ml), distilled H20  (5.8 ml), 1.5 
M Tris-HCl (pH 6.8, 2.5 ml), 10% SDS (0.1 ml), 10% APS (0.1 ml), Temed (10 1^).
A stock solution of 10X running buffer (pH 8.3) was stored at room temperature until 
SDS-PAGE was performed: 0.23 M Trizma Base, 1.92 M Glycine, 0.1% SDS. A IX 
dilution of this solution was utilised for SDS-PAGE.
Protein sample loading buffer contains: 10% SDS (4 ml), Glycerol (2 ml), 0.5 M Tris 
(2.4 ml, pH 6.8 upper buffer), H20  (1.6 ml) and Bromophenol Blue (~1 mg). Prior to 
use DTT (15.5 mg/ml) was added.
2.5.5 (pg. 57) Transfer Buffer and TBS-TSolution
Transfer buffer was made up fresh just before the transferring procedure and 
contained: 0.25 M Trizma Base, 1.92 M Glycine, 20% Methanol
A stock solution of 10X TBS-T contains: 12.1 g Trizma base, 58 g NaCl, 5 ml Tween 
20, and 15ml5M HC1.
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A IX dilution of this solution is utilized as the antibody diluent and washing buffer.
2.6.2.1 (pg. 60) Sucrose Storage Medium
Sucrose storage medium (SSM) was made and stored at -20°C until utilized. SSM 
contained: 42.8 g sucrose, 0.33 g MgCl2 dissolved in 250 ml PBS, followed by the 
addition of 250 ml glycerol.
2.6.2.2 (pg. 60) Formal Saline (FS) Solution
Formal saline solution was stored at room temperature contained the following: 4.5 g 
NaCl, 450 ml H20, 50 ml Formaldehyde.
2.6.2.3 (pg. 60) 2.5% Phenol Formal Saline (pFS) Solution
Phenol formal saline was made on the day of fixation and contained: 0.5 g phenol in 
20 ml formal saline.
2.6.2.4 (pg. 61) 2% Paraformaldehyde Vanadate (PFV) Solution
The 2% paraformaldehyde vanadate (vanadate maintains integrity of phosphorylation 
site) solution was made fresh on the day of cell fixation. Paraformaldehyde (0.25 g) 
was weighed out into a glass beaker and a small volume of PBS (3 ml) was added. 
With gentle agitation the mixture was heated to 60°C, until the solid 
paraformaldehyde had dissolved. In order to clear the solution, 1M NaOH (10 pi) 
was added, followed by the remaining volume of PBS (9.5 ml). After adding 1 M 
HC1 (10 pi), the pH was checked to verify the solution was approximately 7.4. Just 
before fixation 2% sodium orthovanadate (NaVO,*, 100 mM) was added.
2.6.2.5 (pg. 61) Methanol Vanadate Solution
The methanol vanadate solution was made fresh on the day of cell fixation. 2% 
sodium orthovanadate (NaV04, 100 mM) was added to cooled methanol (-10 to 
-30°C, on dry ice).
